
<html lang="en"     class="pb-page"  data-request-id="6f737eff-479f-4ecc-8e7d-0e4faaf2f08f"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;issue:issue:10.1021/jmcmar.2018.61.issue-13;ctype:string:Journal Content;wgroup:string:ACHS website Group;article:article:10.1021/acs.jmedchem.8b00292;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Dual Glucagon-like Peptide 1 (GLP-1)/Glucagon Receptor Agonists Specifically Optimized for Multidose Formulations" /></meta><meta name="dc.Creator" content="Andreas  Evers" /></meta><meta name="dc.Creator" content="Martin  Bossart" /></meta><meta name="dc.Creator" content="Stefania  Pfeiffer-Marek" /></meta><meta name="dc.Creator" content="Ralf  Elvert" /></meta><meta name="dc.Creator" content="Herman  Schreuder" /></meta><meta name="dc.Creator" content="Michael  Kurz" /></meta><meta name="dc.Creator" content="Siegfried  Stengelin" /></meta><meta name="dc.Creator" content="Martin  Lorenz" /></meta><meta name="dc.Creator" content="Andreas  Herling" /></meta><meta name="dc.Creator" content="Anish  Konkar" /></meta><meta name="dc.Creator" content="Ulrike  Lukasczyk" /></meta><meta name="dc.Creator" content="Anja  Pfenninger" /></meta><meta name="dc.Creator" content="Katrin  Lorenz" /></meta><meta name="dc.Creator" content="Torsten  Haack" /></meta><meta name="dc.Creator" content="Dieter  Kadereit" /></meta><meta name="dc.Creator" content="Michael  Wagner" /></meta><meta name="dc.Description" content="Novel peptidic dual agonists of the glucagon-like peptide 1 (GLP-1) and glucagon receptor are reported to have enhanced efficacy over pure GLP-1 receptor agonists with regard to treatment of obesit..." /></meta><meta name="Description" content="Novel peptidic dual agonists of the glucagon-like peptide 1 (GLP-1) and glucagon receptor are reported to have enhanced efficacy over pure GLP-1 receptor agonists with regard to treatment of obesit..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="June 7, 2018" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.8b00292" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright Â© 2018 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b00292" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.8b00292" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b00292" /></link>
        
    
    

<title>Dual Glucagon-like Peptide 1 (GLP-1)/Glucagon Receptor Agonists Specifically Optimized for Multidose Formulations | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.8b00292" /></meta><meta property="og:title" content="Dual Glucagon-like Peptide 1 (GLP-1)/Glucagon Receptor Agonists Specifically Optimized for Multidose Formulations" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-13/acs.jmedchem.8b00292/20180706/images/large/jm-2018-00292s_0012.jpeg" /></meta><meta property="og:description" content="Novel peptidic dual agonists of the glucagon-like peptide 1 (GLP-1) and glucagon receptor are reported to have enhanced efficacy over pure GLP-1 receptor agonists with regard to treatment of obesity and diabetes. We describe novel exendin-4 based dual agonists designed with an activity ratio favoring the GLP-1 versus the glucagon receptor. As result of an iterative optimization procedure that included molecular modeling, structural biological studies (X-ray, NMR), peptide design and synthesis, experimental activity, and solubility profiling, a candidate molecule was identified. Novel SAR points are reported that allowed us to fine-tune the desired receptor activity ratio and increased solubility in the presence of antimicrobial preservatives, findings that can be of general applicability for any peptide discovery project. The peptide was evaluated in chronic in vivo studies in obese diabetic monkeys as translational model for the human situation and demonstrated favorable blood glucose and body weight lowering effects." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.8b00292"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.8b00292">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.8b00292&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.8b00292&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.8b00292&amp;href=/doi/10.1021/acs.jmedchem.8b00292" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2018</span><span class="cit-fg-volume">, 61</span><span class="cit-fg-issue">, 13</span><span class="cit-fg-pageRange">, 5580-5593</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/61/13" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.8b00243" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.8b00328" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Dual Glucagon-like Peptide 1 (GLP-1)/Glucagon Receptor Agonists Specifically Optimized for Multidose Formulations</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Andreas Evers</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Andreas Evers</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Sanofi-Aventis Deutschland GmbH, R&D, Industriepark HÃ¶chst, D-65926 Frankfurt am Main, Germany</div></div><span class="conrtib-corresp"><strong>*</strong>A.E. Phone: +49 305 12636. E-mail: <a href="/cdn-cgi/l/email-protection#a2e3ccc6d0c7c3d18ce7d4c7d0d1e2d1c3cccdc4cb8cc1cdcf"><span class="__cf_email__" data-cfemail="36775852445357451873405344457645575859505f1855595b">[emailÂ protected]</span></a></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Andreas++Evers">Andreas Evers</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-4643-1941" title="Orcid link">http://orcid.org/0000-0003-4643-1941</a></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Martin Bossart</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Martin Bossart</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Sanofi-Aventis Deutschland GmbH, R&D, Industriepark HÃ¶chst, D-65926 Frankfurt am Main, Germany</div></div><span class="conrtib-corresp"><strong>*</strong>M.B. Phone: +49 305 16655. E-mail: <a href="/cdn-cgi/l/email-protection#14597566607d7a3a567b67677566605467757a7b727d3a777b79"><span class="__cf_email__" data-cfemail="e7aa8695938e89c9a5889494869593a794868988818ec984888a">[emailÂ protected]</span></a></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Martin++Bossart">Martin Bossart</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Stefania Pfeiffer-Marek</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Stefania Pfeiffer-Marek</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Sanofi-Aventis Deutschland GmbH, R&D, Industriepark HÃ¶chst, D-65926 Frankfurt am Main, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Stefania++Pfeiffer-Marek">Stefania Pfeiffer-Marek</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Ralf Elvert</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ralf Elvert</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Sanofi-Aventis Deutschland GmbH, R&D, Industriepark HÃ¶chst, D-65926 Frankfurt am Main, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ralf++Elvert">Ralf Elvert</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Herman Schreuder</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Herman Schreuder</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Sanofi-Aventis Deutschland GmbH, R&D, Industriepark HÃ¶chst, D-65926 Frankfurt am Main, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Herman++Schreuder">Herman Schreuder</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-2249-2782" title="Orcid link">http://orcid.org/0000-0003-2249-2782</a></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Michael Kurz</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Michael Kurz</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Sanofi-Aventis Deutschland GmbH, R&D, Industriepark HÃ¶chst, D-65926 Frankfurt am Main, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Michael++Kurz">Michael Kurz</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Siegfried Stengelin</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Siegfried Stengelin</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Sanofi-Aventis Deutschland GmbH, R&D, Industriepark HÃ¶chst, D-65926 Frankfurt am Main, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Siegfried++Stengelin">Siegfried Stengelin</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Martin Lorenz</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Martin Lorenz</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Sanofi-Aventis Deutschland GmbH, R&D, Industriepark HÃ¶chst, D-65926 Frankfurt am Main, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Martin++Lorenz">Martin Lorenz</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Andreas Herling</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Andreas Herling</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Sanofi-Aventis Deutschland GmbH, R&D, Industriepark HÃ¶chst, D-65926 Frankfurt am Main, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Andreas++Herling">Andreas Herling</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Anish Konkar</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Anish Konkar</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Sanofi-Aventis Deutschland GmbH, R&D, Industriepark HÃ¶chst, D-65926 Frankfurt am Main, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Anish++Konkar">Anish Konkar</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Ulrike Lukasczyk</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ulrike Lukasczyk</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Sanofi-Aventis Deutschland GmbH, R&D, Industriepark HÃ¶chst, D-65926 Frankfurt am Main, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ulrike++Lukasczyk">Ulrike Lukasczyk</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Anja Pfenninger</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Anja Pfenninger</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Sanofi-Aventis Deutschland GmbH, R&D, Industriepark HÃ¶chst, D-65926 Frankfurt am Main, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Anja++Pfenninger">Anja Pfenninger</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Katrin Lorenz</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Katrin Lorenz</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Sanofi-Aventis Deutschland GmbH, R&D, Industriepark HÃ¶chst, D-65926 Frankfurt am Main, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Katrin++Lorenz">Katrin Lorenz</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Torsten Haack</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Torsten Haack</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Sanofi-Aventis Deutschland GmbH, R&D, Industriepark HÃ¶chst, D-65926 Frankfurt am Main, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Torsten++Haack">Torsten Haack</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Dieter Kadereit</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Dieter Kadereit</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Sanofi-Aventis Deutschland GmbH, R&D, Industriepark HÃ¶chst, D-65926 Frankfurt am Main, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Dieter++Kadereit">Dieter Kadereit</a></span></div></div></span></li><span class="comma-separator">,Â andÂ </span><li><span><span class="hlFld-ContribAuthor">Michael Wagner</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Michael Wagner</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Sanofi-Aventis Deutschland GmbH, R&D, Industriepark HÃ¶chst, D-65926 Frankfurt am Main, Germany</div></div><span class="conrtib-corresp"><strong>*</strong>M.W. Phone: +49 305 46875. E-mail: <a href="/cdn-cgi/l/email-protection#4c01252f242d2920621b2d2b22293e0c3f2d22232a25622f2321"><span class="__cf_email__" data-cfemail="e7aa8e848f86828bc9b08680898295a794868988818ec984888a">[emailÂ protected]</span></a></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Michael++Wagner">Michael Wagner</a></span></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b00292&amp;href=/doi/10.1021%2Facs.jmedchem.8b00292" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2018</span></span><span class="cit-volume">, 61</span><span class="cit-issue">, 13</span><span class="cit-pageRange">, 5580â5593</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">June 7, 2018</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>20 February 2018</li><li><span class="item_label"><b>Published</b> online</span>7 June 2018</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 12 July 2018</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.8b00292" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00292</a></div><div class="article_header-article-copyright"><strong>Copyright Â© 2018 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D5580%26pageCount%3D14%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DAndreas%2BEvers%252C%2BMartin%2BBossart%252C%2BStefania%2BPfeiffer-Marek%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D61%26issueNum%3D13%26contentID%3Dacs.jmedchem.8b00292%26title%3DDual%2BGlucagon-like%2BPeptide%2B1%2B%2528GLP-1%2529%252FGlucagon%2BReceptor%2BAgonists%2BSpecifically%2BOptimized%2Bfor%2BMultidose%2BFormulations%26numPages%3D14%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D5593%26publicationDate%3DJuly%2B2018">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.8b00292"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2531</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">20</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.8b00292" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Dual Glucagon-like Peptide 1 (GLP-1)/Glucagon Receptor Agonists Specifically Optimized for Multidose Formulations&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Andreas&quot;,&quot;last_name&quot;:&quot;Evers&quot;},{&quot;first_name&quot;:&quot;Martin&quot;,&quot;last_name&quot;:&quot;Bossart&quot;},{&quot;first_name&quot;:&quot;Stefania&quot;,&quot;last_name&quot;:&quot;Pfeiffer-Marek&quot;},{&quot;first_name&quot;:&quot;Ralf&quot;,&quot;last_name&quot;:&quot;Elvert&quot;},{&quot;first_name&quot;:&quot;Herman&quot;,&quot;last_name&quot;:&quot;Schreuder&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;Kurz&quot;},{&quot;first_name&quot;:&quot;Siegfried&quot;,&quot;last_name&quot;:&quot;Stengelin&quot;},{&quot;first_name&quot;:&quot;Martin&quot;,&quot;last_name&quot;:&quot;Lorenz&quot;},{&quot;first_name&quot;:&quot;Andreas&quot;,&quot;last_name&quot;:&quot;Herling&quot;},{&quot;first_name&quot;:&quot;Anish&quot;,&quot;last_name&quot;:&quot;Konkar&quot;},{&quot;first_name&quot;:&quot;Ulrike&quot;,&quot;last_name&quot;:&quot;Lukasczyk&quot;},{&quot;first_name&quot;:&quot;Anja&quot;,&quot;last_name&quot;:&quot;Pfenninger&quot;},{&quot;first_name&quot;:&quot;Katrin&quot;,&quot;last_name&quot;:&quot;Lorenz&quot;},{&quot;first_name&quot;:&quot;Torsten&quot;,&quot;last_name&quot;:&quot;Haack&quot;},{&quot;first_name&quot;:&quot;Dieter&quot;,&quot;last_name&quot;:&quot;Kadereit&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;Wagner&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2018&quot;,&quot;month&quot;:&quot;06&quot;,&quot;day&quot;:&quot;07&quot;,&quot;issue&quot;:&quot;13&quot;,&quot;volume&quot;:&quot;61&quot;,&quot;pages&quot;:&quot;5580-5593&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.8b00292&quot;},&quot;abstract&quot;:&quot;Novel peptidic dual agonists of the glucagon-like peptide 1 (GLP-1) and glucagon receptor are reported to have enhanced efficacy over pure GLP-1 receptor agonists with regard to treatment of obesity and diabetes. We describe novel exendin-4 based dual agonists designed with an activity ratio favoring the GLP-1 versus the glucagon receptor. As result of an iterative optimization procedure that included molecular modeling, structural biological studies (X-ray, NMR), peptide design and synthesis, experimental activity, and solubility profiling, a candidate molecule was identified. Novel SAR points are reported that allowed us to fine-tune the desired receptor activity ratio and increased solubility in the presence of antimicrobial preservatives, findings that can be of general applicability for any peptide discovery project. The peptide was evaluated in chronic in vivo studies in obese diabetic monkeys as translational model for the human situation and demonstrated favorable blood glucose and body weight lowerin&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b00292&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00292" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b00292&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00292" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b00292&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00292" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b00292&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00292&amp;href=/doi/10.1021/acs.jmedchem.8b00292" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.8b00292" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.8b00292" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (6 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00292&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.8b00292%26sid%3Dliteratum%253Aachs%26pmid%3D29879354%26genre%3Darticle%26aulast%3DEvers%26date%3D2018%26atitle%3DDual%2BGlucagon-like%2BPeptide%2B1%2B%2528GLP-1%2529%252FGlucagon%2BReceptor%2BAgonists%2BSpecifically%2BOptimized%2Bfor%2BMultidose%2BFormulations%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D61%26issue%3D13%26spage%3D5580%26epage%3D5593%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">Â»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=292589" title="Agonists">Agonists</a>,</li><li><a href="/action/doSearch?ConceptID=290831" title="Monomers">Monomers</a>,</li><li><a href="/action/doSearch?ConceptID=291454" title="Solubility">Solubility</a>,</li><li><a href="/action/doSearch?ConceptID=292186" title="Receptors">Receptors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/61/13" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-13/jmcmar.2018.61.issue-13/20180712/jmcmar.2018.61.issue-13.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-13/acs.jmedchem.8b00292/20180706/images/medium/jm-2018-00292s_0012.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-13/acs.jmedchem.8b00292/20180706/images/large/jm-2018-00292s_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00292&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Novel peptidic dual agonists of the glucagon-like peptide 1 (GLP-1) and glucagon receptor are reported to have enhanced efficacy over pure GLP-1 receptor agonists with regard to treatment of obesity and diabetes. We describe novel exendin-4 based dual agonists designed with an activity ratio favoring the GLP-1 versus the glucagon receptor. As result of an iterative optimization procedure that included molecular modeling, structural biological studies (X-ray, NMR), peptide design and synthesis, experimental activity, and solubility profiling, a candidate molecule was identified. Novel SAR points are reported that allowed us to fine-tune the desired receptor activity ratio and increased solubility in the presence of antimicrobial preservatives, findings that can be of general applicability for any peptide discovery project. The peptide was evaluated in chronic <i>in vivo</i> studies in obese diabetic monkeys as translational model for the human situation and demonstrated favorable blood glucose and body weight lowering effects.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_15305" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_15305" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Type 2 diabetes (T2D) has reached pandemic levels and therefore represents a major health burden to modern society. Currently there are more than 400 million patients living worldwide with T2D;<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> still many of them are not diagnosed, not treated at all, or not treated in the right way to achieve their target glycemic status. Very often, T2D is coupled with obesity, in fact 80â90% of the patients with T2D are obese.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Both conditions, diabetes and obesity, have been proven to be risk factors for many associated diseases, such as micro- and macrovascular complications, but also nonalcoholic steatohepatitis (NASH).<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Consequently, there is major interest in the search for new therapies that provide adequate glycemic control in patients with T2D and in addition also lead to a significant body weight reduction in overweight to obese people. There are currently only two classes of medications approved that besides their glucose lowering effect lead to a moderate weight reduction: orally available small molecule sodiumâglucose cotransporter 2 inhibitors (SGLT2-I) and injectable peptidic glucagon-like peptide 1 (GLP-1) receptor agonists. For the latter class, novel formulations and dose regimens are currently being explored to further increase efficacy, especially with regards to weight loss.<a onclick="showRef(event, 'ref4 ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref4 ref5 ref6">(4â6)</a></div><div class="NLM_p">In recent years, novel unimolecular peptides with activity at multiple target receptors have emerged as a promising approach to enhance antidiabetic properties and reduce body weight.<a onclick="showRef(event, 'ref7 ref8 ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref7 ref8 ref9 ref10">(7â10)</a> A prominent approach is the combination of GLP-1 receptor mediated food intake suppression with glucagon-receptor mediated increase in energy expenditure for synergistic and improved body weight loss. Such dual GLP-1/glucagon receptor agonists have first been described by Day et al.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> and Pocai et al.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Meanwhile, numerous dual agonists have been reported by other groups, including us, and quite a few of them have progressed into the clinic; see refs <a onclick="showRef(event, 'ref12 ref13 ref14 ref15 ref16 ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref12 ref13 ref14 ref15 ref16 ref17 ref18">(12â18)</a> or recent reviews.<a onclick="showRef(event, 'ref7 ref8 ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref7 ref8 ref9 ref10">(7â10)</a></div><div class="NLM_p">Despite the recent progress of GLP-1/glucagon receptor dual agonists, it is still not clear today what is the optimal ratio between GLP-1 and glucagon receptor activation.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> GLP-1 receptor activation leads to glucose lowering, in conjunction with moderate body weight reduction, whereas an excessive enhancement of the glucagon receptor activity provides more significant weight loss, but at the risk of glucose elevation. In preclinical studies performed in diet-induced obese (DIO) mice, Day et al. showed that a nearly equally balanced coagonist demonstrated intermediate weight loss but with glucose control comparable to that of the most GLP-1 receptor-selective peptide.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> It was concluded that the optimal GLP-1/glucagon activity ratio needs to be carefully evaluated and could be different for different species. These findings suggest additional investigation in more translational animal models, such as obese diabetic monkeys.</div><div class="NLM_p">Besides the pharmacological profile, pharmaceutical properties such as solubility and aggregation properties of peptides need to be optimized to ensure clinical use in humans. Peptide drugs that are formulated in a ready-to-use solution for subcutaneous injection are frequently presented to the patient using multiple-dose pen devices. Such drugâdevice combinations require a low-viscosity solution, long-term chemical and physical stability, and the compatibility of the peptide with aromatic preservatives, such as phenol, <i>m</i>-cresol, or benzyl alcohol to inhibit the growth of microorganisms that may be introduced from repeatedly withdrawing individual use doses.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Indeed, aggregation or solubility issues have been reported under certain conditions for several peptides with agonistic activity at the GLP-1, glucagon, or glucose-dependent insulinotropic peptide (GIP) receptor.<a onclick="showRef(event, 'ref22 ref23 ref24 ref25 ref26'); return false;" href="javascript:void(0);" class="ref ref22 ref23 ref24 ref25 ref26">(22â26)</a> Consequently, in order to maximize the probability of success during drug development, it is increasingly recognized that physical stability should be assessed as early as possible in a discovery program, to provide robust development candidates with respect to the final drug product and to physical stress conditions that will be encountered in the downstream processes.<a onclick="showRef(event, 'ref27 ref28 ref29'); return false;" href="javascript:void(0);" class="ref ref27 ref28 ref29">(27â29)</a></div><div class="NLM_p">In our recently published article, we described identification of a potent dual GLP-1/glucagon receptor agonist based on the exendin-4 structure (peptide <b>1</b>, <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>).<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> The goal of the present study was to design an exendin-4 based dual GLP-1/glucagon receptor agonist with an approximately 10â15-fold lower preference for the glucagon versus GLP-1 receptor for pharmacological evaluation with respect to body weight loss and glycemic control in obese diabetic monkeys as a translational model for the human situation. Further target attributes were (i) selectivity versus the GIP receptor and (ii) sufficient solubility for the candidate molecule over a broad pH range (pH 4.5â7.4) in the presence of antimicrobial preservatives. We conducted an iterative optimization procedure that included molecular modeling, structural biological studies (X-ray, NMR), peptide design and synthesis, and experimental activity and solubility profiling under relevant conditions. Novel SAR points were found that represent selectivity switches to fine-tune the desired GLP-1/glucagon/GIP receptor selectivity ratio. Optimization of solubility in the presence of a phenolic preservative was achieved by structure-based identification of an aggregation hot spot and subsequent introduction of a novel solubility-enhancing motif. Finally, the beneficial effects on body weight and glucose control in a 6-week trial (using once-daily subcutaneous injection) in obese diabetic monkeys, a relevant translational model for the human situation, are described.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. (a) Amino Acid Sequences of Glucagon, Exendin-4, Peptide <b>1</b>, Native GLP-1, Liraglutide, and Native GIP<a class="ref internalNav" href="#tbl1-fn1" aria-label="a">a</a> and (b) EC<sub>50</sub> Values at the Human GLP-1, Glucagon (GCG), and GIP Receptor as Measured in a cAMP Assay in Receptor Overexpressing HEK-293 Cell Lines with SEM Values and Number of Measurements (<i>n</i>)</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-13/acs.jmedchem.8b00292/20180706/images/medium/jm-2018-00292s_0008.gif" alt="" id="gr8" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl1-fn1"><div class="footnote" id="tbl1-fn1"><sup><sup>a</sup></sup><p class="last">Amino acids that are identical among glucagon and exendin-4 are colored green, residues unique to glucagon are shown in yellow, residues unique to exendin-4 are colored grey, residues unique to GLP-1 are white, residues unique to GIP are violet, and further modifications are shown in orange. Residue 14 in peptide <b>1</b> and residue 20 in liraglutide are modified by addition of a C16 fatty acid (palmitic acid) at the Îµ-amino group of lysine using a Î³-glutamic acid spacer.</p></div></div><div></div></div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_32311" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_32311" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In the following, we will present an overview over relevant published structural data (X-ray, NMR) for the recognition of exendin-4 at the extracellular domain (ECD) of the GLP-1 receptor and describe key features with respect to ECD glucagon and GIP receptor binding. These insights were used as structural basis for optimization of a lead peptide (peptide <b>2</b>, <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>) toward the desired GLP-1/glucagon/GIP receptor activity ratio.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. (a) Peptide Sequences<a class="ref internalNav" href="#tbl2-fn1" aria-label="a">a</a> and (b) EC<sub>50</sub> Values<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a> at the Human GLP-1, Glucagon and GIP Receptors with SEM Values and Number of Measurements (<i>n</i>)</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-13/acs.jmedchem.8b00292/20180706/images/medium/jm-2018-00292s_0009.gif" alt="" id="gr10" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl2-fn1"><div class="footnote" id="tbl2-fn1"><sup><sup>a</sup></sup><p class="last">Color coding of amino acids is identical to <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>.</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">Measured in a cAMP assay in receptor overexpressing HEK-293 cell lines.</p></div></div><div></div></div><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> Structural Analysis of Peptides and Binding Hypotheses to the GLP-1, Glucagon and GIP Receptor ECDs</h3><div class="NLM_p">Molecular recognition of exendin-4 and glucagon at the ECDs of the GLP-1 and glucagon receptor has been described in detail previously.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a><a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>a shows the solution-state NMR ensemble of exendin-4 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1jrj">1jrj</a>).<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> In exendin-4, the C-terminal sequence stretch (residues 30â39) cages Trp25 (tryptophan cage), which enhances helicity and structural stability of the peptide by intramolecular interactions and thereby provides improved physicochemical and metabolic stability.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> A three-dimensional alignment of the X-ray structures of the GLP-1 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3c59">3c59</a>),<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> glucagon (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ers">4ers</a>),<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> and GIP receptor (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2qkh">2qkh</a>)<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> ECDs is shown in <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>b. Furthermore, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>b depicts the solution-state NMR structure of exendin-4 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1jrj">1jrj</a>) that was superimposed onto exendin(9â39) in the GLP-1 receptor-bound conformation (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3c59">3c59</a>).<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> This structural model (shown in <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>b) was used as reference for the generation of peptide binding models to guide the design of peptides toward the desired GLP-1/glucagon/GIP receptor activity ratio (for details, see <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>). <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>c highlights two positions where the receptors have dissimilar residues. These residues are close to Lys27 of exendin-4, suggesting that the GLP-1/glucagon/GIP receptor activity and selectivity ratio might be specifically optimized by peptide modifications in position 27.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-13/acs.jmedchem.8b00292/20180706/images/medium/jm-2018-00292s_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-13/acs.jmedchem.8b00292/20180706/images/large/jm-2018-00292s_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. (a) Ensemble of solution-state NMR structure of exendin-4 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1jrj">1jrj</a>). (b) Three-dimensional alignment of the extracellular domain (ECD) of the GLP-1 (GLP-1R, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3c59">3c59</a>), glucagon (GCGR, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ers">4ers</a>), and GIP receptor (GIPR, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2qkh">2qkh</a>) and binding hypothesis of exendin-4 (derived from the NMR structure in solution, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1jrj">1jrj</a>) to the GLP-1 receptor ECD. The color coding of peptide amino acids is equivalent to the sequence color coding outlined in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>. Residue Trp25 is shown in space fill representation. (c) Magnified view of the peptide binding interface of the receptor ECDs highlighting specific amino acids. According to the binding hypothesis, these amino acids are interacting with Lys27 of exendin-4 and are assumed to represent a spot for modulation of peptide activity and selectivity at different receptors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-13/acs.jmedchem.8b00292/20180706/images/large/jm-2018-00292s_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00292&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">The conformations of the ECDs and the exendin-4 binding mode shown in <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a> are highly similar to recently published full-length structures of the peptide-bound GLP-1<a onclick="showRef(event, 'ref35 ref36'); return false;" href="javascript:void(0);" class="ref ref35 ref36">(35,36)</a> and glucagon<a onclick="showRef(event, 'ref37 ref38'); return false;" href="javascript:void(0);" class="ref ref37 ref38">(37,38)</a> receptor.</div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> Peptide Design and Optimization</h3><div class="NLM_p">In the search for a new dual GLP-1/glucagon receptor agonist with lower glucagon agonism, peptide <b>2</b> was identified, which shows a slightly higher activity at the glucagon (EC<sub>50</sub> = 1.9 pM) than the GLP-1 receptor (EC<sub>50</sub> = 2.5 pM), see <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>. The presence of the 2-aminoisobutyric acid (Aib) residue in position 2 renders the peptide resistant to DPPIV-mediated degradation, and a glutamine residue in position 3 is essential for activity at the glucagon receptor. Among further modifications compared to exendin-4, this peptide is modified in position 14 by addition of a stearic acid at the Îµ-amino group of a lysine using a Î³-glutamic acid spacer. A similar fatty acid modification was shown to have beneficial effects on the activity at the GLP-1 and glucagon receptors in the case of peptide <b>1</b> in our previous study.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> However, it was found that peptide <b>2</b> not only shows high activity at the GLP-1 and glucagon receptors but also demonstrates considerable activity at the GIP receptor (EC<sub>50</sub> = 39.7 pM).</div><div class="NLM_p last">Starting from peptide <b>2</b>, we designed variants aiming to (1) maintain high potency at the GLP-1 receptor, (2) reduce the relative ratio of GLP-1/glucagon receptor activity to a factor of approximately 1:10 to 1:15, and (3) introduce sufficient selectivity toward the GIP receptor (GLP-1/GIP receptor activity ratio in the order <1:200). As shown in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>, only three modifications were sufficient to introduce the desired activity profile: (1) Guided by the structural receptor differences close to residue 27 of exendin-4 (see <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>c), an Aib residue was introduced in position 27 (peptide <b>3</b>), which modified the GLP-1/glucagon receptor selectivity ratio in favor of GLP-1R activity (activity ratio GLP-1/glucagon receptor = 1:5) and simultaneously improved selectivity toward the GIP receptor (activity ratio GLP-1/GIP receptor = 1:73). (2) Selectivity toward the GIP receptor could be further increased by mutating the glutamate residue in position 21 to leucine (peptide <b>4</b>, activity ratio GLP-1/GIP receptor = 1:181), but at the cost of reduced absolute activity at the GLP-1 receptor; whereas peptide <b>3</b> activates the GLP-1 receptor with an EC<sub>50</sub> value of 1.4 pM, the activity of peptide <b>4</b> drops to 6.4 pM. (3) Finally, it was found that modification of the lysine side chain in position 14 by introduction of a second Î³-glutamic acid spacer and exchange of the stearic against palmitic acid restored high GLP-1 receptor activity (peptide <b>5</b>, EC<sub>50</sub> = 2.2 pM), while further improving selectivity toward the GIP receptor (EC<sub>50</sub> = 2031.7 pM) and providing the desired GLP-1/glucagon receptor activity ratio (1:13).</div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> SAR and Modeling Studies Rationalizing Selectivity Determining Features in Peptide Positions 14 and 27</h3><div class="NLM_p">We designed and synthesized variants of peptide <b>5</b> to rationalize the effect of the mutations in positions 14 and 27 on receptor activity and selectivity (peptides <b>6</b>â<b>10</b>).</div><div id="sec2_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i9" class="anchor-spacer"></div><h4 class="article-section__title" id="_i9"> Role of Aib27 for Receptor Selectivity</h4><div class="NLM_p">The selective GLP-1 receptor agonist exendin-4 has a lysine in position 27, whereas the native hormones glucagon and GIP(1â42) bear hydrophobic residues in this position (Met27 and Leu27, respectively, see <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Therefore, it was somewhat surprising that mutating Lys27 in peptide <b>2</b> into the hydrophobic residue Aib (peptide <b>3</b>) increased activity at the GLP-1 receptor and simultaneously reduced activity at the glucagon and GIP receptor. To further investigate the role of residue 27 for receptor selectivity in detail, Aib27 in peptide <b>5</b> was back-mutated to lysine (peptide <b>6</b>), leucine (peptide <b>7</b>), or isoleucine (peptide <b>8</b>). Indeed, these single-point mutations improved activity at the glucagon and GIP receptors while maintaining or worsening activity at the GLP-1 receptor (see <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). For example, the mutation Aib27Ile reduces GLP-1 receptor activity by a factor of 2, while improving glucagon activity by a factor of 11 and GIP receptor activity by a factor of 35 (compare peptide <b>5</b> versus peptide <b>8</b>). Inspection of the predicted binding modes (for details, see <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>) for peptides <b>5</b> and <b>8</b> to the GLP-1, glucagon, and GIP receptor ECDs provides a structural rationale for the selectivity switch of the Aib27Ile mutant (see <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). Residue 27 is pointing to a region where the three receptors bear different residues (GLP-1 receptor, Leu123; glucagon receptor, Ala118; and GIP receptor, His115). In peptide <b>5</b>, the small side chain on the Aib27 residue is at ideal distance for an attractive van-der-Waals interaction with Leu123 of the GLP-1 receptor. The glucagon receptor, however, bears only a small alanine (Ala118) in this position, which is too distant for an attractive interaction with Aib27 of peptide <b>5</b>; the GIP receptor has a histidine (His115) in the corresponding position, which is supposedly, due to its planar imidazole ring, restricted in its conformational freedom and, thus, also unable to form an attractive interaction with Aib27 of peptide <b>5</b>. In contrast, the hydrophobic side chain of Ile27 in peptide <b>8</b> is large enough to establish attractive van-der-Waals interactions with Ala118 in the glucagon receptor and His115 in the GIP receptor, resulting in a significant activity increase at the glucagon and GIP receptor versus peptide <b>5</b>. At the same time, there seems to be a repulsion of Ile27 in peptide <b>8</b> with Leu123 in the GLP-1 receptor, resulting in the slight activity loss of factor 2.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-13/acs.jmedchem.8b00292/20180706/images/medium/jm-2018-00292s_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-13/acs.jmedchem.8b00292/20180706/images/large/jm-2018-00292s_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Predicted binding hypothesis for peptides <b>5</b> and <b>8</b> at the extracellular domain of the GLP-1 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3c59">3c59</a>), glucagon (GCG, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ers">4ers</a>), and GIP (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2qkh">2qkh</a>) receptors. Both peptides have identical sequences except for residue 27. Introduction of Aib27 in peptide <b>5</b> and Ile27 in peptide <b>8</b> causes different activity profiles at the receptors, supposedly due to differential interactions with Leu123 (GLP-1 receptor), Ala118 (glucagon receptor), and His115 (GIP receptor).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-13/acs.jmedchem.8b00292/20180706/images/large/jm-2018-00292s_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00292&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i10" class="anchor-spacer"></div><h4 class="article-section__title" id="_i10"> Role of the Fatty Acid in Position <b>14</b> for Receptor Selectivity</h4><div class="NLM_p last">Peptides <b>9</b> and <b>10</b> were synthesized to investigate the effect of the fatty acid side chain in position 14 on receptor activity. Peptide <b>9</b> is an analogue of peptide <b>5</b>, where the lipophilic side chain attached to Lys14 was simply removed. This mutation results in a considerable activity loss at the GLP-1 receptor (factor 10) and significant activity loss at the glucagon and GIP receptors (factor 1554 and factor 87, respectively). Subsequently, a leucine residue was introduced in position 14. This residue is also present in glucagon, oxyntomodulin, and other peptides that show high potency at the GLP-1, glucagon or GIP receptors.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> This analogue (peptide <b>10</b>) maintains considerable activity at the GLP-1 receptor (EC<sub>50</sub> = 8.0 pM) but also shows significant activity loss at the glucagon and GIP receptor (EC<sub>50</sub> = 3090 pM and 114000 pM, respectively, see <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). It was already observed and discussed in earlier studies (e.g. refs <a onclick="showRef(event, 'ref13 ref40'); return false;" href="javascript:void(0);" class="ref ref13 ref40">(13and40)</a>) that introduction of a fatty acid substituent may provide enhanced activity compared with the natural amino acid, potentially due to stabilization of relevant bioactive conformations, establishment of additional hydrophobic peptideâreceptor interactions or increase of the local peptide concentration in the proximity of membrane-bound receptors due to membrane association.</div></div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Crystal Structure of GLP-1 Receptor Extracellular Domain (ECD)</h3><div class="NLM_p">For experimental validation of the predicted peptide binding mode, crystallization of peptide <b>5</b> in complex with the GLP-1 receptor ECD was attempted. These activities did not produce crystals, presumably due to conformationally flexible regions in the peptide. NMR structure determination (see below) indicated that in particular the N-terminal residues of the peptide (residues 1â8) and the fatty acid substituent in position 14 had high structural flexibility. Guided by analysis of the NMR structure and receptorâpeptide modeling hypothesis, we used the following strategy to design peptide <b>11</b> as a stable variant of peptide <b>5</b> for subsequent crystallization trials: (i) Elimination of residues 1 to 8. The corresponding variant of exendin-4, exendin(9â39), was successfully crystallized in the presence of the GLP-1 receptor ECD.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> This N-terminal truncation was shown to lead to a competitive antagonist (exendin(9â39)), displacing both GLP-1 and exendin-4 from receptor binding.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> (ii) Replacement of the fatty-acid substituted lysine residue in position 14 by a leucine residue, a strategy that has also been applied to obtain a crystal structure for the semaglutide backbone with the GLP-1 receptor ECD.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> (iii) Peptide cyclization by introduction of an intramolecular disulfide bond between residues 18 and 39 (see <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). With peptide <b>11</b>, crystals of the complex with the GLP-1 receptor ECD were obtained that were suitable for X-ray diffraction studies, resulting in a 2.7 Ã crystal structure of the complex (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6gb1">6gb1</a>) as shown in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>a. The region of the N-terminal truncation and the position of the disulfide bridge are indicated. As expected, the resulting complex structure is highly similar to the GLP-1 receptorâexendin(9â39) complex (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3c59">3c59</a>, see three-dimensional alignment in <a href="/doi/suppl/10.1021/acs.jmedchem.8b00292/suppl_file/jm8b00292_si_001.pdf" class="ext-link">Figure S2a</a>). Whereas in the crystal structure of the GLP-1 receptorâexendin(9â39) complex (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3c59">3c59</a>) the C-terminus (residues 36â39) is disordered, these residues are well ordered in our structure, due to the tethering of the C-terminus to the center of the helix by the engineered Cys18âCys39 disulfide link (see <a href="/doi/suppl/10.1021/acs.jmedchem.8b00292/suppl_file/jm8b00292_si_001.pdf" class="ext-link">Figure S2</a>). Surprisingly, there are only two direct hydrogen bonds between the peptide (p) and the receptor (r) between Asp15p â Leu32r and Aib27pâArg121r (not shown). As is shown in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>b, at the âtopâ of the bound peptide, a hydrogen bonding network is present involving the side chains of Glu68r, Arg121r, and Ser32p, the main chain carbonyl oxygens of Phe66r, Asp67r, Leu26p, and Aib27p, and three bound water molecules. However, the majority of the contacts are nonpolar van der Waals interactions, for example, between the residues Phe22, Ile23, Trp25, Leu26, Aib27, and Trp25 of the peptide and hydrophobic regions of the receptor.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-13/acs.jmedchem.8b00292/20180706/images/medium/jm-2018-00292s_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-13/acs.jmedchem.8b00292/20180706/images/large/jm-2018-00292s_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Crystal structure of peptide <b>11</b> in complex with the GLP-1 receptor extracellular domain (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6gb1">6gb1</a>). Peptide residues are colored according to the scheme of <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>. (a) Overall structure. The GLP1 receptor ECD is shown as a white surface, the bound peptide <b>11</b> as a stick model. (b) Close-up of a hydrogen bonding network at the âtopâ of the peptide. This hydrogen bonding network involves the side chains of the receptor residues Glu68 and Arg121 and Ser32 of the peptide, the main chain carbonyl oxygens of the receptor residues Phe66 and Asp67 and of the peptide residues Leu26 and Aib27, and three bound water molecules.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-13/acs.jmedchem.8b00292/20180706/images/large/jm-2018-00292s_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00292&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">This crystal structure is very similar to the ECDâpeptide binding mode of the recently published full-length structure of the GLP-1 receptor in complex with the exendin-4 analogue exendin-P5 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6b3j">6b3j</a>)<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> (see <a href="/doi/suppl/10.1021/acs.jmedchem.8b00292/suppl_file/jm8b00292_si_001.pdf" class="ext-link">Figure S2b</a>). Structural comparison furthermore revealed that the crystal structure of peptide <b>11</b> is nearly identical to the predicted binding mode of peptide <b>5</b> (see <a href="/doi/suppl/10.1021/acs.jmedchem.8b00292/suppl_file/jm8b00292_si_001.pdf" class="ext-link">Figure S3</a>). In summary, these data indicate that our structure-based molecular modeling approach leads to realistic and relevant receptorâpeptide binding modes.</div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Receptor Binding</h3><div class="NLM_p">To further validate the relevance of the binding mode of peptide <b>11</b>, characterization of receptor binding at the GLP-1 receptor was investigated for peptide <b>11</b> and the nontruncated analogue peptide <b>10</b> in a radioligand binding assay using [<sup>125</sup>I]GLP-1 as tracer. Peptide <b>10</b> shows an EC<sub>50</sub> value of 8.0 pM in the functional cAMP assay at the GLP-1 receptor (see <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). Due to truncation of residues 1â8, peptide <b>11</b> does not reveal agonistic activity in the functional cAMP assay (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). The binding data demonstrate that peptide <b>11</b> (IC<sub>50</sub> = 1132.3 nM) is binding in a specific and competitive manner to the GLP-1 receptor. Its binding affinity is, however, significantly (43-fold) lower compared to peptide <b>10</b> (IC<sub>50</sub> = 26.0 nM) (see <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). According to published data, the corresponding truncation results in a lower affinity drop in the case of exendin-4 (leading to the antagonist exendin(9â39))<a onclick="showRef(event, 'ref44 ref45'); return false;" href="javascript:void(0);" class="ref ref44 ref45">(44,45)</a> but a similar or even higher affinity drop in the case of GLP-1 or exendin-4/GLP-1 chimeric peptides.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> These data demonstrate that the N-terminal peptide segment, which is interacting with the transmembrane domain of the receptor, is not only relevant for receptor activation but may also have significant contributions to receptor affinity.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. IC<sub>50</sub> Values with SEM Values and Number of Experiments (<i>n</i>) of Binding Experiments Based on [<sup>125</sup>I]GLP-1 Displacement Studies in GLP-1 Receptor Overexpressing HEK-293 Cell Lines</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">peptide</th><th class="colsep0 rowsep0" align="center" char=".">IC<sub>50</sub> [nM]</th><th class="colsep0 rowsep0" align="center" char=".">SEM</th><th class="colsep0 rowsep0" align="center" char="."><i>n</i></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10</b></td><td class="colsep0 rowsep0" align="char" char=".">26.0</td><td class="colsep0 rowsep0" align="char" char=".">6.2</td><td class="colsep0 rowsep0" align="char" char=".">3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11</b></td><td class="colsep0 rowsep0" align="char" char=".">1132.3</td><td class="colsep0 rowsep0" align="char" char=".">104.2</td><td class="colsep0 rowsep0" align="char" char=".">3</td></tr></tbody></table></div></div></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Solubility Characterization and Optimization of Peptide <b>5</b></h3><div class="NLM_p">In order to provide development candidates that fulfill the desired criteria not only with respect to target activity, it is essential to assess several requirements of the final drug product during compound optimization. Peptide formulations that are intended for subcutaneous application in a multiple-dose pen device require the presence of antimicrobial preservatives, such as <i>m</i>-cresol, phenol, or benzyl alcohol, to prevent the growth of microbes and bacteria that may be introduced from repeated use of the multiple-dose device.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Since peptide <b>5</b> showed the desired activity profile at the GLP-1, glucagon, and GIP receptors, its solubility was tested at a concentration of 10 mg/mL in different buffers at pH 4.5 and pH 7.4 (see <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>), either in the absence or presence of 0.5% phenol as antimicrobial preservative. A good solubility (â¥10 mg/mL) was obtained in both buffers in the absence of phenol. However, solubility significantly decreased at pH 4.5 in the presence of phenol down to 1.2 mg/mL. This solubility behavior is considered as a potential issue, since it might restrict the final peptide formulation to nonacidic pH ranges. In addition, the downstream process of drug substance manufacturing runs at acidic pH at high peptide concentrations. The sensitivity to the presence of aromatic preservatives indicates a certain aggregation propensity at lower pH values.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Solubility Profile of Peptide <b>5</b> in Different Buffers at pH 4.5 and pH 7.4<a class="ref internalNav" href="#tbl4-fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="," /></col><col align="left" /></col><col align="char" char="," /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">buffer</th><th class="colsep0 rowsep0" align="center" char=",">pH</th><th class="colsep0 rowsep0" align="center">preservative</th><th class="colsep0 rowsep0" align="center" char=",">solubility [mg/mL]</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">acetate</td><td class="colsep0 rowsep0" align="char" char=",">4.5</td><td class="colsep0 rowsep0" align="left">none</td><td class="colsep0 rowsep0" align="char" char=",">â¥10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">acetate</td><td class="colsep0 rowsep0" align="char" char=",">4.5</td><td class="colsep0 rowsep0" align="left">0.5% phenol</td><td class="colsep0 rowsep0" align="char" char=",">1.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">phosphate</td><td class="colsep0 rowsep0" align="char" char=",">7.4</td><td class="colsep0 rowsep0" align="left">none</td><td class="colsep0 rowsep0" align="char" char=",">â¥10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">phosphate</td><td class="colsep0 rowsep0" align="char" char=",">7.4</td><td class="colsep0 rowsep0" align="left">0.5% phenol</td><td class="colsep0 rowsep0" align="char" char=",">â¥10</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl4-fn1"><div class="footnote" id="tbl4-fn1"><sup><sup>a</sup></sup><p class="last">Solubility was measured at a peptide concentration of 10 mg/mL in the absence or presence of 0.5% phenol as antimicrobial preservative.</p></div></div></div><div class="NLM_p">Preservative-induced peptide aggregation can lead to immunogenic and toxic side effects in patients. The aggregation event may be induced by weak binding of the preservative to the peptide and favor an increase in the level of partially unfolded, aggregation-competent species.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> Furthermore, addition of preservatives can increase the attractive forces between peptide oligomers, leading to aggregate formation.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Thus, a strategy for optimizing preservative-induced aggregation of a peptide might be (1) stabilization of the native conformation at potential preservative binding sites or (2) introduction of modifications that reduce the binding tendency for preservatives.</div><div class="NLM_p">To eliminate preservative-induced solubility issues for peptide <b>5</b>, a search for potential aggregation hot spots was performed by identifying clusters of hydrophobic residues on the peptide surface that might represent interaction sites for phenolic molecules. As shown in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>a (red color), a region around Trp25 was identified. This aggregation spot includes residues Ala19, Leu21, Phe22, Ile23, Trp25, Leu26, Aib27, Ala28, Gly29, Gly30, Pro31, Gly34, Ala35, and Pro36â38. Several residues in this hydrophobic spot are conserved among incretin peptides (e.g., Phe22, Trp25, Leu26; see <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>) and establish important interactions with their respective receptors. Replacement of these amino acids by polar residues would result in significant activity decrease. According to our binding hypothesis (see <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>a), the C-terminal peptide tail, ranging from residue 30 to 39, points away from the receptor. This sequence stretch forms a stable fold around Trp25 (the tryptophan cage) and was shown to be essential for favorable physicochemical properties of exendin-4 analogues,<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> but data from internal studies and literature demonstrated that it does not significantly impact activity at the receptors.<a onclick="showRef(event, 'ref13 ref31'); return false;" href="javascript:void(0);" class="ref ref13 ref31">(13,31)</a> We were therefore looking for modifications of the C-terminal sequence that would (1) preserve the structural fold of the tryptophan cage, (2) alter the polarity environment in this region, and (3) maintain the activity profile at the GLP-1, glucagon, and GIP receptors. Optimization activities resulted in peptide <b>12</b>, where the following mutations have been introduced into peptide <b>5</b> (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>b and <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>): Ser32Pro, Gly34Aib, Ala35Lys and Ser39Lys. Pro32 and Aib34 are both more conformationally constrained than the corresponding amino acids of peptide <b>5</b> (Ser32 and Gly34). The lysine residues in position 35 and 39 increase charge and reduce hydrophobicity in this region, which is otherwise composed of mainly neutral and hydrophobic amino acids.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-13/acs.jmedchem.8b00292/20180706/images/medium/jm-2018-00292s_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-13/acs.jmedchem.8b00292/20180706/images/large/jm-2018-00292s_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Predicted binding hypothesis of (a) peptide <b>5</b> and (b) peptide <b>12</b> at the GLP-1 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3c59">3c59</a>), glucagon (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ers">4ers</a>), or GIP (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2qkh">2qkh</a>) receptor ECDs. Amino acids that are part of the predicted aggregation hot spot and represent a potential interaction site for phenol, are colored red. Residues that were introduced into peptide <b>12</b> to increase conformational stability or polarity are colored blue or green, respectively.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-13/acs.jmedchem.8b00292/20180706/images/large/jm-2018-00292s_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00292&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Amino Acid Sequences<a class="ref internalNav" href="#tbl5-fn2" aria-label="a">a</a> and EC<sub>50</sub> Values<a class="ref internalNav" href="#tbl5-fn1" aria-label="b">b</a> of Peptides <b>5</b> and <b>12</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-13/acs.jmedchem.8b00292/20180706/images/medium/jm-2018-00292s_0010.gif" alt="" id="gr12" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl5-fn2"><div class="footnote" id="tbl5-fn2"><sup><sup>a</sup></sup><p class="last">Amino acids that are part of the predicted aggregation hot spot and represent a potential interaction site for phenol are colored red. Residues that were introduced into peptide <b>12</b> to increase conformational stability or polarity are colored blue or green, respectively.</p></div><div class="footnote" id="tbl5-fn1"><sup><sup>b</sup></sup><p class="last">Measured in a cAMP assay in receptor overexpressing HEK-293 cell lines.</p></div></div><div></div></div><div class="NLM_p"><i>In vitro</i> testing of peptide <b>12</b> demonstrates that, in agreement with our design rationale, the activity profile at the GLP-1, glucagon, and GIP receptors is nearly identical to that of peptide <b>5</b> (see <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). Furthermore, peptide <b>12</b> showed high solubility (â¥10 mg/mL) at pH 4.5 and pH 7.4 in the absence and, as desired, in the presence of phenol (see <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>).</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Solubility Profile of Peptide <b>12</b> in Different Buffers at pH 4.5 and pH 7.4<a class="ref internalNav" href="#tbl6-fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">buffer</th><th class="colsep0 rowsep0" align="center" char=".">pH</th><th class="colsep0 rowsep0" align="center">preservative</th><th class="colsep0 rowsep0" align="center" char=".">solubility [mg/mL]</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">acetate</td><td class="colsep0 rowsep0" align="char" char=".">4.5</td><td class="colsep0 rowsep0" align="left">none</td><td class="colsep0 rowsep0" align="char" char=".">â¥10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">acetate</td><td class="colsep0 rowsep0" align="char" char=".">4.5</td><td class="colsep0 rowsep0" align="left">0.5% phenol</td><td class="colsep0 rowsep0" align="char" char=".">â¥10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">phosphate</td><td class="colsep0 rowsep0" align="char" char=".">7.4</td><td class="colsep0 rowsep0" align="left">none</td><td class="colsep0 rowsep0" align="char" char=".">â¥10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">phosphate</td><td class="colsep0 rowsep0" align="char" char=".">7.4</td><td class="colsep0 rowsep0" align="left">0.5% phenol</td><td class="colsep0 rowsep0" align="char" char=".">â¥10</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl6-fn1"><div class="footnote" id="tbl6-fn1"><sup><sup>a</sup></sup><p class="last">Solubility was measured at a peptide concentration of 10 mg/mL in the absence or presence of 0.5% phenol as antimicrobial preservative.</p></div></div></div></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> NMR Structure of Peptides <b>5</b> and <b>12</b> in Solution</h3><div class="NLM_p">We performed NMR studies to investigate the structural preferences of peptides <b>5</b> and <b>12</b> in solution. Three dimensional structures were determined by restrained molecular dynamics (MD) simulations and energy minimization, imposing distance constraints obtained from NOESY spectra (<a href="/doi/suppl/10.1021/acs.jmedchem.8b00292/suppl_file/jm8b00292_si_001.pdf" class="ext-link">Tables S1âS4</a>). In total, 402 distance constraints were obtained from analysis of the NOESY spectra for peptide <b>5</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.8b00292/suppl_file/jm8b00292_si_001.pdf" class="ext-link">Table S2</a>) and 360 distance constraints were obtained for peptide <b>12</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.8b00292/suppl_file/jm8b00292_si_001.pdf" class="ext-link">Table S4</a>) and used for the MD simulation.</div><div class="NLM_p">Overall, peptides <b>5</b> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6gdz">6gdz</a>) and <b>12</b> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6ge2">6ge2</a>) show high structural similarity to exendin-4 (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>a,b), although both peptides differ in 10 or 14 positions from exendin-4 (see <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>). Of particular note and in full agreement with our design rationales, the solution NMR structure of peptide <b>5</b> reveals a high similarity to our receptor-bound modeling hypothesis (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>) and receptor-bound conformation of peptide <b>11</b>, which was obtained by X-ray diffraction studies (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). A three-dimensional alignment of these peptides onto the receptor-bound conformation of peptide <b>11</b> is provided in <a href="/doi/suppl/10.1021/acs.jmedchem.8b00292/suppl_file/jm8b00292_si_001.pdf" class="ext-link">Figure S2</a>.</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-13/acs.jmedchem.8b00292/20180706/images/medium/jm-2018-00292s_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-13/acs.jmedchem.8b00292/20180706/images/large/jm-2018-00292s_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (a) NMR ensemble structures of peptide <b>5</b> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6gdz">6gdz</a>), peptide <b>12</b> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6ge2">6ge2</a>), and exendin-4 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1jrj">1jrj</a>) in solution. For structural clarity, only heavy atoms are depicted. Side-chain atoms of residue 14 (palmitic acid linked to the Îµ-amino group of lysine using two Î³-glutamic acid spacers) of peptides <b>5</b> and <b>12</b> are indicated in gray. (b) 3D-alignment of NMR structures of peptide <b>5</b>, peptide <b>12</b>, and exendin-4. (c) Magnified view of 3D-alignment of the tryptophan cage of peptides <b>5</b> and <b>12</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-13/acs.jmedchem.8b00292/20180706/images/large/jm-2018-00292s_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00292&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Sequences of Exendin-4 and Peptides <b>5</b> and <b>12</b><a class="ref internalNav" href="#tbl7-fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-13/acs.jmedchem.8b00292/20180706/images/medium/jm-2018-00292s_0011.gif" alt="" id="gr14" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl7-fn1"><div class="footnote" id="tbl7-fn1"><sup><sup>a</sup></sup><p class="last">Amino acid differences from exendin-4 are indicated by different colors.</p></div></div><div></div></div><div class="NLM_p">Our 3D-modeling hypothesis (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>) suggests that the C-terminal modifications introduced into positions 32, 34, 35, and 39 of peptide <b>5</b> have only minor effects on the structural preferences of the tryptophan cage, which seemed to be confirmed by the fact that the activity profile at the target receptors remained nearly identical. <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>b shows a superposition of NMR conformers of peptide <b>5</b> (10 conformers), peptide <b>12</b> (10 conformers), and exendin-4 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1jrj">1jrj</a>, 36 conformers). For all peptides, a certain degree of structural flexibility is observed in the N-terminal region (residues 1â10), whereas the upper part of the helix and, in particular, the tryptophan cage motif show very high structural stability. A very high degree of flexibility is observed for the fatty acid side chain in position 14 for peptides <b>5</b> and <b>12</b>. No NOEs were observed between the fatty acid side chain and any other amino acid of the peptide.</div><div class="NLM_p last">Two further observations and conclusions can be derived from the structural alignment shown in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>c: (1) Backbone conformation around residue 27 is nearly identical between exendin-4 and peptides <b>5</b> and <b>12</b>, indicating that the amino acid difference in this position (lysine in exendin-4, Aib in peptide <b>5</b> and <b>12</b>) does not alter the conformational preference in this region. The mutation Lys27Aib (see peptide <b>6</b> versus peptide <b>5</b> in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>) was shown to reduce activity at the glucagon (factor 6) and GIP receptor (factor 9) while maintaining activity at the GLP-1 receptor. These activity differences are obviously caused by differential interactions with the receptors as indicated in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a> and are not due to changes in backbone conformation. (2) The modifications introduced in the C-terminal peptide tail (peptide <b>5</b> versus <b>12</b>) have an effect on the conformation of the tryptophan cage. Whereas the C-terminal sequence stretch (residues 30â39) of peptide <b>5</b> aligns nearly perfectly with exendin-4 (CÎ± rmsd = 1.1 Ã, standard deviation 0.3 Ã), peptide <b>12</b> shows a larger deviation (CÎ± rmsd = 3.4 Ã, standard deviation 0.3 Ã). Notably, these conformational differences in the C-terminal tail do not impact the helical part or the conformational stability of peptide <b>12</b>.</div></div><div id="sec2_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> <i>In Vivo</i> Evaluation in Monkeys</h3><div class="NLM_p">The above-described dual GLP-1/glucagon receptor agonist peptide <b>12</b> was evaluated in a 6-week multiple dose study in obese diabetic monkeys following once-daily subcutaneous dosing. The marketed selective GLP-1 receptor agonist liraglutide was used as reference compound. Liraglutide carries, as does peptide <b>12</b>, a fatty acid side chain, leading to a significantly prolonged exposure and duration of action when compared with the natural hormones GLP-1, glucagon, oxyntomodulin, or exendin-4.</div><div class="NLM_p">For pharmacological interpretation, agonist activities of peptide <b>12</b>, liraglutide, and the natural hormones GLP-1 and glucagon were determined at the monkey and human GLP-1, glucagon, and GIP receptors (<a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a></a>). Potency is rather conserved for the GLP-1 receptors across both species. Both natural glucagon and peptide <b>12</b> show a somewhat lower activity at the monkey versus human glucagon receptor (factor 3 for glucagon and factor 4 for peptide <b>12</b>). Thus, in terms of relative potency (i.e., receptor potency versus the natural hormone), peptide <b>12</b> shows a similar GLP-1/glucagon activity preference in humans as in monkeys.</div><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. EC<sub>50</sub> Values<a class="ref internalNav" href="#tbl8-fn1" aria-label="a">a</a> of Peptides at the Monkey or Human Receptors</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Â </th><th class="rowsep1 colsep0" colspan="3" align="center" char=".">EC<sub>50</sub> monkey [pM]</th><th class="rowsep1 colsep0" colspan="3" align="center" char=".">EC<sub>50</sub> human [pM]</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">peptide</th><th class="colsep0 rowsep0" align="center" char=".">GLP-1R</th><th class="colsep0 rowsep0" align="center">GCGR</th><th class="colsep0 rowsep0" align="center">GIPR</th><th class="colsep0 rowsep0" align="center" char=".">GLP-1R</th><th class="colsep0 rowsep0" align="center">GCGR</th><th class="colsep0 rowsep0" align="center">GIPR</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12</b></td><td class="colsep0 rowsep0" align="char" char=".">2.0Â Â±Â 0.2 (3)</td><td class="colsep0 rowsep0" align="left">129Â Â±Â 9.0 (3)</td><td class="colsep0 rowsep0" align="left">2050Â Â±Â 146 (3)</td><td class="colsep0 rowsep0" align="char" char=".">1.8Â Â±Â 0.3 (3)</td><td class="colsep0 rowsep0" align="left">29Â Â±Â 2.1 (3)</td><td class="colsep0 rowsep0" align="left">2032Â Â±Â 172 (3)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">liraglutide</td><td class="colsep0 rowsep0" align="char" char=".">4.1Â Â±Â 0.4 (3)</td><td class="colsep0 rowsep0" align="left">>1.0Â ÃÂ 10<sup>8</sup> (3)</td><td class="colsep0 rowsep0" align="left">>1.0Â ÃÂ 10<sup>8</sup> (3)</td><td class="colsep0 rowsep0" align="char" char=".">6.4Â Â±Â 0.7 (3)</td><td class="colsep0 rowsep0" align="left">>1.0Â ÃÂ 10<sup>8</sup> (3)</td><td class="colsep0 rowsep0" align="left">>1.0Â ÃÂ 10<sup>8</sup> (3)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GLP-1</td><td class="colsep0 rowsep0" align="char" char=".">1.1Â Â±Â 0.04 (35)</td><td class="colsep0 rowsep0" align="left">>1.0Â ÃÂ 10<sup>8</sup> (3)</td><td class="colsep0 rowsep0" align="left">>1.0Â ÃÂ 10<sup>8</sup> (3)</td><td class="colsep0 rowsep0" align="char" char=".">0.9Â Â±Â 0.05 (38)</td><td class="colsep0 rowsep0" align="left">>1.0Â ÃÂ 10<sup>8</sup> (3)</td><td class="colsep0 rowsep0" align="left">>1.0Â ÃÂ 10<sup>8</sup> (3)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">glucagon</td><td class="colsep0 rowsep0" align="char" char=".">30.8Â Â±Â 1.3 (42)</td><td class="colsep0 rowsep0" align="left">1.5Â Â±Â 0.04 (60)</td><td class="colsep0 rowsep0" align="left">>1.0Â ÃÂ 10<sup>8</sup> (3)</td><td class="colsep0 rowsep0" align="char" char=".">43.9Â Â±Â 2.2 (59)</td><td class="colsep0 rowsep0" align="left">0.5Â Â±Â 0.05 (180)</td><td class="colsep0 rowsep0" align="left">>1.0Â ÃÂ 10<sup>8</sup> (3)</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl8-fn1"><div class="footnote" id="tbl8-fn1"><sup><sup>a</sup></sup><p class="last">Measured in a cAMP assay in receptor overexpressing HEK-293 cell lines stably expressing GLP-1, glucagon or GIP receptor. Values are mean Â± SEM. Number of measurements is given in parentheses.</p></div></div></div><div class="NLM_p">Liraglutide and peptide <b>12</b> were dosed once daily to ensure sufficient and approximately continuous plasma levels repeatedly over the study duration of 6 weeks. To reduce the well-known gastrointestinal side effects like nausea and vomiting, GLP-1 receptor agonists are dose-ramped in humans.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> We used a similar up-titration protocol, considering the impact on total energy intake as a major indicator for tolerability. Liraglutide was dose-ramped from 10 to 40 Î¼g/kg, and peptide <b>12</b> was ramped from 1.5 to 8 Î¼g/kg (see <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>). While vehicle-treated monkeys lost 2.1% Â± 0.74% of body weight during the study, liraglutide treatment led to a weight loss of 4.9% Â± 1.0% (not significant). The dual GLP-1/glucagon receptor agonist peptide <b>12</b> had the highest impact and decreased body weight by 6.9% Â± 1.1% (<i>P</i> < 0.01, <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>).</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-13/acs.jmedchem.8b00292/20180706/images/medium/jm-2018-00292s_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-13/acs.jmedchem.8b00292/20180706/images/large/jm-2018-00292s_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Absolute body weight (top) and relative body weight change (bottom) in obese diabetic cynomolgus monkeys during study period. Values are mean Â± SEM, <i>n</i> = 8â10/group. ##<i>P</i> < 0.01 peptide <b>12</b> versus vehicle control. Liraglutide was dosed during the dose-ramping period from 10 (day 1â3) to 20 (day 4â6) to 30 Î¼g/kg (day 7â9) and was maintained at 40 Î¼g/kg sc from day 10 to completion of the study. Peptide <b>12</b> was dosed during the dose-ramping period from 1.5 (day 1â3) to 3 (day 4â6) to 4.5 (day 7â9) to 6 Î¼g/kg (day 10â17) and was maintained at 8 Î¼g/kg sc from day 18 to completion of the study.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-13/acs.jmedchem.8b00292/20180706/images/large/jm-2018-00292s_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00292&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Pharmacokinetic analysis on day 43 showed that the 40 Î¼g/kg daily dose of liraglutide translated into a 14-fold higher exposure than the 8 Î¼g/kg daily dose of peptide <b>12</b> as estimated by AUC comparison (see <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>). The liraglutide AUC in monkeys is somewhat higher than the AUC observed in human clinical trials for liraglutide 3.0 mg, confirming that the up-titration scheme leads to the identification of relevant doses.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a></div><div class="NLM_table-wrap" id="tbl9"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 9. Plasma Drug Concentration (ng/mL) on Day 43 after Administration of 8 Î¼g/kg sc of Peptide <b>12</b> and 40 Î¼g/kg sc of Liraglutide<a class="ref internalNav" href="#tbl9-fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Â </th><th class="rowsep1 colsep0" colspan="6" align="center" char=".">hours postdosing</th><th class="colsep0 rowsep0" align="center" char=".">Â </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">peptide</th><th class="colsep0 rowsep0" align="center" char=".">0</th><th class="colsep0 rowsep0" align="center" char=".">1</th><th class="colsep0 rowsep0" align="center" char=".">2</th><th class="colsep0 rowsep0" align="center" char=".">4</th><th class="colsep0 rowsep0" align="center" char=".">8</th><th class="colsep0 rowsep0" align="center" char=".">22</th><th class="colsep0 rowsep0" align="center" char=".">AUC<sub>0â22</sub> (hÂ·ng/mL)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12</b></td><td class="colsep0 rowsep0" align="char" char=".">0.66</td><td class="colsep0 rowsep0" align="char" char=".">21.6Â Â±Â 2.4</td><td class="colsep0 rowsep0" align="char" char=".">28.0Â Â±Â 2.9</td><td class="colsep0 rowsep0" align="char" char=".">24.3Â Â±Â 3.1</td><td class="colsep0 rowsep0" align="char" char=".">12.4Â Â±Â 2.3</td><td class="colsep0 rowsep0" align="char" char=".">0.69</td><td class="colsep0 rowsep0" align="char" char=".">254</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">liraglutide</td><td class="colsep0 rowsep0" align="char" char=".">87.8Â Â±Â 17.2</td><td class="colsep0 rowsep0" align="char" char=".">145.0Â Â±Â 24.6</td><td class="colsep0 rowsep0" align="char" char=".">206.0Â Â±Â 36.7</td><td class="colsep0 rowsep0" align="char" char=".">279.0Â Â±Â 51.0</td><td class="colsep0 rowsep0" align="char" char=".">184.0Â Â±Â 31.4</td><td class="colsep0 rowsep0" align="char" char=".">93.7Â Â±Â 19.9</td><td class="colsep0 rowsep0" align="char" char=".">3580</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl9-fn1"><div class="footnote" id="tbl9-fn1"><sup><sup>a</sup></sup><p class="last">Values are mean Â± SEM, <i>n</i> = 8â10/group.</p></div></div></div><div class="NLM_p">Measurements of the long-term blood glucose marker %HbA<sub>1C</sub> were performed on day â25 to obtain baseline values and on day +43 following chronic treatment. While HbA<sub>1C</sub> in the vehicle-treated group slightly increased during the study period (increase from 6.4% Â± 0.5% to 6.9% Â± 0.5%), liraglutide treatment improved HbA<sub>1C</sub> (8.3% Â± 0.6% at baseline to 7.8% Â± 0.6%, not significant). A significant decrease and therefore improvement in HbA<sub>1C</sub> was observed in monkeys treated with peptide <b>12</b>, clearly superior to liraglutide (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>, <i>P</i> < 0.001): baseline value of 8.7% Â± 0.8% declined to 7.1% Â± 0.7% on day +43. These findings suggest that the 10â15-fold weaker glucagon versus GLP-1 receptor activity of the dual agonist peptide <b>12</b> does not negatively impact GLP-1 receptor mediated glucose control.</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-13/acs.jmedchem.8b00292/20180706/images/medium/jm-2018-00292s_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-13/acs.jmedchem.8b00292/20180706/images/large/jm-2018-00292s_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. HbA<sub>1C</sub> determination after 43 days of chronic treatment in obese diabetic cynomolgus monkeys compared to baseline according to the dosing scheme as described in <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>. Values are mean Â± SEM, <i>n</i> = 8â10/group. ***<i>P</i> < 0.001 versus baseline.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-13/acs.jmedchem.8b00292/20180706/images/large/jm-2018-00292s_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00292&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i23">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_25453" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_25453" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Several dual GLP-1/glucagon receptor agonists have entered clinical trials for the treatment of obese patients with T2D and are assessed to show improved therapeutic benefits versus sole GLP-1 receptor agonists. The key question to be still answered is the optimal ratio of relative GLP-1/glucagon receptor activities to optimize beneficial weight loss efficacy without negatively elevating blood glucose due to excessive glucagon pharmacology. Day and colleagues recommended that the relative ratio of GLP-1 and glucagon dual agonism needs to be carefully selected for each species. It was shown in mice that a rather GLP-1 receptor biased agonistic ratio leads to weight loss and glucose lowering. On the other hand, extensive enhancement of the relative glucagon receptor agonistic potency yielded greater weight loss but at the expense of considerable glucose elevation.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a></div><div class="NLM_p">The goal of the present study was the design of a dual agonist candidate with a 10â15-fold higher GLP-1 receptor activity compared to the glucagon receptor activity for chronic pharmacological evaluation with respect to weight loss and glucose control in monkeys, a relevant translational model for the human situation. In this study, daily administration of the dual GLP-1/glucagon receptor agonist peptide <b>12</b> at a 5-fold lower dose compared to the selective GLP-1 receptor agonist liraglutide (8 versus 40 Î¼g/kg, sc) produced higher body weight loss. Body weight reduction and HbA<sub>1C</sub> improvement was greater despite a 14-fold lower exposure of the dual agonist at the highest dose tested. These findings indicate that the relatively low glucagon versus GLP-1 activity of peptide <b>12</b> does not negatively impact the favorable effects on glycemic control of the GLP-1 component. Hence, the relative glucagon receptor activity of a dual agonist might be further increased for additional glucagon-receptor mediated weight loss. We have conducted further detailed monkey studies on a peptide with a higher relative glucagon receptor activity than peptide <b>12</b> to address the important question on how much glucagon activation provides beneficial effects in total, which will be published in due time (Elvert et al. 2018, manuscript submitted). The therapeutic potential of dual GLP-1/glucagon receptor agonists will certainly depend on the question in how far the efficacy with respect to body weight reduction exceeds the benefits of marketed GLP-1 receptor agonists without impacting glucoregulatory effects in humans. Several dual GLP-1/glucagon coagonists are undergoing clinical testing,<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> and the confirmation of their potential in human proof of concept (POC) studies is urgently awaited.</div><div class="NLM_p">Besides these pharmacological aspects, we have demonstrated how peptide optimization of solubility aspects under relevant conditions of the targeted formulation (e.g., with respect to the application pH range and the presence of antimicrobial preservatives) should be considered as an additional attribute in rational multiparameter optimization. Molecular modeling, experimental structure determination, and SAR analysis were used to introduce a novel solubility-enhancing motif (Pro32-Aib34-Lys35-Lys39) that significantly improved solubility in the presence of phenol as preservative at different pH values while maintaining the favorable receptor activity profile.</div><div class="NLM_p last">Overall, peptide <b>12</b> with its promising pharmacological profile and well optimized solubility properties was suitable for entry into preclinical development.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i24">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_67050" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_67050" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> Homology Modeling of Peptides and Generation of Peptide Binding Hypotheses at the Receptors (ECD)</h3><div class="NLM_p last">ECDs of the GLP-1 receptor (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3c59">3c59</a>), glucagon receptor (GCGR, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ers">4ers</a>), and GIP receptor (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2qkh">2qkh</a>) were structurally aligned. The NMR structure of exendin-4 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1jrj">1jrj</a>) was then structurally superimposed to receptor-bound exendin(9â39) (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3c59">3c59</a>), followed by energy minimization of the receptorâpeptide complex. Structural models of peptides were generated by homology modeling, using the predicted binding mode of exendin-4 as structural template. For this purpose, a customized routine that allows us to consider unnatural and modified amino acids was used that has been implemented by Schrodinger. Subsequently, the peptides were minimized in the rigid GLP-1 receptor extracellular domain structure using MacroModel.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> Molecular graphics were generated using PyMol.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a></div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> Synthesis of Peptides</h3><div class="NLM_p last">Solid phase synthesis was carried out on Rink-resin (e.g., from Agilent Technologies with a loading of 0.38 mmol/g, 75â150 Î¼m). The Fmoc-synthesis strategy was applied with HBTU/DIPEA activation. For analogs with fatty acid side chains, in position 14 <i>N</i>-Î±-1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)-3-methylbutyl-<i>N</i>-Îµ-Fmoc-<span class="smallcaps smallerCapital">l</span>-lysine (Fmoc-Lys(ivDde)-OH) and in position 1 <i>N</i><sub>Î±</sub>-Boc-<i>N</i><sub>(im)</sub>-trityl-<span class="smallcaps smallerCapital">l</span>-histidine (Boc-His(Trt)-OH) were used in the solid phase synthesis protocol. The ivDde-group was cleaved from the peptide on resin using hydrazine in DMF according to literature.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> Hereafter, the respective lipophilic side chain was coupled to the liberated amino group using preactivated <i>N</i>-hydroxysuccinimide ester derivatives (e.g., Stea(Î³OSu)(Î±OtBu)Glu) or the side chain was built up stepwise using Fmoc-protected building blocks. The peptide was cleaved from the resin with Kingâs cocktail.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> The crude product was purified via preparative HPLC on a Waters column (e.g., XBridge, BEH130, Prep C18, 5 Î¼M) using an acetonitrile/water gradient (both buffers with 0.1% TFA). Purity and chemical identity of the product were assessed by UPLC and LC-MS (for details see <a href="/doi/suppl/10.1021/acs.jmedchem.8b00292/suppl_file/jm8b00292_si_001.pdf" class="ext-link">Table S5</a>) and confirmed to have â¥95% purity for all key compounds.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> <i>In Vitro</i> Cellular Assays for GLP-1, Glucagon and GIP Receptor Potency</h3><div class="NLM_p last">Agonism of peptides for the three receptors was determined by functional assays measuring cAMP response of HEK-293 cell lines stably expressing human or monkey GLP-1, glucagon, or GIP receptor. cAMP content of cells was determined using a kit from Cisbio Corp. (cat. no. 62AM4PEC) based on HTRF (homogenous time resolved fluorescence). For preparation, cells were split into T175 culture flasks and grown overnight to near confluence in medium (DMEM/10% FBS). Medium was then removed, and cells were washed with PBS lacking calcium and magnesium, followed by proteinase treatment with accutase (Sigma-Aldrich cat. no. A6964). Detached cells were washed and resuspended in assay buffer (1Ã HBSS; 20 mM HEPES, 0.1% BSA, 2 mM IBMX), and cellular density was determined. They were then diluted to 400â¯000 cells/mL, and 25 Î¼L aliquots were dispensed into the wells of 96-well plates. For measurement, 25 Î¼L of test compound in assay buffer was added to the wells, followed by incubation for 30 min at room temperature. After addition of HTRF reagents diluted in lysis buffer (kit components), the plates were incubated for 1 h, followed by measurement of the fluorescence ratio at 665/620 nm. <i>In vitro</i> potency of agonists was quantified by determining the concentrations that caused 50% activation of maximal response (EC<sub>50</sub>). Reported values are mean (SEM) EC<sub>50</sub> (pM) from <i>n</i> â¥ 3 independent experiments.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> Crystallization and Structure Determination</h3><div class="NLM_p last">A 6-fold excess of peptide <b>11</b> was dissolved in a solution of 12 mg/mL GLP-1 receptor-ECD in 10 mM Tris buffer, pH 7.5, 100 mM sodium sulfate, and 2% glycerol. This protein solution (100 nL) and 100 nL of reservoir solution were equilibrated against reservoir solution consisting of 10 mM CoCl<sub>2</sub>, 9.4% (v/v) 1,6-hexanediol, and 100 mM sodium acetate, pH 4.8. Crystals appeared after about 1 week. A crystal was picked up with a nylon loop that just had been dipped in glycerol and flash frozen in liquid nitrogen. X-ray diffraction data were collected at beamline PX-II of the Swiss Light Source (SLS) in Villigen, Switzerland, and processed with XDS<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> and scaled with Aimless<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> as implemented in AutoPROC.<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> The crystal was of space group <i>P</i>4<sub>3</sub>2<sub>1</sub>2 and contained one peptideâGLP-1 receptor ECD complex in the asymmetric unit. The unit cell dimensions of this crystal are as follows: <i>a</i> = <i>b</i> = 55.6 Ã and <i>c</i> = 138.8. The crystal diffracted to 2.73 Ã resolution, and the <i>R</i><sub>mean</sub> was 8.1%. The structure was solved by molecular replacement with Phaser,<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> using a single monomer from PDB entry <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3c59">3c59</a> as a starting model. Clear density was present for the bound peptide (see <a href="/doi/suppl/10.1021/acs.jmedchem.8b00292/suppl_file/jm8b00292_si_001.pdf" class="ext-link">Figure S1</a>). Model building was done with Coot,<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> and refinement was done with Buster.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> The final - was 20.6% and the free R-factor was 26.3%. Final data collection and refinement statistics are given in <a href="/doi/suppl/10.1021/acs.jmedchem.8b00292/suppl_file/jm8b00292_si_001.pdf" class="ext-link">Table S6</a>.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> Radioligand Binding Assay</h3><div class="NLM_p last">The radioligand [<sup>125</sup>I]GLP-1 was purchased from PerkinElmer, USA. Cell membranes from HEK-293 cells expressing recombinant human GLP-1 receptors were used in the binding assays as follows. PVT-WGA SPA beads (0.125 mg/well, cat. no. RPNQ0001, PerkinElmer) coated with HEK-293 cells membranes (1 Î¼g/well of protein) were incubated for 60 min at room temperature in HEPES buffer (20 mM HEPES, 1 mM EDTA, 150 mM NaCl, 5 mM MgCl<sub>2</sub>, and 1 mM CaCl<sub>2</sub> (pH 7.4), with protease inhibitors and 0.1% BSA) with radiolabeled peptide (0.1 nM) in the absence and presence of a range of concentrations of unlabeled peptide. After incubation, the 96-well assay plate (cat. no. 3604, Corning), was read in a Wallac Microbeta plate reader (PerkinElmer) after a 180 min delay to measure cell membrane-associated radioactivity. Specific binding was calculated as the difference between the amount of [<sup>125</sup>I]GLP-1 bound in the absence (total binding) and presence (nonspecific binding) of 1 Î¼M unlabeled exendin-4, respectively. Each condition was measured in triplicate, and reported values are mean IC<sub>50</sub> (nM) from <i>n</i> = 3 independent experiments.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> Solubility Testing</h3><div class="NLM_p last">Prior to the solubility measurement of a peptide batch, its content was determined via UPLC-MS (% purity) and ion chromatography (both cations and anions). For solubility testing the target concentration was 10 mg of pure compound per milliliter. Therefore solutions from solid samples were prepared in a buffer system with a concentration of 10 mg/mL compound based on the previously determined content. The sample was gently agitated for 2 h, and UPLC-UV was performed from the supernatant, which was obtained by centrifugation (15 min at 3000 relative centrifugal force, rcf) and consecutive 1:10 dilution with the respective buffer. Solubility buffer system were (1) acetate buffer, pH 4.5, 100 mM sodium acetate trihydrate, or (2) phosphate buffer, pH 7.4, 100 mM sodium hydrogen phosphate, either with or without 0.5% phenol. The solubility was then determined by comparison of the UV peak area observed at a 2 Î¼L injection of the diluted sample with UV areas of the respective peptide in DMSO (1.2 mg/mL based on the previously determined content) in a standard curve obtained from various injection volumes ranging from 0.2 Î¼L to 2 Î¼L.</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> NMR</h3><div class="NLM_p last">Peptides <b>5</b> and <b>12</b> gave rise to NMR spectra of high quality using a solution of ca. 6 mg/mL peptide in 70% 100 mM phosphate buffer, pH 5.0, H<sub>2</sub>O/D<sub>2</sub>O (9:1), and 30% trifluoroethanol (TFE) at 313 K. Based on the analysis of several 2D-spectra including DQF-COSY, TOCSY, NOESY, <sup>1</sup>H,<sup>15</sup>N-HSQC, and <sup>1</sup>Hâ<sup>13</sup>C-HSQC a complete assignment of <sup>1</sup>H chemical shifts was achieved (see <a href="/doi/suppl/10.1021/acs.jmedchem.8b00292/suppl_file/jm8b00292_si_001.pdf" class="ext-link">Tables S2 and S4</a>). Distance constraints were obtained from NOESY spectra (mixing time was 200 ms) recorded in a mixture of 350 Î¼L of H<sub>2</sub>O/D<sub>2</sub>O, 50 mM phosphate buffer, pH 5.0, and 150 Î¼L of TFE at 313 K. NOEs among protons of side chains have been obtained from NOESY spectra recorded in a mixture of 350 Î¼L of D<sub>2</sub>O, 50 mM phosphate buffer, pH 5.0, and 150 Î¼L of TFE at 313 K (mixing time was 200 ms). The 3D-structures of peptides <b>5</b> and <b>12</b> have been determined by restrained molecular dynamics calculations and energy minimization. Molecular dynamics (MD) simulations and interactive modeling were performed using the software package SYBYL, version 2.1.1. All energy calculations were based on the Tripos force field. For energy minimizations, the Powell method was used. The analysis of the NMR-derived distance restraints was carried out with SPL (<i>Sybyl Programming Language</i>) scripts. For peptide <b>5</b>, the experimental data set used as input for the MD calculations included 402 distance constraints including 48 intraresidual distances, 134 sequential distances, 153 medium distances (2â4 amino acids apart), and 67 long-range distances (>4 amino acids apart). Upper and lower distance limits were set to plus and minus 10% of the calculated (experimental) distances, respectively. For nondiastereotopically assigned methylene protons and methyl groups, 0.9 and 1.0 Ã, respectively were added to the upper bounds as pseudo-atom corrections. The set of utilized distance constraints is summarized in <a href="/doi/suppl/10.1021/acs.jmedchem.8b00292/suppl_file/jm8b00292_si_001.pdf" class="ext-link">Table S2</a>. Dihedral angle constraints and hydrogen bond constraints have not been used. A homology model derived from the NMR structure of exendin-4 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1jrj">1jrj</a>) was used as starting structure. The NOE derived distance constraints were applied with a force constant of 41.9 kJ/molÂ·Ã<sup>2</sup>. The MD simulation was performed in a water box using 6727 explicit water molecules. In the production run at 300 K, conformers were sampled every 50 ps for a duration of 1000 ps yielding a total of 20 structures. The obtained structures were energy-minimized (1000 steps). The 10 structures with the lowest constraint violation were used for further analyses. The average constraint violation is 0.11 Ã. Only 6 constraints are violated by more than 0.6 Ã, the largest violation is 0.73 Ã. Considering only residues 7â37 the rmsd over all backbone atoms (N, NH, CÎ±, HÎ±, Câ², O) is 0.56 Ã with a standard deviation of 0.14 Ã. For the same residues (residue 14 has been excluded), the rmsd over all heavy atoms is 0.80 Ã with a standard deviation of 0.12 Ã. The 3D-structure of peptide <b>12</b> was determined in the same way. For peptide <b>12</b>, the experimental data set used as input for the MD calculations included 361 distance constraints including 55 intra residual distances, 114 sequential distances, 155 medium distances (2â4 amino acids apart), and 37 long-range distances (>4 amino acids apart). The set of utilized distance constraints is summarized in <a href="/doi/suppl/10.1021/acs.jmedchem.8b00292/suppl_file/jm8b00292_si_001.pdf" class="ext-link">Table S4</a>. The MD simulation was performed in a water box using 5760 explicit water molecules. In the production run at 300 K, conformers were sampled every 50 ps for a duration of 1000 ps yielding a total of 20 structures. The 10 structures with the lowest constraint violation were used for further analyses. The average constraint violation is 0.15 Ã. Nineteen constraints are violated by more than 0.6 Ã; the largest violation is 0.84 Ã. Considering only residues 7â37, the rmsd over all backbone atoms (N, NH, CÎ±, HÎ±, Câ², O) is 0.65 Ã with a standard deviation of 0.19 Ã. For the same residues (residue 14 has been excluded), the rmsd over all heavy atoms is 0.98 Ã with a standard deviation of 0.24 Ã.</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> DIO Monkey Study</h3><div class="NLM_p">The monkey study was performed at Kunming Biomed International (KBI, Yunnan Province, China). KBI adheres to the guidelines for the care and use of animals for scientific purposes established by Chinese National Advisory Committee for Laboratory Animal Research (NACLAR) as well as the safety and quality assurance guidelines documented in the Guideline for Experiments Document of Kunming Biomed International (KBI-01-GE v2.0). These guidelines set out the responsibilities of all parties involved in the care and use of animals for scientific purposes in accordance with widely accepted scientific, ethical, and legal principles. The guidelines stipulating the proposed use of animals for scientific purposes must be evaluated by an Institutional Animal Care and Use Committee (IACUC) in compliance with the guidelines. This study was approved by the Institutional Animal Care and Use Committee (IACUC) of KBI prior to start of the experimental phase. The cynomolgus monkey (<i>Macaca fascicularis</i>) was selected as the test species. Up to fifty-one (<i>n</i> = 51) monkeys were trained in order to identify 30 monkeys (<i>n</i> = 8â10 per group) that were used in chronic treatment phase and fulfill metabolic criteria: weighing at least 8â16 kg, age of 12â20 years, fasting glucose >110 mg/dL, and fasting insulin of >70 Î¼U/mL. Monkeys were individually housed in species- and size-appropriate metabolic stainless steel caging. A time controlled lighting system was used (lights on 7:00 am to 7:00 pm) to provide a regular 12-h light/12-h dark diurnal cycle. Monkeys were provided three meals per day with ad libitum access to water. The total offered amount of daily energy was about 680 kcal. Animals were stratified by randomized block stratification into 3 homogeneous groups according body weight, fasted plasma glucose, and %HbA<sub>1C</sub>. During the entire dosing period food and water intake was monitored daily, and body weight was measured every 3â4 days. Two monkeys within the vehicle group were found to be undergoing weight loss despite normal (high) food intake throughout the study. Both were considered advanced diabetic-insulin requiring and were excluded from final data analysis. Therefore baseline mean values for the vehicle treated monkeys were lower compared to treatment groups. Liraglutide was purchased directly from Novo Nordisk distributors in Beijing and Kunming and stored at 4 Â°C in accordance with manufacturer requirements. Victoza pens contain liraglutide at a concentration of 6 mg/mL. The solution was diluted to the desired concentrations of 100, 200, 400 Î¼g/mL using a PBS vehicle solution. Liraglutide was dosed during the dose-ramping period from 10 (day 1â3) to 20 (day 4â6) to 30 Î¼g/kg (day 7â9) and was maintained at 40 Î¼g/kg sc (in 0.1 mL/kg of formulation) from day 10 to completion of the study. Peptide <b>12</b> was diluted with a PBS vehicle volume adjusted for the specific mass of the peptide. It was dosed during the dose-ramping period from 1.5 (day 1â3) to 3 (day 4â6) to 4.5 (day 7â9) to 6 Î¼g/kg (day 10â17) and was maintained at 8 Î¼g/kg sc from day 18 to completion of the study.</div><div id="sec4_8_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> Pharmacokinetics</h4><div class="NLM_p last">Blood samples for PK analysis were collected on day 43 directly before and 1, 2, 4, 8, and 22 h postdosing. The samples were directly transferred into potassium ethylene diamine tetraacetic acid (EDTA-2K) tubes. Plasma was separated by centrifugation at 2500 Ã <i>g</i> for 10 min at 4 Â°C. Plasma samples were analyzed after protein precipitation via liquid chromatography mass spectrometry (LC-MS) for the dual agonist and by ELISA for liraglutide.</div></div><div id="sec4_8_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> Statistical Analysis</h4><div class="NLM_p last">All <i>in vivo</i> data are presented as means Â± SEM. A one-way analysis of variance for factor treatment or two-way analysis including factor time were used followed by Dunnettâs test for multiple comparisons versus the vehicle or high-fat diet control group and NewmanâKeuls test for comparison of the dual agonist versus the reference liraglutide. Statistical significance was considered with <i>P</i> < 0.05. All analyses were performed using SAS (version 9.2) under HP-UX via interface software EverStat V6.0-alpha5.</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i35"><a href="/doi/suppl/10.1021/acs.jmedchem.8b00292" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_70465" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_70465" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.8b00292" class="ext-link">10.1021/acs.jmedchem.8b00292</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline"><sup>1</sup>H-chemical shifts of peptides <b>5</b> and <b>12</b>, distance constraints used for the MD simulation obtained from NOESY spectra, analytical data with RP-HPLC retention times and molecular masses of the synthesized peptides, crystallographic data collection and refinement statistics, omit map of the bound peptide <b>11</b>, three-dimensional alignment of X-ray structure of GLP-1 (ECD) receptor-bound peptide <b>11</b>, receptor-bound modeling hypothesis of peptide <b>5</b>, and NMR structure of peptide <b>5</b> in solution, three-dimensional alignment of X-ray structure of GLP-1 (ECD) receptor-bound peptide <b>11</b> and ECD, X-ray structure of GLP-1 (ECD) receptor-bound exendin(9â39), as well as three-dimensional alignment of X-ray structure of GLP-1 (ECD) receptor-bound peptide <b>11</b> and cryo-EM GLP-1 (full-length) receptor-bound exendin-P5. (<a href="/doi/suppl/10.1021/acs.jmedchem.8b00292/suppl_file/jm8b00292_si_001.pdf" class="ext-link">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b00292/suppl_file/jm8b00292_si_001.pdf">jm8b00292_si_001.pdf (1.2 MB)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">Atomic coordinates for NMR structure of peptides <b>5</b> and <b>12</b> in solution can be accessed using PDB codes <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6GDZ">6GDZ</a> and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6GE2">6GE2</a>. Coordinates of the crystal structure of GLP-1 receptor extracellular domain (ECD) with peptide <b>11</b> can be assessed using PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6GB1">6GB1</a>. The authors will release the atomic coordinates and experimental data upon article publication.</p><div class="testing" data-doi="10.1021/acs.jmedchem.8b00292" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_02766" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_02766" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Andreas Evers</span> - <span class="hlFld-Affiliation affiliation">Sanofi-Aventis
Deutschland
GmbH, R&D, Industriepark HÃ¶chst, D-65926 Frankfurt am Main, Germany</span>;Â 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-4643-1941" title="Orcid link">http://orcid.org/0000-0003-4643-1941</a>;Â 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#11507f75637470623f54677463625162707f7e77783f727e7c"><span class="__cf_email__" data-cfemail="42032c26302723316c07342730310231232c2d242b6c212d2f">[emailÂ protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Martin Bossart</span> - <span class="hlFld-Affiliation affiliation">Sanofi-Aventis
Deutschland
GmbH, R&D, Industriepark HÃ¶chst, D-65926 Frankfurt am Main, Germany</span>;Â 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#da97bba8aeb3b4f498b5a9a9bba8ae9aa9bbb4b5bcb3f4b9b5b7"><span class="__cf_email__" data-cfemail="dc91bdaea8b5b2f29eb3afafbdaea89cafbdb2b3bab5f2bfb3b1">[emailÂ protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael Wagner</span> - <span class="hlFld-Affiliation affiliation">Sanofi-Aventis
Deutschland
GmbH, R&D, Industriepark HÃ¶chst, D-65926 Frankfurt am Main, Germany</span>;Â 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#eda0848e858c8881c3ba8c8a83889fad9e8c83828b84c38e8280"><span class="__cf_email__" data-cfemail="0a476369626b6f66245d6b6d646f784a796b64656c6324696567">[emailÂ protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stefania Pfeiffer-Marek</span> - <span class="hlFld-Affiliation affiliation">Sanofi-Aventis
Deutschland
GmbH, R&D, Industriepark HÃ¶chst, D-65926 Frankfurt am Main, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ralf Elvert</span> - <span class="hlFld-Affiliation affiliation">Sanofi-Aventis
Deutschland
GmbH, R&D, Industriepark HÃ¶chst, D-65926 Frankfurt am Main, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Herman Schreuder</span> - <span class="hlFld-Affiliation affiliation">Sanofi-Aventis
Deutschland
GmbH, R&D, Industriepark HÃ¶chst, D-65926 Frankfurt am Main, Germany</span>;Â 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-2249-2782" title="Orcid link">http://orcid.org/0000-0003-2249-2782</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael Kurz</span> - <span class="hlFld-Affiliation affiliation">Sanofi-Aventis
Deutschland
GmbH, R&D, Industriepark HÃ¶chst, D-65926 Frankfurt am Main, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Siegfried Stengelin</span> - <span class="hlFld-Affiliation affiliation">Sanofi-Aventis
Deutschland
GmbH, R&D, Industriepark HÃ¶chst, D-65926 Frankfurt am Main, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Martin Lorenz</span> - <span class="hlFld-Affiliation affiliation">Sanofi-Aventis
Deutschland
GmbH, R&D, Industriepark HÃ¶chst, D-65926 Frankfurt am Main, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Andreas Herling</span> - <span class="hlFld-Affiliation affiliation">Sanofi-Aventis
Deutschland
GmbH, R&D, Industriepark HÃ¶chst, D-65926 Frankfurt am Main, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Anish Konkar</span> - <span class="hlFld-Affiliation affiliation">Sanofi-Aventis
Deutschland
GmbH, R&D, Industriepark HÃ¶chst, D-65926 Frankfurt am Main, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ulrike Lukasczyk</span> - <span class="hlFld-Affiliation affiliation">Sanofi-Aventis
Deutschland
GmbH, R&D, Industriepark HÃ¶chst, D-65926 Frankfurt am Main, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Anja Pfenninger</span> - <span class="hlFld-Affiliation affiliation">Sanofi-Aventis
Deutschland
GmbH, R&D, Industriepark HÃ¶chst, D-65926 Frankfurt am Main, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Katrin Lorenz</span> - <span class="hlFld-Affiliation affiliation">Sanofi-Aventis
Deutschland
GmbH, R&D, Industriepark HÃ¶chst, D-65926 Frankfurt am Main, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Torsten Haack</span> - <span class="hlFld-Affiliation affiliation">Sanofi-Aventis
Deutschland
GmbH, R&D, Industriepark HÃ¶chst, D-65926 Frankfurt am Main, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dieter Kadereit</span> - <span class="hlFld-Affiliation affiliation">Sanofi-Aventis
Deutschland
GmbH, R&D, Industriepark HÃ¶chst, D-65926 Frankfurt am Main, Germany</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i37">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_74152" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_74152" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank R. Loder, R. Micciche, S. Peukert, S. Rauch, A. Sadikovic, K. Schlitt, C. Schneider, M. Schnierer, and L. WÃ¤Ã for peptide synthesis; M. Schaffrath, S. Kohlitz, R. Hennig, K. Jung, M. Schnierer, and T. Zeisberg for purification of peptides; M. Jung, J. StrÃ¶bele, and N. Jacoby for peptide characterization (purity, solublity, stability); R. Noll, S. Apel, and T. Harth for <i>in vitro</i> potency characterization; A. Liesum for crystallizing the complex, J. Diez for the data collection, and P. Loenze for help with data processing; T. Weiss for program management and organizational support; B. Zhang, T. Wang, P. Higgins, L. Yang, F. Du, N. Lood, and staff at KBI for performing the monkey <i>in vivo</i> study; F. Levai and K. SchrÃ¶ter for providing us the kinetic profiles of compounds used from monkey plasma samples; and G. Tiwari for reading the manuscript and providing valuable comments.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">Aib</td><td class="NLM_def"><p class="first last">2-aminoisobutyric acid</p></td></tr><tr><td class="NLM_term">DIPEA</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-diisopropylethylamine</p></td></tr><tr><td class="NLM_term">DMEM</td><td class="NLM_def"><p class="first last">Dulbeccoâs modified Eagleâs medium</p></td></tr><tr><td class="NLM_term">DPPIV</td><td class="NLM_def"><p class="first last">dipeptidyl peptidase IV</p></td></tr><tr><td class="NLM_term">ECD</td><td class="NLM_def"><p class="first last">extracellular domain</p></td></tr><tr><td class="NLM_term">FBS</td><td class="NLM_def"><p class="first last">fetal bovine serum</p></td></tr><tr><td class="NLM_term">GCGR</td><td class="NLM_def"><p class="first last">glucagon receptor</p></td></tr><tr><td class="NLM_term">GIP</td><td class="NLM_def"><p class="first last">glucose-dependent insulinotropic peptide</p></td></tr><tr><td class="NLM_term">HbA<sub>1C</sub></td><td class="NLM_def"><p class="first last">hemoglobin A1C</p></td></tr><tr><td class="NLM_term">HBSS</td><td class="NLM_def"><p class="first last">Hankâs balanced salt solution</p></td></tr><tr><td class="NLM_term">HBTU</td><td class="NLM_def"><p class="first last"><i>O</i>-(benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate</p></td></tr><tr><td class="NLM_term">HEK</td><td class="NLM_def"><p class="first last">human embryonic kidney</p></td></tr><tr><td class="NLM_term">HEPES</td><td class="NLM_def"><p class="first last">4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid</p></td></tr><tr><td class="NLM_term">HP-UX</td><td class="NLM_def"><p class="first last">Hewlett-Packard Unix</p></td></tr><tr><td class="NLM_term">HTRF</td><td class="NLM_def"><p class="first last">homogenous time resolved fluorescence</p></td></tr><tr><td class="NLM_term">IBMX</td><td class="NLM_def"><p class="first last">isobutylmethylxanthine</p></td></tr><tr><td class="NLM_term">NASH</td><td class="NLM_def"><p class="first last">nonalcoholic steatohepatitis</p></td></tr><tr><td class="NLM_term">OXM</td><td class="NLM_def"><p class="first last">oxyntomodulin</p></td></tr><tr><td class="NLM_term">PVT</td><td class="NLM_def"><p class="first last">polyvinyltoluene</p></td></tr><tr><td class="NLM_term">SEM</td><td class="NLM_def"><p class="first last">standard error of the mean</p></td></tr><tr><td class="NLM_term">SGLT2-I</td><td class="NLM_def"><p class="first last">sodiumâglucose cotransporter 2 inhibitor</p></td></tr><tr><td class="NLM_term">SPA</td><td class="NLM_def"><p class="first last">scintillation proximity assay</p></td></tr><tr><td class="NLM_term">SPL</td><td class="NLM_def"><p class="first last">Sybyl programming language</p></td></tr><tr><td class="NLM_term">TFE</td><td class="NLM_def"><p class="first last">trifluorethanol</p></td></tr><tr><td class="NLM_term">WGA</td><td class="NLM_def"><p class="first last">wheat germ agglutinin</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i39">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_53722" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_53722" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 58 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span>World Health
Organization. Media Centre. Diabetes (Fact sheet no. 312) Available
at <a href="http://www.who.int/mediacentre/factsheets/fs312/en/" class="extLink">http://www.who.int/mediacentre/factsheets/fs312/en/</a> [accessed
23 Jan <span class="NLM_year">2018</span>].</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=World+Health%0AOrganization.+Media+Centre.+Diabetes+%28Fact+sheet+no.+312%29+Available%0Aat+http%3A%2F%2Fwww.who.int%2Fmediacentre%2Ffactsheets%2Ffs312%2Fen%2F+%5Baccessed%0A23+Jan+2018%5D."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span>2014 Diabetes
Report Card - diabetesreportcard2014.pdf [Internet], Available at <a href="http://www.cdc.gov/diabetes/pdfs/library/diabetesreportcard2014.pdf" class="extLink">http://www.cdc.gov/diabetes/pdfs/library/diabetesreportcard2014.pdf</a> [accessed 23 Jan <span class="NLM_year">2018</span>].</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=2014+Diabetes%0AReport+Card+-+diabetesreportcard2014.pdf+%5BInternet%5D%2C+Available+at+http%3A%2F%2Fwww.cdc.gov%2Fdiabetes%2Fpdfs%2Flibrary%2Fdiabetesreportcard2014.pdf+%5Baccessed+23+Jan+2018%5D."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span>Nonalcoholic
Steatohepatitis: Risk Factors and Diagnosis Available at <a href="http://www.medscape.com/viewarticle/731163" class="extLink">http://www.medscape.com/viewarticle/731163</a> [accessed 23 Jan <span class="NLM_year">2018</span>].</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Nonalcoholic%0ASteatohepatitis%3A+Risk+Factors+and+Diagnosis+Available+at+http%3A%2F%2Fwww.medscape.com%2Fviewarticle%2F731163+%5Baccessed+23+Jan+2018%5D."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. Y.</span></span> <span> </span><span class="NLM_article-title">Glucagon-Like Peptide-1 Formulation â the Present and Future Development in Diabetes Treatment</span>. <i>Basic Clin. Pharmacol. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>118</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">173</span>â <span class="NLM_lpage">180</span>, <span class="refDoi">Â DOI: 10.1111/bcpt.12524</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=10.1111%2Fbcpt.12524" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=26551045" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVylur7J" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2016&pages=173-180&issue=3&author=C.+Y.+Lee&title=Glucagon-Like+Peptide-1+Formulation+%E2%80%93+the+Present+and+Future+Development+in+Diabetes+Treatment&doi=10.1111%2Fbcpt.12524"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Glucagon-Like Peptide-1 Formulation - the Present and Future Development in Diabetes Treatment</span></div><div class="casAuthors">Lee, Chooi Yeng</div><div class="citationInfo"><span class="NLM_cas:title">Basic & Clinical Pharmacology & Toxicology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">173-180</span>CODEN:
                <span class="NLM_cas:coden">BCPTBO</span>;
        ISSN:<span class="NLM_cas:issn">1742-7835</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Type 2 diabetes mellitus is a chronic metabolic disorder that has become the fourth leading cause of death in the developed countries.  The disorder is characterized by pancreatic Î²-cells dysfunction, which causes hyperglycemia leading to several other complications.  Treatment by far, which focuses on insulin administration and glycemic control, has not been satisfactory.  Glucagon-like peptide-1 (GLP1) is an endogenous peptide that stimulates post-prandial insulin secretion.  Despite being able to mimic the effect of insulin, GLP1 has not been the target drug in diabetes treatment due to the peptide's metabolic instability.  After a decade-long effort to improve the pharmacokinetics of GLP1, a no. of GLP1 analogs are currently available on the market.  The current Minireview does not discuss these drugs but presents strategies that were undertaken to address the weaknesses of the native GLP1, particularly drug delivery techniques used in developing GLP1 nanoparticles and modified GLP1 mol.  The article highlights how each of the selected prepns. has improved the efficacy of GLP1, and more importantly, through an overview of these studies, it will provide an insight into strategies that may be adopted in the future in the development of a more effective oral GLP1 formulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmCfH3cjgEQbVg90H21EOLACvtfcHk0ljWwk8iyKYbzg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVylur7J&md5=0e9e520b7295ac1956d748edc8cdc24e</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1111%2Fbcpt.12524&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbcpt.12524%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DC.%2BY.%26atitle%3DGlucagon-Like%2520Peptide-1%2520Formulation%2520%25E2%2580%2593%2520the%2520Present%2520and%2520Future%2520Development%2520in%2520Diabetes%2520Treatment%26jtitle%3DBasic%2520Clin.%2520Pharmacol.%2520Toxicol.%26date%3D2016%26volume%3D118%26issue%3D3%26spage%3D173%26epage%3D180%26doi%3D10.1111%2Fbcpt.12524" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McBrayer, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tal-Gan, Y.</span></span> <span> </span><span class="NLM_article-title">Recent Advances in GLP-1 Receptor Agonists for Use in Diabetes Mellitus</span>. <i>Drug Dev. Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>78</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">292</span>â <span class="NLM_lpage">299</span>, <span class="refDoi">Â DOI: 10.1002/ddr.21404</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=10.1002%2Fddr.21404" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2017&pages=292-299&issue=6&author=D.+N.+McBrayerauthor=Y.+Tal-Gan&title=Recent+Advances+in+GLP-1+Receptor+Agonists+for+Use+in+Diabetes+Mellitus&doi=10.1002%2Fddr.21404"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1002%2Fddr.21404&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fddr.21404%26sid%3Dliteratum%253Aachs%26aulast%3DMcBrayer%26aufirst%3DD.%2BN.%26aulast%3DTal-Gan%26aufirst%3DY.%26atitle%3DRecent%2520Advances%2520in%2520GLP-1%2520Receptor%2520Agonists%2520for%2520Use%2520in%2520Diabetes%2520Mellitus%26jtitle%3DDrug%2520Dev.%2520Res.%26date%3D2017%26volume%3D78%26issue%3D6%26spage%3D292%26epage%3D299%26doi%3D10.1002%2Fddr.21404" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Uccellatore, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Genovese, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dicembrini, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mannucci, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ceriello, A.</span></span> <span> </span><span class="NLM_article-title">Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor Agonists</span>. <i>Diabetes Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">239</span>â <span class="NLM_lpage">256</span>, <span class="refDoi">Â DOI: 10.1007/s13300-015-0127-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=10.1007%2Fs13300-015-0127-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=26271795" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFGhsrfJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=239-256&issue=3&author=A.+Uccellatoreauthor=S.+Genoveseauthor=I.+Dicembriniauthor=E.+Mannucciauthor=A.+Ceriello&title=Comparison+Review+of+Short-Acting+and+Long-Acting+Glucagon-like+Peptide-1+Receptor+Agonists&doi=10.1007%2Fs13300-015-0127-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor Agonists</span></div><div class="casAuthors">Uccellatore, Annachiara; Genovese, Stefano; Dicembrini, Ilaria; Mannucci, Edoardo; Ceriello, Antonio</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes Therapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">239-256</span>CODEN:
                <span class="NLM_cas:coden">DTIHAP</span>;
        ISSN:<span class="NLM_cas:issn">1869-6961</span>.
    
            (<span class="NLM_cas:orgname">Springer Healthcare Ltd.</span>)
        </div><div class="casAbstract">Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1 RAs) are useful tools for treating type 2 diabetes mellitus.  In their recent position statement, the American Diabetes Assocn. and European Assocn. for the Study of Diabetes recommend GLP1-RAs as add-on to metformin when therapeutic goals are not achieved with monotherapy, particularly for patients who wish to avoid wt. gain or hypoglycemia.  GLP1-RAs differ substantially in their duration of action, frequency of administration and clin. profile.  Members of this class approved for clin. use include exenatide twice-daily, exenatide once-weekly, liraglutide and lixisenatide once-daily.  Recently, two new once-weekly GLP1-RAs have been approved: dulaglutide and albiglutide.  This article summarizes properties of short- and long-acting GLP-1 analogs, and provides useful information to help choose the most appropriate compd. for individual patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrL73oCtHFWJbVg90H21EOLACvtfcHk0lgxLmrjEoHwpQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFGhsrfJ&md5=074bdad4952922f4d6b2fdc628de08f3</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1007%2Fs13300-015-0127-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs13300-015-0127-x%26sid%3Dliteratum%253Aachs%26aulast%3DUccellatore%26aufirst%3DA.%26aulast%3DGenovese%26aufirst%3DS.%26aulast%3DDicembrini%26aufirst%3DI.%26aulast%3DMannucci%26aufirst%3DE.%26aulast%3DCeriello%26aufirst%3DA.%26atitle%3DComparison%2520Review%2520of%2520Short-Acting%2520and%2520Long-Acting%2520Glucagon-like%2520Peptide-1%2520Receptor%2520Agonists%26jtitle%3DDiabetes%2520Ther.%26date%3D2015%26volume%3D6%26issue%3D3%26spage%3D239%26epage%3D256%26doi%3D10.1007%2Fs13300-015-0127-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Finan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clemmensen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MÃ¼ller, T. D.</span></span> <span> </span><span class="NLM_article-title">Emerging Opportunities for the Treatment of Metabolic Diseases: Glucagon-like Peptide-1 Based Multi-Agonists</span>. <i>Mol. Cell. Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>418</i></span>,  <span class="NLM_fpage">42</span>â <span class="NLM_lpage">54</span>, <span class="refDoi">Â DOI: 10.1016/j.mce.2015.07.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=10.1016%2Fj.mce.2015.07.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=26151488" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht12kurbL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=418&publication_year=2015&pages=42-54&author=B.+Finanauthor=C.+Clemmensenauthor=T.+D.+M%C3%BCller&title=Emerging+Opportunities+for+the+Treatment+of+Metabolic+Diseases%3A+Glucagon-like+Peptide-1+Based+Multi-Agonists&doi=10.1016%2Fj.mce.2015.07.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging opportunities for the treatment of metabolic diseases: Glucagon-like peptide-1 based multi-agonists</span></div><div class="casAuthors">Finan, Brian; Clemmensen, Christoffer; Mueller, Timo D.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Endocrinology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">418</span>
        (<span class="NLM_cas:issue">Part_1</span>),
    <span class="NLM_cas:pages">42-54</span>CODEN:
                <span class="NLM_cas:coden">MCEND6</span>;
        ISSN:<span class="NLM_cas:issn">0303-7207</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">Obesity is a pathogenic gateway to the metabolic syndrome and the complications thereof, thus interventions aimed at preventing or reversing the metabolic derangements underlying obesity hold great therapeutic promise.  However, the complexity of energy balance regulation, combined with the heterologous pathophysiol. of human obesity, renders effective medicinal intervention very difficult.  Indeed, the search for the silver bullet in anti-obesity medicines has been laden with drugs of underwhelming efficacy and unacceptable side effects.  This can partly be the consequence that many of these drug interventions have been historically directed at single mol. targets.  New multi-mol. combination therapies have shown promising clin. outcomes in terms of wt. loss, yet multi-functional single mols. may offer even more advantages than adjunctive co-treatments.  Single mols. with integrated activities derived from multiple hormones involved in the physiol. control of metab. have emerged as one of the more promising candidates for reversing obesity.  The inclusion of glucagon-like peptide-1 (GLP-1) as one of the constituents is a unifying factor amongst the majority of these unimol. multi-agonists.  The scope of this review is to summarize the current preclin. and clin. landscape of GLP-1-based therapies, focusing on combinatorial therapies with a particular emphasis on single mol. compds. displaying multi-agonist properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUBCghH0SQMLVg90H21EOLACvtfcHk0lgxLmrjEoHwpQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht12kurbL&md5=c433f454a29252c16d9d2eafd2b95b08</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.mce.2015.07.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mce.2015.07.003%26sid%3Dliteratum%253Aachs%26aulast%3DFinan%26aufirst%3DB.%26aulast%3DClemmensen%26aufirst%3DC.%26aulast%3DM%25C3%25BCller%26aufirst%3DT.%2BD.%26atitle%3DEmerging%2520Opportunities%2520for%2520the%2520Treatment%2520of%2520Metabolic%2520Diseases%253A%2520Glucagon-like%2520Peptide-1%2520Based%2520Multi-Agonists%26jtitle%3DMol.%2520Cell.%2520Endocrinol.%26date%3D2015%26volume%3D418%26spage%3D42%26epage%3D54%26doi%3D10.1016%2Fj.mce.2015.07.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Knerr, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelfanov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Tilve, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">TschÃ¶p, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiMarchi, R. D.</span></span> <span> </span><span class="NLM_article-title">Optimization of Peptide-Based Polyagonists for Treatment of Diabetes and Obesity</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">2873</span>â <span class="NLM_lpage">2881</span>, <span class="refDoi">Â DOI: 10.1016/j.bmc.2017.10.047</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=10.1016%2Fj.bmc.2017.10.047" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2018&pages=2873-2881&issue=10&author=P.+J.+Knerrauthor=B.+Finanauthor=V.+Gelfanovauthor=D.+Perez-Tilveauthor=M.+H.+Tsch%C3%B6pauthor=R.+D.+DiMarchi&title=Optimization+of+Peptide-Based+Polyagonists+for+Treatment+of+Diabetes+and+Obesity&doi=10.1016%2Fj.bmc.2017.10.047"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2017.10.047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2017.10.047%26sid%3Dliteratum%253Aachs%26aulast%3DKnerr%26aufirst%3DP.%2BJ.%26aulast%3DFinan%26aufirst%3DB.%26aulast%3DGelfanov%26aufirst%3DV.%26aulast%3DPerez-Tilve%26aufirst%3DD.%26aulast%3DTsch%25C3%25B6p%26aufirst%3DM.%2BH.%26aulast%3DDiMarchi%26aufirst%3DR.%2BD.%26atitle%3DOptimization%2520of%2520Peptide-Based%2520Polyagonists%2520for%2520Treatment%2520of%2520Diabetes%2520and%2520Obesity%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2018%26volume%3D26%26issue%3D10%26spage%3D2873%26epage%3D2881%26doi%3D10.1016%2Fj.bmc.2017.10.047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">SÃ¡nchez-Garrido, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandt, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clemmensen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MÃ¼ller, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiMarchi, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">TschÃ¶p, M. H.</span></span> <span> </span><span class="NLM_article-title">GLP-1/Glucagon Receptor Co-Agonism for Treatment of Obesity</span>. <i>Diabetologia</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1851</span>â <span class="NLM_lpage">1861</span>, <span class="refDoi">Â DOI: 10.1007/s00125-017-4354-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=10.1007%2Fs00125-017-4354-8" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=1851-1861&issue=10&author=M.+A.+S%C3%A1nchez-Garridoauthor=S.+J.+Brandtauthor=C.+Clemmensenauthor=T.+D.+M%C3%BCllerauthor=R.+D.+DiMarchiauthor=M.+H.+Tsch%C3%B6p&title=GLP-1%2FGlucagon+Receptor+Co-Agonism+for+Treatment+of+Obesity&doi=10.1007%2Fs00125-017-4354-8"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1007%2Fs00125-017-4354-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00125-017-4354-8%26sid%3Dliteratum%253Aachs%26aulast%3DS%25C3%25A1nchez-Garrido%26aufirst%3DM.%2BA.%26aulast%3DBrandt%26aufirst%3DS.%2BJ.%26aulast%3DClemmensen%26aufirst%3DC.%26aulast%3DM%25C3%25BCller%26aufirst%3DT.%2BD.%26aulast%3DDiMarchi%26aufirst%3DR.%2BD.%26aulast%3DTsch%25C3%25B6p%26aufirst%3DM.%2BH.%26atitle%3DGLP-1%252FGlucagon%2520Receptor%2520Co-Agonism%2520for%2520Treatment%2520of%2520Obesity%26jtitle%3DDiabetologia%26date%3D2017%26volume%3D60%26issue%3D10%26spage%3D1851%26epage%3D1861%26doi%3D10.1007%2Fs00125-017-4354-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">TschÃ¶p, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clemmensen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelfanov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Tilve, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MÃ¼ller, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiMarchi, R. D.</span></span> <span> </span><span class="NLM_article-title">Unimolecular Polypharmacy for Treatment of Diabetes and Obesity</span>. <i>Cell Metab.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">51</span>â <span class="NLM_lpage">62</span>, <span class="refDoi">Â DOI: 10.1016/j.cmet.2016.06.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=10.1016%2Fj.cmet.2016.06.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=27411008" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=1%3ACAS%3A280%3ADC%252BC2s3gtleisQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2016&pages=51-62&issue=1&author=M.+H.+Tsch%C3%B6pauthor=B.+Finanauthor=C.+Clemmensenauthor=V.+Gelfanovauthor=D.+Perez-Tilveauthor=T.+D.+M%C3%BCllerauthor=R.+D.+DiMarchi&title=Unimolecular+Polypharmacy+for+Treatment+of+Diabetes+and+Obesity&doi=10.1016%2Fj.cmet.2016.06.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Unimolecular Polypharmacy for Treatment of Diabetes and Obesity</span></div><div class="casAuthors">Tschop Matthias H; Finan Brian; Clemmensen Christoffer; Muller Timo D; Gelfanov Vasily; Perez-Tilve Diego; DiMarchi Richard D</div><div class="citationInfo"><span class="NLM_cas:title">Cell metabolism</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">51-62</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Many complex diseases have historically proven to be defiant to the best mono-therapeutic approaches.  Several examples of combination therapies have largely overcome such challenges, notably for the treatment of severe hypertension and tuberculosis.  Obesity and its consequences, such as type 2 diabetes, have proven to be equally resistant to therapeutic approaches based on single medicines.  Proper management of type 2 diabetes often requires adjunctive medications, and the recent registration of a few compound mixtures has set the precedent for combinatorial treatment of obesity.  On the other hand, double or triple therapeutic combinations are more difficult to advance to regulatory approval than single molecules.  More recently, several classes of novel unimolecular combination therapeutics have emerged with superior efficacy than currently prescribed options and pose the potential to reverse obesity and type 2 diabetes.  Here, we summarize the discovery, pre-clinical validation, and first clinical test of such peptide hormone poly-agonist drug candidates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSD_iD9oiDSziEJCPKhJPuqfW6udTcc2ebvIFz9P8Bn2Lntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s3gtleisQ%253D%253D&md5=36cbafe2232e829ccc52d5c83895f6a6</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.cmet.2016.06.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cmet.2016.06.021%26sid%3Dliteratum%253Aachs%26aulast%3DTsch%25C3%25B6p%26aufirst%3DM.%2BH.%26aulast%3DFinan%26aufirst%3DB.%26aulast%3DClemmensen%26aufirst%3DC.%26aulast%3DGelfanov%26aufirst%3DV.%26aulast%3DPerez-Tilve%26aufirst%3DD.%26aulast%3DM%25C3%25BCller%26aufirst%3DT.%2BD.%26aulast%3DDiMarchi%26aufirst%3DR.%2BD.%26atitle%3DUnimolecular%2520Polypharmacy%2520for%2520Treatment%2520of%2520Diabetes%2520and%2520Obesity%26jtitle%3DCell%2520Metab.%26date%3D2016%26volume%3D24%26issue%3D1%26spage%3D51%26epage%3D62%26doi%3D10.1016%2Fj.cmet.2016.06.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Day, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ottaway, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patterson, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelfanov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smiley, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gidda, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Findeisen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruemmer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drucker, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaudhary, N.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">A New Glucagon and GLP-1 Co-Agonist Eliminates Obesity in Rodents</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">749</span>â <span class="NLM_lpage">757</span>, <span class="refDoi">Â DOI: 10.1038/nchembio.209</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=10.1038%2Fnchembio.209" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=19597507" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=1%3ACAS%3A528%3ADC%252BD1MXosFWhsLk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2009&pages=749-757&issue=10&author=J.+W.+Dayauthor=N.+Ottawayauthor=J.+T.+Pattersonauthor=V.+Gelfanovauthor=D.+Smileyauthor=J.+Giddaauthor=H.+Findeisenauthor=D.+Bruemmerauthor=D.+J.+Druckerauthor=N.+Chaudhary&title=A+New+Glucagon+and+GLP-1+Co-Agonist+Eliminates+Obesity+in+Rodents&doi=10.1038%2Fnchembio.209"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">A new glucagon and GLP-1 co-agonist eliminates obesity in rodents</span></div><div class="casAuthors">Day, Jonathan W.; Ottaway, Nickki; Patterson, James T.; Gelfanov, Vasily; Smiley, David; Gidda, Jas; Findeisen, Hannes; Bruemmer, Dennis; Drucker, Daniel J.; Chaudhary, Nilika; Holland, Jenna; Hembree, Jazzminn; Abplanalp, William; Grant, Erin; Ruehl, Jennifer; Wilson, Hilary; Kirchner, Henriette; Lockie, Sarah Haas; Hofmann, Susanna; Woods, Stephen C.; Nogueiras, Ruben; Pfluger, Paul T.; Perez-Tilve, Diego; DiMarchi, Richard; Tschoep, Matthias H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">749-757</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We report the efficacy of a new peptide with agonism at the glucagon and GLP-1 receptors that has potent, sustained satiation-inducing and lipolytic effects.  Selective chem. modification to glucagon resulted in a loss of specificity, with minimal change to inherent activity.  The structural basis for the co-agonism appears to be a combination of local positional interactions and a change in secondary structure.  Two co-agonist peptides differing from each other only in their level of glucagon receptor agonism were studied in rodent obesity models.  Administration of PEGylated peptides once per wk normalized adiposity and glucose tolerance in diet-induced obese mice.  Redn. of body wt. was achieved by a loss of body fat resulting from decreased food intake and increased energy expenditure.  These preclin. studies indicate that when full GLP-1 agonism is augmented with an appropriate degree of glucagon receptor activation, body fat redn. can be substantially enhanced without any overt adverse effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4K1-_eVTTKbVg90H21EOLACvtfcHk0lgxF9LH71T54Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXosFWhsLk%253D&md5=74b57672bfd375dd4d073624a25eab9b</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.209&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.209%26sid%3Dliteratum%253Aachs%26aulast%3DDay%26aufirst%3DJ.%2BW.%26aulast%3DOttaway%26aufirst%3DN.%26aulast%3DPatterson%26aufirst%3DJ.%2BT.%26aulast%3DGelfanov%26aufirst%3DV.%26aulast%3DSmiley%26aufirst%3DD.%26aulast%3DGidda%26aufirst%3DJ.%26aulast%3DFindeisen%26aufirst%3DH.%26aulast%3DBruemmer%26aufirst%3DD.%26aulast%3DDrucker%26aufirst%3DD.%2BJ.%26aulast%3DChaudhary%26aufirst%3DN.%26atitle%3DA%2520New%2520Glucagon%2520and%2520GLP-1%2520Co-Agonist%2520Eliminates%2520Obesity%2520in%2520Rodents%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2009%26volume%3D5%26issue%3D10%26spage%3D749%26epage%3D757%26doi%3D10.1038%2Fnchembio.209" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pocai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrington, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eiermann, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lassman, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, G.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Glucagon-Like Peptide 1/Glucagon Receptor Dual Agonism Reverses Obesity in Mice</span>. <i>Diabetes</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">2258</span>â <span class="NLM_lpage">2266</span>, <span class="refDoi">Â DOI: 10.2337/db09-0278</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=10.2337%2Fdb09-0278" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=19602537" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1yku7jK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2009&pages=2258-2266&issue=10&author=A.+Pocaiauthor=P.+E.+Carringtonauthor=J.+R.+Adamsauthor=M.+Wrightauthor=G.+Eiermannauthor=L.+Zhuauthor=X.+Duauthor=A.+Petrovauthor=M.+E.+Lassmanauthor=G.+Jiang&title=Glucagon-Like+Peptide+1%2FGlucagon+Receptor+Dual+Agonism+Reverses+Obesity+in+Mice&doi=10.2337%2Fdb09-0278"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice</span></div><div class="casAuthors">Pocai, Alessandro; Carrington, Paul E.; Adams, Jennifer R.; Wright, Michael; Eiermann, George; Zhu, Lan; Du, Xiaobing; Petrov, Aleksandr; Lassman, Michael E.; Jiang, Guoqiang; Liu, Franklin; Miller, Corey; Tota, Laurie M.; Zhou, Gaochao; Zhang, Xiaoping; Sountis, Michael M.; Santoprete, Alessia; Capito, Elena; Chicchi, Gary G.; Thornberry, Nancy; Bianchi, Elisabetta; Pessi, Antonello; Marsh, Donald J.; Sinha Roy, Ranabir</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2258-2266</span>CODEN:
                <span class="NLM_cas:coden">DIAEAZ</span>;
        ISSN:<span class="NLM_cas:issn">0012-1797</span>.
    
            (<span class="NLM_cas:orgname">American Diabetes Association, Inc.</span>)
        </div><div class="casAbstract">Objective-Oxyntomodulin (OXM) is a glucagon-like peptide 1 (GLP-1) receptor (GLP1R)/glucagon receptor (GCGR) dual agonist peptide that reduces body wt. in obese subjects through increased energy expenditure and decreased energy intake.  The metabolic effects of OXM have been attributed primarily to GLP1R agonism.  We examd. whether a long acting GLP1R/GCGR dual agonist peptide exerts metabolic effects in diet-induced obese mice that are distinct from those obtained with a GLP1R-selective agonist.  Research Design and Methods-We developed a protease-resistant dual GLP1R/GCGR agonist, DualAG, and a corresponding GLP1R-selective agonist, GLPAG, matched for GLP1R agonist potency and pharmacokinetics.  The metabolic effects of these two peptides with respect to wt. loss, caloric redn., glucose control, and lipid lowering, were compared upon chronic dosing in diet-induced obese (DIO) mice.  Acute studies in DIO mice revealed metabolic pathways that were modulated independent of wt. loss.  Studies in Glp1r-/- and Gcgr-/- mice enabled delineation of the contribution of GLP1R vs. GCGR activation to the pharmacol. of DualAG.  Results-Peptide DualAG exhibits superior wt. loss, lipid-lowering activity, and antihyperglycemic efficacy comparable to GLPAG.  Improvements in plasma metabolic parameters including insulin, leptin, and adiponectin were more pronounced upon chronic treatment with DualAG than with GLPAG.  Dual receptor agonism also increased fatty acid oxidn. and reduced hepatic steatosis in DIO mice.  The antiobesity effects of DualAG require activation of both GLP1R and GCGR.  Conclusions-Sustained GLP1R/GCGR dual agonism reverses obesity in DIO mice and is a novel therapeutic approach to the treatment of obesity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoX2C2QNX0zG7Vg90H21EOLACvtfcHk0ljDdDUUJbByow"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1yku7jK&md5=412b04ba021de2fdfb2c6b011c289eeb</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.2337%2Fdb09-0278&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2337%252Fdb09-0278%26sid%3Dliteratum%253Aachs%26aulast%3DPocai%26aufirst%3DA.%26aulast%3DCarrington%26aufirst%3DP.%2BE.%26aulast%3DAdams%26aufirst%3DJ.%2BR.%26aulast%3DWright%26aufirst%3DM.%26aulast%3DEiermann%26aufirst%3DG.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DDu%26aufirst%3DX.%26aulast%3DPetrov%26aufirst%3DA.%26aulast%3DLassman%26aufirst%3DM.%2BE.%26aulast%3DJiang%26aufirst%3DG.%26atitle%3DGlucagon-Like%2520Peptide%25201%252FGlucagon%2520Receptor%2520Dual%2520Agonism%2520Reverses%2520Obesity%2520in%2520Mice%26jtitle%3DDiabetes%26date%3D2009%26volume%3D58%26issue%3D10%26spage%3D2258%26epage%3D2266%26doi%3D10.2337%2Fdb09-0278" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Evers, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haack, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorenz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bossart, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elvert, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henkel, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stengelin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glien, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dudda, A.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Design of Novel Exendin-Based Dual Glucagon-like Peptide 1 (GLP-1)/Glucagon Receptor Agonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">4293</span>â <span class="NLM_lpage">4303</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.7b00174</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00174" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmslKrsr8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=4293-4303&issue=10&author=A.+Eversauthor=T.+Haackauthor=M.+Lorenzauthor=M.+Bossartauthor=R.+Elvertauthor=B.+Henkelauthor=S.+Stengelinauthor=M.+Kurzauthor=M.+Glienauthor=A.+Dudda&title=Design+of+Novel+Exendin-Based+Dual+Glucagon-like+Peptide+1+%28GLP-1%29%2FGlucagon+Receptor+Agonists&doi=10.1021%2Facs.jmedchem.7b00174"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Design of Novel Exendin-Based Dual Glucagon-like Peptide 1 (GLP-1)/Glucagon Receptor Agonists</span></div><div class="casAuthors">Evers, Andreas; Haack, Torsten; Lorenz, Martin; Bossart, Martin; Elvert, Ralf; Henkel, Bernd; Stengelin, Siegfried; Kurz, Michael; Glien, Maike; Dudda, Angela; Lorenz, Katrin; Kadereit, Dieter; Wagner, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4293-4303</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Dual activation of the glucagon-like peptide 1 (GLP-1) and glucagon receptor has the potential to lead to a novel therapy principle for the treatment of diabesity.  Here, we report a series of novel peptides with dual activity on these receptors that were discovered by rational design.  On the basis of sequence anal. and structure-based design, structural elements of glucagon were engineered into the selective GLP-1 receptor agonist exendin-4, resulting in hybrid peptides with potent dual GLP-1/glucagon receptor activity.  Detailed structure-activity relationship data are shown.  Further modifications with unnatural and modified amino acids resulted in novel metabolically stable peptides that demonstrated a significant dose-dependent decrease in blood glucose in chronic studies in diabetic db/db mice and reduced body wt. in diet-induced obese (DIO) mice.  Structural anal. by NMR spectroscopy confirmed that the peptides maintain an exendin-4-like structure with its characteristic tryptophan-cage fold motif that is responsible for favorable chem. and phys. stability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrewDgurwTT4LVg90H21EOLACvtfcHk0ljDdDUUJbByow"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmslKrsr8%253D&md5=b59a7a25cdd56516b78c988860b39211</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00174%26sid%3Dliteratum%253Aachs%26aulast%3DEvers%26aufirst%3DA.%26aulast%3DHaack%26aufirst%3DT.%26aulast%3DLorenz%26aufirst%3DM.%26aulast%3DBossart%26aufirst%3DM.%26aulast%3DElvert%26aufirst%3DR.%26aulast%3DHenkel%26aufirst%3DB.%26aulast%3DStengelin%26aufirst%3DS.%26aulast%3DKurz%26aufirst%3DM.%26aulast%3DGlien%26aufirst%3DM.%26aulast%3DDudda%26aufirst%3DA.%26atitle%3DDesign%2520of%2520Novel%2520Exendin-Based%2520Dual%2520Glucagon-like%2520Peptide%25201%2520%2528GLP-1%2529%252FGlucagon%2520Receptor%2520Agonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26issue%3D10%26spage%3D4293%26epage%3D4303%26doi%3D10.1021%2Facs.jmedchem.7b00174" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Henderson, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konkar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hornigold, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trevaskis, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fritsch Fredin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jansson-LÃ¶fmark, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naylor, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bednarek, M. A.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Robust Anti-Obesity and Metabolic Effects of a Dual GLP-1/Glucagon Receptor Peptide Agonist in Rodents and Non-Human Primates</span>. <i>Diabetes, Obes. Metab.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1176</span>â <span class="NLM_lpage">1190</span>, <span class="refDoi">Â DOI: 10.1111/dom.12735</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=10.1111%2Fdom.12735" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=27377054" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVGgsbnN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2016&pages=1176-1190&issue=12&author=S.+J.+Hendersonauthor=A.+Konkarauthor=D.+C.+Hornigoldauthor=J.+L.+Trevaskisauthor=R.+Jacksonauthor=M.+Fritsch+Fredinauthor=R.+Jansson-L%C3%B6fmarkauthor=J.+Naylorauthor=A.+Rossiauthor=M.+A.+Bednarek&title=Robust+Anti-Obesity+and+Metabolic+Effects+of+a+Dual+GLP-1%2FGlucagon+Receptor+Peptide+Agonist+in+Rodents+and+Non-Human+Primates&doi=10.1111%2Fdom.12735"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates</span></div><div class="casAuthors">Henderson, S. J.; Konkar, A.; Hornigold, D. C.; Trevaskis, J. L.; Jackson, R.; Fritsch Fredin, M.; Jansson-Loefmark, R.; Naylor, J.; Rossi, A.; Bednarek, M. A.; Bhagroo, N.; Salari, H.; Will, S.; Oldham, S.; Hansen, G.; Feigh, M.; Klein, T.; Grimsby, J.; Maguire, S.; Jermutus, L.; Rondinone, C. M.; Coghlan, M. P.</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes, Obesity and Metabolism</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1176-1190</span>CODEN:
                <span class="NLM_cas:coden">DOMEF6</span>;
        ISSN:<span class="NLM_cas:issn">1462-8902</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Aims : To characterize the pharmacol. of MEDI0382, a peptide dual agonist of glucagon-like peptide-1 (GLP-1) and glucagon receptors.  Materials and methods : MEDI0382 was evaluated in vitro for its ability to stimulate cAMP accumulation in cell lines expressing transfected recombinant or endogenous GLP-1 or glucagon receptors, to potentiate glucose-stimulated insulin secretion (GSIS) in pancreatic Î²-cell lines and stimulate hepatic glucose output (HGO) by primary hepatocytes.  The ability of MEDI0382 to reduce body wt. and improve energy balance (i.e. food intake and energy expenditure), as well as control blood glucose, was evaluated in mouse models of obesity and healthy cynomolgus monkeys following single and repeated daily s.c. administration for up to 2 mo.  Results : MEDI0382 potently activated rodent, cynomolgus and human GLP-1 and glucagon receptors and exhibited a fivefold bias for activation of GLP-1 receptor vs. the glucagon receptor.  MEDI0382 produced superior wt. loss and comparable glucose lowering to the GLP-1 peptide analog liraglutide when administered daily at comparable doses in DIO mice.  The addnl. fat mass redn. elicited by MEDI0382 probably results from a glucagon receptor-mediated increase in energy expenditure, whereas food intake suppression results from activation of the GLP-1 receptor.  Notably, the significant wt. loss elicited by MEDI0382 in DIO mice was recapitulated in cynomolgus monkeys.  Conclusions : Repeated administration of MEDI0382 elicits profound wt. loss in DIO mice and non-human primates, produces robust glucose control and reduces hepatic fat content and fasting insulin and glucose levels.  The balance of activities at the GLP-1 and glucagon receptors is considered to be optimal for achieving wt. and glucose control in overweight or obese Type 2 diabetic patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpB5Lj1dV4AsLVg90H21EOLACvtfcHk0lhIcAuarHEtcg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVGgsbnN&md5=e0af76d2553a265b6367aab1cc46df6f</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1111%2Fdom.12735&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fdom.12735%26sid%3Dliteratum%253Aachs%26aulast%3DHenderson%26aufirst%3DS.%2BJ.%26aulast%3DKonkar%26aufirst%3DA.%26aulast%3DHornigold%26aufirst%3DD.%2BC.%26aulast%3DTrevaskis%26aufirst%3DJ.%2BL.%26aulast%3DJackson%26aufirst%3DR.%26aulast%3DFritsch%2BFredin%26aufirst%3DM.%26aulast%3DJansson-L%25C3%25B6fmark%26aufirst%3DR.%26aulast%3DNaylor%26aufirst%3DJ.%26aulast%3DRossi%26aufirst%3DA.%26aulast%3DBednarek%26aufirst%3DM.%2BA.%26atitle%3DRobust%2520Anti-Obesity%2520and%2520Metabolic%2520Effects%2520of%2520a%2520Dual%2520GLP-1%252FGlucagon%2520Receptor%2520Peptide%2520Agonist%2520in%2520Rodents%2520and%2520Non-Human%2520Primates%26jtitle%3DDiabetes%252C%2520Obes.%2520Metab.%26date%3D2016%26volume%3D18%26issue%3D12%26spage%3D1176%26epage%3D1190%26doi%3D10.1111%2Fdom.12735" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pathak, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pathak, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâHarte, F. P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flatt, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Irwin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gault, V. A.</span></span> <span> </span><span class="NLM_article-title">A Novel DPP IV-Resistant C-Terminally Extended Glucagon Analogue Exhibits Weight-Lowering and Diabetes-Protective Effects in High-Fat-Fed Mice Mediated through Glucagon and GLP-1 Receptor Activation</span>. <i>Diabetologia</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1927</span>â <span class="NLM_lpage">1936</span>, <span class="refDoi">Â DOI: 10.1007/s00125-014-3296-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=10.1007%2Fs00125-014-3296-7" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=1927-1936&issue=9&author=A.+M.+Lynchauthor=N.+Pathakauthor=V.+Pathakauthor=F.+P.+M.+O%E2%80%99Harteauthor=P.+R.+Flattauthor=N.+Irwinauthor=V.+A.+Gault&title=A+Novel+DPP+IV-Resistant+C-Terminally+Extended+Glucagon+Analogue+Exhibits+Weight-Lowering+and+Diabetes-Protective+Effects+in+High-Fat-Fed+Mice+Mediated+through+Glucagon+and+GLP-1+Receptor+Activation&doi=10.1007%2Fs00125-014-3296-7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1007%2Fs00125-014-3296-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00125-014-3296-7%26sid%3Dliteratum%253Aachs%26aulast%3DLynch%26aufirst%3DA.%2BM.%26aulast%3DPathak%26aufirst%3DN.%26aulast%3DPathak%26aufirst%3DV.%26aulast%3DO%25E2%2580%2599Harte%26aufirst%3DF.%2BP.%2BM.%26aulast%3DFlatt%26aufirst%3DP.%2BR.%26aulast%3DIrwin%26aufirst%3DN.%26aulast%3DGault%26aufirst%3DV.%2BA.%26atitle%3DA%2520Novel%2520DPP%2520IV-Resistant%2520C-Terminally%2520Extended%2520Glucagon%2520Analogue%2520Exhibits%2520Weight-Lowering%2520and%2520Diabetes-Protective%2520Effects%2520in%2520High-Fat-Fed%2520Mice%2520Mediated%2520through%2520Glucagon%2520and%2520GLP-1%2520Receptor%2520Activation%26jtitle%3DDiabetologia%26date%3D2014%26volume%3D57%26issue%3D9%26spage%3D1927%26epage%3D1936%26doi%3D10.1007%2Fs00125-014-3296-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">OâHarte, F. P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conlon, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flatt, P. R.</span></span> <span> </span><span class="NLM_article-title">Dogfish Glucagon Analogues Counter Hyperglycaemia and Enhance Both Insulin Secretion and Action in Diet-Induced Obese Diabetic Mice</span>. <i>Diabetes, Obes. Metab.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1013</span>â <span class="NLM_lpage">1024</span>, <span class="refDoi">Â DOI: 10.1111/dom.12713</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=10.1111%2Fdom.12713" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=27357054" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsV2qtbzF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2016&pages=1013-1024&issue=10&author=F.+P.+M.+O%E2%80%99Harteauthor=M.+T.+Ngauthor=A.+M.+Lynchauthor=J.+M.+Conlonauthor=P.+R.+Flatt&title=Dogfish+Glucagon+Analogues+Counter+Hyperglycaemia+and+Enhance+Both+Insulin+Secretion+and+Action+in+Diet-Induced+Obese+Diabetic+Mice&doi=10.1111%2Fdom.12713"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Dogfish glucagon analogues counter hyperglycaemia and enhance both insulin secretion and action in diet-induced obese diabetic mice</span></div><div class="casAuthors">O'Harte, F. P. M.; Ng, M. T.; Lynch, A. M.; Conlon, J. M.; Flatt, P. R.</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes, Obesity and Metabolism</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1013-1024</span>CODEN:
                <span class="NLM_cas:coden">DOMEF6</span>;
        ISSN:<span class="NLM_cas:issn">1462-8902</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Aims : To investigate the antidiabetic actions of three dogfish glucagon peptide analogs [known glucagon-like peptide-1 and glucagon receptor co-agonists] after chronic administration in diet-induced high-fat-diet-fed diabetic mice.  Materials and methods : National Institutes of Health Swiss mice were pre-conditioned to a high-fat diet (45% fat) for 100 days, and control mice were fed a normal diet (10% fat).  Normal diet control and high-fat-fed control mice received twice-daily i.p. (i.p.) saline injections, while the high-fat-fed treatment groups (n = 8) received twice-daily injections of exendin-4(1-39), [S2a]dogfish glucagon, [S2a]dogfish glucagon exendin-4(31-39) or [S2a]dogfish glucagon-Lys30-Î³-glutamyl-PAL (25 nmol/kg body wt.) for 51 days.  Results : After dogfish glucagon analog treatment, there was a rapid and sustained decrease in non-fasting blood glucose and an assocd. insulinotropic effect (anal. of variance, p < .05 to <.001) compared with saline-treated high-fat-fed controls.  All peptide treatments significantly improved i.p. and oral glucose tolerance with concomitant increased insulin secretion compared with saline-treated high-fat-fed controls (p <.05 to <.001).  After chronic treatment, no receptor desensitization was obsd. but insulin sensitivity was enhanced for all peptide-treated groups (p < .01 to <.001) except [S2a]dogfish glucagon.  Both exendin-4 and [S2a]dogfish glucagon exendin-4(31-39) significantly reduced plasma triglyceride concns. compared with those found in lean controls (p = .0105 and p = .0048, resp.).  Pancreatic insulin content was not affected by peptide treatments but [S2a]dogfish glucagon and [S2a]dogfish glucagon exendin-4(31-39) decreased pancreatic glucagon by 28%-34% (p = .0221 and p = .0075, resp.).  The percentage of Î²-cell area within islets was increased by exendin-4 and peptide analog treatment groups compared with high-fat-fed controls and the Î²-cell area decreased (p < .05 to <.01).  Conclusions : Overall, dogfish glucagon co-agonist analogs had several beneficial metabolic effects, showing therapeutic potential for type 2 diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr33HIW_8oZO7Vg90H21EOLACvtfcHk0lhIcAuarHEtcg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsV2qtbzF&md5=a6c619b6d47964b961f020ad88ea035a</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1111%2Fdom.12713&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fdom.12713%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Harte%26aufirst%3DF.%2BP.%2BM.%26aulast%3DNg%26aufirst%3DM.%2BT.%26aulast%3DLynch%26aufirst%3DA.%2BM.%26aulast%3DConlon%26aufirst%3DJ.%2BM.%26aulast%3DFlatt%26aufirst%3DP.%2BR.%26atitle%3DDogfish%2520Glucagon%2520Analogues%2520Counter%2520Hyperglycaemia%2520and%2520Enhance%2520Both%2520Insulin%2520Secretion%2520and%2520Action%2520in%2520Diet-Induced%2520Obese%2520Diabetic%2520Mice%26jtitle%3DDiabetes%252C%2520Obes.%2520Metab.%26date%3D2016%26volume%3D18%26issue%3D10%26spage%3D1013%26epage%3D1024%26doi%3D10.1111%2Fdom.12713" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">OâHarte, F. P.
M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conlon, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flatt, P. R.</span></span> <span> </span><span class="NLM_article-title">Novel Dual Agonist Peptide Analogues Derived from Dogfish Glucagon Show Promising in Vitro Insulin Releasing Actions and Antihyperglycaemic Activity in Mice</span>. <i>Mol. Cell. Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>431</i></span>,  <span class="NLM_fpage">133</span>â <span class="NLM_lpage">144</span>, <span class="refDoi">Â DOI: 10.1016/j.mce.2016.05.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=10.1016%2Fj.mce.2016.05.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=27179756" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=1%3ACAS%3A528%3ADC%252BC28Xos1anur0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=431&publication_year=2016&pages=133-144&author=F.+P.%0AM.+O%E2%80%99Harteauthor=M.+T.+Ngauthor=A.+M.+Lynchauthor=J.+M.+Conlonauthor=P.+R.+Flatt&title=Novel+Dual+Agonist+Peptide+Analogues+Derived+from+Dogfish+Glucagon+Show+Promising+in+Vitro+Insulin+Releasing+Actions+and+Antihyperglycaemic+Activity+in+Mice&doi=10.1016%2Fj.mce.2016.05.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Novel dual agonist peptide analogues derived from dogfish glucagon show promising in vitro insulin releasing actions and antihyperglycaemic activity in mice</span></div><div class="casAuthors">O'Harte, F. P. M.; Ng, M. T.; Lynch, A. M.; Conlon, J. M.; Flatt, P. R.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Endocrinology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">431</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">133-144</span>CODEN:
                <span class="NLM_cas:coden">MCEND6</span>;
        ISSN:<span class="NLM_cas:issn">0303-7207</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">The antidiabetic potential of thirteen novel dogfish glucagon derived analogs were assessed in vitro and in acute in vivo studies.  Stable peptide analogs enhanced insulin secretion from BRIN-BD11 Î²-cells (p < 0.001) and reduced acute glycemic responses following i.p. glucose (25 nmol/kg) in healthy NIH Swiss mice (p < 0.05-p<0.001).  The in vitro insulinotropic actions of [S2a]dogfish glucagon, [S2a]dogfish glucagon-exendin-4(31-39) and [S2a]dogfish glucagon-Lys30-Î³-glutamyl-PAL, were blocked (p < 0.05-p<0.001) by the specific GLP-1 and glucagon receptor antagonists, exendin-4(9-39) and (desHis1Pro4Glu9)glucagon amide but not by (Pro3)GIP, indicating lack of GIP receptor involvement.  These analogs dose-dependently stimulated cAMP prodn. in GLP-1 and glucagon (p < 0.05-p<0.001) but not GIP-receptor transfected cells.  They improved acute glycemic and insulinotropic responses in high-fat fed diabetic mice and in wild-type C57BL/6J and GIPR-KO mice (p < 0.05-p<0.001), but not GLP-1R-KO mice, confirming action on GLP-1 but not GIP receptors.  Overall, dogfish glucagon analogs have potential for diabetes therapy, exerting beneficial metabolic effects via GLP-1 and glucagon receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYMG0tNkdC2LVg90H21EOLACvtfcHk0lhIcAuarHEtcg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xos1anur0%253D&md5=50d438aaa6ea3d9910faa9063c66f441</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.mce.2016.05.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mce.2016.05.012%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Harte%26aufirst%3DF.%2BP.%2BM.%26aulast%3DNg%26aufirst%3DM.%2BT.%26aulast%3DLynch%26aufirst%3DA.%2BM.%26aulast%3DConlon%26aufirst%3DJ.%2BM.%26aulast%3DFlatt%26aufirst%3DP.%2BR.%26atitle%3DNovel%2520Dual%2520Agonist%2520Peptide%2520Analogues%2520Derived%2520from%2520Dogfish%2520Glucagon%2520Show%2520Promising%2520in%2520Vitro%2520Insulin%2520Releasing%2520Actions%2520and%2520Antihyperglycaemic%2520Activity%2520in%2520Mice%26jtitle%3DMol.%2520Cell.%2520Endocrinol.%26date%3D2016%26volume%3D431%26spage%3D133%26epage%3D144%26doi%3D10.1016%2Fj.mce.2016.05.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span>Transition
Therapeutics Inc. <a href="http://www.transitiontherapeutics.com/technology/tt401.php" class="extLink">http://www.transitiontherapeutics.com/technology/tt401.php</a> (accessed
Mar 21, <span class="NLM_year">2017</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Transition%0ATherapeutics+Inc.+http%3A%2F%2Fwww.transitiontherapeutics.com%2Ftechnology%2Ftt401.php+%28accessed%0AMar+21%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Soni, H.</span></span> <span> </span><span class="NLM_article-title">Peptide-Based GLP-1/Glucagon Co-Agonists: A Double-Edged Sword to Combat Diabesity. Med</span>. <i>Med. Hypotheses</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>95</i></span>,  <span class="NLM_fpage">5</span>â <span class="NLM_lpage">9</span>, <span class="refDoi">Â DOI: 10.1016/j.mehy.2016.08.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=10.1016%2Fj.mehy.2016.08.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=27692167" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVamsLjN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=2016&pages=5-9&author=H.+Soni&title=Peptide-Based+GLP-1%2FGlucagon+Co-Agonists%3A+A+Double-Edged+Sword+to+Combat+Diabesity.+Med&doi=10.1016%2Fj.mehy.2016.08.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Peptide-based GLP-1/glucagon co-agonists: A double-edged sword to combat diabesity</span></div><div class="casAuthors">Soni, Hitesh</div><div class="citationInfo"><span class="NLM_cas:title">Medical Hypotheses</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">5-9</span>CODEN:
                <span class="NLM_cas:coden">MEHYDY</span>;
        ISSN:<span class="NLM_cas:issn">0306-9877</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Diabesity is a new term for obesity-dependent diabetes, which is also assocd. with cardiovascular and other comorbidities with rising epidemic.  Traditional treatments (sulfonylureas and thiazolidinediones) of diabetes are assocd. with wt. gain, except metformin.  Newer agents such as glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and Sodium glucose co-transporter 2 inhibitors (SGLT2i) are causing a modest wt. redn., whereas dipeptidyl peptidase-4 inhibitors (DPP-4i) are wt. neutral.  Oxyntomodulin, a native GLP-1/glucagon receptor agonist produced a superior wt. loss and antihyperglycemic effects in obese mice and humans.  Recent findings with synthetic dual GLP-1/glucagon receptor agonists have shown a good wt. loss and antihyperglycemic profile in diet-induced obese (DIO) mice.  Targeting combinations of GLP-1 receptor and glucagon receptor simultaneously with a single peptide may be the better strategy to achieve marked wt. loss and considerable glycemic control in diabesity.  Cardiovascular safety is very important with new antidiabetic agents due to rosiglitazone controversy.  Current on-going clin. trials will clarify the cardiovascular effects of incretin-based therapies in near future.  Based on current knowledge and rapid progress in the field, there is a strong possibility that the GLP-1/glucagon receptor co-agonists will likely be the new therapeutic treatment for diabesity for decades to come.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYi16nV6WICrVg90H21EOLACvtfcHk0lia1qq7_Mlsvw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVamsLjN&md5=f14f1d5ff2beb0989d9de3e16bc80581</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.mehy.2016.08.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mehy.2016.08.005%26sid%3Dliteratum%253Aachs%26aulast%3DSoni%26aufirst%3DH.%26atitle%3DPeptide-Based%2520GLP-1%252FGlucagon%2520Co-Agonists%253A%2520A%2520Double-Edged%2520Sword%2520to%2520Combat%2520Diabesity.%2520Med%26jtitle%3DMed.%2520Hypotheses%26date%3D2016%26volume%3D95%26spage%3D5%26epage%3D9%26doi%3D10.1016%2Fj.mehy.2016.08.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Day, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelfanov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smiley, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrington, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eiermann, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chicchi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erion, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gidda, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thornberry, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">TschÃ¶p, M. H.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Optimization of Co-Agonism at GLP-1 and Glucagon Receptors to Safely Maximize Weight Reduction in DIO-Rodents</span>. <i>Biopolymers</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>98</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">443</span>â <span class="NLM_lpage">450</span>, <span class="refDoi">Â DOI: 10.1002/bip.22072</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=10.1002%2Fbip.22072" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2012&pages=443-450&issue=5&author=J.+W.+Dayauthor=V.+Gelfanovauthor=D.+Smileyauthor=P.+E.+Carringtonauthor=G.+Eiermannauthor=G.+Chicchiauthor=M.+D.+Erionauthor=J.+Giddaauthor=N.+A.+Thornberryauthor=M.+H.+Tsch%C3%B6p&title=Optimization+of+Co-Agonism+at+GLP-1+and+Glucagon+Receptors+to+Safely+Maximize+Weight+Reduction+in+DIO-Rodents&doi=10.1002%2Fbip.22072"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1002%2Fbip.22072&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fbip.22072%26sid%3Dliteratum%253Aachs%26aulast%3DDay%26aufirst%3DJ.%2BW.%26aulast%3DGelfanov%26aufirst%3DV.%26aulast%3DSmiley%26aufirst%3DD.%26aulast%3DCarrington%26aufirst%3DP.%2BE.%26aulast%3DEiermann%26aufirst%3DG.%26aulast%3DChicchi%26aufirst%3DG.%26aulast%3DErion%26aufirst%3DM.%2BD.%26aulast%3DGidda%26aufirst%3DJ.%26aulast%3DThornberry%26aufirst%3DN.%2BA.%26aulast%3DTsch%25C3%25B6p%26aufirst%3DM.%2BH.%26atitle%3DOptimization%2520of%2520Co-Agonism%2520at%2520GLP-1%2520and%2520Glucagon%2520Receptors%2520to%2520Safely%2520Maximize%2520Weight%2520Reduction%2520in%2520DIO-Rodents%26jtitle%3DBiopolymers%26date%3D2012%26volume%3D98%26issue%3D5%26spage%3D443%26epage%3D450%26doi%3D10.1002%2Fbip.22072" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span>General
Chapters: â¨51â© ANTIMICROBIAL EFFECTIVENESS TESTING <a href="http://www.pharmacopeia.cn/v29240/usp29nf24s0_c51.html" class="extLink">http://www.pharmacopeia.cn/v29240/usp29nf24s0_c51.html</a> (accessed Jan 23, <span class="NLM_year">2018</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=General%0AChapters%3A+%E2%9F%A851%E2%9F%A9+ANTIMICROBIAL+EFFECTIVENESS+TESTING+http%3A%2F%2Fwww.pharmacopeia.cn%2Fv29240%2Fusp29nf24s0_c51.html+%28accessed+Jan+23%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De
Jong, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Incledon, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yip, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeFelippis, M. R.</span></span> <span> </span><span class="NLM_article-title">Amyloid Fibrils of Glucagon Characterized by High-Resolution Atomic Force Microscopy</span>. <i>Biophys. J.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>91</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1905</span>â <span class="NLM_lpage">1914</span>, <span class="refDoi">Â DOI: 10.1529/biophysj.105.077438</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=10.1529%2Fbiophysj.105.077438" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=2006&pages=1905-1914&issue=5&author=K.+L.+De%0AJongauthor=B.+Incledonauthor=C.+M.+Yipauthor=M.+R.+DeFelippis&title=Amyloid+Fibrils+of+Glucagon+Characterized+by+High-Resolution+Atomic+Force+Microscopy&doi=10.1529%2Fbiophysj.105.077438"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1529%2Fbiophysj.105.077438&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1529%252Fbiophysj.105.077438%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BJong%26aufirst%3DK.%2BL.%26aulast%3DIncledon%26aufirst%3DB.%26aulast%3DYip%26aufirst%3DC.%2BM.%26aulast%3DDeFelippis%26aufirst%3DM.%2BR.%26atitle%3DAmyloid%2520Fibrils%2520of%2520Glucagon%2520Characterized%2520by%2520High-Resolution%2520Atomic%2520Force%2520Microscopy%26jtitle%3DBiophys.%2520J.%26date%3D2006%26volume%3D91%26issue%3D5%26spage%3D1905%26epage%3D1914%26doi%3D10.1529%2Fbiophysj.105.077438" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heljo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarraga, I. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pappenberger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahler, H.-C.</span></span> <span> </span><span class="NLM_article-title">Interactions Between Peptide and Preservatives: Effects on Peptide Self-Interactions and Antimicrobial Efficiency In Aqueous Multi-Dose Formulations</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>32</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">3201</span>â <span class="NLM_lpage">3212</span>, <span class="refDoi">Â DOI: 10.1007/s11095-015-1697-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=10.1007%2Fs11095-015-1697-z" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2015&pages=3201-3212&issue=10&author=P.+Heljoauthor=A.+Rossauthor=I.+E.+Zarragaauthor=A.+Pappenbergerauthor=H.-C.+Mahler&title=Interactions+Between+Peptide+and+Preservatives%3A+Effects+on+Peptide+Self-Interactions+and+Antimicrobial+Efficiency+In+Aqueous+Multi-Dose+Formulations&doi=10.1007%2Fs11095-015-1697-z"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1007%2Fs11095-015-1697-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11095-015-1697-z%26sid%3Dliteratum%253Aachs%26aulast%3DHeljo%26aufirst%3DP.%26aulast%3DRoss%26aufirst%3DA.%26aulast%3DZarraga%26aufirst%3DI.%2BE.%26aulast%3DPappenberger%26aufirst%3DA.%26aulast%3DMahler%26aufirst%3DH.-C.%26atitle%3DInteractions%2520Between%2520Peptide%2520and%2520Preservatives%253A%2520Effects%2520on%2520Peptide%2520Self-Interactions%2520and%2520Antimicrobial%2520Efficiency%2520In%2520Aqueous%2520Multi-Dose%2520Formulations%26jtitle%3DPharm.%2520Res.%26date%3D2015%26volume%3D32%26issue%3D10%26spage%3D3201%26epage%3D3212%26doi%3D10.1007%2Fs11095-015-1697-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pedersen, J. S.</span></span> <span> </span><span class="NLM_article-title">The Nature of Amyloid-like Glucagon Fibrils</span>. <i>J. Diabetes Sci. Technol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1357</span>â <span class="NLM_lpage">1367</span>, <span class="refDoi">Â DOI: 10.1177/193229681000400609</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=10.1177%2F193229681000400609" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=21129330" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=1%3ACAS%3A280%3ADC%252BC3M%252FhvVGmsA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2010&pages=1357-1367&issue=6&author=J.+S.+Pedersen&title=The+Nature+of+Amyloid-like+Glucagon+Fibrils&doi=10.1177%2F193229681000400609"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">The nature of amyloid-like glucagon fibrils</span></div><div class="casAuthors">Pedersen Jesper Sondergaard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of diabetes science and technology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1357-67</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Protein aggregation and formation of amyloid fibrils is a phenomenon usually associated with proteotoxicity and degenerative diseases, such as type 2 diabetes, Alzheimer's disease, and prion diseases.  However, several protein and peptide hormones are known to have a high propensity to form amyloid-like fibrils in vitro raising concerns about safety and stability of pharmaceutical protein solutions.  Comprehensive understanding of the aggregation mechanisms is an important prerequisite to the design of strategies to prevent fibril formation.  Detailed kinetic, spectroscopic, and morphological studies have revealed that glucagon can form several types of fibrils that differ at the level of molecular packing of the peptide.  Each type forms through distinct nucleation-dependent aggregation pathways influenced by solution conditions and can be self-propagated by seeding.  An increasing number of functional amyloid-like structures have been discovered in nature, and it has recently been proposed that an amyloid-like state of glucagon may be utilized by the pancreatic Î±-cells as in vivo storage form.  This article reviews the current state of our knowledge about the nature of the different types of amyloid-like glucagon fibrils, the mechanisms by which they form, and discusses implications for formulation strategies and the safety of glucagon pharmaceuticals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTOCyyMqEaCIUHdcurJClFcfW6udTcc2eZtOrooBTIXA7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3M%252FhvVGmsA%253D%253D&md5=957881a8ec368a36059ff74d6eee4d16</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1177%2F193229681000400609&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F193229681000400609%26sid%3Dliteratum%253Aachs%26aulast%3DPedersen%26aufirst%3DJ.%2BS.%26atitle%3DThe%2520Nature%2520of%2520Amyloid-like%2520Glucagon%2520Fibrils%26jtitle%3DJ.%2520Diabetes%2520Sci.%2520Technol.%26date%3D2010%26volume%3D4%26issue%3D6%26spage%3D1357%26epage%3D1367%26doi%3D10.1177%2F193229681000400609" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pedersen, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dikov, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otzen, D. E.</span></span> <span> </span><span class="NLM_article-title">N- and C-Terminal Hydrophobic Patches Are Involved in Fibrillation of Glucagon</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>45</i></span> (<span class="NLM_issue">48</span>),  <span class="NLM_fpage">14503</span>â <span class="NLM_lpage">14512</span>, <span class="refDoi">Â DOI: 10.1021/bi061228n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi061228n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2006&pages=14503-14512&issue=48&author=J.+S.+Pedersenauthor=D.+Dikovauthor=D.+E.+Otzen&title=N-+and+C-Terminal+Hydrophobic+Patches+Are+Involved+in+Fibrillation+of+Glucagon&doi=10.1021%2Fbi061228n"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fbi061228n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi061228n%26sid%3Dliteratum%253Aachs%26aulast%3DPedersen%26aufirst%3DJ.%2BS.%26aulast%3DDikov%26aufirst%3DD.%26aulast%3DOtzen%26aufirst%3DD.%2BE.%26atitle%3DN-%2520and%2520C-Terminal%2520Hydrophobic%2520Patches%2520Are%2520Involved%2520in%2520Fibrillation%2520of%2520Glucagon%26jtitle%3DBiochemistry%26date%3D2006%26volume%3D45%26issue%3D48%26spage%3D14503%26epage%3D14512%26doi%3D10.1021%2Fbi061228n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pedersen, J.
S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dikov, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flink, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hjuler, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christiansen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otzen, D. E.</span></span> <span> </span><span class="NLM_article-title">The Changing Face of Glucagon Fibrillation: Structural Polymorphism and Conformational Imprinting</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>355</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">501</span>â <span class="NLM_lpage">523</span>, <span class="refDoi">Â DOI: 10.1016/j.jmb.2005.09.100</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=10.1016%2Fj.jmb.2005.09.100" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=355&publication_year=2006&pages=501-523&issue=3&author=J.%0AS.+Pedersenauthor=D.+Dikovauthor=J.+L.+Flinkauthor=H.+A.+Hjulerauthor=G.+Christiansenauthor=D.+E.+Otzen&title=The+Changing+Face+of+Glucagon+Fibrillation%3A+Structural+Polymorphism+and+Conformational+Imprinting&doi=10.1016%2Fj.jmb.2005.09.100"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2005.09.100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2005.09.100%26sid%3Dliteratum%253Aachs%26aulast%3DPedersen%26aufirst%3DJ.%2BS.%26aulast%3DDikov%26aufirst%3DD.%26aulast%3DFlink%26aufirst%3DJ.%2BL.%26aulast%3DHjuler%26aufirst%3DH.%2BA.%26aulast%3DChristiansen%26aufirst%3DG.%26aulast%3DOtzen%26aufirst%3DD.%2BE.%26atitle%3DThe%2520Changing%2520Face%2520of%2520Glucagon%2520Fibrillation%253A%2520Structural%2520Polymorphism%2520and%2520Conformational%2520Imprinting%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2006%26volume%3D355%26issue%3D3%26spage%3D501%26epage%3D523%26doi%3D10.1016%2Fj.jmb.2005.09.100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, W.</span></span> <span> </span><span class="NLM_article-title">Peptide Developability at the Discovery-to-Development InterfaceâCurrent State and Future Opportunities</span>. <i>AAPS J.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">777</span>â <span class="NLM_lpage">779</span>, <span class="refDoi">Â DOI: 10.1208/s12248-015-9755-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=10.1208%2Fs12248-015-9755-3" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2015&pages=777-779&issue=4&author=A.+Bakauthor=W.+Dai&title=Peptide+Developability+at+the+Discovery-to-Development+Interface%E2%80%93Current+State+and+Future+Opportunities&doi=10.1208%2Fs12248-015-9755-3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1208%2Fs12248-015-9755-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1208%252Fs12248-015-9755-3%26sid%3Dliteratum%253Aachs%26aulast%3DBak%26aufirst%3DA.%26aulast%3DDai%26aufirst%3DW.%26atitle%3DPeptide%2520Developability%2520at%2520the%2520Discovery-to-Development%2520Interface%25E2%2580%2593Current%2520State%2520and%2520Future%2520Opportunities%26jtitle%3DAAPS%2520J.%26date%3D2015%26volume%3D17%26issue%3D4%26spage%3D777%26epage%3D779%26doi%3D10.1208%2Fs12248-015-9755-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forster, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minnihan, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leithead, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cunningham, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toussaint, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crocker, L. S.</span></span> <span> </span><span class="NLM_article-title">Physicochemical and Formulation Developability Assessment for Therapeutic Peptide Deliveryâa Primer</span>. <i>AAPS J.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">144</span>â <span class="NLM_lpage">155</span>, <span class="refDoi">Â DOI: 10.1208/s12248-014-9688-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=10.1208%2Fs12248-014-9688-2" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2015&pages=144-155&issue=1&author=A.+Bakauthor=D.+Leungauthor=S.+E.+Barrettauthor=S.+Forsterauthor=E.+C.+Minnihanauthor=A.+W.+Leitheadauthor=J.+Cunninghamauthor=N.+Toussaintauthor=L.+S.+Crocker&title=Physicochemical+and+Formulation+Developability+Assessment+for+Therapeutic+Peptide+Delivery%E2%80%93a+Primer&doi=10.1208%2Fs12248-014-9688-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1208%2Fs12248-014-9688-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1208%252Fs12248-014-9688-2%26sid%3Dliteratum%253Aachs%26aulast%3DBak%26aufirst%3DA.%26aulast%3DLeung%26aufirst%3DD.%26aulast%3DBarrett%26aufirst%3DS.%2BE.%26aulast%3DForster%26aufirst%3DS.%26aulast%3DMinnihan%26aufirst%3DE.%2BC.%26aulast%3DLeithead%26aufirst%3DA.%2BW.%26aulast%3DCunningham%26aufirst%3DJ.%26aulast%3DToussaint%26aufirst%3DN.%26aulast%3DCrocker%26aufirst%3DL.%2BS.%26atitle%3DPhysicochemical%2520and%2520Formulation%2520Developability%2520Assessment%2520for%2520Therapeutic%2520Peptide%2520Delivery%25E2%2580%2593a%2520Primer%26jtitle%3DAAPS%2520J.%26date%3D2015%26volume%3D17%26issue%3D1%26spage%3D144%26epage%3D155%26doi%3D10.1208%2Fs12248-014-9688-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fosgerau, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, T.</span></span> <span> </span><span class="NLM_article-title">Peptide Therapeutics: Current Status and Future Directions</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">122</span>â <span class="NLM_lpage">128</span>, <span class="refDoi">Â DOI: 10.1016/j.drudis.2014.10.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=10.1016%2Fj.drudis.2014.10.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=25450771" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsl2ksLnM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2015&pages=122-128&issue=1&author=K.+Fosgerauauthor=T.+Hoffmann&title=Peptide+Therapeutics%3A+Current+Status+and+Future+Directions&doi=10.1016%2Fj.drudis.2014.10.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Peptide therapeutics: current status and future directions</span></div><div class="casAuthors">Fosgerau, Keld; Hoffmann, Torsten</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">122-128</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Peptides are recognized for being highly selective and efficacious and, at the same time, relatively safe and well tolerated.  Consequently, there is an increased interest in peptides in pharmaceutical research and development (R&D), and approx. 140 peptide therapeutics are currently being evaluated in clin. trials.  Given that the low-hanging fruits in the form of obvious peptide targets have already been picked, it has now become necessary to explore new routes beyond traditional peptide design.  Examples of such approaches are multifunctional and cell penetrating peptides, as well as peptide drug conjugates.  Here, we discuss the current status, strengths, and weaknesses of peptides as medicines and the emerging new opportunities in peptide drug design and development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmhpp8GnJ6JLVg90H21EOLACvtfcHk0lgqkv5ycmeQ4g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsl2ksLnM&md5=f6b74aaa4e3fdb317b091b0450f3618a</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2014.10.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2014.10.003%26sid%3Dliteratum%253Aachs%26aulast%3DFosgerau%26aufirst%3DK.%26aulast%3DHoffmann%26aufirst%3DT.%26atitle%3DPeptide%2520Therapeutics%253A%2520Current%2520Status%2520and%2520Future%2520Directions%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2015%26volume%3D20%26issue%3D1%26spage%3D122%26epage%3D128%26doi%3D10.1016%2Fj.drudis.2014.10.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Neidigh, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fesinmeyer, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prickett, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersen, N. H.</span></span> <span> </span><span class="NLM_article-title">Exendin-4 and Glucagon-like-Peptide-1: NMR Structural Comparisons in the Solution and Micelle-Associated States <sup>â </sup></span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>40</i></span> (<span class="NLM_issue">44</span>),  <span class="NLM_fpage">13188</span>â <span class="NLM_lpage">13200</span>, <span class="refDoi">Â DOI: 10.1021/bi010902s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi010902s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2001&pages=13188-13200&issue=44&author=J.+W.+Neidighauthor=R.+M.+Fesinmeyerauthor=K.+S.+Prickettauthor=N.+H.+Andersen&title=Exendin-4+and+Glucagon-like-Peptide-1%3A+NMR+Structural+Comparisons+in+the+Solution+and+Micelle-Associated+States+%E2%80%A0&doi=10.1021%2Fbi010902s"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fbi010902s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi010902s%26sid%3Dliteratum%253Aachs%26aulast%3DNeidigh%26aufirst%3DJ.%2BW.%26aulast%3DFesinmeyer%26aufirst%3DR.%2BM.%26aulast%3DPrickett%26aufirst%3DK.%2BS.%26aulast%3DAndersen%26aufirst%3DN.%2BH.%26atitle%3DExendin-4%2520and%2520Glucagon-like-Peptide-1%253A%2520NMR%2520Structural%2520Comparisons%2520in%2520the%2520Solution%2520and%2520Micelle-Associated%2520States%2520%25E2%2580%25A0%26jtitle%3DBiochemistry%26date%3D2001%26volume%3D40%26issue%3D44%26spage%3D13188%26epage%3D13200%26doi%3D10.1021%2Fbi010902s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chabenne, J.
R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiMarchi, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelfanov, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiMarchi, R. D.</span></span> <span> </span><span class="NLM_article-title">Optimization of the Native Glucagon Sequence for Medicinal Purposes</span>. <i>J. Diabetes Sci. Technol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1322</span>â <span class="NLM_lpage">1331</span>, <span class="refDoi">Â DOI: 10.1177/193229681000400605</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=10.1177%2F193229681000400605" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=21129326" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=1%3ACAS%3A280%3ADC%252BC3M%252FhvVGnug%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2010&pages=1322-1331&issue=6&author=J.%0AR.+Chabenneauthor=M.+A.+DiMarchiauthor=V.+M.+Gelfanovauthor=R.+D.+DiMarchi&title=Optimization+of+the+Native+Glucagon+Sequence+for+Medicinal+Purposes&doi=10.1177%2F193229681000400605"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of the native glucagon sequence for medicinal purposes</span></div><div class="casAuthors">Chabenne Joseph R; DiMarchi Maria A; Gelfanov Vasily M; DiMarchi Richard D</div><div class="citationInfo"><span class="NLM_cas:title">Journal of diabetes science and technology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1322-31</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Glucagon is a life-saving medication used in the treatment of hypoglycemia.  It possesses poor solubility in aqueous buffers at or near physiological pH values.  At low and high pH, at which the peptide can be formulated to concentrations of a milligram or more per milliliter, the chemical integrity of the hormone is limited, as evidenced by the formation of multiple degradation-related peptides.  Consequently, the commercial preparation is provided as a lyophilized solid with an acidic diluent and directions for rendering it soluble at the time of use.  Any unused material is recommended for disposal immediately after initial use.  METHODS:  A set of glucagon analogs was prepared by solid-phase peptide synthesis to explore the identification of a glucagon analog with enhanced solubility and chemical stability at physiological pH.  The physical properties of the peptide analogs were studied by solubility determination, high-performance chromatography, and mass spectral analysis.  The biochemical properties were determined in engineered human embryonic kidney cell line 293 (HEK293) cells that overexpressed either the human glucagon or glucagon-like peptide-1 (GLP-1) receptors linked to a luciferase reporter gene.  RESULTS:  We observed the previously characterized formation of glucagon degradation products upon incubation of the peptide in dilute acid for extended periods or elevated temperature.  Lowering the isoelectric point of the hormone through the substitution of asparagine-28 with aspartic acid significantly increased the solubility at physiological pH.  Similarly, the C-terminal extension (Cex) of the hormone with an exendin-based, 10-residue, C-terminal sequence yielded a peptide of dramatically enhanced solubility.  These two glucagon analogs, D28 and Cex, maintained high potency and selectivity for the glucagon receptor relative to GLP-1 receptor.  CONCLUSIONS:  Glucagon presents unique structural challenges to the identification of an analog of high biological activity and selectivity that also possesses sufficient aqueous solubility and stability such that it might be developed as a ready-to-use medicine.  The glucagon analogs D28 and Cex demonstrated all of the chemical, physical, and biochemical properties supportive of further study as potential clinical candidates for treatment of hypoglycemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTOCyyMqEaCIRWfpMXQLRstfW6udTcc2ebsqjhsppZzU7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3M%252FhvVGnug%253D%253D&md5=9a27028640295b5f4a6c2bd040bcd120</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1177%2F193229681000400605&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F193229681000400605%26sid%3Dliteratum%253Aachs%26aulast%3DChabenne%26aufirst%3DJ.%2BR.%26aulast%3DDiMarchi%26aufirst%3DM.%2BA.%26aulast%3DGelfanov%26aufirst%3DV.%2BM.%26aulast%3DDiMarchi%26aufirst%3DR.%2BD.%26atitle%3DOptimization%2520of%2520the%2520Native%2520Glucagon%2520Sequence%2520for%2520Medicinal%2520Purposes%26jtitle%3DJ.%2520Diabetes%2520Sci.%2520Technol.%26date%3D2010%26volume%3D4%26issue%3D6%26spage%3D1322%26epage%3D1331%26doi%3D10.1177%2F193229681000400605" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Runge, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">ThÃ¸gersen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madsen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudolph, R.</span></span> <span> </span><span class="NLM_article-title">Crystal Structure of the Ligand-Bound Glucagon-like Peptide-1 Receptor Extracellular Domain</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>283</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">11340</span>â <span class="NLM_lpage">11347</span>, <span class="refDoi">Â DOI: 10.1074/jbc.M708740200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=10.1074%2Fjbc.M708740200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=18287102" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=1%3ACAS%3A528%3ADC%252BD1cXkvVSgtr4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=283&publication_year=2008&pages=11340-11347&issue=17&author=S.+Rungeauthor=H.+Th%C3%B8gersenauthor=K.+Madsenauthor=J.+Lauauthor=R.+Rudolph&title=Crystal+Structure+of+the+Ligand-Bound+Glucagon-like+Peptide-1+Receptor+Extracellular+Domain&doi=10.1074%2Fjbc.M708740200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal Structure of the Ligand-bound Glucagon-like Peptide-1 Receptor Extracellular Domain</span></div><div class="casAuthors">Runge, Steffen; Thogersen, Henning; Madsen, Kjeld; Lau, Jesper; Rudolph, Rainer</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">283</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">11340-11347</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The glucagon-like peptide-1 receptor (GLP-1R) belongs to Family B1 of the seven-transmembrane G protein-coupled receptors, and its natural agonist ligand is the peptide hormone glucagon-like peptide-1 (GLP-1).  GLP-1 is involved in glucose homeostasis, and activation of GLP-1R in the plasma membrane of pancreatic Î²-cells potentiates glucose-dependent insulin secretion.  The N-terminal extracellular domain (nGLP-1R) is an important ligand binding domain that binds GLP-1 and the homologous peptide Exendin-4 with differential affinity.  Exendin-4 has a C-terminal extension of nine amino acid residues known as the "Trp cage", which is absent in GLP-1.  The Trp cage was believed to interact with nGLP-1R and thereby explain the superior affinity of Exendin-4.  However, the mol. details that govern ligand binding and specificity of nGLP-1R remain undefined.  Here the authors report the crystal structure of human nGLP-1R in complex with the antagonist Exendin-4(9-39) solved by the multiwavelength anomalous dispersion method to 2.2Ã resoln.  The structure reveals that Exendin-4(9-39) is an amphipathic Î±-helix forming both hydrophobic and hydrophilic interactions with nGLP-1R.  The Trp cage of Exendin-4 is not involved in binding to nGLP-1R.  The hydrophobic binding site of nGLP-1R is defined by discontinuous segments including primarily a well defined Î±-helix in the N terminus of nGLP-1R and a loop between two antiparallel Î²-strands.  The structure provides for the first time detailed mol. insight into ligand binding of the human GLP-1 receptor, an established target for treatment of type 2 diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquCFNrYkVbPLVg90H21EOLACvtfcHk0lgqkv5ycmeQ4g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXkvVSgtr4%253D&md5=43529117c437b477afb23e0ba196b1b1</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M708740200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M708740200%26sid%3Dliteratum%253Aachs%26aulast%3DRunge%26aufirst%3DS.%26aulast%3DTh%25C3%25B8gersen%26aufirst%3DH.%26aulast%3DMadsen%26aufirst%3DK.%26aulast%3DLau%26aufirst%3DJ.%26aulast%3DRudolph%26aufirst%3DR.%26atitle%3DCrystal%2520Structure%2520of%2520the%2520Ligand-Bound%2520Glucagon-like%2520Peptide-1%2520Receptor%2520Extracellular%2520Domain%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2008%26volume%3D283%26issue%3D17%26spage%3D11340%26epage%3D11347%26doi%3D10.1074%2Fjbc.M708740200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koth, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukund, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madjidi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minn, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiang, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estevez, A.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Molecular Basis for Negative Regulation of the Glucagon Receptor</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>109</i></span> (<span class="NLM_issue">36</span>),  <span class="NLM_fpage">14393</span>â <span class="NLM_lpage">14398</span>, <span class="refDoi">Â DOI: 10.1073/pnas.1206734109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=10.1073%2Fpnas.1206734109" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2012&pages=14393-14398&issue=36&author=C.+M.+Kothauthor=J.+M.+Murrayauthor=S.+Mukundauthor=A.+Madjidiauthor=A.+Minnauthor=H.+J.+Clarkeauthor=T.+Wongauthor=V.+Chiangauthor=E.+Luisauthor=A.+Estevez&title=Molecular+Basis+for+Negative+Regulation+of+the+Glucagon+Receptor&doi=10.1073%2Fpnas.1206734109"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1206734109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1206734109%26sid%3Dliteratum%253Aachs%26aulast%3DKoth%26aufirst%3DC.%2BM.%26aulast%3DMurray%26aufirst%3DJ.%2BM.%26aulast%3DMukund%26aufirst%3DS.%26aulast%3DMadjidi%26aufirst%3DA.%26aulast%3DMinn%26aufirst%3DA.%26aulast%3DClarke%26aufirst%3DH.%2BJ.%26aulast%3DWong%26aufirst%3DT.%26aulast%3DChiang%26aufirst%3DV.%26aulast%3DLuis%26aufirst%3DE.%26aulast%3DEstevez%26aufirst%3DA.%26atitle%3DMolecular%2520Basis%2520for%2520Negative%2520Regulation%2520of%2520the%2520Glucagon%2520Receptor%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2012%26volume%3D109%26issue%3D36%26spage%3D14393%26epage%3D14398%26doi%3D10.1073%2Fpnas.1206734109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Parthier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleinschmidt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neumann, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudolph, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manhart, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlenzig, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">FanghÃ¤nel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahfeld, J.-U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demuth, H.-U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stubbs, M. T.</span></span> <span> </span><span class="NLM_article-title">Crystal Structure of the Incretin-Bound Extracellular Domain of a G Protein-Coupled Receptor</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>104</i></span> (<span class="NLM_issue">35</span>),  <span class="NLM_fpage">13942</span>â <span class="NLM_lpage">13947</span>, <span class="refDoi">Â DOI: 10.1073/pnas.0706404104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=10.1073%2Fpnas.0706404104" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2007&pages=13942-13947&issue=35&author=C.+Parthierauthor=M.+Kleinschmidtauthor=P.+Neumannauthor=R.+Rudolphauthor=S.+Manhartauthor=D.+Schlenzigauthor=J.+Fangh%C3%A4nelauthor=J.-U.+Rahfeldauthor=H.-U.+Demuthauthor=M.+T.+Stubbs&title=Crystal+Structure+of+the+Incretin-Bound+Extracellular+Domain+of+a+G+Protein-Coupled+Receptor&doi=10.1073%2Fpnas.0706404104"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0706404104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0706404104%26sid%3Dliteratum%253Aachs%26aulast%3DParthier%26aufirst%3DC.%26aulast%3DKleinschmidt%26aufirst%3DM.%26aulast%3DNeumann%26aufirst%3DP.%26aulast%3DRudolph%26aufirst%3DR.%26aulast%3DManhart%26aufirst%3DS.%26aulast%3DSchlenzig%26aufirst%3DD.%26aulast%3DFangh%25C3%25A4nel%26aufirst%3DJ.%26aulast%3DRahfeld%26aufirst%3DJ.-U.%26aulast%3DDemuth%26aufirst%3DH.-U.%26aulast%3DStubbs%26aufirst%3DM.%2BT.%26atitle%3DCrystal%2520Structure%2520of%2520the%2520Incretin-Bound%2520Extracellular%2520Domain%2520of%2520a%2520G%2520Protein-Coupled%2520Receptor%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2007%26volume%3D104%26issue%3D35%26spage%3D13942%26epage%3D13947%26doi%3D10.1073%2Fpnas.0706404104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jazayeri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rappas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, A. J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kean, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Errey, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiez-Vandal, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Congreve, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bortolato, A.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Crystal Structure of the GLP-1 Receptor Bound to a Peptide Agonist</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>546</i></span> (<span class="NLM_issue">7657</span>),  <span class="NLM_fpage">254</span>â <span class="NLM_lpage">258</span>, <span class="refDoi">Â DOI: 10.1038/nature22800</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=10.1038%2Fnature22800" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=28562585" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=1%3ACAS%3A528%3ADC%252BC2sXovFCrs70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=546&publication_year=2017&pages=254-258&issue=7657&author=A.+Jazayeriauthor=M.+Rappasauthor=A.+J.+H.+Brownauthor=J.+Keanauthor=J.+C.+Erreyauthor=N.+J.+Robertsonauthor=C.+Fiez-Vandalauthor=S.+P.+Andrewsauthor=M.+Congreveauthor=A.+Bortolato&title=Crystal+Structure+of+the+GLP-1+Receptor+Bound+to+a+Peptide+Agonist&doi=10.1038%2Fnature22800"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of the GLP-1 receptor bound to a peptide agonist</span></div><div class="casAuthors">Jazayeri, Ali; Rappas, Mathieu; Brown, Alastair J. H.; Kean, James; Errey, James C.; Robertson, Nathan J.; Fiez-Vandal, Cedric; Andrews, Stephen P.; Congreve, Miles; Bortolato, Andrea; Mason, Jonathan S.; Baig, Asma H.; Teobald, Iryna; Dore, Andrew S.; Weir, Malcolm; Cooke, Robert M.; Marshall, Fiona H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">546</span>
        (<span class="NLM_cas:issue">7657</span>),
    <span class="NLM_cas:pages">254-258</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Glucagon-like peptide 1 (GLP-1) regulates glucose homeostasis through the control of insulin release from the pancreas.  GLP-1 peptide agonists are efficacious drugs for the treatment of diabetes.  To gain insight into the mol. mechanism of action of GLP-1 peptides, here we report the crystal structure of the full-length GLP-1 receptor bound to a truncated peptide agonist.  The peptide agonist retains an Î±-helical conformation as it sits deep within the receptor-binding pocket.  The arrangement of the transmembrane helixes reveals hallmarks of an active conformation similar to that obsd. in class A receptors.  Guided by this structural information, we design peptide agonists with potent in vivo activity in a mouse model of diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoX6Ibc110QxrVg90H21EOLACvtfcHk0liUAWBjJ6Fadg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXovFCrs70%253D&md5=0a5c99161af8bae506a184e0ab6306c1</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1038%2Fnature22800&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature22800%26sid%3Dliteratum%253Aachs%26aulast%3DJazayeri%26aufirst%3DA.%26aulast%3DRappas%26aufirst%3DM.%26aulast%3DBrown%26aufirst%3DA.%2BJ.%2BH.%26aulast%3DKean%26aufirst%3DJ.%26aulast%3DErrey%26aufirst%3DJ.%2BC.%26aulast%3DRobertson%26aufirst%3DN.%2BJ.%26aulast%3DFiez-Vandal%26aufirst%3DC.%26aulast%3DAndrews%26aufirst%3DS.%2BP.%26aulast%3DCongreve%26aufirst%3DM.%26aulast%3DBortolato%26aufirst%3DA.%26atitle%3DCrystal%2520Structure%2520of%2520the%2520GLP-1%2520Receptor%2520Bound%2520to%2520a%2520Peptide%2520Agonist%26jtitle%3DNature%26date%3D2017%26volume%3D546%26issue%3D7657%26spage%3D254%26epage%3D258%26doi%3D10.1038%2Fnature22800" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarrasch, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun Kobilka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobilka, B. K.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Cryo-EM Structure of the Activated GLP-1 Receptor in Complex with a G Protein</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>546</i></span> (<span class="NLM_issue">7657</span>),  <span class="NLM_fpage">248</span>â <span class="NLM_lpage">253</span>, <span class="refDoi">Â DOI: 10.1038/nature22394</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=10.1038%2Fnature22394" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=28538729" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=1%3ACAS%3A528%3ADC%252BC2sXosVagtLo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=546&publication_year=2017&pages=248-253&issue=7657&author=Y.+Zhangauthor=B.+Sunauthor=D.+Fengauthor=H.+Huauthor=M.+Chuauthor=Q.+Quauthor=J.+T.+Tarraschauthor=S.+Liauthor=T.+Sun+Kobilkaauthor=B.+K.+Kobilka&title=Cryo-EM+Structure+of+the+Activated+GLP-1+Receptor+in+Complex+with+a+G+Protein&doi=10.1038%2Fnature22394"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Cryo-EM structure of the activated GLP-1 receptor in complex with a G protein</span></div><div class="casAuthors">Zhang, Yan; Sun, Bingfa; Feng, Dan; Hu, Hongli; Chu, Matthew; Qu, Qianhui; Tarrasch, Jeffrey T.; Li, Shane; Sun Kobilka, Tong; Kobilka, Brian K.; Skiniotis, Georgios</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">546</span>
        (<span class="NLM_cas:issue">7657</span>),
    <span class="NLM_cas:pages">248-253</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Glucagon-like peptide 1 (GLP-1) is a hormone with essential roles in regulating insulin secretion, carbohydrate metab. and appetite.  GLP-1 effects are mediated through binding to the GLP-1 receptor (GLP-1R), a class B G-protein-coupled receptor (GPCR) that signals primarily through the stimulatory G protein Gs.  Class B GPCRs are important therapeutic targets; however, our understanding of their mechanism of action is limited by the lack of structural information on activated and full-length receptors.  Here we report the cryo-electron microscopy structure of the peptide-activated GLP-1R-Gs complex at near at. resoln.  The peptide is clasped between the N-terminal domain and the transmembrane core of the receptor, and further stabilized by extracellular loops.  Conformational changes in the transmembrane domain result in a sharp kink in the middle of transmembrane helix 6, which pivots its intracellular half outward to accommodate the Î±5-helix of the Ras-like domain of Gs.  These results provide a structural framework for understanding class B GPCR activation through hormone binding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmDRFGRwMs1bVg90H21EOLACvtfcHk0liUAWBjJ6Fadg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXosVagtLo%253D&md5=5e7ebd94012ba47ecc299ad0502975de</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1038%2Fnature22394&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature22394%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DB.%26aulast%3DFeng%26aufirst%3DD.%26aulast%3DHu%26aufirst%3DH.%26aulast%3DChu%26aufirst%3DM.%26aulast%3DQu%26aufirst%3DQ.%26aulast%3DTarrasch%26aufirst%3DJ.%2BT.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DSun%2BKobilka%26aufirst%3DT.%26aulast%3DKobilka%26aufirst%3DB.%2BK.%26atitle%3DCryo-EM%2520Structure%2520of%2520the%2520Activated%2520GLP-1%2520Receptor%2520in%2520Complex%2520with%2520a%2520G%2520Protein%26jtitle%3DNature%26date%3D2017%26volume%3D546%26issue%3D7657%26spage%3D248%26epage%3D253%26doi%3D10.1038%2Fnature22394" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiao, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Graaf, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reedtz-Runge, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dharmarajan, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, G. W.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Structure of the Full-Length Glucagon Class B G-Protein-Coupled Receptor</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>546</i></span> (<span class="NLM_issue">7657</span>),  <span class="NLM_fpage">259</span>â <span class="NLM_lpage">264</span>, <span class="refDoi">Â DOI: 10.1038/nature22363</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=10.1038%2Fnature22363" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=28514451" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnvVCku7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=546&publication_year=2017&pages=259-264&issue=7657&author=H.+Zhangauthor=A.+Qiaoauthor=D.+Yangauthor=L.+Yangauthor=A.+Daiauthor=C.+de+Graafauthor=S.+Reedtz-Rungeauthor=V.+Dharmarajanauthor=H.+Zhangauthor=G.+W.+Han&title=Structure+of+the+Full-Length+Glucagon+Class+B+G-Protein-Coupled+Receptor&doi=10.1038%2Fnature22363"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the full-length glucagon class B G-protein-coupled receptor</span></div><div class="casAuthors">Zhang, Haonan; Qiao, Anna; Yang, Dehua; Yang, Linlin; Dai, Antao; de Graaf, Chris; Reedtz-Runge, Steffen; Dharmarajan, Venkatasubramanian; Zhang, Hui; Han, Gye Won; Grant, Thomas D.; Sierra, Raymond G.; Weierstall, Uwe; Nelson, Garrett; Liu, Wei; Wu, Yanhong; Ma, Limin; Cai, Xiaoqing; Lin, Guangyao; Wu, Xiaoai; Geng, Zhi; Dong, Yuhui; Song, Gaojie; Griffin, Patrick R.; Lau, Jesper; Cherezov, Vadim; Yang, Huaiyu; Hanson, Michael A.; Stevens, Raymond C.; Zhao, Qiang; Jiang, Hualiang; Wang, Ming-Wei; Wu, Beili</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">546</span>
        (<span class="NLM_cas:issue">7657</span>),
    <span class="NLM_cas:pages">259-264</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The human glucagon receptor, GCGR, belongs to the class B G-protein-coupled receptor family and plays a key role in glucose homeostasis and the pathophysiol. of type 2 diabetes.  Here we report the 3.0 Ã crystal structure of full-length GCGR contg. both the extracellular domain and transmembrane domain in an inactive conformation.  The two domains are connected by a 12-residue segment termed the stalk, which adopts a Î²-strand conformation, instead of forming an Î±-helix as obsd. in the previously solved structure of the GCGR transmembrane domain.  The first extracellular loop exhibits a Î²-hairpin conformation and interacts with the stalk to form a compact Î²-sheet structure.  Hydrogen-deuterium exchange, disulfide crosslinking and mol. dynamics studies suggest that the stalk and the first extracellular loop have crit. roles in modulating peptide ligand binding and receptor activation.  These insights into the full-length GCGR structure deepen our understanding of the signalling mechanisms of class B G-protein-coupled receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKhOm2vnpsXrVg90H21EOLACvtfcHk0li61-C7xfw35g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnvVCku7Y%253D&md5=4d00c049ff817cbf720475ce3d555387</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1038%2Fnature22363&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature22363%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DQiao%26aufirst%3DA.%26aulast%3DYang%26aufirst%3DD.%26aulast%3DYang%26aufirst%3DL.%26aulast%3DDai%26aufirst%3DA.%26aulast%3Dde%2BGraaf%26aufirst%3DC.%26aulast%3DReedtz-Runge%26aufirst%3DS.%26aulast%3DDharmarajan%26aufirst%3DV.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DHan%26aufirst%3DG.%2BW.%26atitle%3DStructure%2520of%2520the%2520Full-Length%2520Glucagon%2520Class%2520B%2520G-Protein-Coupled%2520Receptor%26jtitle%3DNature%26date%3D2017%26volume%3D546%26issue%3D7657%26spage%3D259%26epage%3D264%26doi%3D10.1038%2Fnature22363" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiao, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Eps, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frederiksen, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yi, C.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Structure of the Glucagon Receptor in Complex with a Glucagon Analogue</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>553</i></span> (<span class="NLM_issue">7686</span>),  <span class="NLM_fpage">106</span>â <span class="NLM_lpage">110</span>, <span class="refDoi">Â DOI: 10.1038/nature25153</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=10.1038%2Fnature25153" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=29300013" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjsVOrsg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=553&publication_year=2018&pages=106-110&issue=7686&author=H.+Zhangauthor=A.+Qiaoauthor=L.+Yangauthor=N.+Van+Epsauthor=K.+S.+Frederiksenauthor=D.+Yangauthor=A.+Daiauthor=X.+Caiauthor=H.+Zhangauthor=C.+Yi&title=Structure+of+the+Glucagon+Receptor+in+Complex+with+a+Glucagon+Analogue&doi=10.1038%2Fnature25153"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the glucagon receptor in complex with a glucagon analogue</span></div><div class="casAuthors">Zhang, Haonan; Qiao, Anna; Yang, Linlin; Van Eps, Ned; Frederiksen, Klaus S.; Yang, Dehua; Dai, Antao; Cai, Xiaoqing; Zhang, Hui; Yi, Cuiying; Cao, Can; He, Lingli; Yang, Huaiyu; Lau, Jesper; Ernst, Oliver P.; Hanson, Michael A.; Stevens, Raymond C.; Wang, Ming-Wei; Reedtz-Runge, Steffen; Jiang, Hualiang; Zhao, Qiang; Wu, Beili</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">553</span>
        (<span class="NLM_cas:issue">7686</span>),
    <span class="NLM_cas:pages">106-110</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Class B G-protein-coupled receptors (GPCRs), which consist of an extracellular domain (ECD) and a transmembrane domain (TMD), respond to secretin peptides to play a key part in hormonal homeostasis, and are important therapeutic targets for a variety of diseases.  Previous work has suggested that peptide ligands bind to class B GPCRs according to a two-domain binding model, in which the C-terminal region of the peptide targets the ECD and the N-terminal region of the peptide binds to the TMD binding pocket.  Recently, three structures of class B GPCRs in complex with peptide ligands have been solved.  These structures provide essential insights into peptide ligand recognition by class B GPCRs.  However, owing to resoln. limitations, the specific mol. interactions for peptide binding to class B GPCRs remain ambiguous.  Moreover, these previously solved structures have different ECD conformations relative to the TMD, which introduces questions regarding interdomain conformational flexibility and the changes required for receptor activation.  Here we report the 3.0 Ã-resoln. crystal structure of the full-length human glucagon receptor (GCGR) in complex with a glucagon analog and partial agonist, NNC1702.  This structure provides mol. details of the interactions between GCGR and the peptide ligand.  It reveals a marked change in the relative orientation between the ECD and TMD of GCGR compared to the previously solved structure of the inactive GCGR-NNC0640-mAb1 complex.  Notably, the stalk region and the first extracellular loop undergo major conformational changes in secondary structure during peptide binding, forming key interactions with the peptide.  We further propose a dual binding-site trigger model for GCGR activation - which requires conformational changes of the stalk, first extracellular loop and TMD - that extends our understanding of the previously established two-domain peptide-binding model of class B GPCRs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5Y-KdGGlZ_rVg90H21EOLACvtfcHk0li61-C7xfw35g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjsVOrsg%253D%253D&md5=54066c14d972869df876e401c37f8a14</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1038%2Fnature25153&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature25153%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DQiao%26aufirst%3DA.%26aulast%3DYang%26aufirst%3DL.%26aulast%3DVan%2BEps%26aufirst%3DN.%26aulast%3DFrederiksen%26aufirst%3DK.%2BS.%26aulast%3DYang%26aufirst%3DD.%26aulast%3DDai%26aufirst%3DA.%26aulast%3DCai%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DYi%26aufirst%3DC.%26atitle%3DStructure%2520of%2520the%2520Glucagon%2520Receptor%2520in%2520Complex%2520with%2520a%2520Glucagon%2520Analogue%26jtitle%3DNature%26date%3D2018%26volume%3D553%26issue%3D7686%26spage%3D106%26epage%3D110%26doi%3D10.1038%2Fnature25153" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Finan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ottaway, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smiley, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clemmensen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chabenne, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Habegger, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, K.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">A Rationally Designed Monomeric Peptide Triagonist Corrects Obesity and Diabetes in Rodents</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">27</span>â <span class="NLM_lpage">36</span>, <span class="refDoi">Â DOI: 10.1038/nm.3761</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=10.1038%2Fnm.3761" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=25485909" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVCks73J" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=27-36&issue=1&author=B.+Finanauthor=B.+Yangauthor=N.+Ottawayauthor=D.+L.+Smileyauthor=T.+Maauthor=C.+Clemmensenauthor=J.+Chabenneauthor=L.+Zhangauthor=K.+M.+Habeggerauthor=K.+Fischer&title=A+Rationally+Designed+Monomeric+Peptide+Triagonist+Corrects+Obesity+and+Diabetes+in+Rodents&doi=10.1038%2Fnm.3761"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents</span></div><div class="casAuthors">Finan, Brian; Yang, Bin; Ottaway, Nickki; Smiley, David L.; Ma, Tao; Clemmensen, Christoffer; Chabenne, Joe; Zhang, Lianshan; Habegger, Kirk M.; Fischer, Katrin; Campbell, Jonathan E.; Sandoval, Darleen; Seeley, Randy J.; Bleicher, Konrad; Uhles, Sabine; Riboulet, William; Funk, Juergen; Hertel, Cornelia; Belli, Sara; Sebokova, Elena; Conde-Knape, Karin; Konkar, Anish; Drucker, Daniel J.; Gelfanov, Vasily; Pfluger, Paul T.; Mueller, Timo D.; Perez-Tilve, Diego; Di Marchi, Richard D.; Tschoep, Matthias H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">27-36</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We report the discovery of a new monomeric peptide that reduces body wt. and diabetic complications in rodent models of obesity by acting as an agonist at three key metabolically-related peptide hormone receptors: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) and glucagon receptors.  This triple agonist demonstrates supraphysiol. potency and equally aligned constituent activities at each receptor, all without cross-reactivity at other related receptors.  Such balanced unimol. triple agonism proved superior to any existing dual coagonists and best-in-class monoagonists to reduce body wt., enhance glycemic control and reverse hepatic steatosis in relevant rodent models.  Various loss-of-function models, including genetic knockout, pharmacol. blockade and selective chem. knockout, confirmed contributions of each constituent activity in vivo.  We demonstrate that these individual constituent activities harmonize to govern the overall metabolic efficacy, which predominantly results from synergistic glucagon action to increase energy expenditure, GLP-1 action to reduce caloric intake and improve glucose control, and GIP action to potentiate the incretin effect and buffer against the diabetogenic effect of inherent glucagon activity.  These preclin. studies suggest that, so far, this unimol., polypharmaceutical strategy has potential to be the most effective pharmacol. approach to reversing obesity and related metabolic disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDHrGvoJsN6LVg90H21EOLACvtfcHk0lgffrlnReMDqw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVCks73J&md5=9024ca9e43d498db95332d64e9e16039</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1038%2Fnm.3761&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.3761%26sid%3Dliteratum%253Aachs%26aulast%3DFinan%26aufirst%3DB.%26aulast%3DYang%26aufirst%3DB.%26aulast%3DOttaway%26aufirst%3DN.%26aulast%3DSmiley%26aufirst%3DD.%2BL.%26aulast%3DMa%26aufirst%3DT.%26aulast%3DClemmensen%26aufirst%3DC.%26aulast%3DChabenne%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DHabegger%26aufirst%3DK.%2BM.%26aulast%3DFischer%26aufirst%3DK.%26atitle%3DA%2520Rationally%2520Designed%2520Monomeric%2520Peptide%2520Triagonist%2520Corrects%2520Obesity%2520and%2520Diabetes%2520in%2520Rodents%26jtitle%3DNat.%2520Med.%26date%3D2015%26volume%3D21%26issue%3D1%26spage%3D27%26epage%3D36%26doi%3D10.1038%2Fnm.3761" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ward, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ottaway, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Tilve, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelfanov, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">TschÃ¶p, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiMarchi, R. D.</span></span> <span> </span><span class="NLM_article-title">Peptide Lipidation Stabilizes Structure to Enhance Biological Function</span>. <i>Mol. Metab.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">468</span>â <span class="NLM_lpage">479</span>, <span class="refDoi">Â DOI: 10.1016/j.molmet.2013.08.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=10.1016%2Fj.molmet.2013.08.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=24327962" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFOgt77K" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2013&pages=468-479&issue=4&author=B.+P.+Wardauthor=N.+L.+Ottawayauthor=D.+Perez-Tilveauthor=D.+Maauthor=V.+M.+Gelfanovauthor=M.+H.+Tsch%C3%B6pauthor=R.+D.+DiMarchi&title=Peptide+Lipidation+Stabilizes+Structure+to+Enhance+Biological+Function&doi=10.1016%2Fj.molmet.2013.08.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Peptide lipidation stabilizes structure to enhance biological function</span></div><div class="casAuthors">Ward, Brian P.; Ottaway, Nickki L.; Perez-Tilve, Diego; Ma, Dejian; Gelfanov, Vasily M.; Tschop, Matthias H.; DiMarchi, Richard D.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Metabolism</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">468-479</span>CODEN:
                <span class="NLM_cas:coden">MMOEAS</span>;
        ISSN:<span class="NLM_cas:issn">2212-8778</span>.
    
            (<span class="NLM_cas:orgname">Elsevier GmbH</span>)
        </div><div class="casAbstract">Medicines that decrease body wt. and restore nutrient tolerance could improve human diabetes and obesity treatment outcomes.  We developed lipid-acylated glucagon analogs that are co-agonists for the glucagon and glucagon-like peptide 1 receptors, and stimulate wt. loss and plasma glucose lowering in pre-diabetic obese mice.  Our studies identified lipid acylation (lipidation) can increase and balance in vitro potencies of select glucagon analogs for the two aforementioned receptors in a lipidation site-dependent manner.  A general capacity for lipidation to enhance the secondary structure of glucagon analogs was recognized, and the energetics of this effect quantified.  The mol. structure of a lipid-acylated glucagon analog in water was also characterized.  These results support that lipidation can modify biol. activity through thermodynamically-favorable intramol. interactions which stabilize structure.  This establishes use of lipidation to achieve specific pharmacol. and implicates similar endogenous post-translational modifications as physiol. tools capable of refining biol. action in means previously underappreciated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-nclxtgAVyLVg90H21EOLACvtfcHk0lgffrlnReMDqw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFOgt77K&md5=021ed975227b94ca2d47394d22e19d1a</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2Fj.molmet.2013.08.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molmet.2013.08.008%26sid%3Dliteratum%253Aachs%26aulast%3DWard%26aufirst%3DB.%2BP.%26aulast%3DOttaway%26aufirst%3DN.%2BL.%26aulast%3DPerez-Tilve%26aufirst%3DD.%26aulast%3DMa%26aufirst%3DD.%26aulast%3DGelfanov%26aufirst%3DV.%2BM.%26aulast%3DTsch%25C3%25B6p%26aufirst%3DM.%2BH.%26aulast%3DDiMarchi%26aufirst%3DR.%2BD.%26atitle%3DPeptide%2520Lipidation%2520Stabilizes%2520Structure%2520to%2520Enhance%2520Biological%2520Function%26jtitle%3DMol.%2520Metab.%26date%3D2013%26volume%3D2%26issue%3D4%26spage%3D468%26epage%3D479%26doi%3D10.1016%2Fj.molmet.2013.08.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">LÃ³pez
de Maturana, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willshaw, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuntzsch, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudolph, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donnelly, D.</span></span> <span> </span><span class="NLM_article-title">The Isolated N-Terminal Domain of the Glucagon-like Peptide-1 (GLP-1) Receptor Binds Exendin Peptides with Much Higher Affinity than GLP-1</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>278</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">10195</span>â <span class="NLM_lpage">10200</span>, <span class="refDoi">Â DOI: 10.1074/jbc.M212147200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=10.1074%2Fjbc.M212147200" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=278&publication_year=2003&pages=10195-10200&issue=12&author=R.+L%C3%B3pez%0Ade+Maturanaauthor=A.+Willshawauthor=A.+Kuntzschauthor=R.+Rudolphauthor=D.+Donnelly&title=The+Isolated+N-Terminal+Domain+of+the+Glucagon-like+Peptide-1+%28GLP-1%29+Receptor+Binds+Exendin+Peptides+with+Much+Higher+Affinity+than+GLP-1&doi=10.1074%2Fjbc.M212147200"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M212147200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M212147200%26sid%3Dliteratum%253Aachs%26aulast%3DL%25C3%25B3pez%2Bde%2BMaturana%26aufirst%3DR.%26aulast%3DWillshaw%26aufirst%3DA.%26aulast%3DKuntzsch%26aufirst%3DA.%26aulast%3DRudolph%26aufirst%3DR.%26aulast%3DDonnelly%26aufirst%3DD.%26atitle%3DThe%2520Isolated%2520N-Terminal%2520Domain%2520of%2520the%2520Glucagon-like%2520Peptide-1%2520%2528GLP-1%2529%2520Receptor%2520Binds%2520Exendin%2520Peptides%2520with%2520Much%2520Higher%2520Affinity%2520than%2520GLP-1%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2003%26volume%3D278%26issue%3D12%26spage%3D10195%26epage%3D10200%26doi%3D10.1074%2Fjbc.M212147200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lau, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloch, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">SchÃ¤ffer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pettersson, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spetzler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kofoed, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madsen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knudsen, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGuire, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steensgaard, D. B.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">7370</span>â <span class="NLM_lpage">7380</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.5b00726</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00726" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtl2qu7%252FM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=7370-7380&issue=18&author=J.+Lauauthor=P.+Blochauthor=L.+Sch%C3%A4fferauthor=I.+Petterssonauthor=J.+Spetzlerauthor=J.+Kofoedauthor=K.+Madsenauthor=L.+B.+Knudsenauthor=J.+McGuireauthor=D.+B.+Steensgaard&title=Discovery+of+the+Once-Weekly+Glucagon-Like+Peptide-1+%28GLP-1%29+Analogue+Semaglutide&doi=10.1021%2Facs.jmedchem.5b00726"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide</span></div><div class="casAuthors">Lau, Jesper; Bloch, Paw; Schaffer, Lauge; Pettersson, Ingrid; Spetzler, Jane; Kofoed, Jacob; Madsen, Kjeld; Knudsen, Lotte Bjerre; McGuire, James; Steensgaard, Dorte Bjerre; Strauss, Holger Martin; Gram, Dorte X.; Knudsen, Sanne Moeller; Nielsen, Flemming Seier; Thygesen, Peter; Reedtz-Runge, Steffen; Kruse, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">7370-7380</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Liraglutide is an acylated glucagon-like peptide-1 (GLP-1) analog that binds to serum albumin in vivo and is approved for once-daily treatment of diabetes as well as obesity.  The aim of the present studies was to design a once weekly GLP-1 analog by increasing albumin affinity and secure full stability against metabolic degrdn.  The fatty acid moiety and the linking chem. to GLP-1 were the key features to secure high albumin affinity and GLP-1 receptor (GLP-1R) potency and in obtaining a prolonged exposure and action of the GLP-1 analog.  Semaglutide was selected as the optimal once weekly candidate.  Semaglutide has two amino acid substitutions compared to human GLP-1 (Aib8, Arg34) and is derivatized at lysine 26.  The GLP-1R affinity of semaglutide (0.38 Â± 0.06 nM) was three-fold decreased compared to liraglutide, whereas the albumin affinity was increased.  The plasma half-life was 46.1 h in mini-pigs following i.v. administration, and semaglutide has an MRT of 63.6 h after s.c. dosing to mini-pigs.  Semaglutide is currently in phase 3 clin. testing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8tFc0FzEro7Vg90H21EOLACvtfcHk0lgjDBQ3I_snrA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtl2qu7%252FM&md5=0478fe17f9f4dcc0cb58919b1c55869a</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00726&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00726%26sid%3Dliteratum%253Aachs%26aulast%3DLau%26aufirst%3DJ.%26aulast%3DBloch%26aufirst%3DP.%26aulast%3DSch%25C3%25A4ffer%26aufirst%3DL.%26aulast%3DPettersson%26aufirst%3DI.%26aulast%3DSpetzler%26aufirst%3DJ.%26aulast%3DKofoed%26aufirst%3DJ.%26aulast%3DMadsen%26aufirst%3DK.%26aulast%3DKnudsen%26aufirst%3DL.%2BB.%26aulast%3DMcGuire%26aufirst%3DJ.%26aulast%3DSteensgaard%26aufirst%3DD.%2BB.%26atitle%3DDiscovery%2520of%2520the%2520Once-Weekly%2520Glucagon-Like%2520Peptide-1%2520%2528GLP-1%2529%2520Analogue%2520Semaglutide%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26issue%3D18%26spage%3D7370%26epage%3D7380%26doi%3D10.1021%2Facs.jmedchem.5b00726" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khoshouei, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glukhova, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furness, S. G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clydesdale, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koole, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Truong, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thal, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lei, S.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Phase-Plate Cryo-EM Structure of a Biased Agonist-Bound Human GLP-1 Receptor-Gs Complex</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>555</i></span> (<span class="NLM_issue">7694</span>),  <span class="NLM_fpage">121</span>â <span class="NLM_lpage">125</span>, <span class="refDoi">Â DOI: 10.1038/nature25773</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=10.1038%2Fnature25773" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=29466332" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjtFCktrk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=555&publication_year=2018&pages=121-125&issue=7694&author=Y.-L.+Liangauthor=M.+Khoshoueiauthor=A.+Glukhovaauthor=S.+G.+B.+Furnessauthor=P.+Zhaoauthor=L.+Clydesdaleauthor=C.+Kooleauthor=T.+T.+Truongauthor=D.+M.+Thalauthor=S.+Lei&title=Phase-Plate+Cryo-EM+Structure+of+a+Biased+Agonist-Bound+Human+GLP-1+Receptor-Gs+Complex&doi=10.1038%2Fnature25773"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Phase-plate cryo-EM structure of a biased agonist-bound human GLP-1 receptor-Gs complex</span></div><div class="casAuthors">Liang, Yi-Lynn; Khoshouei, Maryam; Glukhova, Alisa; Furness, Sebastian G. B.; Zhao, Peishen; Clydesdale, Lachlan; Koole, Cassandra; Truong, Tin T.; Thal, David M.; Lei, Saifei; Radjainia, Mazdak; Danev, Radostin; Baumeister, Wolfgang; Wang, Ming-Wei; Miller, Laurence J.; Christopoulos, Arthur; Sexton, Patrick M.; Wootten, Denise</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">555</span>
        (<span class="NLM_cas:issue">7694</span>),
    <span class="NLM_cas:pages">121-125</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">The class B glucagon-like peptide-1 (GLP-1) G protein-coupled receptor is a major target for the treatment of type 2 diabetes and obesity.  Endogenous and mimetic GLP-1 peptides exhibit biased agonism-a difference in functional selectivity-that may provide improved therapeutic outcomes.  Here we describe the structure of the human GLP-1 receptor in complex with the G protein-biased peptide exendin-P5 and a GÎ±s heterotrimer, detd. at a global resoln. of 3.3 Ã.  At the extracellular surface, the organization of extracellular loop 3 and proximal transmembrane segments differs between our exendin-P5-bound structure and previous GLP-1-bound GLP-1 receptor structure.  At the intracellular face, there was a six-degree difference in the angle of the GÎ±s-Î±5 helix engagement between structures, which was propagated across the G protein heterotrimer.  In addn., the structures differed in the rate and extent of conformational reorganization of the GÎ±s protein.  Our structure provides insights into the mol. basis of biased agonism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaUGOXZxHlNLVg90H21EOLACvtfcHk0lgjDBQ3I_snrA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjtFCktrk%253D&md5=dbb6b8d6cd394d76b74bfabc26f7b62c</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1038%2Fnature25773&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature25773%26sid%3Dliteratum%253Aachs%26aulast%3DLiang%26aufirst%3DY.-L.%26aulast%3DKhoshouei%26aufirst%3DM.%26aulast%3DGlukhova%26aufirst%3DA.%26aulast%3DFurness%26aufirst%3DS.%2BG.%2BB.%26aulast%3DZhao%26aufirst%3DP.%26aulast%3DClydesdale%26aufirst%3DL.%26aulast%3DKoole%26aufirst%3DC.%26aulast%3DTruong%26aufirst%3DT.%2BT.%26aulast%3DThal%26aufirst%3DD.%2BM.%26aulast%3DLei%26aufirst%3DS.%26atitle%3DPhase-Plate%2520Cryo-EM%2520Structure%2520of%2520a%2520Biased%2520Agonist-Bound%2520Human%2520GLP-1%2520Receptor-Gs%2520Complex%26jtitle%3DNature%26date%3D2018%26volume%3D555%26issue%3D7694%26spage%3D121%26epage%3D125%26doi%3D10.1038%2Fnature25773" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">GÃ¶ke, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fehmann, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linn, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krause, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">GÃ¶ke, B.</span></span> <span> </span><span class="NLM_article-title">Exendin-4 Is a High Potency Agonist and Truncated Exendin-(9â39)-Amide an Antagonist at the Glucagon-like Peptide 1-(7â36)-Amide Receptor of Insulin-Secreting Beta-Cells</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>268</i></span> (<span class="NLM_issue">26</span>),  <span class="NLM_fpage">19650</span>â <span class="NLM_lpage">19655</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=268&publication_year=1993&pages=19650-19655&issue=26&author=R.+G%C3%B6keauthor=H.+C.+Fehmannauthor=T.+Linnauthor=H.+Schmidtauthor=M.+Krauseauthor=J.+Engauthor=B.+G%C3%B6ke&title=Exendin-4+Is+a+High+Potency+Agonist+and+Truncated+Exendin-%289%E2%80%9339%29-Amide+an+Antagonist+at+the+Glucagon-like+Peptide+1-%287%E2%80%9336%29-Amide+Receptor+of+Insulin-Secreting+Beta-Cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DG%25C3%25B6ke%26aufirst%3DR.%26aulast%3DFehmann%26aufirst%3DH.%2BC.%26aulast%3DLinn%26aufirst%3DT.%26aulast%3DSchmidt%26aufirst%3DH.%26aulast%3DKrause%26aufirst%3DM.%26aulast%3DEng%26aufirst%3DJ.%26aulast%3DG%25C3%25B6ke%26aufirst%3DB.%26atitle%3DExendin-4%2520Is%2520a%2520High%2520Potency%2520Agonist%2520and%2520Truncated%2520Exendin-%25289%25E2%2580%259339%2529-Amide%2520an%2520Antagonist%2520at%2520the%2520Glucagon-like%2520Peptide%25201-%25287%25E2%2580%259336%2529-Amide%2520Receptor%2520of%2520Insulin-Secreting%2520Beta-Cells%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1993%26volume%3D268%26issue%3D26%26spage%3D19650%26epage%3D19655" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Montrose-Rafizadeh, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodgers, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beday, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pritchette, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eng, J.</span></span> <span> </span><span class="NLM_article-title">High Potency Antagonists of the Pancreatic Glucagon-like Peptide-1 Receptor</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>272</i></span> (<span class="NLM_issue">34</span>),  <span class="NLM_fpage">21201</span>â <span class="NLM_lpage">21206</span>, <span class="refDoi">Â DOI: 10.1074/jbc.272.34.21201</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=10.1074%2Fjbc.272.34.21201" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=9261127" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=1%3ACAS%3A528%3ADyaK2sXls1Ojt7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=272&publication_year=1997&pages=21201-21206&issue=34&author=C.+Montrose-Rafizadehauthor=H.+Yangauthor=B.+D.+Rodgersauthor=A.+Bedayauthor=L.+A.+Pritchetteauthor=J.+Eng&title=High+Potency+Antagonists+of+the+Pancreatic+Glucagon-like+Peptide-1+Receptor&doi=10.1074%2Fjbc.272.34.21201"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">High potency antagonists of the pancreatic glucagon-like peptide-1 receptor</span></div><div class="casAuthors">Montrose-Rafizadeh, Chahrzad; Yang, Huan; Rodgers, Buel D.; Beday, Alvie; Pritchette, Louella A.; Eng, John</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">272</span>
        (<span class="NLM_cas:issue">34</span>),
    <span class="NLM_cas:pages">21201-21206</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">GLP-1-(7-36)-amide and exendin-4-(1-39) are glucagon-like peptide-1 (GLP-1) receptor agonists, whereas exendin-(9-39) is the only known antagonist.  To analyze the transition from agonist to antagonist and to identify the amino acid residues involved in ligand activation of the GLP-1 receptor, we used exendin analogs with successive N-terminal truncations.  Chinese hamster ovary cells stably transfected with the rat GLP-1 receptor were assayed for changes in intracellular cAMP caused by the test peptides in the absence or presence of half-maximal stimulatory doses of GLP-1.  N-terminal truncation of a single amino acid reduced the agonist activity of the exendin peptide, whereas N-terminal truncation of 3-7 amino acids produced antagonists that were 4-10-fold more potent than exendin-(9-39).  N-terminal truncation of GLP-1 by 2 amino acids resulted in weak agonist activity, but an 8-amino acid N-terminal truncation inactivated the peptide.  Binding studies performed using 125I-labeled GLP-1 confirmed that all bioactive peptides specifically displaced tracer with high potency.  In a set of exendin/GLP-1 chimeric peptides, substitution of GLP-1 sequences into exendin-(3-39) produced loss of antagonist activity with conversion to a weak agonist.  The results show that receptor binding and activation occur in sep. domains of exendin, but they are more closely coupled in GLP-1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpN_gVlQBZ16rVg90H21EOLACvtfcHk0ljm-423THCI7A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXls1Ojt7c%253D&md5=d686fa97a141d335de910a233fd159d2</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1074%2Fjbc.272.34.21201&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.272.34.21201%26sid%3Dliteratum%253Aachs%26aulast%3DMontrose-Rafizadeh%26aufirst%3DC.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DRodgers%26aufirst%3DB.%2BD.%26aulast%3DBeday%26aufirst%3DA.%26aulast%3DPritchette%26aufirst%3DL.%2BA.%26aulast%3DEng%26aufirst%3DJ.%26atitle%3DHigh%2520Potency%2520Antagonists%2520of%2520the%2520Pancreatic%2520Glucagon-like%2520Peptide-1%2520Receptor%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1997%26volume%3D272%26issue%3D34%26spage%3D21201%26epage%3D21206%26doi%3D10.1074%2Fjbc.272.34.21201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishnan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerwin, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manning, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Randolph, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carpenter, J. F.</span></span> <span> </span><span class="NLM_article-title">Mechanism for Benzyl Alcohol-Induced Aggregation of Recombinant Human Interleukin-1 Receptor Antagonist in Aqueous Solution</span>. <i>J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>93</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">3076</span>â <span class="NLM_lpage">3089</span>, <span class="refDoi">Â DOI: 10.1002/jps.20219</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=10.1002%2Fjps.20219" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2004&pages=3076-3089&issue=12&author=Y.+Zhangauthor=S.+Royauthor=L.+S.+Jonesauthor=S.+Krishnanauthor=B.+A.+Kerwinauthor=B.+S.+Changauthor=M.+C.+Manningauthor=T.+W.+Randolphauthor=J.+F.+Carpenter&title=Mechanism+for+Benzyl+Alcohol-Induced+Aggregation+of+Recombinant+Human+Interleukin-1+Receptor+Antagonist+in+Aqueous+Solution&doi=10.1002%2Fjps.20219"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1002%2Fjps.20219&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjps.20219%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DRoy%26aufirst%3DS.%26aulast%3DJones%26aufirst%3DL.%2BS.%26aulast%3DKrishnan%26aufirst%3DS.%26aulast%3DKerwin%26aufirst%3DB.%2BA.%26aulast%3DChang%26aufirst%3DB.%2BS.%26aulast%3DManning%26aufirst%3DM.%2BC.%26aulast%3DRandolph%26aufirst%3DT.%2BW.%26aulast%3DCarpenter%26aufirst%3DJ.%2BF.%26atitle%3DMechanism%2520for%2520Benzyl%2520Alcohol-Induced%2520Aggregation%2520of%2520Recombinant%2520Human%2520Interleukin-1%2520Receptor%2520Antagonist%2520in%2520Aqueous%2520Solution%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2004%26volume%3D93%26issue%3D12%26spage%3D3076%26epage%3D3089%26doi%3D10.1002%2Fjps.20219" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prasad-Reddy, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isaacs, D.</span></span> <span> </span><span class="NLM_article-title">A Clinical Review of GLP-1 Receptor Agonists: Efficacy and Safety in Diabetes and Beyond</span>. <i>Drugs Context</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">1</span>, <span class="refDoi">Â DOI: 10.7573/dic.212283</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=10.7573%2Fdic.212283" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2015&pages=1&author=L.+Prasad-Reddyauthor=D.+Isaacs&title=A+Clinical+Review+of+GLP-1+Receptor+Agonists%3A+Efficacy+and+Safety+in+Diabetes+and+Beyond&doi=10.7573%2Fdic.212283"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.7573%2Fdic.212283&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7573%252Fdic.212283%26sid%3Dliteratum%253Aachs%26aulast%3DPrasad-Reddy%26aufirst%3DL.%26aulast%3DIsaacs%26aufirst%3DD.%26atitle%3DA%2520Clinical%2520Review%2520of%2520GLP-1%2520Receptor%2520Agonists%253A%2520Efficacy%2520and%2520Safety%2520in%2520Diabetes%2520and%2520Beyond%26jtitle%3DDrugs%2520Context%26date%3D2015%26volume%3D4%26spage%3D1%26doi%3D10.7573%2Fdic.212283" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Overgaard, R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petri, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobsen, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, C. B.</span></span> <span> </span><span class="NLM_article-title">Liraglutide 3.0 Mg for Weight Management: A Population Pharmacokinetic Analysis</span>. <i>Clin. Pharmacokinet.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1413</span>â <span class="NLM_lpage">1422</span>, <span class="refDoi">Â DOI: 10.1007/s40262-016-0410-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=10.1007%2Fs40262-016-0410-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=27193270" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=1%3ACAS%3A528%3ADC%252BC28Xot1yrsrg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2016&pages=1413-1422&issue=11&author=R.+V.+Overgaardauthor=K.+C.+Petriauthor=L.+V.+Jacobsenauthor=C.+B.+Jensen&title=Liraglutide+3.0+Mg+for+Weight+Management%3A+A+Population+Pharmacokinetic+Analysis&doi=10.1007%2Fs40262-016-0410-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Liraglutide 3.0 mg for Weight Management: A Population Pharmacokinetic Analysis</span></div><div class="casAuthors">Overgaard, Rune V.; Petri, Kristin C.; Jacobsen, Lisbeth V.; Jensen, Christine B.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1413-1422</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Background and Objectives: This anal. used a population pharmacokinetic approach to identify covariates that influence plasma exposure of liraglutide 3.0 mg, a glucagon-like peptide-1 (GLP-1) receptor agonist approved for wt. management in overweight and obese individuals.  Methods: Samples for pharmacokinetic anal. were drawn at weeks 2, 12 and 28 of the phase IIIa SCALE Obesity and Prediabetes (N = 2339) and SCALE Diabetes (N = 584) trials.  Dose proportionality of liraglutide in obese subjects was investigated using data from a phase II dose-finding study (N = 331).  Results: Dose-proportional exposure of liraglutide up to and including 3.0 mg was confirmed.  Body wt. and sex influenced exposure of liraglutide 3.0 mg, while age â¥70 years, race, ethnicity and baseline glycemic status did not.  Compared with a ref. subject weighing 100 kg, exposure of liraglutide 3.0 mg was 44 % lower for a subject weighing 234 kg (90 % CI 41-47), 41 % higher for a subject weighing 60 kg (90 % CI 37-46), and 32 % higher (90 % CI 28-35) in females than males with the same body wt.  Neither injection site nor renal function significantly influenced exposure of liraglutide 3.0 mg (post hoc anal.).  Conclusion: Population pharmacokinetics of liraglutide up to and including 3.0 mg daily in overweight and obese adults demonstrated dose-proportional exposure, and limited effect of covariates other than sex and body wt.  These findings were similar to those previously obsd. with liraglutide up to 1.8 mg in subjects with type 2 diabetes mellitus.  Further anal. of exposure-response relationship and its effect on dose requirements is addressed in a sep. publication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSoD9Bkl8VebVg90H21EOLACvtfcHk0li1zsTCxT8S8w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xot1yrsrg%253D&md5=daddcec2c0844b13bf3fb22c3495eda3</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1007%2Fs40262-016-0410-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40262-016-0410-7%26sid%3Dliteratum%253Aachs%26aulast%3DOvergaard%26aufirst%3DR.%2BV.%26aulast%3DPetri%26aufirst%3DK.%2BC.%26aulast%3DJacobsen%26aufirst%3DL.%2BV.%26aulast%3DJensen%26aufirst%3DC.%2BB.%26atitle%3DLiraglutide%25203.0%2520Mg%2520for%2520Weight%2520Management%253A%2520A%2520Population%2520Pharmacokinetic%2520Analysis%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D2016%26volume%3D55%26issue%3D11%26spage%3D1413%26epage%3D1422%26doi%3D10.1007%2Fs40262-016-0410-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span> <i>MacroModel</i>; SchrÃ¶dinger <a href="https://www.schrodinger.com/macromodel" class="extLink">https://www.schrodinger.com/macromodel</a> (accessed Jan 31, <span class="NLM_year">2018</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+MacroModel%3B+Schr%C3%B6dinger+https%3A%2F%2Fwww.schrodinger.com%2Fmacromodel+%28accessed+Jan+31%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DMacroModel%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span> <i>PyMOL</i>; SchrÃ¶dinger <a href="https://www.schrodinger.com/pymol" class="extLink">https://www.schrodinger.com/pymol</a> (accessed Jan 31, <span class="NLM_year">2018</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+PyMOL%3B+Schr%C3%B6dinger+https%3A%2F%2Fwww.schrodinger.com%2Fpymol+%28accessed+Jan+31%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DPyMOL%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chhabra, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hothi, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bycroft, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, W. C.</span></span> <span> </span><span class="NLM_article-title">An Appraisal of New Variants of Dde Amine Protecting Group for Solid Phase Peptide Synthesis</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>39</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1603</span>â <span class="NLM_lpage">1606</span>, <span class="refDoi">Â DOI: 10.1016/S0040-4039(97)10828-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=10.1016%2FS0040-4039%2897%2910828-0" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1998&pages=1603-1606&issue=12&author=S.+R.+Chhabraauthor=B.+Hothiauthor=D.+J.+Evansauthor=P.+D.+Whiteauthor=B.+W.+Bycroftauthor=W.+C.+Chan&title=An+Appraisal+of+New+Variants+of+Dde+Amine+Protecting+Group+for+Solid+Phase+Peptide+Synthesis&doi=10.1016%2FS0040-4039%2897%2910828-0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2FS0040-4039%2897%2910828-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0040-4039%252897%252910828-0%26sid%3Dliteratum%253Aachs%26aulast%3DChhabra%26aufirst%3DS.%2BR.%26aulast%3DHothi%26aufirst%3DB.%26aulast%3DEvans%26aufirst%3DD.%2BJ.%26aulast%3DWhite%26aufirst%3DP.%2BD.%26aulast%3DBycroft%26aufirst%3DB.%2BW.%26aulast%3DChan%26aufirst%3DW.%2BC.%26atitle%3DAn%2520Appraisal%2520of%2520New%2520Variants%2520of%2520Dde%2520Amine%2520Protecting%2520Group%2520for%2520Solid%2520Phase%2520Peptide%2520Synthesis%26jtitle%3DTetrahedron%2520Lett.%26date%3D1998%26volume%3D39%26issue%3D12%26spage%3D1603%26epage%3D1606%26doi%3D10.1016%2FS0040-4039%2897%2910828-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">King, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fields, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fields, G. B.</span></span> <span> </span><span class="NLM_article-title">A Cleavage Method Which Minimizes Side Reactions Following Fmoc Solid Phase Peptide Synthesis</span>. <i>Int. J. Pept. Protein Res.</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>36</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">255</span>â <span class="NLM_lpage">266</span>, <span class="refDoi">Â DOI: 10.1111/j.1399-3011.1990.tb00976.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=10.1111%2Fj.1399-3011.1990.tb00976.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=2279849" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=1%3ACAS%3A528%3ADyaK3MXisVGktg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1990&pages=255-266&issue=3&author=D.+S.+Kingauthor=C.+G.+Fieldsauthor=G.+B.+Fields&title=A+Cleavage+Method+Which+Minimizes+Side+Reactions+Following+Fmoc+Solid+Phase+Peptide+Synthesis&doi=10.1111%2Fj.1399-3011.1990.tb00976.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">A cleavage method which minimizes side reactions following Fmoc solid phase peptide synthesis</span></div><div class="casAuthors">King, David S.; Fields, Cynthia G.; Fields, Gregg B.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Peptide & Protein Research</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">255-66</span>CODEN:
                <span class="NLM_cas:coden">IJPPC3</span>;
        ISSN:<span class="NLM_cas:issn">0367-8377</span>.
    </div><div class="casAbstract">The success of solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl (Fmoc) amino acids is often limited by deleterious side reactions which occur during CF3CO2H (TFA) peptide-resin cleavage and side-chain deprotection.  The majority of these side reactions modify susceptible residues, such as Trp, Tyr, Met, and Cys, with TFA-liberated side-chain protecting groups and linkers.  The relative effectiveness of various scavengers in suppressing these side reactions was studied.  The cleavage mixt. 82.5% TFA : 5% H2O : 5% thioanisole : 2.5% 1,2-ethanedithiol (reagent K) was maximally efficient in inhibiting a great variety of side reactions.  Synthesis and cleavage of 10 peptides, each contg. 20-50 residues, demonstrated the complementarity of Fmoc chem. with reagent K for efficient synthesis of complex peptide.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUwcooNm7oD7Vg90H21EOLACvtfcHk0li1zsTCxT8S8w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXisVGktg%253D%253D&md5=ecf761fc6877559af82062c6345306ab</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1111%2Fj.1399-3011.1990.tb00976.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1399-3011.1990.tb00976.x%26sid%3Dliteratum%253Aachs%26aulast%3DKing%26aufirst%3DD.%2BS.%26aulast%3DFields%26aufirst%3DC.%2BG.%26aulast%3DFields%26aufirst%3DG.%2BB.%26atitle%3DA%2520Cleavage%2520Method%2520Which%2520Minimizes%2520Side%2520Reactions%2520Following%2520Fmoc%2520Solid%2520Phase%2520Peptide%2520Synthesis%26jtitle%3DInt.%2520J.%2520Pept.%2520Protein%2520Res.%26date%3D1990%26volume%3D36%26issue%3D3%26spage%3D255%26epage%3D266%26doi%3D10.1111%2Fj.1399-3011.1990.tb00976.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kabsch, W.</span></span> <span> </span><span class="NLM_article-title">XDS</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>66</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">125</span>â <span class="NLM_lpage">132</span>, <span class="refDoi">Â DOI: 10.1107/S0907444909047337</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=10.1107%2FS0907444909047337" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=20124692" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1SisLc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2010&pages=125-132&issue=2&author=W.+Kabsch&title=XDS&doi=10.1107%2FS0907444909047337"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Software XDS for image rotation, recognition and crystal symmetry assignment</span></div><div class="casAuthors">Kabsch, Wolfgang</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">125-132</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">The usage and control of recent modifications of the program package XDS for the processing of rotation images are described in the context of previous versions.  New features include automatic detn. of spot size and reflecting range and recognition and assignment of crystal symmetry.  Moreover, the limitations of earlier package versions on the no. of correction/scaling factors and the representation of pixel contents have been removed.  Large program parts have been restructured for parallel processing so that the quality and completeness of collected data can be assessed soon after measurement.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpv5AyUw00DYbVg90H21EOLACvtfcHk0li1zsTCxT8S8w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1SisLc%253D&md5=1aa9a38aeb3ce95af4ffb7d8b8a142bd</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1107%2FS0907444909047337&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444909047337%26sid%3Dliteratum%253Aachs%26aulast%3DKabsch%26aufirst%3DW.%26atitle%3DXDS%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2010%26volume%3D66%26issue%3D2%26spage%3D125%26epage%3D132%26doi%3D10.1107%2FS0907444909047337" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Evans, P.</span></span> <span> </span><span class="NLM_article-title">Scaling and Assessment of Data Quality</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">72</span>â <span class="NLM_lpage">82</span>, <span class="refDoi">Â DOI: 10.1107/S0907444905036693</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=10.1107%2FS0907444905036693" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=16369096" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlant7jM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2006&pages=72-82&issue=1&author=P.+Evans&title=Scaling+and+Assessment+of+Data+Quality&doi=10.1107%2FS0907444905036693"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Scaling and assessment of data quality</span></div><div class="casAuthors">Evans, Philip</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">D62</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">72-82</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">The various phys. factors affecting measured diffraction intensities are discussed, as are the scaling models which may be used to put the data on a consistent scale.  After scaling, the intensities can be analyzed to set the real resoln. of the data set, to detect bad regions (e.g. bad images), to analyze radiation damage and to assess the overall quality of the data set.  The significance of any anomalous signal may be assessed by probability and correlation anal.  The algorithms used by the CCP4 scaling program SCALA are described.  A requirement for the scaling and merging of intensities is knowledge of the Laue group and point-group symmetries: the possible symmetry of the diffraction pattern may be detd. from scores such as correlation coeffs. between observations which might be symmetry-related.  These scoring functions are implemented in a new program POINTLESS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGravLSLU62RhLVg90H21EOLACvtfcHk0liqm7RW0F8QFA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlant7jM&md5=293d3876e534c0c57813990515bb3c76</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1107%2FS0907444905036693&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444905036693%26sid%3Dliteratum%253Aachs%26aulast%3DEvans%26aufirst%3DP.%26atitle%3DScaling%2520and%2520Assessment%2520of%2520Data%2520Quality%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2006%26volume%3D62%26issue%3D1%26spage%3D72%26epage%3D82%26doi%3D10.1107%2FS0907444905036693" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vonrhein, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flensburg, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharff, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smart, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paciorek, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Womack, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bricogne, G.</span></span> <span> </span><span class="NLM_article-title">Data Processing and Analysis with the AutoPROC Toolbox</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>67</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">293</span>â <span class="NLM_lpage">302</span>, <span class="refDoi">Â DOI: 10.1107/S0907444911007773</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=10.1107%2FS0907444911007773" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=21460447" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktFWqtLs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2011&pages=293-302&issue=4&author=C.+Vonrheinauthor=C.+Flensburgauthor=P.+Kellerauthor=A.+Sharffauthor=O.+Smartauthor=W.+Paciorekauthor=T.+Womackauthor=G.+Bricogne&title=Data+Processing+and+Analysis+with+the+AutoPROC+Toolbox&doi=10.1107%2FS0907444911007773"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Data processing and analysis with the autoPROC toolbox</span></div><div class="casAuthors">Vonrhein, Clemens; Flensburg, Claus; Keller, Peter; Sharff, Andrew; Smart, Oliver; Paciorek, Wlodek; Womack, Thomas; Bricogne, Gerard</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">293-302</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">A typical diffraction expt. will generate many images and data sets from different crystals in a very short time.  This creates a challenge for the high-throughput operation of modern synchrotron beamlines as well as for the subsequent data processing.  Novice users in particular may feel overwhelmed by the tables, plots and nos. that the different data-processing programs and software packages present to them.  Here, some of the more common problems that a user has to deal with when processing a set of images that will finally make up a processed data set are shown, concg. on difficulties that may often show up during the first steps along the path of turning the expt. (i.e. data collection) into a model (i.e. interpreted electron d.).  Difficulties such as unexpected crystal forms, issues in crystal handling and suboptimal choices of data-collection strategies can often be dealt with, or at least diagnosed, by analyzing specific data characteristics during processing.  In the end, one wants to distinguish problems over which one has no immediate control once the expt. is finished from problems that can be remedied a posteriori.  A new software package, autoPROC, is also presented that combines third-party processing programs with new tools and an automated workflow script that is intended to provide users with both guidance and insight into the offline processing of data affected by the difficulties mentioned above, with particular emphasis on the automated treatment of multi-sweep data sets collected on multi-axis goniostats.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmah7iUrMLXLVg90H21EOLACvtfcHk0liqm7RW0F8QFA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktFWqtLs%253D&md5=a0a3579f6b371b6312819883864aa80d</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1107%2FS0907444911007773&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444911007773%26sid%3Dliteratum%253Aachs%26aulast%3DVonrhein%26aufirst%3DC.%26aulast%3DFlensburg%26aufirst%3DC.%26aulast%3DKeller%26aufirst%3DP.%26aulast%3DSharff%26aufirst%3DA.%26aulast%3DSmart%26aufirst%3DO.%26aulast%3DPaciorek%26aufirst%3DW.%26aulast%3DWomack%26aufirst%3DT.%26aulast%3DBricogne%26aufirst%3DG.%26atitle%3DData%2520Processing%2520and%2520Analysis%2520with%2520the%2520AutoPROC%2520Toolbox%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2011%26volume%3D67%26issue%3D4%26spage%3D293%26epage%3D302%26doi%3D10.1107%2FS0907444911007773" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McCoy, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grosse-Kunstleve, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winn, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Storoni, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, R. J.</span></span> <span> </span><span class="NLM_article-title">Phaser Crystallographic Software</span>. <i>J. Appl. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>40</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">658</span>â <span class="NLM_lpage">674</span>, <span class="refDoi">Â DOI: 10.1107/S0021889807021206</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=10.1107%2FS0021889807021206" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=19461840" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnslWqsLk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2007&pages=658-674&issue=4&author=A.+J.+McCoyauthor=R.+W.+Grosse-Kunstleveauthor=P.+D.+Adamsauthor=M.+D.+Winnauthor=L.+C.+Storoniauthor=R.+J.+Read&title=Phaser+Crystallographic+Software&doi=10.1107%2FS0021889807021206"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Phaser crystallographic software</span></div><div class="casAuthors">McCoy, Airlie J.; Grosse-Kunstleve, Ralf W.; Adams, Paul D.; Winn, Martyn D.; Storoni, Laurent C.; Read, Randy J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Applied Crystallography</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">658-674</span>CODEN:
                <span class="NLM_cas:coden">JACGAR</span>;
        ISSN:<span class="NLM_cas:issn">0021-8898</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">Phaser is a program for phasing macromol. crystal structures by both mol. replacement and exptl. phasing methods.  The novel phasing algorithms implemented in Phaser have been developed using max. likelihood and multivariate statistics.  For mol. replacement, the new algorithms have proved to be significantly better than traditional methods in discriminating correct solns. from noise, and for single-wavelength anomalous dispersion exptl. phasing, the new algorithms, which account for correlations between F+ and F-, give better phases (lower mean phase error with respect to the phases given by the refined structure) than those that use mean F and anomalous differences ÎF.  One of the design concepts of Phaser was that it be capable of a high degree of automation.  To this end, Phaser (written in C++) can be called directly from Python, although it can also be called using traditional CCP4 keyword-style input.  Phaser is a platform for future development of improved phasing methods and their release, including source code, to the crystallog. community.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPeVyjN_FMGbVg90H21EOLACvtfcHk0liqm7RW0F8QFA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnslWqsLk%253D&md5=c63b722ae97e0a74e6a5a079d388f09f</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1107%2FS0021889807021206&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0021889807021206%26sid%3Dliteratum%253Aachs%26aulast%3DMcCoy%26aufirst%3DA.%2BJ.%26aulast%3DGrosse-Kunstleve%26aufirst%3DR.%2BW.%26aulast%3DAdams%26aufirst%3DP.%2BD.%26aulast%3DWinn%26aufirst%3DM.%2BD.%26aulast%3DStoroni%26aufirst%3DL.%2BC.%26aulast%3DRead%26aufirst%3DR.%2BJ.%26atitle%3DPhaser%2520Crystallographic%2520Software%26jtitle%3DJ.%2520Appl.%2520Crystallogr.%26date%3D2007%26volume%3D40%26issue%3D4%26spage%3D658%26epage%3D674%26doi%3D10.1107%2FS0021889807021206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Emsley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lohkamp, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowtan, K.</span></span> <span> </span><span class="NLM_article-title">Features and Development of Coot</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>66</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">486</span>â <span class="NLM_lpage">501</span>, <span class="refDoi">Â DOI: 10.1107/S0907444910007493</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=10.1107%2FS0907444910007493" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=20383002" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=1%3ACAS%3A528%3ADC%252BC3cXksFKisb8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2010&pages=486-501&issue=4&author=P.+Emsleyauthor=B.+Lohkampauthor=W.+G.+Scottauthor=K.+Cowtan&title=Features+and+Development+of+Coot&doi=10.1107%2FS0907444910007493"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Features and development of Coot</span></div><div class="casAuthors">Emsley, P.; Lohkamp, B.; Scott, W. G.; Cowtan, K.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">486-501</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">Coot is a mol.-graphics application for model building and validation of biol. macromols.  The program displays electron-d. maps and at. models and allows model manipulations such as idealization, real-space refinement, manual rotation/translation, rigid-body fitting, ligand search, solvation, mutations, rotamers and Ramachandran idealization.  Furthermore, tools are provided for model validation as well as interfaces to external programs for refinement, validation and graphics.  The software is designed to be easy to learn for novice users, which is achieved by ensuring that tools for common tasks are 'discoverable' through familiar user-interface elements (menus and toolbars) or by intuitive behavior (mouse controls).  Recent developments have focused on providing tools for expert users, with customisable key bindings, extensions and an extensive scripting interface.  The software is under rapid development, but has already achieved very widespread use within the crystallog. community.  The current state of the software is presented, with a description of the facilities available and of some of the underlying methods employed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAKBKszbqb_7Vg90H21EOLACvtfcHk0lioGaXBLKCdMg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXksFKisb8%253D&md5=67262cbfc60004de5ef962d5c043c910</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1107%2FS0907444910007493&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444910007493%26sid%3Dliteratum%253Aachs%26aulast%3DEmsley%26aufirst%3DP.%26aulast%3DLohkamp%26aufirst%3DB.%26aulast%3DScott%26aufirst%3DW.%2BG.%26aulast%3DCowtan%26aufirst%3DK.%26atitle%3DFeatures%2520and%2520Development%2520of%2520Coot%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2010%26volume%3D66%26issue%3D4%26spage%3D486%26epage%3D501%26doi%3D10.1107%2FS0907444910007493" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bricogne, G.</span>; <span class="NLM_string-name">Blanc, E.</span>; <span class="NLM_string-name">Brandl, M.</span>; <span class="NLM_string-name">Flensburg, C.</span>; <span class="NLM_string-name">Keller, P.</span>; <span class="NLM_string-name">Paciorek, W.</span>; <span class="NLM_string-name">Roversi, P.</span>; <span class="NLM_string-name">Sharff, A.</span>; <span class="NLM_string-name">Smart, O. S.</span>; <span class="NLM_string-name">Vonrhein, C.</span>; <span class="NLM_string-name">Womack, T. O.</span></span> <i>Buster 2011</i>; <span class="NLM_publisher-name">Global Phasing Ltd</span>: <span class="NLM_publisher-loc">Cambridge, United Kingdom</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=G.+Bricogne&author=E.+Blanc&author=M.+Brandl&author=C.+Flensburg&author=P.+Keller&author=W.+Paciorek&author=P.+Roversi&author=A.+Sharff&author=O.+S.+Smart&author=C.+Vonrhein&author=T.+O.+Womack&title=Buster+2011"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DBricogne%26aufirst%3DG.%26btitle%3DBuster%25202011%26pub%3DGlobal%2520Phasing%2520Ltd%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 20 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Chun Han, Yuqing Sun, Qimeng Yang, Feng Zhou, Xinyu Chen, Lintao Wu, Lidan Sun, <span class="NLM_string-name hlFld-ContribAuthor">Jing Han</span>. </span><span class="cited-content_cbyCitation_article-title">Stapled, Long-Acting Xenopus GLP-1-Based Dual GLP-1/Glucagon Receptor Agonists with Potent Therapeutic Efficacy for Metabolic Disease. </span><span class="cited-content_cbyCitation_journal-name">Molecular Pharmaceutics</span><span> <strong>2021,</strong> <em>18 </em>
                                    (8)
                                     , 2906-2923. <a href="https://doi.org/10.1021/acs.molpharmaceut.0c00995" title="DOI URL">https://doi.org/10.1021/acs.molpharmaceut.0c00995</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.molpharmaceut.0c00995&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.molpharmaceut.0c00995%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Pharmaceutics%26atitle%3DStapled%25252C%252BLong-Acting%252BXenopus%252BGLP-1-Based%252BDual%252BGLP-1%25252FGlucagon%252BReceptor%252BAgonists%252Bwith%252BPotent%252BTherapeutic%252BEfficacy%252Bfor%252BMetabolic%252BDisease%26aulast%3DHan%26aufirst%3DChun%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D2021%26date%3D05102020%26date%3D29062021%26date%3D24062021%26date%3D09072021%26volume%3D18%26issue%3D8%26spage%3D2906%26epage%3D2923" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Katharina Dauer, Walter Kamm, Karl Gerhard Wagner, <span class="NLM_string-name hlFld-ContribAuthor">Stefania Pfeiffer-Marek</span>. </span><span class="cited-content_cbyCitation_article-title">High-Throughput Screening for Colloidal Stability of Peptide Formulations Using Dynamic and Static Light Scattering. </span><span class="cited-content_cbyCitation_journal-name">Molecular Pharmaceutics</span><span> <strong>2021,</strong> <em>18 </em>
                                    (5)
                                     , 1939-1955. <a href="https://doi.org/10.1021/acs.molpharmaceut.0c01028" title="DOI URL">https://doi.org/10.1021/acs.molpharmaceut.0c01028</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.molpharmaceut.0c01028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.molpharmaceut.0c01028%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Pharmaceutics%26atitle%3DHigh-Throughput%252BScreening%252Bfor%252BColloidal%252BStability%252Bof%252BPeptide%252BFormulations%252BUsing%252BDynamic%252Band%252BStatic%252BLight%252BScattering%26aulast%3DDauer%26aufirst%3DKatharina%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D2021%26date%3D16102020%26date%3D18032021%26date%3D18032021%26date%3D31032021%26volume%3D18%26issue%3D5%26spage%3D1939%26epage%3D1955" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Dan Sindhikara, Michael Wagner, Paraskevi Gkeka, Stefan GÃ¼ssregen, Garima Tiwari, Gerhard Hessler, Engin Yapici, Ziyu Li, <span class="NLM_string-name hlFld-ContribAuthor">Andreas Evers</span>. </span><span class="cited-content_cbyCitation_article-title">Automated Design of Macrocycles for Therapeutic Applications: From Small Molecules to Peptides and Proteins. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (20)
                                     , 12100-12115. <a href="https://doi.org/10.1021/acs.jmedchem.0c01500" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01500</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01500&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01500%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DAutomated%252BDesign%252Bof%252BMacrocycles%252Bfor%252BTherapeutic%252BApplications%25253A%252BFrom%252BSmall%252BMolecules%252Bto%252BPeptides%252Band%252BProteins%26aulast%3DSindhikara%26aufirst%3DDan%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D27082020%26date%3D05102020%26volume%3D63%26issue%3D20%26spage%3D12100%26epage%3D12115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Wencheng Su, Huanbo Tan, Robert Janowski, Wenyu Zhang, Pengju Wang, Jie Zhang, Huanhuan Zhai, Jian Li, Dierk Niessing, Michael Sattler, <span class="NLM_string-name hlFld-ContribAuthor">Peijian Zou</span>. </span><span class="cited-content_cbyCitation_article-title">Ferritin-Displayed GLP-1 with Improved Pharmacological Activities and Pharmacokinetics. </span><span class="cited-content_cbyCitation_journal-name">Molecular Pharmaceutics</span><span> <strong>2020,</strong> <em>17 </em>
                                    (5)
                                     , 1663-1673. <a href="https://doi.org/10.1021/acs.molpharmaceut.0c00098" title="DOI URL">https://doi.org/10.1021/acs.molpharmaceut.0c00098</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.molpharmaceut.0c00098&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.molpharmaceut.0c00098%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Pharmaceutics%26atitle%3DFerritin-Displayed%252BGLP-1%252Bwith%252BImproved%252BPharmacological%252BActivities%252Band%252BPharmacokinetics%26aulast%3DSu%26aufirst%3DWencheng%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D30012020%26date%3D03042020%26date%3D02042020%26date%3D13042020%26date%3D03042020%26volume%3D17%26issue%3D5%26spage%3D1663%26epage%3D1673" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Lee E. Eiden, Ki Ann Goosens, Kenneth A. Jacobson, Lorenzo Leggio, <span class="NLM_string-name hlFld-ContribAuthor">Limei Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Peptide-Liganded G Protein-Coupled Receptors as Neurotherapeutics. </span><span class="cited-content_cbyCitation_journal-name">ACS Pharmacology & Translational Science</span><span> <strong>2020,</strong> <em>3 </em>
                                    (2)
                                     , 190-202. <a href="https://doi.org/10.1021/acsptsci.0c00017" title="DOI URL">https://doi.org/10.1021/acsptsci.0c00017</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsptsci.0c00017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsptsci.0c00017%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Pharmacology%2520%2526%2520Translational%2520Science%26atitle%3DPeptide-Liganded%252BG%252BProtein-Coupled%252BReceptors%252Bas%252BNeurotherapeutics%26aulast%3DEiden%26aufirst%3DLee%2BE.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D10022020%26date%3D25032020%26date%3D18032020%26volume%3D3%26issue%3D2%26spage%3D190%26epage%3D202" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">MarÃ­a MÃ©ndez, Hans Matter, Elisabeth Defossa, Michael Kurz, Sylvain Lebreton, Ziyu Li, Matthias Lohmann, Matthias LÃ¶hn, Hartmut Mors, Michael Podeschwa, Nils Rackelmann, Jens Riedel, Pavel Safar, David S. Thorpe, Matthias SchÃ¤fer, Dietmar Weitz, <span class="NLM_string-name hlFld-ContribAuthor">Kristin Breitschopf</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis, and Pharmacological Evaluation of Potent Positive Allosteric Modulators of the Glucagon-like Peptide-1 Receptor (GLP-1R). </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (5)
                                     , 2292-2307. <a href="https://doi.org/10.1021/acs.jmedchem.9b01071" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01071</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b01071%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252BSynthesis%25252C%252Band%252BPharmacological%252BEvaluation%252Bof%252BPotent%252BPositive%252BAllosteric%252BModulators%252Bof%252Bthe%252BGlucagon-like%252BPeptide-1%252BReceptor%252B%252528GLP-1R%252529%26aulast%3DM%25C3%25A9ndez%26aufirst%3DMar%25C3%25ADa%26date%3D2020%26date%3D2019%26date%3D2019%26date%3D03072019%26date%3D23102019%26date%3D09102019%26volume%3D63%26issue%3D5%26spage%3D2292%26epage%3D2307" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Esben
M. Bech, Anette Kaiser, Kathrin Bellmann-Sickert, SÃ¸ren S.-R. Nielsen, Kasper K. SÃ¸rensen, Lisbeth Elster, Nikos Hatzakis, SÃ¸ren L. Pedersen, Annette G. Beck-Sickinger, <span class="NLM_string-name hlFld-ContribAuthor">Knud J. Jensen</span>. </span><span class="cited-content_cbyCitation_article-title">Half-Life Extending Modifications of Peptide YY3â36 Direct Receptor-Mediated Internalization. </span><span class="cited-content_cbyCitation_journal-name">Molecular Pharmaceutics</span><span> <strong>2019,</strong> <em>16 </em>
                                    (8)
                                     , 3665-3677. <a href="https://doi.org/10.1021/acs.molpharmaceut.9b00554" title="DOI URL">https://doi.org/10.1021/acs.molpharmaceut.9b00554</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.molpharmaceut.9b00554&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.molpharmaceut.9b00554%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Pharmaceutics%26atitle%3DHalf-Life%252BExtending%252BModifications%252Bof%252BPeptide%252BYY3%2525E2%252580%25259336%252BDirect%252BReceptor-Mediated%252BInternalization%26aulast%3DBech%26aufirst%3DEsben%2BM.%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D22052019%26date%3D16072019%26date%3D10072019%26date%3D25072019%26date%3D16072019%26volume%3D16%26issue%3D8%26spage%3D3665%26epage%3D3677" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Michael  Wagner</span>, <span class="hlFld-ContribAuthor ">Andreas  Evers</span>, <span class="hlFld-ContribAuthor ">Martin  Bossart</span>, <span class="hlFld-ContribAuthor ">Anish  Konkar</span>. </span><span class="cited-content_cbyCitation_article-title">GlucagonâLike Peptideâ1 Receptor Activators. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 1-69. <a href="https://doi.org/10.1002/0471266949.bmc268" title="DOI URL">https://doi.org/10.1002/0471266949.bmc268</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/0471266949.bmc268&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F0471266949.bmc268%26sid%3Dliteratum%253Aachs%26atitle%3DGlucagon%2525E2%252580%252590Like%252BPeptide%2525E2%252580%2525901%252BReceptor%252BActivators%26aulast%3DWagner%26aufirst%3DMichael%26date%3D2021%26date%3D2021%26spage%3D1%26epage%3D69%26pub%3DWiley%26atitle%3DBurger%252527s%252BMedicinal%252BChemistry%252Band%252BDrug%252BDiscovery%26aulast%3DAbraham%26aufirst%3DDonald%2BJ.%26date%3D2003%26date%3D2003%26volume%3D12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Neng  Jiang</span>, <span class="hlFld-ContribAuthor ">Lin  Jing</span>, <span class="hlFld-ContribAuthor ">Qing  Li</span>, <span class="hlFld-ContribAuthor ">Sibiao  Su</span>, <span class="hlFld-ContribAuthor ">Qimeng  Yang</span>, <span class="hlFld-ContribAuthor ">Feng  Zhou</span>, <span class="hlFld-ContribAuthor ">Xinyu  Chen</span>, <span class="hlFld-ContribAuthor ">Jing  Han</span>, <span class="hlFld-ContribAuthor ">Chunli  Tang</span>, <span class="hlFld-ContribAuthor ">Weizhong  Tang</span>. </span><span class="cited-content_cbyCitation_article-title">Design of novel Xenopus GLP-1-based dual glucagon-like peptide 1 (GLP-1)/glucagon receptor agonists. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>212 </em>, 113118. <a href="https://doi.org/10.1016/j.ejmech.2020.113118" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.113118</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.113118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.113118%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Bof%252Bnovel%252BXenopus%252BGLP-1-based%252Bdual%252Bglucagon-like%252Bpeptide%252B1%252B%252528GLP-1%252529%25252Fglucagon%252Breceptor%252Bagonists%26aulast%3DJiang%26aufirst%3DNeng%26date%3D2021%26volume%3D212%26spage%3D113118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Suzanne M.  D'Addio</span>, <span class="hlFld-ContribAuthor ">Yongchao  Su</span>, <span class="hlFld-ContribAuthor ">Daniel  Yin</span>, <span class="hlFld-ContribAuthor ">Jingtao  Zhang</span>, <span class="hlFld-ContribAuthor ">Eric  Kemp</span>, <span class="hlFld-ContribAuthor ">Marian E.  Gindy</span>. </span><span class="cited-content_cbyCitation_article-title">Antimicrobial Excipient-Induced Reversible Association of Therapeutic Peptides in Parenteral Formulations. </span><span class="cited-content_cbyCitation_journal-name">Journal of Pharmaceutical Sciences</span><span> <strong>2021,</strong> <em>110 </em>
                                    (2)
                                     , 850-859. <a href="https://doi.org/10.1016/j.xphs.2020.09.027" title="DOI URL">https://doi.org/10.1016/j.xphs.2020.09.027</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.xphs.2020.09.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.xphs.2020.09.027%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Pharmaceutical%2520Sciences%26atitle%3DAntimicrobial%252BExcipient-Induced%252BReversible%252BAssociation%252Bof%252BTherapeutic%252BPeptides%252Bin%252BParenteral%252BFormulations%26aulast%3DD%2527Addio%26aufirst%3DSuzanne%2BM.%26date%3D2021%26volume%3D110%26issue%3D2%26spage%3D850%26epage%3D859" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Katharina  Dauer</span>, <span class="hlFld-ContribAuthor ">Stefania  Pfeiffer-Marek</span>, <span class="hlFld-ContribAuthor ">Walter  Kamm</span>, <span class="hlFld-ContribAuthor ">Karl G.  Wagner</span>. </span><span class="cited-content_cbyCitation_article-title">Microwell Plate-Based Dynamic Light Scattering as a High-Throughput Characterization Tool in Biopharmaceutical Development. </span><span class="cited-content_cbyCitation_journal-name">Pharmaceutics</span><span> <strong>2021,</strong> <em>13 </em>
                                    (2)
                                     , 172. <a href="https://doi.org/10.3390/pharmaceutics13020172" title="DOI URL">https://doi.org/10.3390/pharmaceutics13020172</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/pharmaceutics13020172&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fpharmaceutics13020172%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmaceutics%26atitle%3DMicrowell%252BPlate-Based%252BDynamic%252BLight%252BScattering%252Bas%252Ba%252BHigh-Throughput%252BCharacterization%252BTool%252Bin%252BBiopharmaceutical%252BDevelopment%26aulast%3DDauer%26aufirst%3DKatharina%26date%3D2021%26date%3D2021%26volume%3D13%26issue%3D2%26spage%3D172" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Huanbo  Tan</span>, <span class="hlFld-ContribAuthor ">Wencheng  Su</span>, <span class="hlFld-ContribAuthor ">Wenyu  Zhang</span>, <span class="hlFld-ContribAuthor ">Jie  Zhang</span>, <span class="hlFld-ContribAuthor ">Michael  Sattler</span>, <span class="hlFld-ContribAuthor ">Peijian  Zou</span>. </span><span class="cited-content_cbyCitation_article-title">Albumin-binding domain extends half-life of glucagon-like peptide-1. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Pharmacology</span><span> <strong>2021,</strong> <em>890 </em>, 173650. <a href="https://doi.org/10.1016/j.ejphar.2020.173650" title="DOI URL">https://doi.org/10.1016/j.ejphar.2020.173650</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejphar.2020.173650&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejphar.2020.173650%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Pharmacology%26atitle%3DAlbumin-binding%252Bdomain%252Bextends%252Bhalf-life%252Bof%252Bglucagon-like%252Bpeptide-1%26aulast%3DTan%26aufirst%3DHuanbo%26date%3D2021%26volume%3D890%26spage%3D173650" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Andreas  Evers</span>, <span class="hlFld-ContribAuthor ">Stefania  PfeifferâMarek</span>, <span class="hlFld-ContribAuthor ">Martin  Bossart</span>, <span class="hlFld-ContribAuthor ">Ralf  Elvert</span>, <span class="hlFld-ContribAuthor ">Katrin  Lorenz</span>, <span class="hlFld-ContribAuthor ">Christoph  Heubel</span>, <span class="hlFld-ContribAuthor ">Ana Villar  Garea</span>, <span class="hlFld-ContribAuthor ">Katrin  Schroeter</span>, <span class="hlFld-ContribAuthor ">Jens  Riedel</span>, <span class="hlFld-ContribAuthor ">Ursula  Stock</span>, <span class="hlFld-ContribAuthor ">Anish  Konkar</span>, <span class="hlFld-ContribAuthor ">Michael  Wagner</span>. </span><span class="cited-content_cbyCitation_article-title">Multiparameter Peptide Optimization toward Stable Triple Agonists for the Treatment of Diabetes and Obesity. </span><span class="cited-content_cbyCitation_journal-name">Advanced Therapeutics</span><span> <strong>2020,</strong> <em>3 </em>
                                    (9)
                                     , 2000052. <a href="https://doi.org/10.1002/adtp.202000052" title="DOI URL">https://doi.org/10.1002/adtp.202000052</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/adtp.202000052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fadtp.202000052%26sid%3Dliteratum%253Aachs%26jtitle%3DAdvanced%2520Therapeutics%26atitle%3DMultiparameter%252BPeptide%252BOptimization%252Btoward%252BStable%252BTriple%252BAgonists%252Bfor%252Bthe%252BTreatment%252Bof%252BDiabetes%252Band%252BObesity%26aulast%3DEvers%26aufirst%3DAndreas%26date%3D2020%26date%3D2020%26volume%3D3%26issue%3D9%26spage%3D2000052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xinxian  Deng</span>, <span class="hlFld-ContribAuthor ">Mojdeh S.  Tavallaie</span>, <span class="hlFld-ContribAuthor ">Ran  Sun</span>, <span class="hlFld-ContribAuthor ">Juntao  Wang</span>, <span class="hlFld-ContribAuthor ">Qingqing  Cai</span>, <span class="hlFld-ContribAuthor ">Jian  Shen</span>, <span class="hlFld-ContribAuthor ">Shuwen  Lei</span>, <span class="hlFld-ContribAuthor ">Lei  Fu</span>, <span class="hlFld-ContribAuthor ">Faqin  Jiang</span>. </span><span class="cited-content_cbyCitation_article-title">Drug discovery approaches targeting the incretin pathway. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2020,</strong> <em>99 </em>, 103810. <a href="https://doi.org/10.1016/j.bioorg.2020.103810" title="DOI URL">https://doi.org/10.1016/j.bioorg.2020.103810</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2020.103810&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2020.103810%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DDrug%252Bdiscovery%252Bapproaches%252Btargeting%252Bthe%252Bincretin%252Bpathway%26aulast%3DDeng%26aufirst%3DXinxian%26date%3D2020%26volume%3D99%26spage%3D103810" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mohan  Patil</span>, <span class="hlFld-ContribAuthor ">Nitin J.  Deshmukh</span>, <span class="hlFld-ContribAuthor ">Mahesh  Patel</span>, <span class="hlFld-ContribAuthor ">Ganesh V.  Sangle</span>. </span><span class="cited-content_cbyCitation_article-title">Glucagon-based therapy: Past, present and future. </span><span class="cited-content_cbyCitation_journal-name">Peptides</span><span> <strong>2020,</strong> <em>127 </em>, 170296. <a href="https://doi.org/10.1016/j.peptides.2020.170296" title="DOI URL">https://doi.org/10.1016/j.peptides.2020.170296</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.peptides.2020.170296&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.peptides.2020.170296%26sid%3Dliteratum%253Aachs%26jtitle%3DPeptides%26atitle%3DGlucagon-based%252Btherapy%25253A%252BPast%25252C%252Bpresent%252Band%252Bfuture%26aulast%3DPatil%26aufirst%3DMohan%26date%3D2020%26volume%3D127%26spage%3D170296" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Patrick J.  Knerr</span>, <span class="hlFld-ContribAuthor ">Stephanie A.  Mowery</span>, <span class="hlFld-ContribAuthor ">Brian  Finan</span>, <span class="hlFld-ContribAuthor ">Diego  Perez-Tilve</span>, <span class="hlFld-ContribAuthor ">Matthias H.  TschÃ¶p</span>, <span class="hlFld-ContribAuthor ">Richard D.  DiMarchi</span>. </span><span class="cited-content_cbyCitation_article-title">Selection and progression of unimolecular agonists at the GIP, GLP-1, and glucagon receptors as drug candidates. </span><span class="cited-content_cbyCitation_journal-name">Peptides</span><span> <strong>2020,</strong> <em>125 </em>, 170225. <a href="https://doi.org/10.1016/j.peptides.2019.170225" title="DOI URL">https://doi.org/10.1016/j.peptides.2019.170225</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.peptides.2019.170225&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.peptides.2019.170225%26sid%3Dliteratum%253Aachs%26jtitle%3DPeptides%26atitle%3DSelection%252Band%252Bprogression%252Bof%252Bunimolecular%252Bagonists%252Bat%252Bthe%252BGIP%25252C%252BGLP-1%25252C%252Band%252Bglucagon%252Breceptors%252Bas%252Bdrug%252Bcandidates%26aulast%3DKnerr%26aufirst%3DPatrick%2BJ.%26date%3D2020%26volume%3D125%26spage%3D170225" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Andreas  Evers</span>, <span class="hlFld-ContribAuthor ">Stefania  Pfeiffer-Marek</span>, <span class="hlFld-ContribAuthor ">Martin  Bossart</span>, <span class="hlFld-ContribAuthor ">Christoph  Heubel</span>, <span class="hlFld-ContribAuthor ">Ursula  Stock</span>, <span class="hlFld-ContribAuthor ">Garima  Tiwari</span>, <span class="hlFld-ContribAuthor ">Birgit  Gebauer</span>, <span class="hlFld-ContribAuthor ">Bettina  Elshorst</span>, <span class="hlFld-ContribAuthor ">Anja  Pfenninger</span>, <span class="hlFld-ContribAuthor ">Ulrike  Lukasczyk</span>, <span class="hlFld-ContribAuthor ">Gerhard  Hessler</span>, <span class="hlFld-ContribAuthor ">Walter  Kamm</span>, <span class="hlFld-ContribAuthor ">Michael  Wagner</span>. </span><span class="cited-content_cbyCitation_article-title">Peptide Optimization at the Drug Discovery-Development Interface: Tailoring of Physicochemical Properties Toward Specific Formulation Requirements. </span><span class="cited-content_cbyCitation_journal-name">Journal of Pharmaceutical Sciences</span><span> <strong>2019,</strong> <em>108 </em>
                                    (4)
                                     , 1404-1414. <a href="https://doi.org/10.1016/j.xphs.2018.11.043" title="DOI URL">https://doi.org/10.1016/j.xphs.2018.11.043</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.xphs.2018.11.043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.xphs.2018.11.043%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Pharmaceutical%2520Sciences%26atitle%3DPeptide%252BOptimization%252Bat%252Bthe%252BDrug%252BDiscovery-Development%252BInterface%25253A%252BTailoring%252Bof%252BPhysicochemical%252BProperties%252BToward%252BSpecific%252BFormulation%252BRequirements%26aulast%3DEvers%26aufirst%3DAndreas%26date%3D2019%26volume%3D108%26issue%3D4%26spage%3D1404%26epage%3D1414" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Eleni  Pilitsi</span>, <span class="hlFld-ContribAuthor ">Olivia M.  Farr</span>, <span class="hlFld-ContribAuthor ">Stergios A.  Polyzos</span>, <span class="hlFld-ContribAuthor ">Nikolaos  Perakakis</span>, <span class="hlFld-ContribAuthor ">Eric  Nolen-Doerr</span>, <span class="hlFld-ContribAuthor ">Aimilia-Eirini  Papathanasiou</span>, <span class="hlFld-ContribAuthor ">Christos S.  Mantzoros</span>. </span><span class="cited-content_cbyCitation_article-title">Pharmacotherapy of obesity: Available medications and drugs under investigation. </span><span class="cited-content_cbyCitation_journal-name">Metabolism</span><span> <strong>2019,</strong> <em>92 </em>, 170-192. <a href="https://doi.org/10.1016/j.metabol.2018.10.010" title="DOI URL">https://doi.org/10.1016/j.metabol.2018.10.010</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.metabol.2018.10.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.metabol.2018.10.010%26sid%3Dliteratum%253Aachs%26jtitle%3DMetabolism%26atitle%3DPharmacotherapy%252Bof%252Bobesity%25253A%252BAvailable%252Bmedications%252Band%252Bdrugs%252Bunder%252Binvestigation%26aulast%3DPilitsi%26aufirst%3DEleni%26date%3D2019%26volume%3D92%26spage%3D170%26epage%3D192" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Christoffer  Clemmensen</span>, <span class="hlFld-ContribAuthor ">Brian  Finan</span>, <span class="hlFld-ContribAuthor ">Timo D.  MÃ¼ller</span>, <span class="hlFld-ContribAuthor ">Richard D.  DiMarchi</span>, <span class="hlFld-ContribAuthor ">Matthias H.  TschÃ¶p</span>, <span class="hlFld-ContribAuthor ">Susanna M.  Hofmann</span>. </span><span class="cited-content_cbyCitation_article-title">Emerging hormonal-based combination pharmacotherapies for the treatment of metabolic diseases. </span><span class="cited-content_cbyCitation_journal-name">Nature Reviews Endocrinology</span><span> <strong>2019,</strong> <em>15 </em>
                                    (2)
                                     , 90-104. <a href="https://doi.org/10.1038/s41574-018-0118-x" title="DOI URL">https://doi.org/10.1038/s41574-018-0118-x</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41574-018-0118-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41574-018-0118-x%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Reviews%2520Endocrinology%26atitle%3DEmerging%252Bhormonal-based%252Bcombination%252Bpharmacotherapies%252Bfor%252Bthe%252Btreatment%252Bof%252Bmetabolic%252Bdiseases%26aulast%3DClemmensen%26aufirst%3DChristoffer%26date%3D2019%26date%3D2018%26volume%3D15%26issue%3D2%26spage%3D90%26epage%3D104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Richard D.  DiMarchi</span>. </span><span class="cited-content_cbyCitation_article-title">âLet's Stay Togetherâ; GIP and GLP-1 dual agonism in the treatment of metabolic disease. </span><span class="cited-content_cbyCitation_journal-name">Molecular Metabolism</span><span> <strong>2018,</strong> <em>18 </em>, 1-2. <a href="https://doi.org/10.1016/j.molmet.2018.10.004" title="DOI URL">https://doi.org/10.1016/j.molmet.2018.10.004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.molmet.2018.10.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.molmet.2018.10.004%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Metabolism%26atitle%3D%2525E2%252580%25259CLet%252527s%252BStay%252BTogether%2525E2%252580%25259D%25253B%252BGIP%252Band%252BGLP-1%252Bdual%252Bagonism%252Bin%252Bthe%252Btreatment%252Bof%252Bmetabolic%252Bdisease%26aulast%3DDiMarchi%26aufirst%3DRichard%2BD.%26date%3D2018%26volume%3D18%26spage%3D1%26epage%3D2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-13/acs.jmedchem.8b00292/20180706/images/medium/jm-2018-00292s_0012.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-13/acs.jmedchem.8b00292/20180706/images/large/jm-2018-00292s_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00292&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-13/acs.jmedchem.8b00292/20180706/images/medium/jm-2018-00292s_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-13/acs.jmedchem.8b00292/20180706/images/large/jm-2018-00292s_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. (a) Ensemble of solution-state NMR structure of exendin-4 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1jrj">1jrj</a>). (b) Three-dimensional alignment of the extracellular domain (ECD) of the GLP-1 (GLP-1R, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3c59">3c59</a>), glucagon (GCGR, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ers">4ers</a>), and GIP receptor (GIPR, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2qkh">2qkh</a>) and binding hypothesis of exendin-4 (derived from the NMR structure in solution, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1jrj">1jrj</a>) to the GLP-1 receptor ECD. The color coding of peptide amino acids is equivalent to the sequence color coding outlined in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>. Residue Trp25 is shown in space fill representation. (c) Magnified view of the peptide binding interface of the receptor ECDs highlighting specific amino acids. According to the binding hypothesis, these amino acids are interacting with Lys27 of exendin-4 and are assumed to represent a spot for modulation of peptide activity and selectivity at different receptors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-13/acs.jmedchem.8b00292/20180706/images/large/jm-2018-00292s_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00292&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-13/acs.jmedchem.8b00292/20180706/images/medium/jm-2018-00292s_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-13/acs.jmedchem.8b00292/20180706/images/large/jm-2018-00292s_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Predicted binding hypothesis for peptides <b>5</b> and <b>8</b> at the extracellular domain of the GLP-1 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3c59">3c59</a>), glucagon (GCG, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ers">4ers</a>), and GIP (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2qkh">2qkh</a>) receptors. Both peptides have identical sequences except for residue 27. Introduction of Aib27 in peptide <b>5</b> and Ile27 in peptide <b>8</b> causes different activity profiles at the receptors, supposedly due to differential interactions with Leu123 (GLP-1 receptor), Ala118 (glucagon receptor), and His115 (GIP receptor).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-13/acs.jmedchem.8b00292/20180706/images/large/jm-2018-00292s_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00292&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-13/acs.jmedchem.8b00292/20180706/images/medium/jm-2018-00292s_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-13/acs.jmedchem.8b00292/20180706/images/large/jm-2018-00292s_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Crystal structure of peptide <b>11</b> in complex with the GLP-1 receptor extracellular domain (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6gb1">6gb1</a>). Peptide residues are colored according to the scheme of <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>. (a) Overall structure. The GLP1 receptor ECD is shown as a white surface, the bound peptide <b>11</b> as a stick model. (b) Close-up of a hydrogen bonding network at the âtopâ of the peptide. This hydrogen bonding network involves the side chains of the receptor residues Glu68 and Arg121 and Ser32 of the peptide, the main chain carbonyl oxygens of the receptor residues Phe66 and Asp67 and of the peptide residues Leu26 and Aib27, and three bound water molecules.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-13/acs.jmedchem.8b00292/20180706/images/large/jm-2018-00292s_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00292&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-13/acs.jmedchem.8b00292/20180706/images/medium/jm-2018-00292s_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-13/acs.jmedchem.8b00292/20180706/images/large/jm-2018-00292s_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Predicted binding hypothesis of (a) peptide <b>5</b> and (b) peptide <b>12</b> at the GLP-1 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3c59">3c59</a>), glucagon (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ers">4ers</a>), or GIP (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2qkh">2qkh</a>) receptor ECDs. Amino acids that are part of the predicted aggregation hot spot and represent a potential interaction site for phenol, are colored red. Residues that were introduced into peptide <b>12</b> to increase conformational stability or polarity are colored blue or green, respectively.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-13/acs.jmedchem.8b00292/20180706/images/large/jm-2018-00292s_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00292&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-13/acs.jmedchem.8b00292/20180706/images/medium/jm-2018-00292s_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-13/acs.jmedchem.8b00292/20180706/images/large/jm-2018-00292s_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (a) NMR ensemble structures of peptide <b>5</b> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6gdz">6gdz</a>), peptide <b>12</b> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6ge2">6ge2</a>), and exendin-4 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1jrj">1jrj</a>) in solution. For structural clarity, only heavy atoms are depicted. Side-chain atoms of residue 14 (palmitic acid linked to the Îµ-amino group of lysine using two Î³-glutamic acid spacers) of peptides <b>5</b> and <b>12</b> are indicated in gray. (b) 3D-alignment of NMR structures of peptide <b>5</b>, peptide <b>12</b>, and exendin-4. (c) Magnified view of 3D-alignment of the tryptophan cage of peptides <b>5</b> and <b>12</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-13/acs.jmedchem.8b00292/20180706/images/large/jm-2018-00292s_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00292&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-13/acs.jmedchem.8b00292/20180706/images/medium/jm-2018-00292s_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-13/acs.jmedchem.8b00292/20180706/images/large/jm-2018-00292s_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Absolute body weight (top) and relative body weight change (bottom) in obese diabetic cynomolgus monkeys during study period. Values are mean Â± SEM, <i>n</i> = 8â10/group. ##<i>P</i> < 0.01 peptide <b>12</b> versus vehicle control. Liraglutide was dosed during the dose-ramping period from 10 (day 1â3) to 20 (day 4â6) to 30 Î¼g/kg (day 7â9) and was maintained at 40 Î¼g/kg sc from day 10 to completion of the study. Peptide <b>12</b> was dosed during the dose-ramping period from 1.5 (day 1â3) to 3 (day 4â6) to 4.5 (day 7â9) to 6 Î¼g/kg (day 10â17) and was maintained at 8 Î¼g/kg sc from day 18 to completion of the study.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-13/acs.jmedchem.8b00292/20180706/images/large/jm-2018-00292s_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00292&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-13/acs.jmedchem.8b00292/20180706/images/medium/jm-2018-00292s_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-13/acs.jmedchem.8b00292/20180706/images/large/jm-2018-00292s_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. HbA<sub>1C</sub> determination after 43 days of chronic treatment in obese diabetic cynomolgus monkeys compared to baseline according to the dosing scheme as described in <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>. Values are mean Â± SEM, <i>n</i> = 8â10/group. ***<i>P</i> < 0.001 versus baseline.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-13/acs.jmedchem.8b00292/20180706/images/large/jm-2018-00292s_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00292&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i39">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_35027" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_35027" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 58 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span>World Health
Organization. Media Centre. Diabetes (Fact sheet no. 312) Available
at <a href="http://www.who.int/mediacentre/factsheets/fs312/en/" class="extLink">http://www.who.int/mediacentre/factsheets/fs312/en/</a> [accessed
23 Jan <span class="NLM_year">2018</span>].</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=World+Health%0AOrganization.+Media+Centre.+Diabetes+%28Fact+sheet+no.+312%29+Available%0Aat+http%3A%2F%2Fwww.who.int%2Fmediacentre%2Ffactsheets%2Ffs312%2Fen%2F+%5Baccessed%0A23+Jan+2018%5D."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span>2014 Diabetes
Report Card - diabetesreportcard2014.pdf [Internet], Available at <a href="http://www.cdc.gov/diabetes/pdfs/library/diabetesreportcard2014.pdf" class="extLink">http://www.cdc.gov/diabetes/pdfs/library/diabetesreportcard2014.pdf</a> [accessed 23 Jan <span class="NLM_year">2018</span>].</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=2014+Diabetes%0AReport+Card+-+diabetesreportcard2014.pdf+%5BInternet%5D%2C+Available+at+http%3A%2F%2Fwww.cdc.gov%2Fdiabetes%2Fpdfs%2Flibrary%2Fdiabetesreportcard2014.pdf+%5Baccessed+23+Jan+2018%5D."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span>Nonalcoholic
Steatohepatitis: Risk Factors and Diagnosis Available at <a href="http://www.medscape.com/viewarticle/731163" class="extLink">http://www.medscape.com/viewarticle/731163</a> [accessed 23 Jan <span class="NLM_year">2018</span>].</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Nonalcoholic%0ASteatohepatitis%3A+Risk+Factors+and+Diagnosis+Available+at+http%3A%2F%2Fwww.medscape.com%2Fviewarticle%2F731163+%5Baccessed+23+Jan+2018%5D."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. Y.</span></span> <span> </span><span class="NLM_article-title">Glucagon-Like Peptide-1 Formulation â the Present and Future Development in Diabetes Treatment</span>. <i>Basic Clin. Pharmacol. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>118</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">173</span>â <span class="NLM_lpage">180</span>, <span class="refDoi">Â DOI: 10.1111/bcpt.12524</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=10.1111%2Fbcpt.12524" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=26551045" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVylur7J" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2016&pages=173-180&issue=3&author=C.+Y.+Lee&title=Glucagon-Like+Peptide-1+Formulation+%E2%80%93+the+Present+and+Future+Development+in+Diabetes+Treatment&doi=10.1111%2Fbcpt.12524"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Glucagon-Like Peptide-1 Formulation - the Present and Future Development in Diabetes Treatment</span></div><div class="casAuthors">Lee, Chooi Yeng</div><div class="citationInfo"><span class="NLM_cas:title">Basic & Clinical Pharmacology & Toxicology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">173-180</span>CODEN:
                <span class="NLM_cas:coden">BCPTBO</span>;
        ISSN:<span class="NLM_cas:issn">1742-7835</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Type 2 diabetes mellitus is a chronic metabolic disorder that has become the fourth leading cause of death in the developed countries.  The disorder is characterized by pancreatic Î²-cells dysfunction, which causes hyperglycemia leading to several other complications.  Treatment by far, which focuses on insulin administration and glycemic control, has not been satisfactory.  Glucagon-like peptide-1 (GLP1) is an endogenous peptide that stimulates post-prandial insulin secretion.  Despite being able to mimic the effect of insulin, GLP1 has not been the target drug in diabetes treatment due to the peptide's metabolic instability.  After a decade-long effort to improve the pharmacokinetics of GLP1, a no. of GLP1 analogs are currently available on the market.  The current Minireview does not discuss these drugs but presents strategies that were undertaken to address the weaknesses of the native GLP1, particularly drug delivery techniques used in developing GLP1 nanoparticles and modified GLP1 mol.  The article highlights how each of the selected prepns. has improved the efficacy of GLP1, and more importantly, through an overview of these studies, it will provide an insight into strategies that may be adopted in the future in the development of a more effective oral GLP1 formulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmCfH3cjgEQbVg90H21EOLACvtfcHk0lheFjOLtZYThQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVylur7J&md5=0e9e520b7295ac1956d748edc8cdc24e</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1111%2Fbcpt.12524&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbcpt.12524%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DC.%2BY.%26atitle%3DGlucagon-Like%2520Peptide-1%2520Formulation%2520%25E2%2580%2593%2520the%2520Present%2520and%2520Future%2520Development%2520in%2520Diabetes%2520Treatment%26jtitle%3DBasic%2520Clin.%2520Pharmacol.%2520Toxicol.%26date%3D2016%26volume%3D118%26issue%3D3%26spage%3D173%26epage%3D180%26doi%3D10.1111%2Fbcpt.12524" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McBrayer, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tal-Gan, Y.</span></span> <span> </span><span class="NLM_article-title">Recent Advances in GLP-1 Receptor Agonists for Use in Diabetes Mellitus</span>. <i>Drug Dev. Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>78</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">292</span>â <span class="NLM_lpage">299</span>, <span class="refDoi">Â DOI: 10.1002/ddr.21404</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=10.1002%2Fddr.21404" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2017&pages=292-299&issue=6&author=D.+N.+McBrayerauthor=Y.+Tal-Gan&title=Recent+Advances+in+GLP-1+Receptor+Agonists+for+Use+in+Diabetes+Mellitus&doi=10.1002%2Fddr.21404"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1002%2Fddr.21404&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fddr.21404%26sid%3Dliteratum%253Aachs%26aulast%3DMcBrayer%26aufirst%3DD.%2BN.%26aulast%3DTal-Gan%26aufirst%3DY.%26atitle%3DRecent%2520Advances%2520in%2520GLP-1%2520Receptor%2520Agonists%2520for%2520Use%2520in%2520Diabetes%2520Mellitus%26jtitle%3DDrug%2520Dev.%2520Res.%26date%3D2017%26volume%3D78%26issue%3D6%26spage%3D292%26epage%3D299%26doi%3D10.1002%2Fddr.21404" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Uccellatore, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Genovese, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dicembrini, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mannucci, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ceriello, A.</span></span> <span> </span><span class="NLM_article-title">Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor Agonists</span>. <i>Diabetes Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">239</span>â <span class="NLM_lpage">256</span>, <span class="refDoi">Â DOI: 10.1007/s13300-015-0127-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=10.1007%2Fs13300-015-0127-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=26271795" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFGhsrfJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=239-256&issue=3&author=A.+Uccellatoreauthor=S.+Genoveseauthor=I.+Dicembriniauthor=E.+Mannucciauthor=A.+Ceriello&title=Comparison+Review+of+Short-Acting+and+Long-Acting+Glucagon-like+Peptide-1+Receptor+Agonists&doi=10.1007%2Fs13300-015-0127-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor Agonists</span></div><div class="casAuthors">Uccellatore, Annachiara; Genovese, Stefano; Dicembrini, Ilaria; Mannucci, Edoardo; Ceriello, Antonio</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes Therapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">239-256</span>CODEN:
                <span class="NLM_cas:coden">DTIHAP</span>;
        ISSN:<span class="NLM_cas:issn">1869-6961</span>.
    
            (<span class="NLM_cas:orgname">Springer Healthcare Ltd.</span>)
        </div><div class="casAbstract">Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1 RAs) are useful tools for treating type 2 diabetes mellitus.  In their recent position statement, the American Diabetes Assocn. and European Assocn. for the Study of Diabetes recommend GLP1-RAs as add-on to metformin when therapeutic goals are not achieved with monotherapy, particularly for patients who wish to avoid wt. gain or hypoglycemia.  GLP1-RAs differ substantially in their duration of action, frequency of administration and clin. profile.  Members of this class approved for clin. use include exenatide twice-daily, exenatide once-weekly, liraglutide and lixisenatide once-daily.  Recently, two new once-weekly GLP1-RAs have been approved: dulaglutide and albiglutide.  This article summarizes properties of short- and long-acting GLP-1 analogs, and provides useful information to help choose the most appropriate compd. for individual patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrL73oCtHFWJbVg90H21EOLACvtfcHk0lheFjOLtZYThQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFGhsrfJ&md5=074bdad4952922f4d6b2fdc628de08f3</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1007%2Fs13300-015-0127-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs13300-015-0127-x%26sid%3Dliteratum%253Aachs%26aulast%3DUccellatore%26aufirst%3DA.%26aulast%3DGenovese%26aufirst%3DS.%26aulast%3DDicembrini%26aufirst%3DI.%26aulast%3DMannucci%26aufirst%3DE.%26aulast%3DCeriello%26aufirst%3DA.%26atitle%3DComparison%2520Review%2520of%2520Short-Acting%2520and%2520Long-Acting%2520Glucagon-like%2520Peptide-1%2520Receptor%2520Agonists%26jtitle%3DDiabetes%2520Ther.%26date%3D2015%26volume%3D6%26issue%3D3%26spage%3D239%26epage%3D256%26doi%3D10.1007%2Fs13300-015-0127-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Finan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clemmensen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MÃ¼ller, T. D.</span></span> <span> </span><span class="NLM_article-title">Emerging Opportunities for the Treatment of Metabolic Diseases: Glucagon-like Peptide-1 Based Multi-Agonists</span>. <i>Mol. Cell. Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>418</i></span>,  <span class="NLM_fpage">42</span>â <span class="NLM_lpage">54</span>, <span class="refDoi">Â DOI: 10.1016/j.mce.2015.07.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=10.1016%2Fj.mce.2015.07.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=26151488" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht12kurbL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=418&publication_year=2015&pages=42-54&author=B.+Finanauthor=C.+Clemmensenauthor=T.+D.+M%C3%BCller&title=Emerging+Opportunities+for+the+Treatment+of+Metabolic+Diseases%3A+Glucagon-like+Peptide-1+Based+Multi-Agonists&doi=10.1016%2Fj.mce.2015.07.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging opportunities for the treatment of metabolic diseases: Glucagon-like peptide-1 based multi-agonists</span></div><div class="casAuthors">Finan, Brian; Clemmensen, Christoffer; Mueller, Timo D.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Endocrinology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">418</span>
        (<span class="NLM_cas:issue">Part_1</span>),
    <span class="NLM_cas:pages">42-54</span>CODEN:
                <span class="NLM_cas:coden">MCEND6</span>;
        ISSN:<span class="NLM_cas:issn">0303-7207</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">Obesity is a pathogenic gateway to the metabolic syndrome and the complications thereof, thus interventions aimed at preventing or reversing the metabolic derangements underlying obesity hold great therapeutic promise.  However, the complexity of energy balance regulation, combined with the heterologous pathophysiol. of human obesity, renders effective medicinal intervention very difficult.  Indeed, the search for the silver bullet in anti-obesity medicines has been laden with drugs of underwhelming efficacy and unacceptable side effects.  This can partly be the consequence that many of these drug interventions have been historically directed at single mol. targets.  New multi-mol. combination therapies have shown promising clin. outcomes in terms of wt. loss, yet multi-functional single mols. may offer even more advantages than adjunctive co-treatments.  Single mols. with integrated activities derived from multiple hormones involved in the physiol. control of metab. have emerged as one of the more promising candidates for reversing obesity.  The inclusion of glucagon-like peptide-1 (GLP-1) as one of the constituents is a unifying factor amongst the majority of these unimol. multi-agonists.  The scope of this review is to summarize the current preclin. and clin. landscape of GLP-1-based therapies, focusing on combinatorial therapies with a particular emphasis on single mol. compds. displaying multi-agonist properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUBCghH0SQMLVg90H21EOLACvtfcHk0lg-Edp6EFH0hw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht12kurbL&md5=c433f454a29252c16d9d2eafd2b95b08</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.mce.2015.07.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mce.2015.07.003%26sid%3Dliteratum%253Aachs%26aulast%3DFinan%26aufirst%3DB.%26aulast%3DClemmensen%26aufirst%3DC.%26aulast%3DM%25C3%25BCller%26aufirst%3DT.%2BD.%26atitle%3DEmerging%2520Opportunities%2520for%2520the%2520Treatment%2520of%2520Metabolic%2520Diseases%253A%2520Glucagon-like%2520Peptide-1%2520Based%2520Multi-Agonists%26jtitle%3DMol.%2520Cell.%2520Endocrinol.%26date%3D2015%26volume%3D418%26spage%3D42%26epage%3D54%26doi%3D10.1016%2Fj.mce.2015.07.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Knerr, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelfanov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Tilve, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">TschÃ¶p, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiMarchi, R. D.</span></span> <span> </span><span class="NLM_article-title">Optimization of Peptide-Based Polyagonists for Treatment of Diabetes and Obesity</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">2873</span>â <span class="NLM_lpage">2881</span>, <span class="refDoi">Â DOI: 10.1016/j.bmc.2017.10.047</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=10.1016%2Fj.bmc.2017.10.047" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2018&pages=2873-2881&issue=10&author=P.+J.+Knerrauthor=B.+Finanauthor=V.+Gelfanovauthor=D.+Perez-Tilveauthor=M.+H.+Tsch%C3%B6pauthor=R.+D.+DiMarchi&title=Optimization+of+Peptide-Based+Polyagonists+for+Treatment+of+Diabetes+and+Obesity&doi=10.1016%2Fj.bmc.2017.10.047"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2017.10.047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2017.10.047%26sid%3Dliteratum%253Aachs%26aulast%3DKnerr%26aufirst%3DP.%2BJ.%26aulast%3DFinan%26aufirst%3DB.%26aulast%3DGelfanov%26aufirst%3DV.%26aulast%3DPerez-Tilve%26aufirst%3DD.%26aulast%3DTsch%25C3%25B6p%26aufirst%3DM.%2BH.%26aulast%3DDiMarchi%26aufirst%3DR.%2BD.%26atitle%3DOptimization%2520of%2520Peptide-Based%2520Polyagonists%2520for%2520Treatment%2520of%2520Diabetes%2520and%2520Obesity%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2018%26volume%3D26%26issue%3D10%26spage%3D2873%26epage%3D2881%26doi%3D10.1016%2Fj.bmc.2017.10.047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">SÃ¡nchez-Garrido, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandt, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clemmensen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MÃ¼ller, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiMarchi, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">TschÃ¶p, M. H.</span></span> <span> </span><span class="NLM_article-title">GLP-1/Glucagon Receptor Co-Agonism for Treatment of Obesity</span>. <i>Diabetologia</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1851</span>â <span class="NLM_lpage">1861</span>, <span class="refDoi">Â DOI: 10.1007/s00125-017-4354-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=10.1007%2Fs00125-017-4354-8" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=1851-1861&issue=10&author=M.+A.+S%C3%A1nchez-Garridoauthor=S.+J.+Brandtauthor=C.+Clemmensenauthor=T.+D.+M%C3%BCllerauthor=R.+D.+DiMarchiauthor=M.+H.+Tsch%C3%B6p&title=GLP-1%2FGlucagon+Receptor+Co-Agonism+for+Treatment+of+Obesity&doi=10.1007%2Fs00125-017-4354-8"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1007%2Fs00125-017-4354-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00125-017-4354-8%26sid%3Dliteratum%253Aachs%26aulast%3DS%25C3%25A1nchez-Garrido%26aufirst%3DM.%2BA.%26aulast%3DBrandt%26aufirst%3DS.%2BJ.%26aulast%3DClemmensen%26aufirst%3DC.%26aulast%3DM%25C3%25BCller%26aufirst%3DT.%2BD.%26aulast%3DDiMarchi%26aufirst%3DR.%2BD.%26aulast%3DTsch%25C3%25B6p%26aufirst%3DM.%2BH.%26atitle%3DGLP-1%252FGlucagon%2520Receptor%2520Co-Agonism%2520for%2520Treatment%2520of%2520Obesity%26jtitle%3DDiabetologia%26date%3D2017%26volume%3D60%26issue%3D10%26spage%3D1851%26epage%3D1861%26doi%3D10.1007%2Fs00125-017-4354-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">TschÃ¶p, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clemmensen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelfanov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Tilve, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MÃ¼ller, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiMarchi, R. D.</span></span> <span> </span><span class="NLM_article-title">Unimolecular Polypharmacy for Treatment of Diabetes and Obesity</span>. <i>Cell Metab.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">51</span>â <span class="NLM_lpage">62</span>, <span class="refDoi">Â DOI: 10.1016/j.cmet.2016.06.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=10.1016%2Fj.cmet.2016.06.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=27411008" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=1%3ACAS%3A280%3ADC%252BC2s3gtleisQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2016&pages=51-62&issue=1&author=M.+H.+Tsch%C3%B6pauthor=B.+Finanauthor=C.+Clemmensenauthor=V.+Gelfanovauthor=D.+Perez-Tilveauthor=T.+D.+M%C3%BCllerauthor=R.+D.+DiMarchi&title=Unimolecular+Polypharmacy+for+Treatment+of+Diabetes+and+Obesity&doi=10.1016%2Fj.cmet.2016.06.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Unimolecular Polypharmacy for Treatment of Diabetes and Obesity</span></div><div class="casAuthors">Tschop Matthias H; Finan Brian; Clemmensen Christoffer; Muller Timo D; Gelfanov Vasily; Perez-Tilve Diego; DiMarchi Richard D</div><div class="citationInfo"><span class="NLM_cas:title">Cell metabolism</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">51-62</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Many complex diseases have historically proven to be defiant to the best mono-therapeutic approaches.  Several examples of combination therapies have largely overcome such challenges, notably for the treatment of severe hypertension and tuberculosis.  Obesity and its consequences, such as type 2 diabetes, have proven to be equally resistant to therapeutic approaches based on single medicines.  Proper management of type 2 diabetes often requires adjunctive medications, and the recent registration of a few compound mixtures has set the precedent for combinatorial treatment of obesity.  On the other hand, double or triple therapeutic combinations are more difficult to advance to regulatory approval than single molecules.  More recently, several classes of novel unimolecular combination therapeutics have emerged with superior efficacy than currently prescribed options and pose the potential to reverse obesity and type 2 diabetes.  Here, we summarize the discovery, pre-clinical validation, and first clinical test of such peptide hormone poly-agonist drug candidates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSD_iD9oiDSziEJCPKhJPuqfW6udTcc2eZi_Yv29B3hMLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s3gtleisQ%253D%253D&md5=36cbafe2232e829ccc52d5c83895f6a6</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.cmet.2016.06.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cmet.2016.06.021%26sid%3Dliteratum%253Aachs%26aulast%3DTsch%25C3%25B6p%26aufirst%3DM.%2BH.%26aulast%3DFinan%26aufirst%3DB.%26aulast%3DClemmensen%26aufirst%3DC.%26aulast%3DGelfanov%26aufirst%3DV.%26aulast%3DPerez-Tilve%26aufirst%3DD.%26aulast%3DM%25C3%25BCller%26aufirst%3DT.%2BD.%26aulast%3DDiMarchi%26aufirst%3DR.%2BD.%26atitle%3DUnimolecular%2520Polypharmacy%2520for%2520Treatment%2520of%2520Diabetes%2520and%2520Obesity%26jtitle%3DCell%2520Metab.%26date%3D2016%26volume%3D24%26issue%3D1%26spage%3D51%26epage%3D62%26doi%3D10.1016%2Fj.cmet.2016.06.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Day, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ottaway, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patterson, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelfanov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smiley, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gidda, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Findeisen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruemmer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drucker, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaudhary, N.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">A New Glucagon and GLP-1 Co-Agonist Eliminates Obesity in Rodents</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">749</span>â <span class="NLM_lpage">757</span>, <span class="refDoi">Â DOI: 10.1038/nchembio.209</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=10.1038%2Fnchembio.209" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=19597507" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=1%3ACAS%3A528%3ADC%252BD1MXosFWhsLk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2009&pages=749-757&issue=10&author=J.+W.+Dayauthor=N.+Ottawayauthor=J.+T.+Pattersonauthor=V.+Gelfanovauthor=D.+Smileyauthor=J.+Giddaauthor=H.+Findeisenauthor=D.+Bruemmerauthor=D.+J.+Druckerauthor=N.+Chaudhary&title=A+New+Glucagon+and+GLP-1+Co-Agonist+Eliminates+Obesity+in+Rodents&doi=10.1038%2Fnchembio.209"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">A new glucagon and GLP-1 co-agonist eliminates obesity in rodents</span></div><div class="casAuthors">Day, Jonathan W.; Ottaway, Nickki; Patterson, James T.; Gelfanov, Vasily; Smiley, David; Gidda, Jas; Findeisen, Hannes; Bruemmer, Dennis; Drucker, Daniel J.; Chaudhary, Nilika; Holland, Jenna; Hembree, Jazzminn; Abplanalp, William; Grant, Erin; Ruehl, Jennifer; Wilson, Hilary; Kirchner, Henriette; Lockie, Sarah Haas; Hofmann, Susanna; Woods, Stephen C.; Nogueiras, Ruben; Pfluger, Paul T.; Perez-Tilve, Diego; DiMarchi, Richard; Tschoep, Matthias H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">749-757</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We report the efficacy of a new peptide with agonism at the glucagon and GLP-1 receptors that has potent, sustained satiation-inducing and lipolytic effects.  Selective chem. modification to glucagon resulted in a loss of specificity, with minimal change to inherent activity.  The structural basis for the co-agonism appears to be a combination of local positional interactions and a change in secondary structure.  Two co-agonist peptides differing from each other only in their level of glucagon receptor agonism were studied in rodent obesity models.  Administration of PEGylated peptides once per wk normalized adiposity and glucose tolerance in diet-induced obese mice.  Redn. of body wt. was achieved by a loss of body fat resulting from decreased food intake and increased energy expenditure.  These preclin. studies indicate that when full GLP-1 agonism is augmented with an appropriate degree of glucagon receptor activation, body fat redn. can be substantially enhanced without any overt adverse effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4K1-_eVTTKbVg90H21EOLACvtfcHk0lhTASxuY2YXTg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXosFWhsLk%253D&md5=74b57672bfd375dd4d073624a25eab9b</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.209&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.209%26sid%3Dliteratum%253Aachs%26aulast%3DDay%26aufirst%3DJ.%2BW.%26aulast%3DOttaway%26aufirst%3DN.%26aulast%3DPatterson%26aufirst%3DJ.%2BT.%26aulast%3DGelfanov%26aufirst%3DV.%26aulast%3DSmiley%26aufirst%3DD.%26aulast%3DGidda%26aufirst%3DJ.%26aulast%3DFindeisen%26aufirst%3DH.%26aulast%3DBruemmer%26aufirst%3DD.%26aulast%3DDrucker%26aufirst%3DD.%2BJ.%26aulast%3DChaudhary%26aufirst%3DN.%26atitle%3DA%2520New%2520Glucagon%2520and%2520GLP-1%2520Co-Agonist%2520Eliminates%2520Obesity%2520in%2520Rodents%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2009%26volume%3D5%26issue%3D10%26spage%3D749%26epage%3D757%26doi%3D10.1038%2Fnchembio.209" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pocai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrington, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eiermann, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lassman, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, G.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Glucagon-Like Peptide 1/Glucagon Receptor Dual Agonism Reverses Obesity in Mice</span>. <i>Diabetes</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">2258</span>â <span class="NLM_lpage">2266</span>, <span class="refDoi">Â DOI: 10.2337/db09-0278</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=10.2337%2Fdb09-0278" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=19602537" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1yku7jK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2009&pages=2258-2266&issue=10&author=A.+Pocaiauthor=P.+E.+Carringtonauthor=J.+R.+Adamsauthor=M.+Wrightauthor=G.+Eiermannauthor=L.+Zhuauthor=X.+Duauthor=A.+Petrovauthor=M.+E.+Lassmanauthor=G.+Jiang&title=Glucagon-Like+Peptide+1%2FGlucagon+Receptor+Dual+Agonism+Reverses+Obesity+in+Mice&doi=10.2337%2Fdb09-0278"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice</span></div><div class="casAuthors">Pocai, Alessandro; Carrington, Paul E.; Adams, Jennifer R.; Wright, Michael; Eiermann, George; Zhu, Lan; Du, Xiaobing; Petrov, Aleksandr; Lassman, Michael E.; Jiang, Guoqiang; Liu, Franklin; Miller, Corey; Tota, Laurie M.; Zhou, Gaochao; Zhang, Xiaoping; Sountis, Michael M.; Santoprete, Alessia; Capito, Elena; Chicchi, Gary G.; Thornberry, Nancy; Bianchi, Elisabetta; Pessi, Antonello; Marsh, Donald J.; Sinha Roy, Ranabir</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2258-2266</span>CODEN:
                <span class="NLM_cas:coden">DIAEAZ</span>;
        ISSN:<span class="NLM_cas:issn">0012-1797</span>.
    
            (<span class="NLM_cas:orgname">American Diabetes Association, Inc.</span>)
        </div><div class="casAbstract">Objective-Oxyntomodulin (OXM) is a glucagon-like peptide 1 (GLP-1) receptor (GLP1R)/glucagon receptor (GCGR) dual agonist peptide that reduces body wt. in obese subjects through increased energy expenditure and decreased energy intake.  The metabolic effects of OXM have been attributed primarily to GLP1R agonism.  We examd. whether a long acting GLP1R/GCGR dual agonist peptide exerts metabolic effects in diet-induced obese mice that are distinct from those obtained with a GLP1R-selective agonist.  Research Design and Methods-We developed a protease-resistant dual GLP1R/GCGR agonist, DualAG, and a corresponding GLP1R-selective agonist, GLPAG, matched for GLP1R agonist potency and pharmacokinetics.  The metabolic effects of these two peptides with respect to wt. loss, caloric redn., glucose control, and lipid lowering, were compared upon chronic dosing in diet-induced obese (DIO) mice.  Acute studies in DIO mice revealed metabolic pathways that were modulated independent of wt. loss.  Studies in Glp1r-/- and Gcgr-/- mice enabled delineation of the contribution of GLP1R vs. GCGR activation to the pharmacol. of DualAG.  Results-Peptide DualAG exhibits superior wt. loss, lipid-lowering activity, and antihyperglycemic efficacy comparable to GLPAG.  Improvements in plasma metabolic parameters including insulin, leptin, and adiponectin were more pronounced upon chronic treatment with DualAG than with GLPAG.  Dual receptor agonism also increased fatty acid oxidn. and reduced hepatic steatosis in DIO mice.  The antiobesity effects of DualAG require activation of both GLP1R and GCGR.  Conclusions-Sustained GLP1R/GCGR dual agonism reverses obesity in DIO mice and is a novel therapeutic approach to the treatment of obesity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoX2C2QNX0zG7Vg90H21EOLACvtfcHk0lhTASxuY2YXTg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1yku7jK&md5=412b04ba021de2fdfb2c6b011c289eeb</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.2337%2Fdb09-0278&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2337%252Fdb09-0278%26sid%3Dliteratum%253Aachs%26aulast%3DPocai%26aufirst%3DA.%26aulast%3DCarrington%26aufirst%3DP.%2BE.%26aulast%3DAdams%26aufirst%3DJ.%2BR.%26aulast%3DWright%26aufirst%3DM.%26aulast%3DEiermann%26aufirst%3DG.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DDu%26aufirst%3DX.%26aulast%3DPetrov%26aufirst%3DA.%26aulast%3DLassman%26aufirst%3DM.%2BE.%26aulast%3DJiang%26aufirst%3DG.%26atitle%3DGlucagon-Like%2520Peptide%25201%252FGlucagon%2520Receptor%2520Dual%2520Agonism%2520Reverses%2520Obesity%2520in%2520Mice%26jtitle%3DDiabetes%26date%3D2009%26volume%3D58%26issue%3D10%26spage%3D2258%26epage%3D2266%26doi%3D10.2337%2Fdb09-0278" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Evers, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haack, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorenz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bossart, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elvert, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henkel, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stengelin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glien, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dudda, A.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Design of Novel Exendin-Based Dual Glucagon-like Peptide 1 (GLP-1)/Glucagon Receptor Agonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">4293</span>â <span class="NLM_lpage">4303</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.7b00174</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00174" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmslKrsr8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=4293-4303&issue=10&author=A.+Eversauthor=T.+Haackauthor=M.+Lorenzauthor=M.+Bossartauthor=R.+Elvertauthor=B.+Henkelauthor=S.+Stengelinauthor=M.+Kurzauthor=M.+Glienauthor=A.+Dudda&title=Design+of+Novel+Exendin-Based+Dual+Glucagon-like+Peptide+1+%28GLP-1%29%2FGlucagon+Receptor+Agonists&doi=10.1021%2Facs.jmedchem.7b00174"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Design of Novel Exendin-Based Dual Glucagon-like Peptide 1 (GLP-1)/Glucagon Receptor Agonists</span></div><div class="casAuthors">Evers, Andreas; Haack, Torsten; Lorenz, Martin; Bossart, Martin; Elvert, Ralf; Henkel, Bernd; Stengelin, Siegfried; Kurz, Michael; Glien, Maike; Dudda, Angela; Lorenz, Katrin; Kadereit, Dieter; Wagner, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4293-4303</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Dual activation of the glucagon-like peptide 1 (GLP-1) and glucagon receptor has the potential to lead to a novel therapy principle for the treatment of diabesity.  Here, we report a series of novel peptides with dual activity on these receptors that were discovered by rational design.  On the basis of sequence anal. and structure-based design, structural elements of glucagon were engineered into the selective GLP-1 receptor agonist exendin-4, resulting in hybrid peptides with potent dual GLP-1/glucagon receptor activity.  Detailed structure-activity relationship data are shown.  Further modifications with unnatural and modified amino acids resulted in novel metabolically stable peptides that demonstrated a significant dose-dependent decrease in blood glucose in chronic studies in diabetic db/db mice and reduced body wt. in diet-induced obese (DIO) mice.  Structural anal. by NMR spectroscopy confirmed that the peptides maintain an exendin-4-like structure with its characteristic tryptophan-cage fold motif that is responsible for favorable chem. and phys. stability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrewDgurwTT4LVg90H21EOLACvtfcHk0linLPneEnjymg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmslKrsr8%253D&md5=b59a7a25cdd56516b78c988860b39211</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00174%26sid%3Dliteratum%253Aachs%26aulast%3DEvers%26aufirst%3DA.%26aulast%3DHaack%26aufirst%3DT.%26aulast%3DLorenz%26aufirst%3DM.%26aulast%3DBossart%26aufirst%3DM.%26aulast%3DElvert%26aufirst%3DR.%26aulast%3DHenkel%26aufirst%3DB.%26aulast%3DStengelin%26aufirst%3DS.%26aulast%3DKurz%26aufirst%3DM.%26aulast%3DGlien%26aufirst%3DM.%26aulast%3DDudda%26aufirst%3DA.%26atitle%3DDesign%2520of%2520Novel%2520Exendin-Based%2520Dual%2520Glucagon-like%2520Peptide%25201%2520%2528GLP-1%2529%252FGlucagon%2520Receptor%2520Agonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26issue%3D10%26spage%3D4293%26epage%3D4303%26doi%3D10.1021%2Facs.jmedchem.7b00174" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Henderson, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konkar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hornigold, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trevaskis, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fritsch Fredin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jansson-LÃ¶fmark, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naylor, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bednarek, M. A.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Robust Anti-Obesity and Metabolic Effects of a Dual GLP-1/Glucagon Receptor Peptide Agonist in Rodents and Non-Human Primates</span>. <i>Diabetes, Obes. Metab.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1176</span>â <span class="NLM_lpage">1190</span>, <span class="refDoi">Â DOI: 10.1111/dom.12735</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=10.1111%2Fdom.12735" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=27377054" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVGgsbnN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2016&pages=1176-1190&issue=12&author=S.+J.+Hendersonauthor=A.+Konkarauthor=D.+C.+Hornigoldauthor=J.+L.+Trevaskisauthor=R.+Jacksonauthor=M.+Fritsch+Fredinauthor=R.+Jansson-L%C3%B6fmarkauthor=J.+Naylorauthor=A.+Rossiauthor=M.+A.+Bednarek&title=Robust+Anti-Obesity+and+Metabolic+Effects+of+a+Dual+GLP-1%2FGlucagon+Receptor+Peptide+Agonist+in+Rodents+and+Non-Human+Primates&doi=10.1111%2Fdom.12735"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates</span></div><div class="casAuthors">Henderson, S. J.; Konkar, A.; Hornigold, D. C.; Trevaskis, J. L.; Jackson, R.; Fritsch Fredin, M.; Jansson-Loefmark, R.; Naylor, J.; Rossi, A.; Bednarek, M. A.; Bhagroo, N.; Salari, H.; Will, S.; Oldham, S.; Hansen, G.; Feigh, M.; Klein, T.; Grimsby, J.; Maguire, S.; Jermutus, L.; Rondinone, C. M.; Coghlan, M. P.</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes, Obesity and Metabolism</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1176-1190</span>CODEN:
                <span class="NLM_cas:coden">DOMEF6</span>;
        ISSN:<span class="NLM_cas:issn">1462-8902</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Aims : To characterize the pharmacol. of MEDI0382, a peptide dual agonist of glucagon-like peptide-1 (GLP-1) and glucagon receptors.  Materials and methods : MEDI0382 was evaluated in vitro for its ability to stimulate cAMP accumulation in cell lines expressing transfected recombinant or endogenous GLP-1 or glucagon receptors, to potentiate glucose-stimulated insulin secretion (GSIS) in pancreatic Î²-cell lines and stimulate hepatic glucose output (HGO) by primary hepatocytes.  The ability of MEDI0382 to reduce body wt. and improve energy balance (i.e. food intake and energy expenditure), as well as control blood glucose, was evaluated in mouse models of obesity and healthy cynomolgus monkeys following single and repeated daily s.c. administration for up to 2 mo.  Results : MEDI0382 potently activated rodent, cynomolgus and human GLP-1 and glucagon receptors and exhibited a fivefold bias for activation of GLP-1 receptor vs. the glucagon receptor.  MEDI0382 produced superior wt. loss and comparable glucose lowering to the GLP-1 peptide analog liraglutide when administered daily at comparable doses in DIO mice.  The addnl. fat mass redn. elicited by MEDI0382 probably results from a glucagon receptor-mediated increase in energy expenditure, whereas food intake suppression results from activation of the GLP-1 receptor.  Notably, the significant wt. loss elicited by MEDI0382 in DIO mice was recapitulated in cynomolgus monkeys.  Conclusions : Repeated administration of MEDI0382 elicits profound wt. loss in DIO mice and non-human primates, produces robust glucose control and reduces hepatic fat content and fasting insulin and glucose levels.  The balance of activities at the GLP-1 and glucagon receptors is considered to be optimal for achieving wt. and glucose control in overweight or obese Type 2 diabetic patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpB5Lj1dV4AsLVg90H21EOLACvtfcHk0linLPneEnjymg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVGgsbnN&md5=e0af76d2553a265b6367aab1cc46df6f</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1111%2Fdom.12735&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fdom.12735%26sid%3Dliteratum%253Aachs%26aulast%3DHenderson%26aufirst%3DS.%2BJ.%26aulast%3DKonkar%26aufirst%3DA.%26aulast%3DHornigold%26aufirst%3DD.%2BC.%26aulast%3DTrevaskis%26aufirst%3DJ.%2BL.%26aulast%3DJackson%26aufirst%3DR.%26aulast%3DFritsch%2BFredin%26aufirst%3DM.%26aulast%3DJansson-L%25C3%25B6fmark%26aufirst%3DR.%26aulast%3DNaylor%26aufirst%3DJ.%26aulast%3DRossi%26aufirst%3DA.%26aulast%3DBednarek%26aufirst%3DM.%2BA.%26atitle%3DRobust%2520Anti-Obesity%2520and%2520Metabolic%2520Effects%2520of%2520a%2520Dual%2520GLP-1%252FGlucagon%2520Receptor%2520Peptide%2520Agonist%2520in%2520Rodents%2520and%2520Non-Human%2520Primates%26jtitle%3DDiabetes%252C%2520Obes.%2520Metab.%26date%3D2016%26volume%3D18%26issue%3D12%26spage%3D1176%26epage%3D1190%26doi%3D10.1111%2Fdom.12735" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pathak, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pathak, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâHarte, F. P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flatt, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Irwin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gault, V. A.</span></span> <span> </span><span class="NLM_article-title">A Novel DPP IV-Resistant C-Terminally Extended Glucagon Analogue Exhibits Weight-Lowering and Diabetes-Protective Effects in High-Fat-Fed Mice Mediated through Glucagon and GLP-1 Receptor Activation</span>. <i>Diabetologia</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1927</span>â <span class="NLM_lpage">1936</span>, <span class="refDoi">Â DOI: 10.1007/s00125-014-3296-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=10.1007%2Fs00125-014-3296-7" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=1927-1936&issue=9&author=A.+M.+Lynchauthor=N.+Pathakauthor=V.+Pathakauthor=F.+P.+M.+O%E2%80%99Harteauthor=P.+R.+Flattauthor=N.+Irwinauthor=V.+A.+Gault&title=A+Novel+DPP+IV-Resistant+C-Terminally+Extended+Glucagon+Analogue+Exhibits+Weight-Lowering+and+Diabetes-Protective+Effects+in+High-Fat-Fed+Mice+Mediated+through+Glucagon+and+GLP-1+Receptor+Activation&doi=10.1007%2Fs00125-014-3296-7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1007%2Fs00125-014-3296-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00125-014-3296-7%26sid%3Dliteratum%253Aachs%26aulast%3DLynch%26aufirst%3DA.%2BM.%26aulast%3DPathak%26aufirst%3DN.%26aulast%3DPathak%26aufirst%3DV.%26aulast%3DO%25E2%2580%2599Harte%26aufirst%3DF.%2BP.%2BM.%26aulast%3DFlatt%26aufirst%3DP.%2BR.%26aulast%3DIrwin%26aufirst%3DN.%26aulast%3DGault%26aufirst%3DV.%2BA.%26atitle%3DA%2520Novel%2520DPP%2520IV-Resistant%2520C-Terminally%2520Extended%2520Glucagon%2520Analogue%2520Exhibits%2520Weight-Lowering%2520and%2520Diabetes-Protective%2520Effects%2520in%2520High-Fat-Fed%2520Mice%2520Mediated%2520through%2520Glucagon%2520and%2520GLP-1%2520Receptor%2520Activation%26jtitle%3DDiabetologia%26date%3D2014%26volume%3D57%26issue%3D9%26spage%3D1927%26epage%3D1936%26doi%3D10.1007%2Fs00125-014-3296-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">OâHarte, F. P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conlon, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flatt, P. R.</span></span> <span> </span><span class="NLM_article-title">Dogfish Glucagon Analogues Counter Hyperglycaemia and Enhance Both Insulin Secretion and Action in Diet-Induced Obese Diabetic Mice</span>. <i>Diabetes, Obes. Metab.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1013</span>â <span class="NLM_lpage">1024</span>, <span class="refDoi">Â DOI: 10.1111/dom.12713</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=10.1111%2Fdom.12713" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=27357054" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsV2qtbzF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2016&pages=1013-1024&issue=10&author=F.+P.+M.+O%E2%80%99Harteauthor=M.+T.+Ngauthor=A.+M.+Lynchauthor=J.+M.+Conlonauthor=P.+R.+Flatt&title=Dogfish+Glucagon+Analogues+Counter+Hyperglycaemia+and+Enhance+Both+Insulin+Secretion+and+Action+in+Diet-Induced+Obese+Diabetic+Mice&doi=10.1111%2Fdom.12713"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Dogfish glucagon analogues counter hyperglycaemia and enhance both insulin secretion and action in diet-induced obese diabetic mice</span></div><div class="casAuthors">O'Harte, F. P. M.; Ng, M. T.; Lynch, A. M.; Conlon, J. M.; Flatt, P. R.</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes, Obesity and Metabolism</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1013-1024</span>CODEN:
                <span class="NLM_cas:coden">DOMEF6</span>;
        ISSN:<span class="NLM_cas:issn">1462-8902</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Aims : To investigate the antidiabetic actions of three dogfish glucagon peptide analogs [known glucagon-like peptide-1 and glucagon receptor co-agonists] after chronic administration in diet-induced high-fat-diet-fed diabetic mice.  Materials and methods : National Institutes of Health Swiss mice were pre-conditioned to a high-fat diet (45% fat) for 100 days, and control mice were fed a normal diet (10% fat).  Normal diet control and high-fat-fed control mice received twice-daily i.p. (i.p.) saline injections, while the high-fat-fed treatment groups (n = 8) received twice-daily injections of exendin-4(1-39), [S2a]dogfish glucagon, [S2a]dogfish glucagon exendin-4(31-39) or [S2a]dogfish glucagon-Lys30-Î³-glutamyl-PAL (25 nmol/kg body wt.) for 51 days.  Results : After dogfish glucagon analog treatment, there was a rapid and sustained decrease in non-fasting blood glucose and an assocd. insulinotropic effect (anal. of variance, p < .05 to <.001) compared with saline-treated high-fat-fed controls.  All peptide treatments significantly improved i.p. and oral glucose tolerance with concomitant increased insulin secretion compared with saline-treated high-fat-fed controls (p <.05 to <.001).  After chronic treatment, no receptor desensitization was obsd. but insulin sensitivity was enhanced for all peptide-treated groups (p < .01 to <.001) except [S2a]dogfish glucagon.  Both exendin-4 and [S2a]dogfish glucagon exendin-4(31-39) significantly reduced plasma triglyceride concns. compared with those found in lean controls (p = .0105 and p = .0048, resp.).  Pancreatic insulin content was not affected by peptide treatments but [S2a]dogfish glucagon and [S2a]dogfish glucagon exendin-4(31-39) decreased pancreatic glucagon by 28%-34% (p = .0221 and p = .0075, resp.).  The percentage of Î²-cell area within islets was increased by exendin-4 and peptide analog treatment groups compared with high-fat-fed controls and the Î²-cell area decreased (p < .05 to <.01).  Conclusions : Overall, dogfish glucagon co-agonist analogs had several beneficial metabolic effects, showing therapeutic potential for type 2 diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr33HIW_8oZO7Vg90H21EOLACvtfcHk0linLPneEnjymg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsV2qtbzF&md5=a6c619b6d47964b961f020ad88ea035a</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1111%2Fdom.12713&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fdom.12713%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Harte%26aufirst%3DF.%2BP.%2BM.%26aulast%3DNg%26aufirst%3DM.%2BT.%26aulast%3DLynch%26aufirst%3DA.%2BM.%26aulast%3DConlon%26aufirst%3DJ.%2BM.%26aulast%3DFlatt%26aufirst%3DP.%2BR.%26atitle%3DDogfish%2520Glucagon%2520Analogues%2520Counter%2520Hyperglycaemia%2520and%2520Enhance%2520Both%2520Insulin%2520Secretion%2520and%2520Action%2520in%2520Diet-Induced%2520Obese%2520Diabetic%2520Mice%26jtitle%3DDiabetes%252C%2520Obes.%2520Metab.%26date%3D2016%26volume%3D18%26issue%3D10%26spage%3D1013%26epage%3D1024%26doi%3D10.1111%2Fdom.12713" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">OâHarte, F. P.
M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conlon, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flatt, P. R.</span></span> <span> </span><span class="NLM_article-title">Novel Dual Agonist Peptide Analogues Derived from Dogfish Glucagon Show Promising in Vitro Insulin Releasing Actions and Antihyperglycaemic Activity in Mice</span>. <i>Mol. Cell. Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>431</i></span>,  <span class="NLM_fpage">133</span>â <span class="NLM_lpage">144</span>, <span class="refDoi">Â DOI: 10.1016/j.mce.2016.05.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=10.1016%2Fj.mce.2016.05.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=27179756" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=1%3ACAS%3A528%3ADC%252BC28Xos1anur0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=431&publication_year=2016&pages=133-144&author=F.+P.%0AM.+O%E2%80%99Harteauthor=M.+T.+Ngauthor=A.+M.+Lynchauthor=J.+M.+Conlonauthor=P.+R.+Flatt&title=Novel+Dual+Agonist+Peptide+Analogues+Derived+from+Dogfish+Glucagon+Show+Promising+in+Vitro+Insulin+Releasing+Actions+and+Antihyperglycaemic+Activity+in+Mice&doi=10.1016%2Fj.mce.2016.05.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Novel dual agonist peptide analogues derived from dogfish glucagon show promising in vitro insulin releasing actions and antihyperglycaemic activity in mice</span></div><div class="casAuthors">O'Harte, F. P. M.; Ng, M. T.; Lynch, A. M.; Conlon, J. M.; Flatt, P. R.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Endocrinology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">431</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">133-144</span>CODEN:
                <span class="NLM_cas:coden">MCEND6</span>;
        ISSN:<span class="NLM_cas:issn">0303-7207</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">The antidiabetic potential of thirteen novel dogfish glucagon derived analogs were assessed in vitro and in acute in vivo studies.  Stable peptide analogs enhanced insulin secretion from BRIN-BD11 Î²-cells (p < 0.001) and reduced acute glycemic responses following i.p. glucose (25 nmol/kg) in healthy NIH Swiss mice (p < 0.05-p<0.001).  The in vitro insulinotropic actions of [S2a]dogfish glucagon, [S2a]dogfish glucagon-exendin-4(31-39) and [S2a]dogfish glucagon-Lys30-Î³-glutamyl-PAL, were blocked (p < 0.05-p<0.001) by the specific GLP-1 and glucagon receptor antagonists, exendin-4(9-39) and (desHis1Pro4Glu9)glucagon amide but not by (Pro3)GIP, indicating lack of GIP receptor involvement.  These analogs dose-dependently stimulated cAMP prodn. in GLP-1 and glucagon (p < 0.05-p<0.001) but not GIP-receptor transfected cells.  They improved acute glycemic and insulinotropic responses in high-fat fed diabetic mice and in wild-type C57BL/6J and GIPR-KO mice (p < 0.05-p<0.001), but not GLP-1R-KO mice, confirming action on GLP-1 but not GIP receptors.  Overall, dogfish glucagon analogs have potential for diabetes therapy, exerting beneficial metabolic effects via GLP-1 and glucagon receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYMG0tNkdC2LVg90H21EOLACvtfcHk0lj1Gfon379Ueg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xos1anur0%253D&md5=50d438aaa6ea3d9910faa9063c66f441</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.mce.2016.05.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mce.2016.05.012%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Harte%26aufirst%3DF.%2BP.%2BM.%26aulast%3DNg%26aufirst%3DM.%2BT.%26aulast%3DLynch%26aufirst%3DA.%2BM.%26aulast%3DConlon%26aufirst%3DJ.%2BM.%26aulast%3DFlatt%26aufirst%3DP.%2BR.%26atitle%3DNovel%2520Dual%2520Agonist%2520Peptide%2520Analogues%2520Derived%2520from%2520Dogfish%2520Glucagon%2520Show%2520Promising%2520in%2520Vitro%2520Insulin%2520Releasing%2520Actions%2520and%2520Antihyperglycaemic%2520Activity%2520in%2520Mice%26jtitle%3DMol.%2520Cell.%2520Endocrinol.%26date%3D2016%26volume%3D431%26spage%3D133%26epage%3D144%26doi%3D10.1016%2Fj.mce.2016.05.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span>Transition
Therapeutics Inc. <a href="http://www.transitiontherapeutics.com/technology/tt401.php" class="extLink">http://www.transitiontherapeutics.com/technology/tt401.php</a> (accessed
Mar 21, <span class="NLM_year">2017</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Transition%0ATherapeutics+Inc.+http%3A%2F%2Fwww.transitiontherapeutics.com%2Ftechnology%2Ftt401.php+%28accessed%0AMar+21%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Soni, H.</span></span> <span> </span><span class="NLM_article-title">Peptide-Based GLP-1/Glucagon Co-Agonists: A Double-Edged Sword to Combat Diabesity. Med</span>. <i>Med. Hypotheses</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>95</i></span>,  <span class="NLM_fpage">5</span>â <span class="NLM_lpage">9</span>, <span class="refDoi">Â DOI: 10.1016/j.mehy.2016.08.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=10.1016%2Fj.mehy.2016.08.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=27692167" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVamsLjN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=2016&pages=5-9&author=H.+Soni&title=Peptide-Based+GLP-1%2FGlucagon+Co-Agonists%3A+A+Double-Edged+Sword+to+Combat+Diabesity.+Med&doi=10.1016%2Fj.mehy.2016.08.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Peptide-based GLP-1/glucagon co-agonists: A double-edged sword to combat diabesity</span></div><div class="casAuthors">Soni, Hitesh</div><div class="citationInfo"><span class="NLM_cas:title">Medical Hypotheses</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">5-9</span>CODEN:
                <span class="NLM_cas:coden">MEHYDY</span>;
        ISSN:<span class="NLM_cas:issn">0306-9877</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Diabesity is a new term for obesity-dependent diabetes, which is also assocd. with cardiovascular and other comorbidities with rising epidemic.  Traditional treatments (sulfonylureas and thiazolidinediones) of diabetes are assocd. with wt. gain, except metformin.  Newer agents such as glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and Sodium glucose co-transporter 2 inhibitors (SGLT2i) are causing a modest wt. redn., whereas dipeptidyl peptidase-4 inhibitors (DPP-4i) are wt. neutral.  Oxyntomodulin, a native GLP-1/glucagon receptor agonist produced a superior wt. loss and antihyperglycemic effects in obese mice and humans.  Recent findings with synthetic dual GLP-1/glucagon receptor agonists have shown a good wt. loss and antihyperglycemic profile in diet-induced obese (DIO) mice.  Targeting combinations of GLP-1 receptor and glucagon receptor simultaneously with a single peptide may be the better strategy to achieve marked wt. loss and considerable glycemic control in diabesity.  Cardiovascular safety is very important with new antidiabetic agents due to rosiglitazone controversy.  Current on-going clin. trials will clarify the cardiovascular effects of incretin-based therapies in near future.  Based on current knowledge and rapid progress in the field, there is a strong possibility that the GLP-1/glucagon receptor co-agonists will likely be the new therapeutic treatment for diabesity for decades to come.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYi16nV6WICrVg90H21EOLACvtfcHk0lj1Gfon379Ueg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVamsLjN&md5=f14f1d5ff2beb0989d9de3e16bc80581</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.mehy.2016.08.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mehy.2016.08.005%26sid%3Dliteratum%253Aachs%26aulast%3DSoni%26aufirst%3DH.%26atitle%3DPeptide-Based%2520GLP-1%252FGlucagon%2520Co-Agonists%253A%2520A%2520Double-Edged%2520Sword%2520to%2520Combat%2520Diabesity.%2520Med%26jtitle%3DMed.%2520Hypotheses%26date%3D2016%26volume%3D95%26spage%3D5%26epage%3D9%26doi%3D10.1016%2Fj.mehy.2016.08.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Day, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelfanov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smiley, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrington, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eiermann, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chicchi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erion, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gidda, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thornberry, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">TschÃ¶p, M. H.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Optimization of Co-Agonism at GLP-1 and Glucagon Receptors to Safely Maximize Weight Reduction in DIO-Rodents</span>. <i>Biopolymers</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>98</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">443</span>â <span class="NLM_lpage">450</span>, <span class="refDoi">Â DOI: 10.1002/bip.22072</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=10.1002%2Fbip.22072" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2012&pages=443-450&issue=5&author=J.+W.+Dayauthor=V.+Gelfanovauthor=D.+Smileyauthor=P.+E.+Carringtonauthor=G.+Eiermannauthor=G.+Chicchiauthor=M.+D.+Erionauthor=J.+Giddaauthor=N.+A.+Thornberryauthor=M.+H.+Tsch%C3%B6p&title=Optimization+of+Co-Agonism+at+GLP-1+and+Glucagon+Receptors+to+Safely+Maximize+Weight+Reduction+in+DIO-Rodents&doi=10.1002%2Fbip.22072"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1002%2Fbip.22072&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fbip.22072%26sid%3Dliteratum%253Aachs%26aulast%3DDay%26aufirst%3DJ.%2BW.%26aulast%3DGelfanov%26aufirst%3DV.%26aulast%3DSmiley%26aufirst%3DD.%26aulast%3DCarrington%26aufirst%3DP.%2BE.%26aulast%3DEiermann%26aufirst%3DG.%26aulast%3DChicchi%26aufirst%3DG.%26aulast%3DErion%26aufirst%3DM.%2BD.%26aulast%3DGidda%26aufirst%3DJ.%26aulast%3DThornberry%26aufirst%3DN.%2BA.%26aulast%3DTsch%25C3%25B6p%26aufirst%3DM.%2BH.%26atitle%3DOptimization%2520of%2520Co-Agonism%2520at%2520GLP-1%2520and%2520Glucagon%2520Receptors%2520to%2520Safely%2520Maximize%2520Weight%2520Reduction%2520in%2520DIO-Rodents%26jtitle%3DBiopolymers%26date%3D2012%26volume%3D98%26issue%3D5%26spage%3D443%26epage%3D450%26doi%3D10.1002%2Fbip.22072" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span>General
Chapters: â¨51â© ANTIMICROBIAL EFFECTIVENESS TESTING <a href="http://www.pharmacopeia.cn/v29240/usp29nf24s0_c51.html" class="extLink">http://www.pharmacopeia.cn/v29240/usp29nf24s0_c51.html</a> (accessed Jan 23, <span class="NLM_year">2018</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=General%0AChapters%3A+%E2%9F%A851%E2%9F%A9+ANTIMICROBIAL+EFFECTIVENESS+TESTING+http%3A%2F%2Fwww.pharmacopeia.cn%2Fv29240%2Fusp29nf24s0_c51.html+%28accessed+Jan+23%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De
Jong, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Incledon, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yip, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeFelippis, M. R.</span></span> <span> </span><span class="NLM_article-title">Amyloid Fibrils of Glucagon Characterized by High-Resolution Atomic Force Microscopy</span>. <i>Biophys. J.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>91</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1905</span>â <span class="NLM_lpage">1914</span>, <span class="refDoi">Â DOI: 10.1529/biophysj.105.077438</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=10.1529%2Fbiophysj.105.077438" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=2006&pages=1905-1914&issue=5&author=K.+L.+De%0AJongauthor=B.+Incledonauthor=C.+M.+Yipauthor=M.+R.+DeFelippis&title=Amyloid+Fibrils+of+Glucagon+Characterized+by+High-Resolution+Atomic+Force+Microscopy&doi=10.1529%2Fbiophysj.105.077438"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1529%2Fbiophysj.105.077438&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1529%252Fbiophysj.105.077438%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BJong%26aufirst%3DK.%2BL.%26aulast%3DIncledon%26aufirst%3DB.%26aulast%3DYip%26aufirst%3DC.%2BM.%26aulast%3DDeFelippis%26aufirst%3DM.%2BR.%26atitle%3DAmyloid%2520Fibrils%2520of%2520Glucagon%2520Characterized%2520by%2520High-Resolution%2520Atomic%2520Force%2520Microscopy%26jtitle%3DBiophys.%2520J.%26date%3D2006%26volume%3D91%26issue%3D5%26spage%3D1905%26epage%3D1914%26doi%3D10.1529%2Fbiophysj.105.077438" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heljo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarraga, I. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pappenberger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahler, H.-C.</span></span> <span> </span><span class="NLM_article-title">Interactions Between Peptide and Preservatives: Effects on Peptide Self-Interactions and Antimicrobial Efficiency In Aqueous Multi-Dose Formulations</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>32</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">3201</span>â <span class="NLM_lpage">3212</span>, <span class="refDoi">Â DOI: 10.1007/s11095-015-1697-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=10.1007%2Fs11095-015-1697-z" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2015&pages=3201-3212&issue=10&author=P.+Heljoauthor=A.+Rossauthor=I.+E.+Zarragaauthor=A.+Pappenbergerauthor=H.-C.+Mahler&title=Interactions+Between+Peptide+and+Preservatives%3A+Effects+on+Peptide+Self-Interactions+and+Antimicrobial+Efficiency+In+Aqueous+Multi-Dose+Formulations&doi=10.1007%2Fs11095-015-1697-z"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1007%2Fs11095-015-1697-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11095-015-1697-z%26sid%3Dliteratum%253Aachs%26aulast%3DHeljo%26aufirst%3DP.%26aulast%3DRoss%26aufirst%3DA.%26aulast%3DZarraga%26aufirst%3DI.%2BE.%26aulast%3DPappenberger%26aufirst%3DA.%26aulast%3DMahler%26aufirst%3DH.-C.%26atitle%3DInteractions%2520Between%2520Peptide%2520and%2520Preservatives%253A%2520Effects%2520on%2520Peptide%2520Self-Interactions%2520and%2520Antimicrobial%2520Efficiency%2520In%2520Aqueous%2520Multi-Dose%2520Formulations%26jtitle%3DPharm.%2520Res.%26date%3D2015%26volume%3D32%26issue%3D10%26spage%3D3201%26epage%3D3212%26doi%3D10.1007%2Fs11095-015-1697-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pedersen, J. S.</span></span> <span> </span><span class="NLM_article-title">The Nature of Amyloid-like Glucagon Fibrils</span>. <i>J. Diabetes Sci. Technol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1357</span>â <span class="NLM_lpage">1367</span>, <span class="refDoi">Â DOI: 10.1177/193229681000400609</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=10.1177%2F193229681000400609" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=21129330" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=1%3ACAS%3A280%3ADC%252BC3M%252FhvVGmsA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2010&pages=1357-1367&issue=6&author=J.+S.+Pedersen&title=The+Nature+of+Amyloid-like+Glucagon+Fibrils&doi=10.1177%2F193229681000400609"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">The nature of amyloid-like glucagon fibrils</span></div><div class="casAuthors">Pedersen Jesper Sondergaard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of diabetes science and technology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1357-67</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Protein aggregation and formation of amyloid fibrils is a phenomenon usually associated with proteotoxicity and degenerative diseases, such as type 2 diabetes, Alzheimer's disease, and prion diseases.  However, several protein and peptide hormones are known to have a high propensity to form amyloid-like fibrils in vitro raising concerns about safety and stability of pharmaceutical protein solutions.  Comprehensive understanding of the aggregation mechanisms is an important prerequisite to the design of strategies to prevent fibril formation.  Detailed kinetic, spectroscopic, and morphological studies have revealed that glucagon can form several types of fibrils that differ at the level of molecular packing of the peptide.  Each type forms through distinct nucleation-dependent aggregation pathways influenced by solution conditions and can be self-propagated by seeding.  An increasing number of functional amyloid-like structures have been discovered in nature, and it has recently been proposed that an amyloid-like state of glucagon may be utilized by the pancreatic Î±-cells as in vivo storage form.  This article reviews the current state of our knowledge about the nature of the different types of amyloid-like glucagon fibrils, the mechanisms by which they form, and discusses implications for formulation strategies and the safety of glucagon pharmaceuticals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTOCyyMqEaCIUHdcurJClFcfW6udTcc2eZV7ISFgM3_QLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3M%252FhvVGmsA%253D%253D&md5=957881a8ec368a36059ff74d6eee4d16</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1177%2F193229681000400609&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F193229681000400609%26sid%3Dliteratum%253Aachs%26aulast%3DPedersen%26aufirst%3DJ.%2BS.%26atitle%3DThe%2520Nature%2520of%2520Amyloid-like%2520Glucagon%2520Fibrils%26jtitle%3DJ.%2520Diabetes%2520Sci.%2520Technol.%26date%3D2010%26volume%3D4%26issue%3D6%26spage%3D1357%26epage%3D1367%26doi%3D10.1177%2F193229681000400609" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pedersen, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dikov, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otzen, D. E.</span></span> <span> </span><span class="NLM_article-title">N- and C-Terminal Hydrophobic Patches Are Involved in Fibrillation of Glucagon</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>45</i></span> (<span class="NLM_issue">48</span>),  <span class="NLM_fpage">14503</span>â <span class="NLM_lpage">14512</span>, <span class="refDoi">Â DOI: 10.1021/bi061228n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi061228n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2006&pages=14503-14512&issue=48&author=J.+S.+Pedersenauthor=D.+Dikovauthor=D.+E.+Otzen&title=N-+and+C-Terminal+Hydrophobic+Patches+Are+Involved+in+Fibrillation+of+Glucagon&doi=10.1021%2Fbi061228n"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fbi061228n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi061228n%26sid%3Dliteratum%253Aachs%26aulast%3DPedersen%26aufirst%3DJ.%2BS.%26aulast%3DDikov%26aufirst%3DD.%26aulast%3DOtzen%26aufirst%3DD.%2BE.%26atitle%3DN-%2520and%2520C-Terminal%2520Hydrophobic%2520Patches%2520Are%2520Involved%2520in%2520Fibrillation%2520of%2520Glucagon%26jtitle%3DBiochemistry%26date%3D2006%26volume%3D45%26issue%3D48%26spage%3D14503%26epage%3D14512%26doi%3D10.1021%2Fbi061228n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pedersen, J.
S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dikov, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flink, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hjuler, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christiansen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otzen, D. E.</span></span> <span> </span><span class="NLM_article-title">The Changing Face of Glucagon Fibrillation: Structural Polymorphism and Conformational Imprinting</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>355</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">501</span>â <span class="NLM_lpage">523</span>, <span class="refDoi">Â DOI: 10.1016/j.jmb.2005.09.100</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=10.1016%2Fj.jmb.2005.09.100" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=355&publication_year=2006&pages=501-523&issue=3&author=J.%0AS.+Pedersenauthor=D.+Dikovauthor=J.+L.+Flinkauthor=H.+A.+Hjulerauthor=G.+Christiansenauthor=D.+E.+Otzen&title=The+Changing+Face+of+Glucagon+Fibrillation%3A+Structural+Polymorphism+and+Conformational+Imprinting&doi=10.1016%2Fj.jmb.2005.09.100"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2005.09.100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2005.09.100%26sid%3Dliteratum%253Aachs%26aulast%3DPedersen%26aufirst%3DJ.%2BS.%26aulast%3DDikov%26aufirst%3DD.%26aulast%3DFlink%26aufirst%3DJ.%2BL.%26aulast%3DHjuler%26aufirst%3DH.%2BA.%26aulast%3DChristiansen%26aufirst%3DG.%26aulast%3DOtzen%26aufirst%3DD.%2BE.%26atitle%3DThe%2520Changing%2520Face%2520of%2520Glucagon%2520Fibrillation%253A%2520Structural%2520Polymorphism%2520and%2520Conformational%2520Imprinting%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2006%26volume%3D355%26issue%3D3%26spage%3D501%26epage%3D523%26doi%3D10.1016%2Fj.jmb.2005.09.100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, W.</span></span> <span> </span><span class="NLM_article-title">Peptide Developability at the Discovery-to-Development InterfaceâCurrent State and Future Opportunities</span>. <i>AAPS J.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">777</span>â <span class="NLM_lpage">779</span>, <span class="refDoi">Â DOI: 10.1208/s12248-015-9755-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=10.1208%2Fs12248-015-9755-3" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2015&pages=777-779&issue=4&author=A.+Bakauthor=W.+Dai&title=Peptide+Developability+at+the+Discovery-to-Development+Interface%E2%80%93Current+State+and+Future+Opportunities&doi=10.1208%2Fs12248-015-9755-3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1208%2Fs12248-015-9755-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1208%252Fs12248-015-9755-3%26sid%3Dliteratum%253Aachs%26aulast%3DBak%26aufirst%3DA.%26aulast%3DDai%26aufirst%3DW.%26atitle%3DPeptide%2520Developability%2520at%2520the%2520Discovery-to-Development%2520Interface%25E2%2580%2593Current%2520State%2520and%2520Future%2520Opportunities%26jtitle%3DAAPS%2520J.%26date%3D2015%26volume%3D17%26issue%3D4%26spage%3D777%26epage%3D779%26doi%3D10.1208%2Fs12248-015-9755-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forster, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minnihan, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leithead, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cunningham, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toussaint, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crocker, L. S.</span></span> <span> </span><span class="NLM_article-title">Physicochemical and Formulation Developability Assessment for Therapeutic Peptide Deliveryâa Primer</span>. <i>AAPS J.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">144</span>â <span class="NLM_lpage">155</span>, <span class="refDoi">Â DOI: 10.1208/s12248-014-9688-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=10.1208%2Fs12248-014-9688-2" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2015&pages=144-155&issue=1&author=A.+Bakauthor=D.+Leungauthor=S.+E.+Barrettauthor=S.+Forsterauthor=E.+C.+Minnihanauthor=A.+W.+Leitheadauthor=J.+Cunninghamauthor=N.+Toussaintauthor=L.+S.+Crocker&title=Physicochemical+and+Formulation+Developability+Assessment+for+Therapeutic+Peptide+Delivery%E2%80%93a+Primer&doi=10.1208%2Fs12248-014-9688-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1208%2Fs12248-014-9688-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1208%252Fs12248-014-9688-2%26sid%3Dliteratum%253Aachs%26aulast%3DBak%26aufirst%3DA.%26aulast%3DLeung%26aufirst%3DD.%26aulast%3DBarrett%26aufirst%3DS.%2BE.%26aulast%3DForster%26aufirst%3DS.%26aulast%3DMinnihan%26aufirst%3DE.%2BC.%26aulast%3DLeithead%26aufirst%3DA.%2BW.%26aulast%3DCunningham%26aufirst%3DJ.%26aulast%3DToussaint%26aufirst%3DN.%26aulast%3DCrocker%26aufirst%3DL.%2BS.%26atitle%3DPhysicochemical%2520and%2520Formulation%2520Developability%2520Assessment%2520for%2520Therapeutic%2520Peptide%2520Delivery%25E2%2580%2593a%2520Primer%26jtitle%3DAAPS%2520J.%26date%3D2015%26volume%3D17%26issue%3D1%26spage%3D144%26epage%3D155%26doi%3D10.1208%2Fs12248-014-9688-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fosgerau, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, T.</span></span> <span> </span><span class="NLM_article-title">Peptide Therapeutics: Current Status and Future Directions</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">122</span>â <span class="NLM_lpage">128</span>, <span class="refDoi">Â DOI: 10.1016/j.drudis.2014.10.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=10.1016%2Fj.drudis.2014.10.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=25450771" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsl2ksLnM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2015&pages=122-128&issue=1&author=K.+Fosgerauauthor=T.+Hoffmann&title=Peptide+Therapeutics%3A+Current+Status+and+Future+Directions&doi=10.1016%2Fj.drudis.2014.10.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Peptide therapeutics: current status and future directions</span></div><div class="casAuthors">Fosgerau, Keld; Hoffmann, Torsten</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">122-128</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Peptides are recognized for being highly selective and efficacious and, at the same time, relatively safe and well tolerated.  Consequently, there is an increased interest in peptides in pharmaceutical research and development (R&D), and approx. 140 peptide therapeutics are currently being evaluated in clin. trials.  Given that the low-hanging fruits in the form of obvious peptide targets have already been picked, it has now become necessary to explore new routes beyond traditional peptide design.  Examples of such approaches are multifunctional and cell penetrating peptides, as well as peptide drug conjugates.  Here, we discuss the current status, strengths, and weaknesses of peptides as medicines and the emerging new opportunities in peptide drug design and development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmhpp8GnJ6JLVg90H21EOLACvtfcHk0lg0m1d2VRifhg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsl2ksLnM&md5=f6b74aaa4e3fdb317b091b0450f3618a</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2014.10.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2014.10.003%26sid%3Dliteratum%253Aachs%26aulast%3DFosgerau%26aufirst%3DK.%26aulast%3DHoffmann%26aufirst%3DT.%26atitle%3DPeptide%2520Therapeutics%253A%2520Current%2520Status%2520and%2520Future%2520Directions%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2015%26volume%3D20%26issue%3D1%26spage%3D122%26epage%3D128%26doi%3D10.1016%2Fj.drudis.2014.10.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Neidigh, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fesinmeyer, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prickett, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersen, N. H.</span></span> <span> </span><span class="NLM_article-title">Exendin-4 and Glucagon-like-Peptide-1: NMR Structural Comparisons in the Solution and Micelle-Associated States <sup>â </sup></span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>40</i></span> (<span class="NLM_issue">44</span>),  <span class="NLM_fpage">13188</span>â <span class="NLM_lpage">13200</span>, <span class="refDoi">Â DOI: 10.1021/bi010902s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi010902s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2001&pages=13188-13200&issue=44&author=J.+W.+Neidighauthor=R.+M.+Fesinmeyerauthor=K.+S.+Prickettauthor=N.+H.+Andersen&title=Exendin-4+and+Glucagon-like-Peptide-1%3A+NMR+Structural+Comparisons+in+the+Solution+and+Micelle-Associated+States+%E2%80%A0&doi=10.1021%2Fbi010902s"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fbi010902s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi010902s%26sid%3Dliteratum%253Aachs%26aulast%3DNeidigh%26aufirst%3DJ.%2BW.%26aulast%3DFesinmeyer%26aufirst%3DR.%2BM.%26aulast%3DPrickett%26aufirst%3DK.%2BS.%26aulast%3DAndersen%26aufirst%3DN.%2BH.%26atitle%3DExendin-4%2520and%2520Glucagon-like-Peptide-1%253A%2520NMR%2520Structural%2520Comparisons%2520in%2520the%2520Solution%2520and%2520Micelle-Associated%2520States%2520%25E2%2580%25A0%26jtitle%3DBiochemistry%26date%3D2001%26volume%3D40%26issue%3D44%26spage%3D13188%26epage%3D13200%26doi%3D10.1021%2Fbi010902s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chabenne, J.
R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiMarchi, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelfanov, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiMarchi, R. D.</span></span> <span> </span><span class="NLM_article-title">Optimization of the Native Glucagon Sequence for Medicinal Purposes</span>. <i>J. Diabetes Sci. Technol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1322</span>â <span class="NLM_lpage">1331</span>, <span class="refDoi">Â DOI: 10.1177/193229681000400605</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=10.1177%2F193229681000400605" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=21129326" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=1%3ACAS%3A280%3ADC%252BC3M%252FhvVGnug%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2010&pages=1322-1331&issue=6&author=J.%0AR.+Chabenneauthor=M.+A.+DiMarchiauthor=V.+M.+Gelfanovauthor=R.+D.+DiMarchi&title=Optimization+of+the+Native+Glucagon+Sequence+for+Medicinal+Purposes&doi=10.1177%2F193229681000400605"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of the native glucagon sequence for medicinal purposes</span></div><div class="casAuthors">Chabenne Joseph R; DiMarchi Maria A; Gelfanov Vasily M; DiMarchi Richard D</div><div class="citationInfo"><span class="NLM_cas:title">Journal of diabetes science and technology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1322-31</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Glucagon is a life-saving medication used in the treatment of hypoglycemia.  It possesses poor solubility in aqueous buffers at or near physiological pH values.  At low and high pH, at which the peptide can be formulated to concentrations of a milligram or more per milliliter, the chemical integrity of the hormone is limited, as evidenced by the formation of multiple degradation-related peptides.  Consequently, the commercial preparation is provided as a lyophilized solid with an acidic diluent and directions for rendering it soluble at the time of use.  Any unused material is recommended for disposal immediately after initial use.  METHODS:  A set of glucagon analogs was prepared by solid-phase peptide synthesis to explore the identification of a glucagon analog with enhanced solubility and chemical stability at physiological pH.  The physical properties of the peptide analogs were studied by solubility determination, high-performance chromatography, and mass spectral analysis.  The biochemical properties were determined in engineered human embryonic kidney cell line 293 (HEK293) cells that overexpressed either the human glucagon or glucagon-like peptide-1 (GLP-1) receptors linked to a luciferase reporter gene.  RESULTS:  We observed the previously characterized formation of glucagon degradation products upon incubation of the peptide in dilute acid for extended periods or elevated temperature.  Lowering the isoelectric point of the hormone through the substitution of asparagine-28 with aspartic acid significantly increased the solubility at physiological pH.  Similarly, the C-terminal extension (Cex) of the hormone with an exendin-based, 10-residue, C-terminal sequence yielded a peptide of dramatically enhanced solubility.  These two glucagon analogs, D28 and Cex, maintained high potency and selectivity for the glucagon receptor relative to GLP-1 receptor.  CONCLUSIONS:  Glucagon presents unique structural challenges to the identification of an analog of high biological activity and selectivity that also possesses sufficient aqueous solubility and stability such that it might be developed as a ready-to-use medicine.  The glucagon analogs D28 and Cex demonstrated all of the chemical, physical, and biochemical properties supportive of further study as potential clinical candidates for treatment of hypoglycemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTOCyyMqEaCIRWfpMXQLRstfW6udTcc2eapL9YnfpaBXbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3M%252FhvVGnug%253D%253D&md5=9a27028640295b5f4a6c2bd040bcd120</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1177%2F193229681000400605&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F193229681000400605%26sid%3Dliteratum%253Aachs%26aulast%3DChabenne%26aufirst%3DJ.%2BR.%26aulast%3DDiMarchi%26aufirst%3DM.%2BA.%26aulast%3DGelfanov%26aufirst%3DV.%2BM.%26aulast%3DDiMarchi%26aufirst%3DR.%2BD.%26atitle%3DOptimization%2520of%2520the%2520Native%2520Glucagon%2520Sequence%2520for%2520Medicinal%2520Purposes%26jtitle%3DJ.%2520Diabetes%2520Sci.%2520Technol.%26date%3D2010%26volume%3D4%26issue%3D6%26spage%3D1322%26epage%3D1331%26doi%3D10.1177%2F193229681000400605" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Runge, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">ThÃ¸gersen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madsen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudolph, R.</span></span> <span> </span><span class="NLM_article-title">Crystal Structure of the Ligand-Bound Glucagon-like Peptide-1 Receptor Extracellular Domain</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>283</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">11340</span>â <span class="NLM_lpage">11347</span>, <span class="refDoi">Â DOI: 10.1074/jbc.M708740200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=10.1074%2Fjbc.M708740200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=18287102" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=1%3ACAS%3A528%3ADC%252BD1cXkvVSgtr4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=283&publication_year=2008&pages=11340-11347&issue=17&author=S.+Rungeauthor=H.+Th%C3%B8gersenauthor=K.+Madsenauthor=J.+Lauauthor=R.+Rudolph&title=Crystal+Structure+of+the+Ligand-Bound+Glucagon-like+Peptide-1+Receptor+Extracellular+Domain&doi=10.1074%2Fjbc.M708740200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal Structure of the Ligand-bound Glucagon-like Peptide-1 Receptor Extracellular Domain</span></div><div class="casAuthors">Runge, Steffen; Thogersen, Henning; Madsen, Kjeld; Lau, Jesper; Rudolph, Rainer</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">283</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">11340-11347</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The glucagon-like peptide-1 receptor (GLP-1R) belongs to Family B1 of the seven-transmembrane G protein-coupled receptors, and its natural agonist ligand is the peptide hormone glucagon-like peptide-1 (GLP-1).  GLP-1 is involved in glucose homeostasis, and activation of GLP-1R in the plasma membrane of pancreatic Î²-cells potentiates glucose-dependent insulin secretion.  The N-terminal extracellular domain (nGLP-1R) is an important ligand binding domain that binds GLP-1 and the homologous peptide Exendin-4 with differential affinity.  Exendin-4 has a C-terminal extension of nine amino acid residues known as the "Trp cage", which is absent in GLP-1.  The Trp cage was believed to interact with nGLP-1R and thereby explain the superior affinity of Exendin-4.  However, the mol. details that govern ligand binding and specificity of nGLP-1R remain undefined.  Here the authors report the crystal structure of human nGLP-1R in complex with the antagonist Exendin-4(9-39) solved by the multiwavelength anomalous dispersion method to 2.2Ã resoln.  The structure reveals that Exendin-4(9-39) is an amphipathic Î±-helix forming both hydrophobic and hydrophilic interactions with nGLP-1R.  The Trp cage of Exendin-4 is not involved in binding to nGLP-1R.  The hydrophobic binding site of nGLP-1R is defined by discontinuous segments including primarily a well defined Î±-helix in the N terminus of nGLP-1R and a loop between two antiparallel Î²-strands.  The structure provides for the first time detailed mol. insight into ligand binding of the human GLP-1 receptor, an established target for treatment of type 2 diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquCFNrYkVbPLVg90H21EOLACvtfcHk0lgtsAUSHs0HKw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXkvVSgtr4%253D&md5=43529117c437b477afb23e0ba196b1b1</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M708740200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M708740200%26sid%3Dliteratum%253Aachs%26aulast%3DRunge%26aufirst%3DS.%26aulast%3DTh%25C3%25B8gersen%26aufirst%3DH.%26aulast%3DMadsen%26aufirst%3DK.%26aulast%3DLau%26aufirst%3DJ.%26aulast%3DRudolph%26aufirst%3DR.%26atitle%3DCrystal%2520Structure%2520of%2520the%2520Ligand-Bound%2520Glucagon-like%2520Peptide-1%2520Receptor%2520Extracellular%2520Domain%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2008%26volume%3D283%26issue%3D17%26spage%3D11340%26epage%3D11347%26doi%3D10.1074%2Fjbc.M708740200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koth, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukund, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madjidi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minn, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiang, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estevez, A.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Molecular Basis for Negative Regulation of the Glucagon Receptor</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>109</i></span> (<span class="NLM_issue">36</span>),  <span class="NLM_fpage">14393</span>â <span class="NLM_lpage">14398</span>, <span class="refDoi">Â DOI: 10.1073/pnas.1206734109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=10.1073%2Fpnas.1206734109" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2012&pages=14393-14398&issue=36&author=C.+M.+Kothauthor=J.+M.+Murrayauthor=S.+Mukundauthor=A.+Madjidiauthor=A.+Minnauthor=H.+J.+Clarkeauthor=T.+Wongauthor=V.+Chiangauthor=E.+Luisauthor=A.+Estevez&title=Molecular+Basis+for+Negative+Regulation+of+the+Glucagon+Receptor&doi=10.1073%2Fpnas.1206734109"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1206734109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1206734109%26sid%3Dliteratum%253Aachs%26aulast%3DKoth%26aufirst%3DC.%2BM.%26aulast%3DMurray%26aufirst%3DJ.%2BM.%26aulast%3DMukund%26aufirst%3DS.%26aulast%3DMadjidi%26aufirst%3DA.%26aulast%3DMinn%26aufirst%3DA.%26aulast%3DClarke%26aufirst%3DH.%2BJ.%26aulast%3DWong%26aufirst%3DT.%26aulast%3DChiang%26aufirst%3DV.%26aulast%3DLuis%26aufirst%3DE.%26aulast%3DEstevez%26aufirst%3DA.%26atitle%3DMolecular%2520Basis%2520for%2520Negative%2520Regulation%2520of%2520the%2520Glucagon%2520Receptor%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2012%26volume%3D109%26issue%3D36%26spage%3D14393%26epage%3D14398%26doi%3D10.1073%2Fpnas.1206734109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Parthier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleinschmidt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neumann, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudolph, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manhart, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlenzig, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">FanghÃ¤nel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahfeld, J.-U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demuth, H.-U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stubbs, M. T.</span></span> <span> </span><span class="NLM_article-title">Crystal Structure of the Incretin-Bound Extracellular Domain of a G Protein-Coupled Receptor</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>104</i></span> (<span class="NLM_issue">35</span>),  <span class="NLM_fpage">13942</span>â <span class="NLM_lpage">13947</span>, <span class="refDoi">Â DOI: 10.1073/pnas.0706404104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=10.1073%2Fpnas.0706404104" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2007&pages=13942-13947&issue=35&author=C.+Parthierauthor=M.+Kleinschmidtauthor=P.+Neumannauthor=R.+Rudolphauthor=S.+Manhartauthor=D.+Schlenzigauthor=J.+Fangh%C3%A4nelauthor=J.-U.+Rahfeldauthor=H.-U.+Demuthauthor=M.+T.+Stubbs&title=Crystal+Structure+of+the+Incretin-Bound+Extracellular+Domain+of+a+G+Protein-Coupled+Receptor&doi=10.1073%2Fpnas.0706404104"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0706404104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0706404104%26sid%3Dliteratum%253Aachs%26aulast%3DParthier%26aufirst%3DC.%26aulast%3DKleinschmidt%26aufirst%3DM.%26aulast%3DNeumann%26aufirst%3DP.%26aulast%3DRudolph%26aufirst%3DR.%26aulast%3DManhart%26aufirst%3DS.%26aulast%3DSchlenzig%26aufirst%3DD.%26aulast%3DFangh%25C3%25A4nel%26aufirst%3DJ.%26aulast%3DRahfeld%26aufirst%3DJ.-U.%26aulast%3DDemuth%26aufirst%3DH.-U.%26aulast%3DStubbs%26aufirst%3DM.%2BT.%26atitle%3DCrystal%2520Structure%2520of%2520the%2520Incretin-Bound%2520Extracellular%2520Domain%2520of%2520a%2520G%2520Protein-Coupled%2520Receptor%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2007%26volume%3D104%26issue%3D35%26spage%3D13942%26epage%3D13947%26doi%3D10.1073%2Fpnas.0706404104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jazayeri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rappas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, A. J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kean, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Errey, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiez-Vandal, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Congreve, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bortolato, A.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Crystal Structure of the GLP-1 Receptor Bound to a Peptide Agonist</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>546</i></span> (<span class="NLM_issue">7657</span>),  <span class="NLM_fpage">254</span>â <span class="NLM_lpage">258</span>, <span class="refDoi">Â DOI: 10.1038/nature22800</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=10.1038%2Fnature22800" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=28562585" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=1%3ACAS%3A528%3ADC%252BC2sXovFCrs70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=546&publication_year=2017&pages=254-258&issue=7657&author=A.+Jazayeriauthor=M.+Rappasauthor=A.+J.+H.+Brownauthor=J.+Keanauthor=J.+C.+Erreyauthor=N.+J.+Robertsonauthor=C.+Fiez-Vandalauthor=S.+P.+Andrewsauthor=M.+Congreveauthor=A.+Bortolato&title=Crystal+Structure+of+the+GLP-1+Receptor+Bound+to+a+Peptide+Agonist&doi=10.1038%2Fnature22800"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of the GLP-1 receptor bound to a peptide agonist</span></div><div class="casAuthors">Jazayeri, Ali; Rappas, Mathieu; Brown, Alastair J. H.; Kean, James; Errey, James C.; Robertson, Nathan J.; Fiez-Vandal, Cedric; Andrews, Stephen P.; Congreve, Miles; Bortolato, Andrea; Mason, Jonathan S.; Baig, Asma H.; Teobald, Iryna; Dore, Andrew S.; Weir, Malcolm; Cooke, Robert M.; Marshall, Fiona H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">546</span>
        (<span class="NLM_cas:issue">7657</span>),
    <span class="NLM_cas:pages">254-258</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Glucagon-like peptide 1 (GLP-1) regulates glucose homeostasis through the control of insulin release from the pancreas.  GLP-1 peptide agonists are efficacious drugs for the treatment of diabetes.  To gain insight into the mol. mechanism of action of GLP-1 peptides, here we report the crystal structure of the full-length GLP-1 receptor bound to a truncated peptide agonist.  The peptide agonist retains an Î±-helical conformation as it sits deep within the receptor-binding pocket.  The arrangement of the transmembrane helixes reveals hallmarks of an active conformation similar to that obsd. in class A receptors.  Guided by this structural information, we design peptide agonists with potent in vivo activity in a mouse model of diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoX6Ibc110QxrVg90H21EOLACvtfcHk0lgtsAUSHs0HKw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXovFCrs70%253D&md5=0a5c99161af8bae506a184e0ab6306c1</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1038%2Fnature22800&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature22800%26sid%3Dliteratum%253Aachs%26aulast%3DJazayeri%26aufirst%3DA.%26aulast%3DRappas%26aufirst%3DM.%26aulast%3DBrown%26aufirst%3DA.%2BJ.%2BH.%26aulast%3DKean%26aufirst%3DJ.%26aulast%3DErrey%26aufirst%3DJ.%2BC.%26aulast%3DRobertson%26aufirst%3DN.%2BJ.%26aulast%3DFiez-Vandal%26aufirst%3DC.%26aulast%3DAndrews%26aufirst%3DS.%2BP.%26aulast%3DCongreve%26aufirst%3DM.%26aulast%3DBortolato%26aufirst%3DA.%26atitle%3DCrystal%2520Structure%2520of%2520the%2520GLP-1%2520Receptor%2520Bound%2520to%2520a%2520Peptide%2520Agonist%26jtitle%3DNature%26date%3D2017%26volume%3D546%26issue%3D7657%26spage%3D254%26epage%3D258%26doi%3D10.1038%2Fnature22800" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarrasch, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun Kobilka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobilka, B. K.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Cryo-EM Structure of the Activated GLP-1 Receptor in Complex with a G Protein</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>546</i></span> (<span class="NLM_issue">7657</span>),  <span class="NLM_fpage">248</span>â <span class="NLM_lpage">253</span>, <span class="refDoi">Â DOI: 10.1038/nature22394</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=10.1038%2Fnature22394" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=28538729" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=1%3ACAS%3A528%3ADC%252BC2sXosVagtLo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=546&publication_year=2017&pages=248-253&issue=7657&author=Y.+Zhangauthor=B.+Sunauthor=D.+Fengauthor=H.+Huauthor=M.+Chuauthor=Q.+Quauthor=J.+T.+Tarraschauthor=S.+Liauthor=T.+Sun+Kobilkaauthor=B.+K.+Kobilka&title=Cryo-EM+Structure+of+the+Activated+GLP-1+Receptor+in+Complex+with+a+G+Protein&doi=10.1038%2Fnature22394"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Cryo-EM structure of the activated GLP-1 receptor in complex with a G protein</span></div><div class="casAuthors">Zhang, Yan; Sun, Bingfa; Feng, Dan; Hu, Hongli; Chu, Matthew; Qu, Qianhui; Tarrasch, Jeffrey T.; Li, Shane; Sun Kobilka, Tong; Kobilka, Brian K.; Skiniotis, Georgios</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">546</span>
        (<span class="NLM_cas:issue">7657</span>),
    <span class="NLM_cas:pages">248-253</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Glucagon-like peptide 1 (GLP-1) is a hormone with essential roles in regulating insulin secretion, carbohydrate metab. and appetite.  GLP-1 effects are mediated through binding to the GLP-1 receptor (GLP-1R), a class B G-protein-coupled receptor (GPCR) that signals primarily through the stimulatory G protein Gs.  Class B GPCRs are important therapeutic targets; however, our understanding of their mechanism of action is limited by the lack of structural information on activated and full-length receptors.  Here we report the cryo-electron microscopy structure of the peptide-activated GLP-1R-Gs complex at near at. resoln.  The peptide is clasped between the N-terminal domain and the transmembrane core of the receptor, and further stabilized by extracellular loops.  Conformational changes in the transmembrane domain result in a sharp kink in the middle of transmembrane helix 6, which pivots its intracellular half outward to accommodate the Î±5-helix of the Ras-like domain of Gs.  These results provide a structural framework for understanding class B GPCR activation through hormone binding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmDRFGRwMs1bVg90H21EOLACvtfcHk0liIgdpfr_5d6g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXosVagtLo%253D&md5=5e7ebd94012ba47ecc299ad0502975de</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1038%2Fnature22394&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature22394%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DB.%26aulast%3DFeng%26aufirst%3DD.%26aulast%3DHu%26aufirst%3DH.%26aulast%3DChu%26aufirst%3DM.%26aulast%3DQu%26aufirst%3DQ.%26aulast%3DTarrasch%26aufirst%3DJ.%2BT.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DSun%2BKobilka%26aufirst%3DT.%26aulast%3DKobilka%26aufirst%3DB.%2BK.%26atitle%3DCryo-EM%2520Structure%2520of%2520the%2520Activated%2520GLP-1%2520Receptor%2520in%2520Complex%2520with%2520a%2520G%2520Protein%26jtitle%3DNature%26date%3D2017%26volume%3D546%26issue%3D7657%26spage%3D248%26epage%3D253%26doi%3D10.1038%2Fnature22394" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiao, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Graaf, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reedtz-Runge, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dharmarajan, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, G. W.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Structure of the Full-Length Glucagon Class B G-Protein-Coupled Receptor</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>546</i></span> (<span class="NLM_issue">7657</span>),  <span class="NLM_fpage">259</span>â <span class="NLM_lpage">264</span>, <span class="refDoi">Â DOI: 10.1038/nature22363</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=10.1038%2Fnature22363" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=28514451" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnvVCku7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=546&publication_year=2017&pages=259-264&issue=7657&author=H.+Zhangauthor=A.+Qiaoauthor=D.+Yangauthor=L.+Yangauthor=A.+Daiauthor=C.+de+Graafauthor=S.+Reedtz-Rungeauthor=V.+Dharmarajanauthor=H.+Zhangauthor=G.+W.+Han&title=Structure+of+the+Full-Length+Glucagon+Class+B+G-Protein-Coupled+Receptor&doi=10.1038%2Fnature22363"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the full-length glucagon class B G-protein-coupled receptor</span></div><div class="casAuthors">Zhang, Haonan; Qiao, Anna; Yang, Dehua; Yang, Linlin; Dai, Antao; de Graaf, Chris; Reedtz-Runge, Steffen; Dharmarajan, Venkatasubramanian; Zhang, Hui; Han, Gye Won; Grant, Thomas D.; Sierra, Raymond G.; Weierstall, Uwe; Nelson, Garrett; Liu, Wei; Wu, Yanhong; Ma, Limin; Cai, Xiaoqing; Lin, Guangyao; Wu, Xiaoai; Geng, Zhi; Dong, Yuhui; Song, Gaojie; Griffin, Patrick R.; Lau, Jesper; Cherezov, Vadim; Yang, Huaiyu; Hanson, Michael A.; Stevens, Raymond C.; Zhao, Qiang; Jiang, Hualiang; Wang, Ming-Wei; Wu, Beili</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">546</span>
        (<span class="NLM_cas:issue">7657</span>),
    <span class="NLM_cas:pages">259-264</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The human glucagon receptor, GCGR, belongs to the class B G-protein-coupled receptor family and plays a key role in glucose homeostasis and the pathophysiol. of type 2 diabetes.  Here we report the 3.0 Ã crystal structure of full-length GCGR contg. both the extracellular domain and transmembrane domain in an inactive conformation.  The two domains are connected by a 12-residue segment termed the stalk, which adopts a Î²-strand conformation, instead of forming an Î±-helix as obsd. in the previously solved structure of the GCGR transmembrane domain.  The first extracellular loop exhibits a Î²-hairpin conformation and interacts with the stalk to form a compact Î²-sheet structure.  Hydrogen-deuterium exchange, disulfide crosslinking and mol. dynamics studies suggest that the stalk and the first extracellular loop have crit. roles in modulating peptide ligand binding and receptor activation.  These insights into the full-length GCGR structure deepen our understanding of the signalling mechanisms of class B G-protein-coupled receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKhOm2vnpsXrVg90H21EOLACvtfcHk0liIgdpfr_5d6g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnvVCku7Y%253D&md5=4d00c049ff817cbf720475ce3d555387</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1038%2Fnature22363&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature22363%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DQiao%26aufirst%3DA.%26aulast%3DYang%26aufirst%3DD.%26aulast%3DYang%26aufirst%3DL.%26aulast%3DDai%26aufirst%3DA.%26aulast%3Dde%2BGraaf%26aufirst%3DC.%26aulast%3DReedtz-Runge%26aufirst%3DS.%26aulast%3DDharmarajan%26aufirst%3DV.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DHan%26aufirst%3DG.%2BW.%26atitle%3DStructure%2520of%2520the%2520Full-Length%2520Glucagon%2520Class%2520B%2520G-Protein-Coupled%2520Receptor%26jtitle%3DNature%26date%3D2017%26volume%3D546%26issue%3D7657%26spage%3D259%26epage%3D264%26doi%3D10.1038%2Fnature22363" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiao, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Eps, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frederiksen, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yi, C.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Structure of the Glucagon Receptor in Complex with a Glucagon Analogue</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>553</i></span> (<span class="NLM_issue">7686</span>),  <span class="NLM_fpage">106</span>â <span class="NLM_lpage">110</span>, <span class="refDoi">Â DOI: 10.1038/nature25153</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=10.1038%2Fnature25153" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=29300013" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjsVOrsg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=553&publication_year=2018&pages=106-110&issue=7686&author=H.+Zhangauthor=A.+Qiaoauthor=L.+Yangauthor=N.+Van+Epsauthor=K.+S.+Frederiksenauthor=D.+Yangauthor=A.+Daiauthor=X.+Caiauthor=H.+Zhangauthor=C.+Yi&title=Structure+of+the+Glucagon+Receptor+in+Complex+with+a+Glucagon+Analogue&doi=10.1038%2Fnature25153"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the glucagon receptor in complex with a glucagon analogue</span></div><div class="casAuthors">Zhang, Haonan; Qiao, Anna; Yang, Linlin; Van Eps, Ned; Frederiksen, Klaus S.; Yang, Dehua; Dai, Antao; Cai, Xiaoqing; Zhang, Hui; Yi, Cuiying; Cao, Can; He, Lingli; Yang, Huaiyu; Lau, Jesper; Ernst, Oliver P.; Hanson, Michael A.; Stevens, Raymond C.; Wang, Ming-Wei; Reedtz-Runge, Steffen; Jiang, Hualiang; Zhao, Qiang; Wu, Beili</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">553</span>
        (<span class="NLM_cas:issue">7686</span>),
    <span class="NLM_cas:pages">106-110</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Class B G-protein-coupled receptors (GPCRs), which consist of an extracellular domain (ECD) and a transmembrane domain (TMD), respond to secretin peptides to play a key part in hormonal homeostasis, and are important therapeutic targets for a variety of diseases.  Previous work has suggested that peptide ligands bind to class B GPCRs according to a two-domain binding model, in which the C-terminal region of the peptide targets the ECD and the N-terminal region of the peptide binds to the TMD binding pocket.  Recently, three structures of class B GPCRs in complex with peptide ligands have been solved.  These structures provide essential insights into peptide ligand recognition by class B GPCRs.  However, owing to resoln. limitations, the specific mol. interactions for peptide binding to class B GPCRs remain ambiguous.  Moreover, these previously solved structures have different ECD conformations relative to the TMD, which introduces questions regarding interdomain conformational flexibility and the changes required for receptor activation.  Here we report the 3.0 Ã-resoln. crystal structure of the full-length human glucagon receptor (GCGR) in complex with a glucagon analog and partial agonist, NNC1702.  This structure provides mol. details of the interactions between GCGR and the peptide ligand.  It reveals a marked change in the relative orientation between the ECD and TMD of GCGR compared to the previously solved structure of the inactive GCGR-NNC0640-mAb1 complex.  Notably, the stalk region and the first extracellular loop undergo major conformational changes in secondary structure during peptide binding, forming key interactions with the peptide.  We further propose a dual binding-site trigger model for GCGR activation - which requires conformational changes of the stalk, first extracellular loop and TMD - that extends our understanding of the previously established two-domain peptide-binding model of class B GPCRs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5Y-KdGGlZ_rVg90H21EOLACvtfcHk0liIgdpfr_5d6g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjsVOrsg%253D%253D&md5=54066c14d972869df876e401c37f8a14</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1038%2Fnature25153&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature25153%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DQiao%26aufirst%3DA.%26aulast%3DYang%26aufirst%3DL.%26aulast%3DVan%2BEps%26aufirst%3DN.%26aulast%3DFrederiksen%26aufirst%3DK.%2BS.%26aulast%3DYang%26aufirst%3DD.%26aulast%3DDai%26aufirst%3DA.%26aulast%3DCai%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DYi%26aufirst%3DC.%26atitle%3DStructure%2520of%2520the%2520Glucagon%2520Receptor%2520in%2520Complex%2520with%2520a%2520Glucagon%2520Analogue%26jtitle%3DNature%26date%3D2018%26volume%3D553%26issue%3D7686%26spage%3D106%26epage%3D110%26doi%3D10.1038%2Fnature25153" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Finan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ottaway, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smiley, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clemmensen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chabenne, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Habegger, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, K.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">A Rationally Designed Monomeric Peptide Triagonist Corrects Obesity and Diabetes in Rodents</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">27</span>â <span class="NLM_lpage">36</span>, <span class="refDoi">Â DOI: 10.1038/nm.3761</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=10.1038%2Fnm.3761" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=25485909" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVCks73J" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=27-36&issue=1&author=B.+Finanauthor=B.+Yangauthor=N.+Ottawayauthor=D.+L.+Smileyauthor=T.+Maauthor=C.+Clemmensenauthor=J.+Chabenneauthor=L.+Zhangauthor=K.+M.+Habeggerauthor=K.+Fischer&title=A+Rationally+Designed+Monomeric+Peptide+Triagonist+Corrects+Obesity+and+Diabetes+in+Rodents&doi=10.1038%2Fnm.3761"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents</span></div><div class="casAuthors">Finan, Brian; Yang, Bin; Ottaway, Nickki; Smiley, David L.; Ma, Tao; Clemmensen, Christoffer; Chabenne, Joe; Zhang, Lianshan; Habegger, Kirk M.; Fischer, Katrin; Campbell, Jonathan E.; Sandoval, Darleen; Seeley, Randy J.; Bleicher, Konrad; Uhles, Sabine; Riboulet, William; Funk, Juergen; Hertel, Cornelia; Belli, Sara; Sebokova, Elena; Conde-Knape, Karin; Konkar, Anish; Drucker, Daniel J.; Gelfanov, Vasily; Pfluger, Paul T.; Mueller, Timo D.; Perez-Tilve, Diego; Di Marchi, Richard D.; Tschoep, Matthias H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">27-36</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We report the discovery of a new monomeric peptide that reduces body wt. and diabetic complications in rodent models of obesity by acting as an agonist at three key metabolically-related peptide hormone receptors: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) and glucagon receptors.  This triple agonist demonstrates supraphysiol. potency and equally aligned constituent activities at each receptor, all without cross-reactivity at other related receptors.  Such balanced unimol. triple agonism proved superior to any existing dual coagonists and best-in-class monoagonists to reduce body wt., enhance glycemic control and reverse hepatic steatosis in relevant rodent models.  Various loss-of-function models, including genetic knockout, pharmacol. blockade and selective chem. knockout, confirmed contributions of each constituent activity in vivo.  We demonstrate that these individual constituent activities harmonize to govern the overall metabolic efficacy, which predominantly results from synergistic glucagon action to increase energy expenditure, GLP-1 action to reduce caloric intake and improve glucose control, and GIP action to potentiate the incretin effect and buffer against the diabetogenic effect of inherent glucagon activity.  These preclin. studies suggest that, so far, this unimol., polypharmaceutical strategy has potential to be the most effective pharmacol. approach to reversing obesity and related metabolic disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDHrGvoJsN6LVg90H21EOLACvtfcHk0lie8lmcBjhO6g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVCks73J&md5=9024ca9e43d498db95332d64e9e16039</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1038%2Fnm.3761&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.3761%26sid%3Dliteratum%253Aachs%26aulast%3DFinan%26aufirst%3DB.%26aulast%3DYang%26aufirst%3DB.%26aulast%3DOttaway%26aufirst%3DN.%26aulast%3DSmiley%26aufirst%3DD.%2BL.%26aulast%3DMa%26aufirst%3DT.%26aulast%3DClemmensen%26aufirst%3DC.%26aulast%3DChabenne%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DHabegger%26aufirst%3DK.%2BM.%26aulast%3DFischer%26aufirst%3DK.%26atitle%3DA%2520Rationally%2520Designed%2520Monomeric%2520Peptide%2520Triagonist%2520Corrects%2520Obesity%2520and%2520Diabetes%2520in%2520Rodents%26jtitle%3DNat.%2520Med.%26date%3D2015%26volume%3D21%26issue%3D1%26spage%3D27%26epage%3D36%26doi%3D10.1038%2Fnm.3761" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ward, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ottaway, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Tilve, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelfanov, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">TschÃ¶p, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiMarchi, R. D.</span></span> <span> </span><span class="NLM_article-title">Peptide Lipidation Stabilizes Structure to Enhance Biological Function</span>. <i>Mol. Metab.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">468</span>â <span class="NLM_lpage">479</span>, <span class="refDoi">Â DOI: 10.1016/j.molmet.2013.08.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=10.1016%2Fj.molmet.2013.08.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=24327962" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFOgt77K" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2013&pages=468-479&issue=4&author=B.+P.+Wardauthor=N.+L.+Ottawayauthor=D.+Perez-Tilveauthor=D.+Maauthor=V.+M.+Gelfanovauthor=M.+H.+Tsch%C3%B6pauthor=R.+D.+DiMarchi&title=Peptide+Lipidation+Stabilizes+Structure+to+Enhance+Biological+Function&doi=10.1016%2Fj.molmet.2013.08.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Peptide lipidation stabilizes structure to enhance biological function</span></div><div class="casAuthors">Ward, Brian P.; Ottaway, Nickki L.; Perez-Tilve, Diego; Ma, Dejian; Gelfanov, Vasily M.; Tschop, Matthias H.; DiMarchi, Richard D.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Metabolism</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">468-479</span>CODEN:
                <span class="NLM_cas:coden">MMOEAS</span>;
        ISSN:<span class="NLM_cas:issn">2212-8778</span>.
    
            (<span class="NLM_cas:orgname">Elsevier GmbH</span>)
        </div><div class="casAbstract">Medicines that decrease body wt. and restore nutrient tolerance could improve human diabetes and obesity treatment outcomes.  We developed lipid-acylated glucagon analogs that are co-agonists for the glucagon and glucagon-like peptide 1 receptors, and stimulate wt. loss and plasma glucose lowering in pre-diabetic obese mice.  Our studies identified lipid acylation (lipidation) can increase and balance in vitro potencies of select glucagon analogs for the two aforementioned receptors in a lipidation site-dependent manner.  A general capacity for lipidation to enhance the secondary structure of glucagon analogs was recognized, and the energetics of this effect quantified.  The mol. structure of a lipid-acylated glucagon analog in water was also characterized.  These results support that lipidation can modify biol. activity through thermodynamically-favorable intramol. interactions which stabilize structure.  This establishes use of lipidation to achieve specific pharmacol. and implicates similar endogenous post-translational modifications as physiol. tools capable of refining biol. action in means previously underappreciated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-nclxtgAVyLVg90H21EOLACvtfcHk0lie8lmcBjhO6g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFOgt77K&md5=021ed975227b94ca2d47394d22e19d1a</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2Fj.molmet.2013.08.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molmet.2013.08.008%26sid%3Dliteratum%253Aachs%26aulast%3DWard%26aufirst%3DB.%2BP.%26aulast%3DOttaway%26aufirst%3DN.%2BL.%26aulast%3DPerez-Tilve%26aufirst%3DD.%26aulast%3DMa%26aufirst%3DD.%26aulast%3DGelfanov%26aufirst%3DV.%2BM.%26aulast%3DTsch%25C3%25B6p%26aufirst%3DM.%2BH.%26aulast%3DDiMarchi%26aufirst%3DR.%2BD.%26atitle%3DPeptide%2520Lipidation%2520Stabilizes%2520Structure%2520to%2520Enhance%2520Biological%2520Function%26jtitle%3DMol.%2520Metab.%26date%3D2013%26volume%3D2%26issue%3D4%26spage%3D468%26epage%3D479%26doi%3D10.1016%2Fj.molmet.2013.08.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">LÃ³pez
de Maturana, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willshaw, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuntzsch, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudolph, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donnelly, D.</span></span> <span> </span><span class="NLM_article-title">The Isolated N-Terminal Domain of the Glucagon-like Peptide-1 (GLP-1) Receptor Binds Exendin Peptides with Much Higher Affinity than GLP-1</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>278</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">10195</span>â <span class="NLM_lpage">10200</span>, <span class="refDoi">Â DOI: 10.1074/jbc.M212147200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=10.1074%2Fjbc.M212147200" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=278&publication_year=2003&pages=10195-10200&issue=12&author=R.+L%C3%B3pez%0Ade+Maturanaauthor=A.+Willshawauthor=A.+Kuntzschauthor=R.+Rudolphauthor=D.+Donnelly&title=The+Isolated+N-Terminal+Domain+of+the+Glucagon-like+Peptide-1+%28GLP-1%29+Receptor+Binds+Exendin+Peptides+with+Much+Higher+Affinity+than+GLP-1&doi=10.1074%2Fjbc.M212147200"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M212147200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M212147200%26sid%3Dliteratum%253Aachs%26aulast%3DL%25C3%25B3pez%2Bde%2BMaturana%26aufirst%3DR.%26aulast%3DWillshaw%26aufirst%3DA.%26aulast%3DKuntzsch%26aufirst%3DA.%26aulast%3DRudolph%26aufirst%3DR.%26aulast%3DDonnelly%26aufirst%3DD.%26atitle%3DThe%2520Isolated%2520N-Terminal%2520Domain%2520of%2520the%2520Glucagon-like%2520Peptide-1%2520%2528GLP-1%2529%2520Receptor%2520Binds%2520Exendin%2520Peptides%2520with%2520Much%2520Higher%2520Affinity%2520than%2520GLP-1%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2003%26volume%3D278%26issue%3D12%26spage%3D10195%26epage%3D10200%26doi%3D10.1074%2Fjbc.M212147200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lau, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloch, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">SchÃ¤ffer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pettersson, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spetzler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kofoed, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madsen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knudsen, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGuire, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steensgaard, D. B.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">7370</span>â <span class="NLM_lpage">7380</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.5b00726</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00726" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtl2qu7%252FM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=7370-7380&issue=18&author=J.+Lauauthor=P.+Blochauthor=L.+Sch%C3%A4fferauthor=I.+Petterssonauthor=J.+Spetzlerauthor=J.+Kofoedauthor=K.+Madsenauthor=L.+B.+Knudsenauthor=J.+McGuireauthor=D.+B.+Steensgaard&title=Discovery+of+the+Once-Weekly+Glucagon-Like+Peptide-1+%28GLP-1%29+Analogue+Semaglutide&doi=10.1021%2Facs.jmedchem.5b00726"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide</span></div><div class="casAuthors">Lau, Jesper; Bloch, Paw; Schaffer, Lauge; Pettersson, Ingrid; Spetzler, Jane; Kofoed, Jacob; Madsen, Kjeld; Knudsen, Lotte Bjerre; McGuire, James; Steensgaard, Dorte Bjerre; Strauss, Holger Martin; Gram, Dorte X.; Knudsen, Sanne Moeller; Nielsen, Flemming Seier; Thygesen, Peter; Reedtz-Runge, Steffen; Kruse, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">7370-7380</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Liraglutide is an acylated glucagon-like peptide-1 (GLP-1) analog that binds to serum albumin in vivo and is approved for once-daily treatment of diabetes as well as obesity.  The aim of the present studies was to design a once weekly GLP-1 analog by increasing albumin affinity and secure full stability against metabolic degrdn.  The fatty acid moiety and the linking chem. to GLP-1 were the key features to secure high albumin affinity and GLP-1 receptor (GLP-1R) potency and in obtaining a prolonged exposure and action of the GLP-1 analog.  Semaglutide was selected as the optimal once weekly candidate.  Semaglutide has two amino acid substitutions compared to human GLP-1 (Aib8, Arg34) and is derivatized at lysine 26.  The GLP-1R affinity of semaglutide (0.38 Â± 0.06 nM) was three-fold decreased compared to liraglutide, whereas the albumin affinity was increased.  The plasma half-life was 46.1 h in mini-pigs following i.v. administration, and semaglutide has an MRT of 63.6 h after s.c. dosing to mini-pigs.  Semaglutide is currently in phase 3 clin. testing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8tFc0FzEro7Vg90H21EOLACvtfcHk0ljZZmpJjjgNkw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtl2qu7%252FM&md5=0478fe17f9f4dcc0cb58919b1c55869a</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00726&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00726%26sid%3Dliteratum%253Aachs%26aulast%3DLau%26aufirst%3DJ.%26aulast%3DBloch%26aufirst%3DP.%26aulast%3DSch%25C3%25A4ffer%26aufirst%3DL.%26aulast%3DPettersson%26aufirst%3DI.%26aulast%3DSpetzler%26aufirst%3DJ.%26aulast%3DKofoed%26aufirst%3DJ.%26aulast%3DMadsen%26aufirst%3DK.%26aulast%3DKnudsen%26aufirst%3DL.%2BB.%26aulast%3DMcGuire%26aufirst%3DJ.%26aulast%3DSteensgaard%26aufirst%3DD.%2BB.%26atitle%3DDiscovery%2520of%2520the%2520Once-Weekly%2520Glucagon-Like%2520Peptide-1%2520%2528GLP-1%2529%2520Analogue%2520Semaglutide%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26issue%3D18%26spage%3D7370%26epage%3D7380%26doi%3D10.1021%2Facs.jmedchem.5b00726" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khoshouei, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glukhova, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furness, S. G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clydesdale, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koole, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Truong, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thal, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lei, S.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Phase-Plate Cryo-EM Structure of a Biased Agonist-Bound Human GLP-1 Receptor-Gs Complex</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>555</i></span> (<span class="NLM_issue">7694</span>),  <span class="NLM_fpage">121</span>â <span class="NLM_lpage">125</span>, <span class="refDoi">Â DOI: 10.1038/nature25773</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=10.1038%2Fnature25773" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=29466332" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjtFCktrk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=555&publication_year=2018&pages=121-125&issue=7694&author=Y.-L.+Liangauthor=M.+Khoshoueiauthor=A.+Glukhovaauthor=S.+G.+B.+Furnessauthor=P.+Zhaoauthor=L.+Clydesdaleauthor=C.+Kooleauthor=T.+T.+Truongauthor=D.+M.+Thalauthor=S.+Lei&title=Phase-Plate+Cryo-EM+Structure+of+a+Biased+Agonist-Bound+Human+GLP-1+Receptor-Gs+Complex&doi=10.1038%2Fnature25773"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Phase-plate cryo-EM structure of a biased agonist-bound human GLP-1 receptor-Gs complex</span></div><div class="casAuthors">Liang, Yi-Lynn; Khoshouei, Maryam; Glukhova, Alisa; Furness, Sebastian G. B.; Zhao, Peishen; Clydesdale, Lachlan; Koole, Cassandra; Truong, Tin T.; Thal, David M.; Lei, Saifei; Radjainia, Mazdak; Danev, Radostin; Baumeister, Wolfgang; Wang, Ming-Wei; Miller, Laurence J.; Christopoulos, Arthur; Sexton, Patrick M.; Wootten, Denise</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">555</span>
        (<span class="NLM_cas:issue">7694</span>),
    <span class="NLM_cas:pages">121-125</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">The class B glucagon-like peptide-1 (GLP-1) G protein-coupled receptor is a major target for the treatment of type 2 diabetes and obesity.  Endogenous and mimetic GLP-1 peptides exhibit biased agonism-a difference in functional selectivity-that may provide improved therapeutic outcomes.  Here we describe the structure of the human GLP-1 receptor in complex with the G protein-biased peptide exendin-P5 and a GÎ±s heterotrimer, detd. at a global resoln. of 3.3 Ã.  At the extracellular surface, the organization of extracellular loop 3 and proximal transmembrane segments differs between our exendin-P5-bound structure and previous GLP-1-bound GLP-1 receptor structure.  At the intracellular face, there was a six-degree difference in the angle of the GÎ±s-Î±5 helix engagement between structures, which was propagated across the G protein heterotrimer.  In addn., the structures differed in the rate and extent of conformational reorganization of the GÎ±s protein.  Our structure provides insights into the mol. basis of biased agonism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaUGOXZxHlNLVg90H21EOLACvtfcHk0ljZZmpJjjgNkw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjtFCktrk%253D&md5=dbb6b8d6cd394d76b74bfabc26f7b62c</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1038%2Fnature25773&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature25773%26sid%3Dliteratum%253Aachs%26aulast%3DLiang%26aufirst%3DY.-L.%26aulast%3DKhoshouei%26aufirst%3DM.%26aulast%3DGlukhova%26aufirst%3DA.%26aulast%3DFurness%26aufirst%3DS.%2BG.%2BB.%26aulast%3DZhao%26aufirst%3DP.%26aulast%3DClydesdale%26aufirst%3DL.%26aulast%3DKoole%26aufirst%3DC.%26aulast%3DTruong%26aufirst%3DT.%2BT.%26aulast%3DThal%26aufirst%3DD.%2BM.%26aulast%3DLei%26aufirst%3DS.%26atitle%3DPhase-Plate%2520Cryo-EM%2520Structure%2520of%2520a%2520Biased%2520Agonist-Bound%2520Human%2520GLP-1%2520Receptor-Gs%2520Complex%26jtitle%3DNature%26date%3D2018%26volume%3D555%26issue%3D7694%26spage%3D121%26epage%3D125%26doi%3D10.1038%2Fnature25773" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">GÃ¶ke, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fehmann, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linn, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krause, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">GÃ¶ke, B.</span></span> <span> </span><span class="NLM_article-title">Exendin-4 Is a High Potency Agonist and Truncated Exendin-(9â39)-Amide an Antagonist at the Glucagon-like Peptide 1-(7â36)-Amide Receptor of Insulin-Secreting Beta-Cells</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>268</i></span> (<span class="NLM_issue">26</span>),  <span class="NLM_fpage">19650</span>â <span class="NLM_lpage">19655</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=268&publication_year=1993&pages=19650-19655&issue=26&author=R.+G%C3%B6keauthor=H.+C.+Fehmannauthor=T.+Linnauthor=H.+Schmidtauthor=M.+Krauseauthor=J.+Engauthor=B.+G%C3%B6ke&title=Exendin-4+Is+a+High+Potency+Agonist+and+Truncated+Exendin-%289%E2%80%9339%29-Amide+an+Antagonist+at+the+Glucagon-like+Peptide+1-%287%E2%80%9336%29-Amide+Receptor+of+Insulin-Secreting+Beta-Cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DG%25C3%25B6ke%26aufirst%3DR.%26aulast%3DFehmann%26aufirst%3DH.%2BC.%26aulast%3DLinn%26aufirst%3DT.%26aulast%3DSchmidt%26aufirst%3DH.%26aulast%3DKrause%26aufirst%3DM.%26aulast%3DEng%26aufirst%3DJ.%26aulast%3DG%25C3%25B6ke%26aufirst%3DB.%26atitle%3DExendin-4%2520Is%2520a%2520High%2520Potency%2520Agonist%2520and%2520Truncated%2520Exendin-%25289%25E2%2580%259339%2529-Amide%2520an%2520Antagonist%2520at%2520the%2520Glucagon-like%2520Peptide%25201-%25287%25E2%2580%259336%2529-Amide%2520Receptor%2520of%2520Insulin-Secreting%2520Beta-Cells%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1993%26volume%3D268%26issue%3D26%26spage%3D19650%26epage%3D19655" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Montrose-Rafizadeh, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodgers, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beday, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pritchette, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eng, J.</span></span> <span> </span><span class="NLM_article-title">High Potency Antagonists of the Pancreatic Glucagon-like Peptide-1 Receptor</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>272</i></span> (<span class="NLM_issue">34</span>),  <span class="NLM_fpage">21201</span>â <span class="NLM_lpage">21206</span>, <span class="refDoi">Â DOI: 10.1074/jbc.272.34.21201</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=10.1074%2Fjbc.272.34.21201" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=9261127" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=1%3ACAS%3A528%3ADyaK2sXls1Ojt7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=272&publication_year=1997&pages=21201-21206&issue=34&author=C.+Montrose-Rafizadehauthor=H.+Yangauthor=B.+D.+Rodgersauthor=A.+Bedayauthor=L.+A.+Pritchetteauthor=J.+Eng&title=High+Potency+Antagonists+of+the+Pancreatic+Glucagon-like+Peptide-1+Receptor&doi=10.1074%2Fjbc.272.34.21201"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">High potency antagonists of the pancreatic glucagon-like peptide-1 receptor</span></div><div class="casAuthors">Montrose-Rafizadeh, Chahrzad; Yang, Huan; Rodgers, Buel D.; Beday, Alvie; Pritchette, Louella A.; Eng, John</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">272</span>
        (<span class="NLM_cas:issue">34</span>),
    <span class="NLM_cas:pages">21201-21206</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">GLP-1-(7-36)-amide and exendin-4-(1-39) are glucagon-like peptide-1 (GLP-1) receptor agonists, whereas exendin-(9-39) is the only known antagonist.  To analyze the transition from agonist to antagonist and to identify the amino acid residues involved in ligand activation of the GLP-1 receptor, we used exendin analogs with successive N-terminal truncations.  Chinese hamster ovary cells stably transfected with the rat GLP-1 receptor were assayed for changes in intracellular cAMP caused by the test peptides in the absence or presence of half-maximal stimulatory doses of GLP-1.  N-terminal truncation of a single amino acid reduced the agonist activity of the exendin peptide, whereas N-terminal truncation of 3-7 amino acids produced antagonists that were 4-10-fold more potent than exendin-(9-39).  N-terminal truncation of GLP-1 by 2 amino acids resulted in weak agonist activity, but an 8-amino acid N-terminal truncation inactivated the peptide.  Binding studies performed using 125I-labeled GLP-1 confirmed that all bioactive peptides specifically displaced tracer with high potency.  In a set of exendin/GLP-1 chimeric peptides, substitution of GLP-1 sequences into exendin-(3-39) produced loss of antagonist activity with conversion to a weak agonist.  The results show that receptor binding and activation occur in sep. domains of exendin, but they are more closely coupled in GLP-1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpN_gVlQBZ16rVg90H21EOLACvtfcHk0ljZZmpJjjgNkw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXls1Ojt7c%253D&md5=d686fa97a141d335de910a233fd159d2</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1074%2Fjbc.272.34.21201&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.272.34.21201%26sid%3Dliteratum%253Aachs%26aulast%3DMontrose-Rafizadeh%26aufirst%3DC.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DRodgers%26aufirst%3DB.%2BD.%26aulast%3DBeday%26aufirst%3DA.%26aulast%3DPritchette%26aufirst%3DL.%2BA.%26aulast%3DEng%26aufirst%3DJ.%26atitle%3DHigh%2520Potency%2520Antagonists%2520of%2520the%2520Pancreatic%2520Glucagon-like%2520Peptide-1%2520Receptor%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1997%26volume%3D272%26issue%3D34%26spage%3D21201%26epage%3D21206%26doi%3D10.1074%2Fjbc.272.34.21201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishnan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerwin, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manning, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Randolph, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carpenter, J. F.</span></span> <span> </span><span class="NLM_article-title">Mechanism for Benzyl Alcohol-Induced Aggregation of Recombinant Human Interleukin-1 Receptor Antagonist in Aqueous Solution</span>. <i>J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>93</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">3076</span>â <span class="NLM_lpage">3089</span>, <span class="refDoi">Â DOI: 10.1002/jps.20219</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=10.1002%2Fjps.20219" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2004&pages=3076-3089&issue=12&author=Y.+Zhangauthor=S.+Royauthor=L.+S.+Jonesauthor=S.+Krishnanauthor=B.+A.+Kerwinauthor=B.+S.+Changauthor=M.+C.+Manningauthor=T.+W.+Randolphauthor=J.+F.+Carpenter&title=Mechanism+for+Benzyl+Alcohol-Induced+Aggregation+of+Recombinant+Human+Interleukin-1+Receptor+Antagonist+in+Aqueous+Solution&doi=10.1002%2Fjps.20219"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1002%2Fjps.20219&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjps.20219%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DRoy%26aufirst%3DS.%26aulast%3DJones%26aufirst%3DL.%2BS.%26aulast%3DKrishnan%26aufirst%3DS.%26aulast%3DKerwin%26aufirst%3DB.%2BA.%26aulast%3DChang%26aufirst%3DB.%2BS.%26aulast%3DManning%26aufirst%3DM.%2BC.%26aulast%3DRandolph%26aufirst%3DT.%2BW.%26aulast%3DCarpenter%26aufirst%3DJ.%2BF.%26atitle%3DMechanism%2520for%2520Benzyl%2520Alcohol-Induced%2520Aggregation%2520of%2520Recombinant%2520Human%2520Interleukin-1%2520Receptor%2520Antagonist%2520in%2520Aqueous%2520Solution%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2004%26volume%3D93%26issue%3D12%26spage%3D3076%26epage%3D3089%26doi%3D10.1002%2Fjps.20219" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prasad-Reddy, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isaacs, D.</span></span> <span> </span><span class="NLM_article-title">A Clinical Review of GLP-1 Receptor Agonists: Efficacy and Safety in Diabetes and Beyond</span>. <i>Drugs Context</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">1</span>, <span class="refDoi">Â DOI: 10.7573/dic.212283</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=10.7573%2Fdic.212283" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2015&pages=1&author=L.+Prasad-Reddyauthor=D.+Isaacs&title=A+Clinical+Review+of+GLP-1+Receptor+Agonists%3A+Efficacy+and+Safety+in+Diabetes+and+Beyond&doi=10.7573%2Fdic.212283"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.7573%2Fdic.212283&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7573%252Fdic.212283%26sid%3Dliteratum%253Aachs%26aulast%3DPrasad-Reddy%26aufirst%3DL.%26aulast%3DIsaacs%26aufirst%3DD.%26atitle%3DA%2520Clinical%2520Review%2520of%2520GLP-1%2520Receptor%2520Agonists%253A%2520Efficacy%2520and%2520Safety%2520in%2520Diabetes%2520and%2520Beyond%26jtitle%3DDrugs%2520Context%26date%3D2015%26volume%3D4%26spage%3D1%26doi%3D10.7573%2Fdic.212283" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Overgaard, R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petri, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobsen, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, C. B.</span></span> <span> </span><span class="NLM_article-title">Liraglutide 3.0 Mg for Weight Management: A Population Pharmacokinetic Analysis</span>. <i>Clin. Pharmacokinet.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1413</span>â <span class="NLM_lpage">1422</span>, <span class="refDoi">Â DOI: 10.1007/s40262-016-0410-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=10.1007%2Fs40262-016-0410-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=27193270" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=1%3ACAS%3A528%3ADC%252BC28Xot1yrsrg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2016&pages=1413-1422&issue=11&author=R.+V.+Overgaardauthor=K.+C.+Petriauthor=L.+V.+Jacobsenauthor=C.+B.+Jensen&title=Liraglutide+3.0+Mg+for+Weight+Management%3A+A+Population+Pharmacokinetic+Analysis&doi=10.1007%2Fs40262-016-0410-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Liraglutide 3.0 mg for Weight Management: A Population Pharmacokinetic Analysis</span></div><div class="casAuthors">Overgaard, Rune V.; Petri, Kristin C.; Jacobsen, Lisbeth V.; Jensen, Christine B.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1413-1422</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Background and Objectives: This anal. used a population pharmacokinetic approach to identify covariates that influence plasma exposure of liraglutide 3.0 mg, a glucagon-like peptide-1 (GLP-1) receptor agonist approved for wt. management in overweight and obese individuals.  Methods: Samples for pharmacokinetic anal. were drawn at weeks 2, 12 and 28 of the phase IIIa SCALE Obesity and Prediabetes (N = 2339) and SCALE Diabetes (N = 584) trials.  Dose proportionality of liraglutide in obese subjects was investigated using data from a phase II dose-finding study (N = 331).  Results: Dose-proportional exposure of liraglutide up to and including 3.0 mg was confirmed.  Body wt. and sex influenced exposure of liraglutide 3.0 mg, while age â¥70 years, race, ethnicity and baseline glycemic status did not.  Compared with a ref. subject weighing 100 kg, exposure of liraglutide 3.0 mg was 44 % lower for a subject weighing 234 kg (90 % CI 41-47), 41 % higher for a subject weighing 60 kg (90 % CI 37-46), and 32 % higher (90 % CI 28-35) in females than males with the same body wt.  Neither injection site nor renal function significantly influenced exposure of liraglutide 3.0 mg (post hoc anal.).  Conclusion: Population pharmacokinetics of liraglutide up to and including 3.0 mg daily in overweight and obese adults demonstrated dose-proportional exposure, and limited effect of covariates other than sex and body wt.  These findings were similar to those previously obsd. with liraglutide up to 1.8 mg in subjects with type 2 diabetes mellitus.  Further anal. of exposure-response relationship and its effect on dose requirements is addressed in a sep. publication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSoD9Bkl8VebVg90H21EOLACvtfcHk0lj7KVPOSM29nw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xot1yrsrg%253D&md5=daddcec2c0844b13bf3fb22c3495eda3</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1007%2Fs40262-016-0410-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40262-016-0410-7%26sid%3Dliteratum%253Aachs%26aulast%3DOvergaard%26aufirst%3DR.%2BV.%26aulast%3DPetri%26aufirst%3DK.%2BC.%26aulast%3DJacobsen%26aufirst%3DL.%2BV.%26aulast%3DJensen%26aufirst%3DC.%2BB.%26atitle%3DLiraglutide%25203.0%2520Mg%2520for%2520Weight%2520Management%253A%2520A%2520Population%2520Pharmacokinetic%2520Analysis%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D2016%26volume%3D55%26issue%3D11%26spage%3D1413%26epage%3D1422%26doi%3D10.1007%2Fs40262-016-0410-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span> <i>MacroModel</i>; SchrÃ¶dinger <a href="https://www.schrodinger.com/macromodel" class="extLink">https://www.schrodinger.com/macromodel</a> (accessed Jan 31, <span class="NLM_year">2018</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+MacroModel%3B+Schr%C3%B6dinger+https%3A%2F%2Fwww.schrodinger.com%2Fmacromodel+%28accessed+Jan+31%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DMacroModel%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span> <i>PyMOL</i>; SchrÃ¶dinger <a href="https://www.schrodinger.com/pymol" class="extLink">https://www.schrodinger.com/pymol</a> (accessed Jan 31, <span class="NLM_year">2018</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+PyMOL%3B+Schr%C3%B6dinger+https%3A%2F%2Fwww.schrodinger.com%2Fpymol+%28accessed+Jan+31%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DPyMOL%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chhabra, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hothi, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bycroft, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, W. C.</span></span> <span> </span><span class="NLM_article-title">An Appraisal of New Variants of Dde Amine Protecting Group for Solid Phase Peptide Synthesis</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>39</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1603</span>â <span class="NLM_lpage">1606</span>, <span class="refDoi">Â DOI: 10.1016/S0040-4039(97)10828-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=10.1016%2FS0040-4039%2897%2910828-0" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1998&pages=1603-1606&issue=12&author=S.+R.+Chhabraauthor=B.+Hothiauthor=D.+J.+Evansauthor=P.+D.+Whiteauthor=B.+W.+Bycroftauthor=W.+C.+Chan&title=An+Appraisal+of+New+Variants+of+Dde+Amine+Protecting+Group+for+Solid+Phase+Peptide+Synthesis&doi=10.1016%2FS0040-4039%2897%2910828-0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2FS0040-4039%2897%2910828-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0040-4039%252897%252910828-0%26sid%3Dliteratum%253Aachs%26aulast%3DChhabra%26aufirst%3DS.%2BR.%26aulast%3DHothi%26aufirst%3DB.%26aulast%3DEvans%26aufirst%3DD.%2BJ.%26aulast%3DWhite%26aufirst%3DP.%2BD.%26aulast%3DBycroft%26aufirst%3DB.%2BW.%26aulast%3DChan%26aufirst%3DW.%2BC.%26atitle%3DAn%2520Appraisal%2520of%2520New%2520Variants%2520of%2520Dde%2520Amine%2520Protecting%2520Group%2520for%2520Solid%2520Phase%2520Peptide%2520Synthesis%26jtitle%3DTetrahedron%2520Lett.%26date%3D1998%26volume%3D39%26issue%3D12%26spage%3D1603%26epage%3D1606%26doi%3D10.1016%2FS0040-4039%2897%2910828-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">King, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fields, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fields, G. B.</span></span> <span> </span><span class="NLM_article-title">A Cleavage Method Which Minimizes Side Reactions Following Fmoc Solid Phase Peptide Synthesis</span>. <i>Int. J. Pept. Protein Res.</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>36</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">255</span>â <span class="NLM_lpage">266</span>, <span class="refDoi">Â DOI: 10.1111/j.1399-3011.1990.tb00976.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=10.1111%2Fj.1399-3011.1990.tb00976.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=2279849" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=1%3ACAS%3A528%3ADyaK3MXisVGktg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1990&pages=255-266&issue=3&author=D.+S.+Kingauthor=C.+G.+Fieldsauthor=G.+B.+Fields&title=A+Cleavage+Method+Which+Minimizes+Side+Reactions+Following+Fmoc+Solid+Phase+Peptide+Synthesis&doi=10.1111%2Fj.1399-3011.1990.tb00976.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">A cleavage method which minimizes side reactions following Fmoc solid phase peptide synthesis</span></div><div class="casAuthors">King, David S.; Fields, Cynthia G.; Fields, Gregg B.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Peptide & Protein Research</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">255-66</span>CODEN:
                <span class="NLM_cas:coden">IJPPC3</span>;
        ISSN:<span class="NLM_cas:issn">0367-8377</span>.
    </div><div class="casAbstract">The success of solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl (Fmoc) amino acids is often limited by deleterious side reactions which occur during CF3CO2H (TFA) peptide-resin cleavage and side-chain deprotection.  The majority of these side reactions modify susceptible residues, such as Trp, Tyr, Met, and Cys, with TFA-liberated side-chain protecting groups and linkers.  The relative effectiveness of various scavengers in suppressing these side reactions was studied.  The cleavage mixt. 82.5% TFA : 5% H2O : 5% thioanisole : 2.5% 1,2-ethanedithiol (reagent K) was maximally efficient in inhibiting a great variety of side reactions.  Synthesis and cleavage of 10 peptides, each contg. 20-50 residues, demonstrated the complementarity of Fmoc chem. with reagent K for efficient synthesis of complex peptide.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUwcooNm7oD7Vg90H21EOLACvtfcHk0lhwzh-LMME2-Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXisVGktg%253D%253D&md5=ecf761fc6877559af82062c6345306ab</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1111%2Fj.1399-3011.1990.tb00976.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1399-3011.1990.tb00976.x%26sid%3Dliteratum%253Aachs%26aulast%3DKing%26aufirst%3DD.%2BS.%26aulast%3DFields%26aufirst%3DC.%2BG.%26aulast%3DFields%26aufirst%3DG.%2BB.%26atitle%3DA%2520Cleavage%2520Method%2520Which%2520Minimizes%2520Side%2520Reactions%2520Following%2520Fmoc%2520Solid%2520Phase%2520Peptide%2520Synthesis%26jtitle%3DInt.%2520J.%2520Pept.%2520Protein%2520Res.%26date%3D1990%26volume%3D36%26issue%3D3%26spage%3D255%26epage%3D266%26doi%3D10.1111%2Fj.1399-3011.1990.tb00976.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kabsch, W.</span></span> <span> </span><span class="NLM_article-title">XDS</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>66</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">125</span>â <span class="NLM_lpage">132</span>, <span class="refDoi">Â DOI: 10.1107/S0907444909047337</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=10.1107%2FS0907444909047337" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=20124692" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1SisLc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2010&pages=125-132&issue=2&author=W.+Kabsch&title=XDS&doi=10.1107%2FS0907444909047337"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Software XDS for image rotation, recognition and crystal symmetry assignment</span></div><div class="casAuthors">Kabsch, Wolfgang</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">125-132</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">The usage and control of recent modifications of the program package XDS for the processing of rotation images are described in the context of previous versions.  New features include automatic detn. of spot size and reflecting range and recognition and assignment of crystal symmetry.  Moreover, the limitations of earlier package versions on the no. of correction/scaling factors and the representation of pixel contents have been removed.  Large program parts have been restructured for parallel processing so that the quality and completeness of collected data can be assessed soon after measurement.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpv5AyUw00DYbVg90H21EOLACvtfcHk0lhwzh-LMME2-Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1SisLc%253D&md5=1aa9a38aeb3ce95af4ffb7d8b8a142bd</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1107%2FS0907444909047337&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444909047337%26sid%3Dliteratum%253Aachs%26aulast%3DKabsch%26aufirst%3DW.%26atitle%3DXDS%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2010%26volume%3D66%26issue%3D2%26spage%3D125%26epage%3D132%26doi%3D10.1107%2FS0907444909047337" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Evans, P.</span></span> <span> </span><span class="NLM_article-title">Scaling and Assessment of Data Quality</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">72</span>â <span class="NLM_lpage">82</span>, <span class="refDoi">Â DOI: 10.1107/S0907444905036693</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=10.1107%2FS0907444905036693" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=16369096" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlant7jM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2006&pages=72-82&issue=1&author=P.+Evans&title=Scaling+and+Assessment+of+Data+Quality&doi=10.1107%2FS0907444905036693"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Scaling and assessment of data quality</span></div><div class="casAuthors">Evans, Philip</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">D62</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">72-82</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">The various phys. factors affecting measured diffraction intensities are discussed, as are the scaling models which may be used to put the data on a consistent scale.  After scaling, the intensities can be analyzed to set the real resoln. of the data set, to detect bad regions (e.g. bad images), to analyze radiation damage and to assess the overall quality of the data set.  The significance of any anomalous signal may be assessed by probability and correlation anal.  The algorithms used by the CCP4 scaling program SCALA are described.  A requirement for the scaling and merging of intensities is knowledge of the Laue group and point-group symmetries: the possible symmetry of the diffraction pattern may be detd. from scores such as correlation coeffs. between observations which might be symmetry-related.  These scoring functions are implemented in a new program POINTLESS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGravLSLU62RhLVg90H21EOLACvtfcHk0lhwzh-LMME2-Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlant7jM&md5=293d3876e534c0c57813990515bb3c76</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1107%2FS0907444905036693&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444905036693%26sid%3Dliteratum%253Aachs%26aulast%3DEvans%26aufirst%3DP.%26atitle%3DScaling%2520and%2520Assessment%2520of%2520Data%2520Quality%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2006%26volume%3D62%26issue%3D1%26spage%3D72%26epage%3D82%26doi%3D10.1107%2FS0907444905036693" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vonrhein, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flensburg, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharff, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smart, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paciorek, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Womack, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bricogne, G.</span></span> <span> </span><span class="NLM_article-title">Data Processing and Analysis with the AutoPROC Toolbox</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>67</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">293</span>â <span class="NLM_lpage">302</span>, <span class="refDoi">Â DOI: 10.1107/S0907444911007773</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=10.1107%2FS0907444911007773" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=21460447" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktFWqtLs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2011&pages=293-302&issue=4&author=C.+Vonrheinauthor=C.+Flensburgauthor=P.+Kellerauthor=A.+Sharffauthor=O.+Smartauthor=W.+Paciorekauthor=T.+Womackauthor=G.+Bricogne&title=Data+Processing+and+Analysis+with+the+AutoPROC+Toolbox&doi=10.1107%2FS0907444911007773"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Data processing and analysis with the autoPROC toolbox</span></div><div class="casAuthors">Vonrhein, Clemens; Flensburg, Claus; Keller, Peter; Sharff, Andrew; Smart, Oliver; Paciorek, Wlodek; Womack, Thomas; Bricogne, Gerard</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">293-302</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">A typical diffraction expt. will generate many images and data sets from different crystals in a very short time.  This creates a challenge for the high-throughput operation of modern synchrotron beamlines as well as for the subsequent data processing.  Novice users in particular may feel overwhelmed by the tables, plots and nos. that the different data-processing programs and software packages present to them.  Here, some of the more common problems that a user has to deal with when processing a set of images that will finally make up a processed data set are shown, concg. on difficulties that may often show up during the first steps along the path of turning the expt. (i.e. data collection) into a model (i.e. interpreted electron d.).  Difficulties such as unexpected crystal forms, issues in crystal handling and suboptimal choices of data-collection strategies can often be dealt with, or at least diagnosed, by analyzing specific data characteristics during processing.  In the end, one wants to distinguish problems over which one has no immediate control once the expt. is finished from problems that can be remedied a posteriori.  A new software package, autoPROC, is also presented that combines third-party processing programs with new tools and an automated workflow script that is intended to provide users with both guidance and insight into the offline processing of data affected by the difficulties mentioned above, with particular emphasis on the automated treatment of multi-sweep data sets collected on multi-axis goniostats.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmah7iUrMLXLVg90H21EOLACvtfcHk0lh8AECjIgcjww"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktFWqtLs%253D&md5=a0a3579f6b371b6312819883864aa80d</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1107%2FS0907444911007773&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444911007773%26sid%3Dliteratum%253Aachs%26aulast%3DVonrhein%26aufirst%3DC.%26aulast%3DFlensburg%26aufirst%3DC.%26aulast%3DKeller%26aufirst%3DP.%26aulast%3DSharff%26aufirst%3DA.%26aulast%3DSmart%26aufirst%3DO.%26aulast%3DPaciorek%26aufirst%3DW.%26aulast%3DWomack%26aufirst%3DT.%26aulast%3DBricogne%26aufirst%3DG.%26atitle%3DData%2520Processing%2520and%2520Analysis%2520with%2520the%2520AutoPROC%2520Toolbox%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2011%26volume%3D67%26issue%3D4%26spage%3D293%26epage%3D302%26doi%3D10.1107%2FS0907444911007773" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McCoy, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grosse-Kunstleve, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winn, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Storoni, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, R. J.</span></span> <span> </span><span class="NLM_article-title">Phaser Crystallographic Software</span>. <i>J. Appl. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>40</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">658</span>â <span class="NLM_lpage">674</span>, <span class="refDoi">Â DOI: 10.1107/S0021889807021206</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=10.1107%2FS0021889807021206" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=19461840" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnslWqsLk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2007&pages=658-674&issue=4&author=A.+J.+McCoyauthor=R.+W.+Grosse-Kunstleveauthor=P.+D.+Adamsauthor=M.+D.+Winnauthor=L.+C.+Storoniauthor=R.+J.+Read&title=Phaser+Crystallographic+Software&doi=10.1107%2FS0021889807021206"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Phaser crystallographic software</span></div><div class="casAuthors">McCoy, Airlie J.; Grosse-Kunstleve, Ralf W.; Adams, Paul D.; Winn, Martyn D.; Storoni, Laurent C.; Read, Randy J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Applied Crystallography</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">658-674</span>CODEN:
                <span class="NLM_cas:coden">JACGAR</span>;
        ISSN:<span class="NLM_cas:issn">0021-8898</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">Phaser is a program for phasing macromol. crystal structures by both mol. replacement and exptl. phasing methods.  The novel phasing algorithms implemented in Phaser have been developed using max. likelihood and multivariate statistics.  For mol. replacement, the new algorithms have proved to be significantly better than traditional methods in discriminating correct solns. from noise, and for single-wavelength anomalous dispersion exptl. phasing, the new algorithms, which account for correlations between F+ and F-, give better phases (lower mean phase error with respect to the phases given by the refined structure) than those that use mean F and anomalous differences ÎF.  One of the design concepts of Phaser was that it be capable of a high degree of automation.  To this end, Phaser (written in C++) can be called directly from Python, although it can also be called using traditional CCP4 keyword-style input.  Phaser is a platform for future development of improved phasing methods and their release, including source code, to the crystallog. community.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPeVyjN_FMGbVg90H21EOLACvtfcHk0lh8AECjIgcjww"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnslWqsLk%253D&md5=c63b722ae97e0a74e6a5a079d388f09f</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1107%2FS0021889807021206&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0021889807021206%26sid%3Dliteratum%253Aachs%26aulast%3DMcCoy%26aufirst%3DA.%2BJ.%26aulast%3DGrosse-Kunstleve%26aufirst%3DR.%2BW.%26aulast%3DAdams%26aufirst%3DP.%2BD.%26aulast%3DWinn%26aufirst%3DM.%2BD.%26aulast%3DStoroni%26aufirst%3DL.%2BC.%26aulast%3DRead%26aufirst%3DR.%2BJ.%26atitle%3DPhaser%2520Crystallographic%2520Software%26jtitle%3DJ.%2520Appl.%2520Crystallogr.%26date%3D2007%26volume%3D40%26issue%3D4%26spage%3D658%26epage%3D674%26doi%3D10.1107%2FS0021889807021206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Emsley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lohkamp, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowtan, K.</span></span> <span> </span><span class="NLM_article-title">Features and Development of Coot</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>66</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">486</span>â <span class="NLM_lpage">501</span>, <span class="refDoi">Â DOI: 10.1107/S0907444910007493</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=10.1107%2FS0907444910007493" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=20383002" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;key=1%3ACAS%3A528%3ADC%252BC3cXksFKisb8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2010&pages=486-501&issue=4&author=P.+Emsleyauthor=B.+Lohkampauthor=W.+G.+Scottauthor=K.+Cowtan&title=Features+and+Development+of+Coot&doi=10.1107%2FS0907444910007493"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Features and development of Coot</span></div><div class="casAuthors">Emsley, P.; Lohkamp, B.; Scott, W. G.; Cowtan, K.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">486-501</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">Coot is a mol.-graphics application for model building and validation of biol. macromols.  The program displays electron-d. maps and at. models and allows model manipulations such as idealization, real-space refinement, manual rotation/translation, rigid-body fitting, ligand search, solvation, mutations, rotamers and Ramachandran idealization.  Furthermore, tools are provided for model validation as well as interfaces to external programs for refinement, validation and graphics.  The software is designed to be easy to learn for novice users, which is achieved by ensuring that tools for common tasks are 'discoverable' through familiar user-interface elements (menus and toolbars) or by intuitive behavior (mouse controls).  Recent developments have focused on providing tools for expert users, with customisable key bindings, extensions and an extensive scripting interface.  The software is under rapid development, but has already achieved very widespread use within the crystallog. community.  The current state of the software is presented, with a description of the facilities available and of some of the underlying methods employed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAKBKszbqb_7Vg90H21EOLACvtfcHk0lh8AECjIgcjww"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXksFKisb8%253D&md5=67262cbfc60004de5ef962d5c043c910</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1107%2FS0907444910007493&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444910007493%26sid%3Dliteratum%253Aachs%26aulast%3DEmsley%26aufirst%3DP.%26aulast%3DLohkamp%26aufirst%3DB.%26aulast%3DScott%26aufirst%3DW.%2BG.%26aulast%3DCowtan%26aufirst%3DK.%26atitle%3DFeatures%2520and%2520Development%2520of%2520Coot%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2010%26volume%3D66%26issue%3D4%26spage%3D486%26epage%3D501%26doi%3D10.1107%2FS0907444910007493" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bricogne, G.</span>; <span class="NLM_string-name">Blanc, E.</span>; <span class="NLM_string-name">Brandl, M.</span>; <span class="NLM_string-name">Flensburg, C.</span>; <span class="NLM_string-name">Keller, P.</span>; <span class="NLM_string-name">Paciorek, W.</span>; <span class="NLM_string-name">Roversi, P.</span>; <span class="NLM_string-name">Sharff, A.</span>; <span class="NLM_string-name">Smart, O. S.</span>; <span class="NLM_string-name">Vonrhein, C.</span>; <span class="NLM_string-name">Womack, T. O.</span></span> <i>Buster 2011</i>; <span class="NLM_publisher-name">Global Phasing Ltd</span>: <span class="NLM_publisher-loc">Cambridge, United Kingdom</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=G.+Bricogne&author=E.+Blanc&author=M.+Brandl&author=C.+Flensburg&author=P.+Keller&author=W.+Paciorek&author=P.+Roversi&author=A.+Sharff&author=O.+S.+Smart&author=C.+Vonrhein&author=T.+O.+Womack&title=Buster+2011"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DBricogne%26aufirst%3DG.%26btitle%3DBuster%25202011%26pub%3DGlobal%2520Phasing%2520Ltd%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1jrj" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1jrj','PDB','1jrj'); return false;">PDB: 1jrj</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3c59" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3c59','PDB','3c59'); return false;">PDB: 3c59</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ers" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ers','PDB','4ers'); return false;">PDB: 4ers</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2qkh" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2qkh','PDB','2qkh'); return false;">PDB: 2qkh</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6gb1" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6gb1','PDB','6gb1'); return false;">PDB: 6gb1</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6b3j" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6b3j','PDB','6b3j'); return false;">PDB: 6b3j</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6gdz" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6gdz','PDB','6gdz'); return false;">PDB: 6gdz</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6ge2" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6ge2','PDB','6ge2'); return false;">PDB: 6ge2</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6GDZ" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6GDZ','PDB','6GDZ'); return false;">PDB: 6GDZ</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6GE2" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6GE2','PDB','6GE2'); return false;">PDB: 6GE2</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6GB1" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6GB1','PDB','6GB1'); return false;">PDB: 6GB1</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i35"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b00292">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_44874"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.8b00292">10.1021/acs.jmedchem.8b00292</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline"><sup>1</sup>H-chemical shifts of peptides <b>5</b> and <b>12</b>, distance constraints used for the MD simulation obtained from NOESY spectra, analytical data with RP-HPLC retention times and molecular masses of the synthesized peptides, crystallographic data collection and refinement statistics, omit map of the bound peptide <b>11</b>, three-dimensional alignment of X-ray structure of GLP-1 (ECD) receptor-bound peptide <b>11</b>, receptor-bound modeling hypothesis of peptide <b>5</b>, and NMR structure of peptide <b>5</b> in solution, three-dimensional alignment of X-ray structure of GLP-1 (ECD) receptor-bound peptide <b>11</b> and ECD, X-ray structure of GLP-1 (ECD) receptor-bound exendin(9â39), as well as three-dimensional alignment of X-ray structure of GLP-1 (ECD) receptor-bound peptide <b>11</b> and cryo-EM GLP-1 (full-length) receptor-bound exendin-P5. (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b00292/suppl_file/jm8b00292_si_001.pdf">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b00292/suppl_file/jm8b00292_si_001.pdf">jm8b00292_si_001.pdf (1.2 MB)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">Atomic coordinates for NMR structure of peptides <b>5</b> and <b>12</b> in solution can be accessed using PDB codes <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6GDZ">6GDZ</a> and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6GE2">6GE2</a>. Coordinates of the crystal structure of GLP-1 receptor extracellular domain (ECD) with peptide <b>11</b> can be assessed using PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6GB1">6GB1</a>. The authors will release the atomic coordinates and experimental data upon article publication.</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.8b00292&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2018.61.issue-13%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.8b00292%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.8b00292" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                6MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright Â© 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">Youâve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679987d6df193c46","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
